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THE HUMAN GERM CELL LINEAGE: PLURIPOTENCY, 
TUMOURIGENESIS AND PROLIFERATION 
by Rebecca Mary Perrett 
 
A pluripotent stem is characterised by indefinite self-renewal in culture, with the retained 
capacity to form derivatives of all three germ layers of the early embryo: endoderm, 
ectoderm and mesoderm. There are three clear sources of pluripotent stem cell; embryonic 
stem cells (ESCs), embryonal carcinoma cells (ECCs) and embryonic germ cells (EGCs). 
Human (h) ESCs are derived from the inner cell mass (ICM) of the early embryo, whereas 
hEGCs are derived from primordial germ cells (PGCs), the embryonic precursors of the 
gametes. hECCs also arise from the germ cell lineage, however, only after malignant 
transformation when they act as the stem cells of teratocarcinoma. Work described herein 
used these three human cell sources to investigate the regulators of pluripotency, the 
transcription factors OCT4, NANOG and SOX2. 
OCT4 and NANOG were expressed by hESCs, hECCs and hPGCs/hEGCs. SOX2 
was expressed by hESCs and hECCs and detected within mouse (m) PGCs. Surprisingly, 
SOX2 was absent from hPGCs/EGCs by RT-PCR, expression microarray analysis, 
immunohistochemistry and immunoblotting. Sox2 is required for mESC growth. Its 
absence may explain the difficulties of maintaining hEGCs in long-term culture. Consistent 
with this interpretation, Sox2-positive mEGC cultures are relatively easy to establish and 
maintain. Interestingly, this paradigm extends to germ cell tumour biology. Seminomas, 
which do not possess stem cells and resemble undifferentiated germ cells, lack SOX2 
expression, whereas embryonal carcinoma specimens are SOX2-positive. This expression 
pattern is consistent with SOX2 playing important roles in pluripotency, and may indicate 
a determining role for SOX2 in gonadal tumour type.  
Additional work undertaken within this thesis attempted to identify genes which 
could promote hPGC - and therefore hEGC - proliferation. Comparing gene expression 
levels by expression microarray and RT-PCR in developing ovary and testis highlighted a 
number of genes which are more highly expressed in ovary, and which also promote 
proliferation in other tissues. These data are informing ongoing work aimed at improving 
hPGC culture/hEGC derivation.  
Finally, studies herein have demonstrated that expression of the OCT4-SOX2-
NANOG transcription factor complex is not required for expression of target genes 
identified by biometric analysis. In addition, the potential shortcomings of the use of 
SSEA3, SSEA4, TRA-1-60 and TRA-1-81 to mark pluripotent cells have been identified. 
Differentiated cells - neuroprogenitors and stomach epithelial cells - also express these 
markers. Therefore their use to characterise stem cell lines is limited highlighting the 
necessity of a combination of functionally relevant markers for characterisation. 
This study has unearthed a fundamental
  difference in gene expression between 
human and mouse germ cells, demonstrating
 the limitations of interspecies extrapolation. 
The data highlight
 SOX2 as an important transcription factor for further investigation
 in 
attempts to understand the relationship between human PGCs,
 GCTs, and the derivation, 
self-renewal, and pluripotency of
  human EGCs. The information is also instructive in 
attempts
  to generate human gametes from stem cell sources for ambitious
  fertility 
treatments.   2
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TGCT, testicular germ cell tumour 
TGF, transforming growth factor 
Tiar, T-cell restricted intracellular antigen-related 
protein 
TIN, testicular intraepithelial neoplasia 
TNAP, tissue non-specific alkaline phosphatase 
TNFα, tumour necrosis factor α 
TR, Texas red 
Utf1, undifferentiated embryonic cell 
transcription factor 1 
UTR, untranslated region 
Vrk2, vaccinia virus-related protein kinase 2 
WNT, wingless-type mammary tumour virus 
integration site  
wpc, weeks post-conception 
YST, yolk sac tumour 
Zfp, zinc finger protein 
Zic3, zinc finger protein of the cerebellum 3 
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CHAPTER 1: Introduction 
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1.1 Pluripotent Stem Cells 
A pluripotent stem cell is defined according to two characteristics: being able to 
reproduce indefinitely (undergo self-renewal); and to differentiate into any of the three 
germ layers of the embryo (so-called ‘pluripotency’) (Weissman 2000). The existence of 
stem cells was first demonstrated in 1963 (Becker et al. 1963; Siminovitch et al. 1963), 
and they can be derived from embryonic, fetal or adult tissues. 
Of all three types, it appears that embryonic stem cells have the greatest 
differentiation capability (Verfaillie et al. 2002), although some fetal stem cells can 
differentiate into cells of a lineage other than that from which they were originally derived, 
a property termed ‘transdifferentiation’ or ‘plasticity’. For example, Suzuki et al. (2002) 
isolated cells from mouse fetal liver that could be clonally expanded and could reconstitute 
liver and biliary
 epithelial cells and also epithelium of pancreas and the gastrointestinal 
(GI)
  tract. However, generating enough cells for therapeutic use in the pure form is 
difficult, reservations exist regarding collection and use of tissues from abortions and the 
problem of immune rejection needs to be overcome (O'Donoghue and Fisk 2004). 
Of adult stem cells, those derived from the bone marrow (haematopoietic and 
mesenchymal stem cells [HSCs and MSCs, respectively]) show the greatest degree of 
plasticity. HSCs can generate all mature blood cell types of the haematolymphatic system, 
and in numerous studies have been shown to differentiate into cells of other lineages 
(reviewed in Bellantuono 2004). MSCs can differentiate into mesenchymal derivatives, as 
well as cells of other lineages (reviewed in Kemp et al. 2005). However, the numbers of 
MSCs obtained from bone marrow are small; 0.001–0.01% of mononuclear cells isolated 
from a ficoll density gradient of bone marrow aspirate are MSCs (Pittenger et al. 1999). 
Cells can be amplified in vitro, however spontaneous transformation of adult MSCs after 
long-term culture has been reported (Rubio et al. 2005). Therefore, whilst adult stem cells 
do offer some potential, and circumvent the issue of immunorejection, limitations remain: 
restricted differentiation potential and the inability to obtain large amounts of pure cells for 
transplantation. 
Stem cells derived from the embryo overcome some of these restrictions as 
unlimited amounts can be grown in culture, and they are unequivocally able to differentiate 
to derivatives of all three germ layers. Three pluripotent cell types can be derived from the 
embryo: embryonic stem cells (ESCs), embryonic germ cells (EGCs) and embryonal 
carcinoma cells (ECCs) (Figure 1.1).   18
 
Figure 1.1 Pluripotent cells which can be derived from the human embryo 
Human embryonic stem cells (hESCs) are derived from the inner cell mass (ICM) of 
the blastocyst, human embryonic germ cells (hEGCs) are derived from the precursors 
of the gametes, primordial germ cells (PGCs), and human embryonal carcinoma cells 
(ECCs) are transformed PGCs. [Reproduced from Turnpenny et al. (2006).]  
 
In order to understand the origin and biology of these cells, it is first necessary to 
briefly review human embryonic development and differentiation. 
 
1.2 Human Embryogenesis 
Human embryogenesis (Figure 1.2) begins with fertilisation of an egg by a sperm, 
forming a zygote, which then undergoes a series of rapid divisions, known as cleavage, 
generating cells termed blastomeres. After the 8-cell stage, these cells undergo 
‘compaction’, in which they bind tightly to each other, forming a compact sphere. The 
cells continue to divide, and, at the 16-cell stage, the embryo is termed a morula. The outer 
layer of cells, the trophoblast, secrete water into the morula, forming a central, fluid-filled 
cavity (blastocoel); a process termed cavitation. The outer layer of the embryo, the zona 
pellucia, begins to degenerate, and the embryo increases in volume. At this stage, four to 
six days after fertilisation, the embryo is termed a blastocyst. Cells then make their first 
cell fate ‘decision’, either becoming part of the inner cell mass (ICM), which will 
ultimately form the embryo, or part of the outer trophoblast, which will form the placenta. 
The ICM is composed of the epiblast, which will give rise to the embryo proper, and the 
hypoblast which will give rise to extraembryonic structures only, such as the lining of the 
yolk sac. Cells from the ICM are pluripotent; they can form cells of all three germ layers  19
and the germ line of the developing embryo, but they cannot give rise to the placenta and 
supporting tissues (Figure 1.2). Cells derived from the zygote and the first 2 to 16 
blastomeres have the greatest developmental potential; these cells are termed totipotent as 
they can form both the embryo and the trophoblast of the placenta.  
 
 
Figure 1.2 Development of the human embryo  
[Adapted from National Centre for Biotechnology Information (NCBI) website: 
http://www.ncbi.nih.gov/] 
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The germ layers of the embryo (Figure 1.2 and 1.3) comprise the ectoderm, which 
will ultimately form cells of the skin and nervous system; the mesoderm, which will form 
the bones, most of the circulatory system, muscle, reproductive and urinary systems; and 
the endoderm, which will form the respiratory tracts and GI system, including the liver and 
pancreas. These layers arise during a process termed gastrulation. 
 
 
Figure 1.3 The three germ layers of the embryo, and the germline  
[Reproduced from National Centre for Biotechnology Information (NCBI) website: 
http://www.ncbi.nih.gov/] 
 
1.3 Embryonic Stem Cells 
ESCs are, chronologically, the first stem cell that can be derived from the embryo 
(from the ICM). Mouse ESCs (mESCs) were first derived independently in 1981 by two 
groups (Evans and Kaufman 1981; Martin 1981). Evans and Kaufman used a feeder layer 
of mitotically inactivated primary mouse embryonic fibroblasts (pMEFs) to derive mESCs 
from blastocysts, whereas Martin used conditioned medium from another pluripotent stem 
cell, embryonal carcinoma cells (ECCs; Section 1.5). To isolate ICM cells from a 
blastocyst, the trophectoderm (TE) is removed by immunosurgery, and the ICM plated 
onto a feeder layer of pMEFs. The cells attach and divide, and the outgrowth is 
disaggregated and plated onto another feeder layer. Colonies with an undifferentiated  21
morphology are individually dissociated and re-plated. These form colonies and are 
dissociated in the same way, generating ESC lines. They fulfill all criteria for pluripotency 
(Table 1.1). When injected into immunocompromised mice they form teratomas containing 
cells of the three germ layers, and when introduced into blastocysts, chimaeric mice are 
generated demonstrating that they can contribute to all cell lineages including the germ line 
(Bradley et al. 1984). They are pluripotent in vitro (Evans and Kaufman 1981; Wobus et 
al. 1984; Doetschman et al. 1985) and can develop into cells of the germ line (Hubner et 
al. 2003; Toyooka et al. 2003; Geijsen et al. 2004). Following a similar procedure to that 
for mESC derivation, Thomson et al. (1998) derived human ESCs (hESCs) from in vitro 
fertilised embryos. Again, these lines remained undifferentiated in vitro, and were able to 
form derivatives of all three embryonic germ layers.   
 
 
 
 
 
 
 
Table 1.1 Criteria for pluripotent stem cells 
 
1.4 Embryonic Germ Cells 
EGCs are derived from primordial germ cells (PGCs), the precursors of the 
gametes, and are defined as PGCs which continue to proliferate in vitro beyond the time 
point at which they would cease to do so in vivo. During embryonic development, PGCs 
migrate to the genital ridges of the developing gonads. If the gonads are dissected, and 
plated onto MEFs, these PGCs sometimes develop into EGCs. These were also first 
derived from the mouse, independently by two groups (Matsui et al. 1992; Resnick et al. 
1992), and subsequently from the human (Shamblott et al. 1998). Whilst mEGCs 
unequivocally fulfill all criteria for pluripotency, hEGCs are somewhat less convincing.  
 
Clonally derived cultures are capable of spontaneous differentiation into derivatives 
of all three germ layers in vivo (teratomas) or in vitro 
When injected into blastocysts, contribute to all cell lineages in chimaeric mice, 
including the germ line 
Maintain normal karyotype 
Immortal and propagate indefinitely in the embryonic state  22
1.5 Embryonal Carcinoma Cells 
ECCs are transformed PGCs, originally isolated from mouse germ cell tumours 
(GCTs) (Kahan and Ephrussi 1970). These tumours occur spontaneously in the testes of 
mice (and men) and can be divided into two groups based on the degree and type of 
differentiation: seminomas, which are relatively uniform and resemble undifferentiated 
PGCs, and the more aggressive nonseminomas, which as well as containing an 
undifferentiated component also show varying degrees of embryonic and extraembryonic 
patterns of differentiation (Ulbright 1993; Chaganti and Houldsworth 2000). The 
nonseminomas are further subdivided into teratoma, embryonal carcinoma, 
teratocarcinoma, yolk sac carcinoma, and choriocarcinoma. Table 1.2 summarises the 
range of manifestations of GCTs (Andrews et al. 2001). 
 
Histological 
type 
Description 
 
Comments 
Teratoma  A tumour containing an 
array of differentiated 
somatic cell types. 
The differentiated cells may be organised into 
well recognisable anatomical structures (e.g. 
teeth) or be haphazardly arranged. Often 
benign, but their malignant potential is well 
known. Most common form is benign ‘dermoid 
cyst’ of the ovary. 
Embryonal 
carcinoma 
‘Undifferentiated’ epithelial 
cells resembling embryonic 
cells of the ICM and the 
primitive ectoderm. 
Highly malignant tumours; cells are regarded 
as stem cells with the ability to differentiate into 
a range of histological cell types.  
Teratocarcinoma  Contains both teratoma 
and embryonal carcinoma. 
Malignancy is due to the embryonal carcinoma 
component. 
Yolk sac 
carcinoma 
Cells resemble those of the 
extraembryonic ‘yolk sac’. 
In mouse may resemble parietal or visceral yolk 
sac; in humans no such clear distinction is 
evident.  
Choriocarcinoma  Cells resemble cyto- and 
syncytiotrophoblast of the 
placenta. 
Do not occur in GCTs of the laboratory mouse. 
Seminoma  Relatively uniform cells 
resembling primordial germ 
cells. 
A malignancy tumour that does not occur in the 
laboratory mouse; known as dysgerminoma in 
females. 
Spermatocytic 
seminoma 
Heterogeneous cells 
resembling a caricature of 
spermatogenesis. 
A low malignancy tumour occurring in older 
men, and generally regarded as distinct from all 
other GCTs. 
 
Table 1.2 Classification of germ cell tumours in laboratory mice and men 
These classifications, while oversimplifications to experienced pathologists, represent 
common usage by biologists. [Adapted from Andrews et al. (2001).] 
 
In humans, GCTs account for almost all testicular tumours and are always 
malignant. They typically occur in young post-pubertal men, with a peak incidence in the  23
third decade of life (Moller 1993). They appear to arise from a common precursor, the 
carcinoma in situ (CIS) cell within the seminiferous tubules (Skakkebaek 1972). Figure 1.4 
depicts the varying morphology of GCTs. 
 
 
Figure 1.4 Testicular germ cell tumour morphology 
Histological appearance of carcinoma in situ, nonseminoma (EC) and seminoma. The 
uniform undifferentiated appearance of the seminoma contrasts markedly with the 
differentiated cells within the nonseminoma. Size bar represents 100 μm. 
 
Mouse ECCs are the progenitors of the differentiated elements of GCTs, i.e. they 
are the stem cells of the tumours (Kleinsmith and Pierce 1964). These cells can be 
expanded continuously in vitro in the undifferentiated state. They differentiate both in vitro 
and  in vivo: the cells form benign teratomas or malignant teratocarcinomas when 
transplanted into extra-uterine sites of mice (reviewed in Andrews 1998); and when 
introduced into the ICM of early mouse embryos, some lines participate in embryonic 
development and contribute to a wide variety of tissues in the resulting chimaeric fetuses 
and mice (Brinster 1974). Therefore, ECCs fulfill all criteria for self-renewing, pluripotent 
stem cells (Table 1.1). Unlike mECCs, many established hECC lines show poor 
differentiation potential, with some being nullipotent, and almost all are aneuploid 
(Damjanov 1990; Harrison et al. 2007). 
Gene expression patterns for hESCs, hECCs and GCTs are similar, indicating 
commonality in the mechanisms for maintaining proliferation and pluripotency in all 
(Sperger et al. 2003).    24
1.6 Characterisation of Pluripotent Cells: Surface Markers 
Expression of particular cell surface antigens, namely stage-specific embryonic 
antigen 1 (SSEA1), SSEA3 and SSEA4, and TRA-1-60 and TRA-1-81
1, is often used to 
assist in confirming pluripotency. The experiments that led to the discovery of these 
surface antigens involved the immunisation of mice with syngeneic embryonic cells, 
generating antisera that recognised antigens on the embryo but not the adult (Artzt et al. 
1973). TRA-1-60 and TRA-1-81 were identified as recognising distinct cell surface 
antigens on hECCs (Andrews et al. 1984). The antigenic determinant of the monoclonal 
antibody embryonic mouse antigen 1 (EMA1) shows a similar expression profile to 
SSEA1, on mESCs and EGCs (Hahnel and Eddy 1987). The surface antigens expressed 
differ between human and mouse ESCs, EGCs and EGCs (Table 1.3).   
 
Marker  mESC mECC mEGC hESC hECC  hEGC  Comments 
Alkaline 
phosphatase 
(AP) 
Yes  Yes  Yes  Yes  Yes  Yes  Alkaline phosphatase activity 
SSEA1 Yes  Yes  Yes  No  No  Yes 
Lactoseries glycolipid; frequently 
appears during differentiation of 
hESCs/ECCs 
EMA1 Yes  Yes  Yes  No  No  Yes 
May recognise different parts or 
prefer different conformations of 
the same carbohydrate chain as 
SSEA1 
SSEA3 No  No  No  Yes  Yes  Variable
2 
Globoseries glycolipid; down-
regulated rapidly during 
differentiation of hESCs/ECCs 
SSEA4 No  No  No  Yes  Yes  Yes  Globoseries  glycolipid 
TRA-1-60 No  No  No  Yes  Yes  Yes 
Keratan sulphate (antibody 
recognises same epitope as 
GCTM2) 
TRA-1-81 No  No  No  Yes  Yes Yes  Keratan  sulphate 
GCTM2 No  No  No  Yes  Yes  Yes  Keratan  sulphate 
 
Table 1.3 Differential expression of characteristic surface marker antigens on 
mouse and human ES, EC and EG cells 
[Adapted from Draper and Andrews (2004) and Turnpenny et al. (2006).] 
 
                                                 
1 Named after the Battle of Trafalgar, not Tumour-Related/Rejection Antigen as sometimes stated (P. 
Andrews; pers. comm.). 
2 Detected weakly and inconsistently by some [Shamblott et al. (1998, 2004), Liu et al. (2004)] but not by 
others [Turnpenny et al. (2003, 2005), Pan et al. (2005)].  25
1.7 Maintenance of Pluripotency 
The crucial molecules involved in pluripotency have been determined through 
studies in ESCs in the main, although much of this work was led by original discoveries 
that had been made in ECCs. Mouse and human ESC pluripotency is maintained by a 
network of transcription factors, of which OCT4 (also known as OCT3 or POU5F1
3), 
SOX2 and NANOG are at the helm (Boyer et al. 2005; Loh et al. 2006). Homozygous 
knock-out of either Oct4,  Sox2  or Nanog in the mouse is embryonic-lethal, with no 
pluripotent epiblast being formed in either case (Nichols et al. 1998; Avilion et al. 2003; 
Mitsui et al. 2003). 
 
1.7.1 OCT4 
OCT4 is the most extensively studied of all the transcription factors involved in 
maintaining pluripotency. A member of the POU (Pit-Oct-Unc)
4 family of transcription 
factors, it binds to the octamer motif ATGC(A/T)AAT found in the regulatory domains of 
some genes. It is the earliest expressed gene known to encode a transcription factor which 
is developmentally regulated during mammalian embryogenesis. In the mouse, zygotic 
Oct4 expression is activated at the four-cell stage (Yeom et al. 1991). Following cavitation, 
human and mouse expression is limited to the ICM and it is down-regulated in the 
differentiated TE (Okamoto et al. 1990; Rosner et al. 1990; Scholer et al. 1990; Hansis et 
al. 2000). Following implantation, expression is restricted to the epiblast (Yeom et al. 
1996), and after gastrulation, PGCs are the only cells which retain Oct4 expression 
(Ginsburg et al. 1990). Oct4 is also expressed by pluripotent mouse and human ESCs, 
ECCs and EGCs (Pera et al. 1989; Okamoto et al. 1990; Rosner et al. 1990; Labosky et al. 
1994; Yeom et al. 1996; Shamblott et al. 1998; Reubinoff et al. 2000). It is down-regulated 
upon differentiation (Scholer et al. 1989; Okamoto et al. 1990; Rosner et al. 1990; 
Brandenberger et al. 2004). Oct4-deficient mouse embryos die before implantation; the 
embryos develop to the blastocyst stage with normal cell numbers in the ICM; however, 
these cells can only form trophoblast cells (Nichols et al. 1998). Therefore, Oct4 is 
essential for the establishment of a pluripotent ICM.  
                                                 
3 According to the The GDB Human Genome Database (http://www.gdb.org/), OCT3/4 should be referred to 
as POU5F1. However, this thesis uses the more familiar term, OCT4. 
4 Contain a POU domain, which was originally identified as a region of approximately 150 amino acids 
shared between the Pit-1, Oct-1, Oct-2, and Unc-86 transcription factors, hence the name ‘POU’.  26
The exact level of Oct4 expression is crucial in determining cell fate (Niwa et al. 
2000): a decrease of 50% compared to endogenous level commits mESCs to the TE 
lineage; whereas a less than two-fold increase in expression causes differentiation into 
primitive endoderm and mesoderm. Oct4 prevents mESCs from differentiating into TE by 
blocking the expression and activity of the transcription factor Cdx2 (Niwa et al. 2005). 
Sustained expression of Oct4 promotes neuronal differentiation of mESCs (Shimozaki et 
al. 2003), and high levels of Oct4 expression were detected in primitive endoderm of the 
ICM at embryonic day (E) 4.5 (Palmieri et al. 1994). Therefore Oct4 can be regarded as a 
three-way switch to determine three different cell states – pluripotency, primitive 
endoderm and TE – in a dose-dependent manner (Niwa 2001). 
 
1.7.2 SOX2 
OCT4 often works in concert with another transcription factor, SOX2, a member of 
the SOX (Sry-related high mobility group [HMG] box containing) DNA-binding protein 
family. Proteins are grouped into the SOX protein family if they contain an HMG domain 
with strong amino acid similarity (usually greater than 50%) to the HMG domain of Sry 
(Sex determining region of the Y chromosome). SOX proteins bind DNA through this 79 
amino acid HMG domain. In contrast to most DNA-binding proteins which bind to the 
major groove of DNA, the HMG box interacts with the minor groove, thereby introducing 
a dramatic bend in the DNA molecule. There are eight subgroups of SOX proteins, A-H, 
based on sequence similarity and genomic organisation (Schepers et al. 2002). Members 
within the same subgroup usually share greater than 80% amino acid identity within the 
HMG domain. SOX2 belongs to the SOXB subgroup, which comprises SOX1, 3, 14 and 
21. SOX1-3 are transcriptional activators (SOXB1 subgroup), and SOX14 and 21 are 
transcriptional repressors (SOXB2 subgroup) (Uchikawa et al. 1999). The 
activator/repressor domain is found at the C-terminal of the protein. 
Mouse Sox2 expression is first detected at the morula stages, and in blastocysts it is 
specifically located within the ICM. It is expressed throughout the epiblast, but its 
expression becomes restricted during gastrulation. By E9.5, it is expressed throughout the 
brain, spinal cord, sensory placodes, branchial arches and gut endoderm, and in male and 
female germ cells (Avilion et al. 2003; Western et al. 2005). Sox2-deficient embryos fail to 
survive, dying shortly after implantation, at E6.0, Sox2-null ICMs contain only TE and 
extraembryonic endoderm, and Sox2-null mESCs cannot be derived. In addition, reduction  27
of SOX2 expression in hESCs and mESCs results in a loss of the undifferentiated state and 
increased expression of TE markers (Chew et al. 2005; Fong et al. 2008). Small increases 
(two-fold or less) in Sox2 protein trigger the differentiation of mESCs (Kopp et al. 2008) 
and inhibit the expression of Sox2-Oct4 target genes (Boer et al. 2007). 
Sox2 and Oct4 cooperatively activate Fibroblast growth factor 4 (Fgf4) 
transcription (Yuan et al. 1995); however Fgf4 is expressed in Sox2-null embryos, which 
cannot be rescued by exogenous Fgf4 (Avilion et al. 2003). This indicates that Fgf4 is not 
the crucial target gene of Sox2 in maintaining the pluripotent ICM. Maternal Sox2 protein 
persists throughout preimplantation development; it accumulates in the cytoplasm of 
growing oocytes and is present in all cells until at least the blastocyst stage (Avilion et al. 
2003). This maternal Sox2 could account for Fgf4 expression in the homozygous 
blastocysts, and may delay lethality until after implantation, when maternal Sox2 protein is 
diluted out due to growth of the embryo. 
 
Both Sox2 and Oct4 are therefore required for the ICM epiblast lineage, and in 
their absence TE is formed. It is proposed that they cooperatively act on a number of target 
genes to maintain pluripotency within the epiblast. 
 
1.7.2(i) SOX2/OCT4 Target Genes 
Sox2 and Oct4 activate Fgf4 transcription by forming a complex and binding to a 
distal enhancer located in the 3’ untranslated region (UTR) of the Fgf4 gene (Yuan et al. 
1995). Sox2/Oct4 also cooperatively activate transcription of genes for the transcription 
factors  Undifferentiated embryonic cell transcription factor 1 (Utf1) (Nishimoto et al. 
1999; Nishimoto et al. 2005), F-box only protein 15 (Fbx15) (Tokuzawa et al. 2003), 
Nanog (Kuroda et al. 2005; Rodda et al. 2005), Zinc finger protein 206 (Zfp206) (Wang et 
al. 2007), Developmental pluripotency associated 4 (Dppa4) (Chakravarthy et al. 2008) 
and  Oct4 and Sox2 themselves (Tomioka et al. 2002; Chew et al. 2005; Okumura-
Nakanishi et al. 2005). Excluding Fbx15, whose function is unknown, these genes have all 
been demonstrated to function in ESCs, as detailed below:  
 
•  Fgf4 is involved in the patterning of the extraembryonic ectoderm by stimulating 
the proliferation of TE cells (Wilder et al. 1997; Tanaka et al. 1998). Fgf4-null 
embryos cannot form an egg cylinder and die soon after implantation. When these  28
embryos were cultured in vitro, proliferation of the ICM was severely impaired; 
growth and differentiation were rescued with exogenous Fgf4 (Feldman et al. 
1995). However, Fgf4-deficient ESCs proliferate, suggesting Fgf4 is not required 
for ESC proliferation (Wilder et al. 1997).  
•  Utf1 is involved in the initiation of ESC differentiation (van den Boom et al. 2007); 
it is not involved in self-renewal or pluripotency per se, but appears to promote 
teratoma formation and proliferation (Nishimoto et al. 2005).  
•  The expression
  profile of Fbx15 in mice is nearly identical to that of Oct4, 
restricted to ESCs, early embryos and testis tissue (Tokuzawa et al. 2003). Null 
mice are normal, however, and Fbx15 is not required for ESC pluripotency or 
differentiation. Although its exact function is unknown, it has been postulated to be 
an E3 ubiquitin ligase.  
•  Zfp206 encodes a zinc finger-containing transcription factor which maintains 
pluripotency in mESCs. It enhances transcription from its own promoter as well as 
that of Oct4 and Nanog (Wang et al. 2007).  
•  Dppa4 is expressed in pluripotent cells and the germ line (Maldonado-Saldivia et 
al. 2007), and it plays an important role in the self-renewal of mESCs (Masaki et 
al. 2007).  
 
1.7.3 NANOG 
Nanog is a relatively new member of the pluripotency orchestra, named after the 
Celtic land of the ever-young, ‘Tir nan Og’
5. It is a dimer-active homeodomain protein 
(Mullin et al. 2008; Wang et al. 2008), whose over-expression confers constitutive self-
renewal on mESCs, independent of LIF (leukaemia inhibitory factor)/STAT3 (signal 
transducers and activators of transcription 3) stimulation (Chambers et al. 2003). Over-
expression of NANOG also allows feeder-free growth of hESCs (Darr et al. 2006); 
however, these cells down-regulate expression of markers
 specific to the ICM and acquire 
expression of a primitive ectoderm marker. Nanog is expressed by human and mouse 
ESCs, EGCs and ECCs, the ICM and PGCs (Hatano et al. 2005; Yamaguchi et al. 2005); 
however, it is absent from oocytes (Hyslop et al. 2005). Nanog-deficient ICM fails to 
generate epiblast and only produces parietal endoderm-like cells, and Nanog-deficient 
                                                 
5 Located on an island far to the west of Ireland, beyond the edges of the map. It could be reached by either 
an arduous voyage or an invitation from one of its fairy residents.  29
mESCs lose pluripotency and differentiate into the extraembryonic endoderm lineage 
(Mitsui et al. 2003). Therefore Nanog appears to function at a later stage than that of Oct4, 
in the development of primitive
 ectoderm. Consistent with this notion, in hESCs, NANOG 
expression increases during early differentiation (Darr et al. 2006).  
Nanog expression is up-regulated in mESCs by the binding of T (Brachyury) and 
Stat3 to an enhancer element in the Nanog gene. It acts to prevent mesoderm 
differentiation by interacting with Smad1 (Small mothers against decapentaplegic 1) and 
interfering with the recruitment of co-activators to the active Smad transcriptional 
complexes (Suzuki et al. 2006). Nanog represses the pro-differentiation activities of NFκB, 
and also cooperates with Stat3 (Section 1.8.1) to activate gene expression and promote 
self-renewal (Torres and Watt 2008). The role of Nanog in pluripotency per se has recently 
been questioned, as Nanog
-/- mESCs can be established and retain pluripotency, albeit with 
an increased propensity to differentiate (Chambers et al. 2007). It is now proposed to act 
primarily in the construction of the ICM and germ cell states rather than in the 
housekeeping machinery of pluripotency, acting as a ‘pluripotency rheostat’, conferring a 
variable resistance to differentiation (Chambers et al. 2007; Rizzino 2008).   
 
1.7.4 Mode of Action of OCT4, SOX2 and NANOG  
OCT4, SOX2 and NANOG maintain pluripotency by activating transcription of 
genes required for pluripotency and repressing those which promote differentiation, in 
human (Brandenberger et al. 2004; Boyer et al. 2005) and mouse ESCs (Loh et al. 2006; 
Zhou et al. 2007). OCT4-SOX2-NANOG target genes have been identified in hESCs by 
using chromatin immunoprecipitation (ChIP) coupled with DNA microarrays (Boyer et al. 
2005). Promoter regions were defined as being within 8kb upstream and 2kb downstream 
of the transcriptional start site. OCT4, SOX2 and NANOG were found to co-occupy a 
substantial proportion of their target genes, at least 353 (Figure 1.5). 
Many of the target genes are transcription factors, some of which function in 
embryonic development. Some of the target genes identified are shown in Figure 1.6 and 
include OCT4, SOX2 and NANOG themselves, as well as components of the WNT
6 and 
transforming growth factor β (TGFβ) signalling pathways, reported to play roles in 
                                                 
6 The name Wnt was coined as a combination of Wg (wingless) and Int (Rijsewijk et al. 1987). The wingless 
gene was idenitifed in Drosophila melanogaster and functions during embryogenesis (Nusslein-Volhard and 
Wieschaus 1980). It is homologous to the vertebrate Int1 gene, present near the integration sites of mouse 
mammary tumour virus (MMTV) (Nusse et al. 1984).  30
pluripotency and self-renewal in human and mouse ESCs (Sato et al. 2004; James et al. 
2005; Sections 1.8.4 and 1.8.5) .  
 
 
Figure 1.5 Venn diagram representing the overlap of OCT4, SOX2 and NANOG 
promoter bound regions 
[Adapted from Boyer et al. (2005).] 
 
The same research group has recently demonstrated that the transcription factor T-
cell factor 3 (Tcf3), a terminal component of the Wnt pathway, co-occupies promoters 
throughout the mESC genome in association with Oct4 and Nanog (Cole et al. 2008). Tcf3 
is highly expressed in mESCs, and is crucial for embryonic development (Korinek et al. 
1998; Merrill et al. 2001); it may act to limit the actions of pluripotency-promoting 
transcription factors (Pereira et al. 2006; Cole et al. 2008; Yi et al. 2008). Most of the 
transcriptionally silent developmental regulators targeted by OCT4, SOX2 and NANOG 
are also occupied by polycomb proteins (Bernstein et al. 2006; Boyer et al. 2006; Lee et al. 
2006). These are epigenetic regulators which facilitate the maintenance of cell state 
through gene silencing. Silent developmental genes co-occupied by OCT4, SOX2 and 
NANOG undergo an unusual form of transcriptional regulation, whereby the genes 
undergo transcriptional initiation but not productive transcript elongation (Guenther et al. 
2007), presumably due to the presence of polycomb proteins at these promoters. In 
mESCs, Oct4 and Nanog associate with transcriptional repressor complexes on their target 
genes, and may thereby act to control ESC fate (Liang et al. 2008). 
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Figure 1.6 Core transcriptional regulatory network in hESCs  
Constructed based on known targets of OCT4, SOX2 and NANOG and the binding of 
the transcription factors to the promoters of genes known to be expressed (green) and 
repressed (red) in hESCs. Regulators are represented by blue circles; gene promoters 
by rectangles; yellow boxes represent putative downstream target genes. OCT4, 
SOX2 and NANOG activate (arrows) transcription of genes required for pluripotency 
and repress (blocked lines) genes required for differentiation. [Adapted from Boyer et 
al. (2005).]  32
Interestingly, a study to identify Oct4 and Nanog target genes in mESCs found only 
9% overlap between Oct4-bound genes and 13% overlap between Nanog-bound genes 
compared with hESCs (Loh et al. 2006). Therefore, there appear to be major differences in 
the regulation of pluripotency between species (Ginis et al. 2004; Sun et al. 2007). Of the 
32 genes bound in both mouse and human ESCs, 18 encoded for transcription factors, 
including Sox2 and Nanog. A further study analysing new and existing gene expression 
and location data has confirmed the key roles of Sox2, Oct4 and Nanog in mESCs, and 
identified coregulators, including Sal-like 4 (Sall4), Liver receptor homologue 1 (Lrh1), 
Stat3 and Estrogen related receptor β (Esrrb), allowing a regulatory network to be 
constructed (Zhou et al. 2007). The central role of these transcription factors is not 
exclusive to mammalian pluripotency: the Oct4 homologue PouV and Nanog regulate 
pluripotency in chick ESCs (Lavial et al. 2007). 
In addition, a recent study has extended the core transcriptional network beyond 
that of Oct4, Sox2 and Nanog in mESCs (Kim et al. 2008). The target promoters of the 
genes for nine transcription factors, including Oct4, Sox2, Krüppel-like factor 4 (Klf4), c-
Myc and Nanog, were identified. Promoters bound by a few of these transcription factors 
tended to be inactive or repressed, whereas those bound by more than four factors were 
expressed. In addition, targets of c-Myc generally fell into a different cluster than the other 
transcription factors, indicating a role in cell proliferation and the regulation of 
chromosomal accessibility rather than in pluripotency per se.  
 
1.7.5 Additional Transcription Factors which Promote Pluripotency  
1.7.5(i) RE1-silencing transcription factor 
 RE1-silencing  transcription  factor (Rest) is a major transcriptional repressor of 
neurogenesis (Ballas and Mandel 2005; Coulson 2005; Majumder 2006; Ooi and Wood 
2007). It is expressed at high levels in mESCs (Ballas et al. 2005), where it acts to 
maintain self-renewal and pluripotency by suppressing the microRNA miR-21, resulting in 
a loss of miR-21 mediated repression of Oct4, Nanog and Sox2 (Singh et al. 2008). 
 
1.7.5(ii) Zinc finger protein of the cerebellum 3 
  Zinc finger protein of the cerebellum 3 (Zic3) is a proposed target of Oct4, Sox2 
and Nanog in human and mouse ESCs (Boyer et al. 2005; Loh et al. 2006; Lim et al.  33
2007). It is proposed to prevent endodermal marker expression, via direct or indirect 
regulation of Nanog, in mESCs (Lim et al. 2007).  
 
1.7.5(iii) Sal-like 4 
Sal-like 4 (Sall4) plays a critical role in maintaining mESC pluripotency by 
modulating Oct4 expression (Elling et al. 2006; Zhang et al. 2006). It also interacts with 
Nanog and co-occupies Nanog genomic sites in mESCs; and Sall4 and Nanog regulate 
their own and each other’s transcription (Wu et al. 2006), similar to the relationship 
between Oct4 and Sox2. 
 
1.7.5(iv) Liver receptor homologue 1 
Liver receptor homologue 1 (Lrh1) is expressed in the ICM and epiblast and knock-
out is embryonically lethal with loss of Oct4 expression. It activates Oct4 reporter gene 
expression by binding to steroidogenic factor 1 (SF1) response elements
 in the proximal 
promoter and proximal enhancer of the Oct4 gene (Gu et al. 2005).
   
 
1.7.5(v) Forkhead box D3 
Forkhead box D3 (FoxD3), a member of the forkhead family of transcription 
factors, is expressed in human and mouse ESCs and in mouse epiblast and neural crest 
cells (Hanna et al. 2002). It is required for maintenance of the multipotent mammalian 
neural crest (Teng et al. 2008). FoxD3-null embryos die at E6.5 with a loss of epiblast and 
expansion of the proximal extraembryonic, endodermic and ectodermic tissues, and a lack 
of primitive streak. Oct4, Sox2 and Fgf4 expression are normal at E3.5; therefore, FoxD3 is 
thought to act downstream of Sox2 and Oct4. FoxD3 is not required for establishment of 
the ICM but for maintenance of the epiblast and the TE lineage in mouse embryos 
(Tompers  et al. 2005). Oct4 inhibits FoxD3 activation of the FoxA1 and FoxA2 
endodermal promoters in vitro (Guo et al. 2002). 
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1.7.5(vi) Krüppel-like Factors 
Interest in Krüppel-like factors (Klfs) stems from the use of Klf4 in groundbreaking 
reprogramming experiments initiated by the group of Professor Yamanaka: somatic cells 
transduced with Klf4, Oct4, Sox2 and c-Myc become pluripotent (Takahashi and Yamanaka 
2006). However, Klf4 alone is not required for the maintenance of pluripotency in ESCs. It 
appears there is a degree of redundancy within the Klf gene family group: simultaneous 
depletion of Klf2, Klf4 and Klf5 leads to mESC differentiation (Jiang et al. 2008). These 
Klf proteins share many common target genes with Nanog, and regulate key pluripotency 
genes, including Nanog itself (Jiang et al. 2008). Klf4 is part of an extended pluripotency 
maintaining network identified in mESCs, where it is proposed to act upstream of Oct4, 
Sox2 and Nanog, and also occupy the c-Myc promoter (Kim et al. 2008). 
 
1.7.6 MicroRNAs 
MicroRNAs (miRNAs) are small (~21 nucleotide) RNAs which are processed from 
larger RNA molecules by the RNase III enzymes Drosha and Dicer. These small RNA 
molecules are then loaded into an RNA-induced silencing complex (RISC), where they 
induce mRNA degradation by base pairing with their complementary mRNA molecules. 
This degradation is catalysed by argonaute proteins - catalytically active members of the 
RISC complex. Thereby, genes containing sequences complementary to the small RNA 
molecules are silenced or down-regulated (Ruvkun 2001). Studies suggest that miRNAs 
play fundamental roles in ESCs. Human and mouse ESCs express a unique repertoire of 
miRNAs (Suh et al. 2004; Calabrese et al. 2007), and the miR-302 family in hESCs is 
orthologous to the zebrafish miR-430 family, expression of which is critical for 
development (Giraldez et al. 2006). Loss of Dicer causes differentiation defects in mESCs: 
the ESCs do not contribute to chimaeric mice or generate teratomas in vivo, and have 
limited differentiation in vitro (Kanellopoulou et al. 2005). The loss of Dgcr8, a protein 
involved in miRNA maturation, affects differentiation of mESCs: during retinoic acid-
induced differentiation, cells do not fully down-regulate pluripotency markers and they 
retain the ability to produce ESC colonies (Wang et al. 2007). miRNAs also regulate de 
novo DNA methylation in differentiating mESCs (Sinkkonen et al. 2008).  
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1.8 Signal Transduction Pathways 
1.8.1 LIF/STAT3 Pathway 
STAT proteins play a role in transmitting signals from the membrane to the 
nucleus. When cytokines bind to their cell surface receptors, the receptor-associated JAK 
tyrosine kinases become activated and in turn phosphorylate a single tyrosine residue in the 
STAT molecule. Phosphorylated STATs enter the nucleus as dimers and bind to and 
activate transcription at gene promoters. STAT3 mediates signalling in response to the 
glycoprotein 130 (gp130) family of cytokines, which includes interleukin 6 (IL6), 
oncostatin M (OSM) and LIF. Disruption of the mouse Stat3 gene is embryonic-lethal 
(Takeda  et al. 1997). mESCs can be maintained under feeder-free conditions
  with the 
addition of LIF to the medium (Smith et al. 1988; Williams et al. 1988). LIF mediated self-
renewal of mESCs requires Stat3 activation (Niwa et al. 1998; Raz et al. 1999; Kristensen 
et al. 2005). However, LIF/STAT3 signalling fails to maintain self-renewal of hESCs 
(Daheron et al. 2004; Humphrey et al. 2004). This indicates that mechanisms governing 
pluripotency in mouse and human ESCs differ, and that there is an unidentified factor 
secreted by feeder cells which promotes hESC self-renewal. The LIF receptor (LIFR) 
consists of two subunits: gp130, which is common
 to all the cytokines from the IL6 family, 
and LIFRβ
 (or gp190), specific for LIF (Taga and Kishimoto 1997). The combination
 of 
IL6 and soluble IL6 receptor also interacts with and activates
 a homodimer of gp130 and 
has been used to maintain mESCs
 without involvement of the LIFR (Nichols et al. 1994; 
Yoshida et al. 1994). 
 
1.8.2 MAPK/ERK Pathway 
It appears that multiple signalling molecules may converge to activate MAPK/ERK 
(mitogen-activated protein kinase kinase/extracellular regulated kinase) signalling in ESCs. 
LIF treatment of mESCs increases MAPK activity (Boeuf et al. 1997) and induces 
phosphorylation of ERK1 and ERK2 (Burdon et al. 1999). The bridging factor between the 
LIFR and MAPK is the tyrosine phosphatase SHP-2, implicated in ESC proliferation and 
differentiation (Niwa et al. 1998; Qu and Feng 1998). In mESCs, MAPK/ERK signalling 
interferes with self-renewal, and mESCs show high ERK activity when they are stimulated 
to undergo differentiation (Burdon et al. 2002). MAPK/ERK kinases are targets of the FGF 
pathway in hESCs, and, in contrast to mESCs, high basal MAPK/ERK activity is required  36
to maintain pluripotency. MAPK/ERK signalling cooperates with PI3K/AKT signalling in 
maintaining pluripotency (Section 1.8.3). However, in contrast to PI3K/AKT signalling, it 
has no effect on regulating hESC proliferation or survival (Li et al. 2007).  
 
1.8.3 PI3K/AKT Pathway 
  Phosphoinositide-3 kinases (PI3K) are a family of lipid kinases whose products 
PI(3,4)P2 and PI(3,4,5)P3 act as intracellular messengers and are implicated in a wide 
range of cellular processes, including cell proliferation and survival (Vanhaesebroeck and 
Waterfield 1999; Vanhaesebroeck et al. 2001). Akt is a serine/threonine kinase and acts 
downstream of PI3K. PI3K activation promotes mESC proliferation (Takahashi et al. 
2003), and might also be crucial for self-renewal (Takahashi et al. 2005). Inhibition of 
PI3K and Akt induces differentiation of mESCs suggesting that PI3K/Akt signalling is 
necessary for mESC pluripotency (Paling et al. 2004). Activation of Akt signalling can 
maintain mESC pluripotency independent of Wnt/β-catenin signalling (Section 1.8.4) 
(Watanabe et al. 2006). PI3K-mediated signalling is also important for the maintenance of 
hESC pluripotency (Armstrong et al. 2006). A mechanism for PI3K signalling in 
pluripotency may relate, at least in part, to its ability to maintain Nanog expression (Storm 
et al. 2007). The growth factors LIF and FGF2, which are required for mESC pluripotency, 
activate PI3K/Akt signalling (Jirmanova et al. 2002; Xu et al. 2005). In addition, PI3K/Akt 
signalling suppresses apoptosis in mESCs (Gross et al. 2005) and hESCs (Pyle et al. 
2006). 
 
1.8.4 Wnt Pathway 
Wnts are secretory proteins which regulate gene expression, cell differentiation and 
proliferation (Wodarz and Nusse 1998). Activation of the Wnt pathway by use of the 
glycogen synthase kinase-3 (GSK3) inhibitor 6-bromoindirubin-3 can maintain human and 
mouse ESC pluripotency independently of LIF/STAT3 signalling (Sato et al. 2004). 
However, Ogawa et al. demonstrated that Wnt signalling is not sufficient to maintain self-
renewal but enhances the effect of LIF in doing so in mESCs (Ogawa et al. 2006). 
Conditioned medium from Wnt3a-expressing cells can maintain mESC pluripotency 
(Singla et al. 2006). In contrast to other signalling pathways, Wnt signalling appears to 
play the same role in human and mouse ESCs. Wnt signalling up-regulates Stat3  37
expression, and therefore may also converge on the LIF/Stat3 pathway (Hao et al. 2006). 
In addition, Wnt signalling up-regulates c-Myc, also a Stat3 target (Cartwright et al. 2005; 
Kristensen et al. 2005) implicated in mESC pluripotency (Kim et al. 2008). LIF elevates 
levels of β-catenin, a component of the Wnt pathway, which, via an interaction with Oct4, 
up-regulates Nanog (Anton et al. 2007; Takao et al. 2007).  
 
1.8.5 TGFβ/Activin/Nodal Pathways 
Several studies indicate that members of the TGFβ superfamily function in ESC 
pluripotency. The TGFβ family contains over 40 members, including TGFβ, Activin, 
Nodal and Bone morphogenetic proteins (BMPs) (Roberts et al. 1986; Massague 1998). 
Members signal by binding to a heteromeric complex of type I and type II receptors 
(Heldin et al. 1997). TGFβ and Activin have high affinity for type II receptors whereas 
BMPs have higher affinity for type I receptors (Valdimarsdottir and Mummery 2005). 
Binding causes the type II receptor kinase to phosphorylate the type I receptor, which 
activates intracellular signalling cascades, including Smad pathways. Activated Smads 
form complexes with a common partner Smad, i.e. Smad 4, translocate into the nucleus 
and regulate the expression of target genes in cooperation with various transcription 
factors. 
Smad4-null mice display defective epiblast proliferation and retarded ICM 
outgrowth (Sirard et al. 1998). Nodal-null mice show reduced epiblast size with markedly 
reduced Oct4 expression (Conlon et al. 1994; Robertson et al. 2003). TGFβ, Activin and 
Nodal activate Smad2/3 (Valdimarsdottir and Mummery 2005); and activation of Smad2/3 
is required for maintenance of the undifferentiated state (James et al. 2005). TGFβ and 
correlated factors, Nodal, Cripto, Lefty1 and Lefty2, are expressed at high levels in hESCs 
(Sato et al. 2003), as are genes downstream of TGF superfamily signalling (Zeng et al. 
2004). In addition, Activin A may be sufficient to maintain pluripotency of hESCs without 
conditioned medium or STAT3 activation (Beattie et al. 2005; Xiao et al. 2006). Over-
expression of Nodal in hESCs can block neuroectoderm differentiation, and its expression 
disappears upon differentiation (Vallier et al. 2004). Inhibition of the Activin/Nodal/TGFβ 
signalling pathway induces differentiation of hESCs (Vallier et al. 2005).  
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1.8.6 FGF2 Pathway 
Human and mouse ESCs are routinely cultured in the presence of FGF2 (Evans and 
Kaufman 1981; Thomson et al. 1998). hESCs express four FGF receptors, particularly 
FGFR1, along with some components of their downstream cascades (Bhattacharya et al. 
2004; Brandenberger et al. 2004; Dvash et al. 2004; Ginis et al. 2004). Modulation of FGF 
signalling via FGFR1- or FGFR2-null mice, or via FGF2 mutants, alters blastocyst 
development (Deng et al. 1994; Chen et al. 2000; Esner et al. 2002), and inhibition of 
FGFR signalling causes hESC differentiation (Dvorak and Hampl 2005). hESCs are 
maintained with either 4 or 10 ng/ml FGF2. 40 ng/ml FGF2 combined with noggin, which 
inhibits a BMP4-like activity in Knock-Out Serum Replacement (Invitrogen), or 100 ng/ml 
FGF2 alone, maintains hESCs in the absence of feeders (Dvorak et al. 2005; Wang et al. 
2005; Xu et al. 2005). FGF2 may function by mediating chromatin remodelling (Song and 
Ghosh 2004), or by acting on FGF response elements (FREs), which serve to integrate 
FGF signalling with that of other growth factors (Haremaki et al. 2003). FGF signalling is 
necessary, but not sufficient to maintain pluripotency, and effects depend on the TGFβ 
pathway (Vallier et al. 2005). FGF2 can inhibit BMP activity by preventing the nuclear 
translocation of phosphorylated Smad1 (Xu et al. 2005); however, this does not account 
for all of its effects (Vallier et al. 2005). FGF2 can also up-regulate telomerase activity in 
human endothelial cells (Kurz et al. 2003), which may explain another mode of action in 
hESCs; however, this is, as yet, undemonstrated. MEFs produce factors which maintain 
hESCs, evidenced by the fact that hESCs can be maintained by culture with MEF-
conditioned medium. FGF2 treatment of MEFs is required for the production of these 
factors: a recent study has suggested that FGF2 has an indirect effect on hESCs by 
inducing the production of supportive factors from feeders, including TGFβ factors and 
IGFII (insulin-like growth factor-II), which then act directly on hESCs (Bendall et al. 
2007). Another study showed that FGF2-regulated genes in MEFs include inhibin β, which 
leads to the assembly of Activin B, and gremlin 1, which encodes for an antagonist of 
BMPs (Diecke et al. 2008).  
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1.8.7 Heparan Sulphate Chains 
A recent study has implicated heparan sulphate (HS) chains as a central mediator in 
self-renewal and pluripotency in mESCs, by responding to various extrinsic signalling 
factors. Wnt/β-catenin signalling mediated by HS chains regulates Nanog expression, and 
FGF and BMP/Smad signalling is regulated by HS chains (Sasaki et al. 2008). 
 
The above regulatory factors and pathways have been demonstrated in ESCs, and 
in some cases ECCs, and while the mechanisms governing pluripotency are assumed to be 
similar in EGCs, this has not been proven. This is particularly true for hEGCs, which are 
notoriously difficult to derive and culture. This thesis describes work focussed on 
investigating the human germ cell lineage, in particular to determine whether the 
fundamental regulators of pluripotency and self-renewal are expressed in hEGCs. Herein 
follows a brief introduction to the germ cell lineage, followed by a more detailed 
description of EGCs and an overview of the questions addressed by this thesis.  
  
1.9 The Germ Cell Cycle 
Germ cells mediate the transmission of an individual’s genome to future 
generations. In contrast to somatic cells, which make up an organism and die with it, germ 
cells form the organisms for subsequent generations (Figure 1.7). PGCs, the founder cells 
of the germ cell lineage, are usually established early during embryonic development. 
Specification can either occur through the inheritance of germ cell determinants already 
present in the egg, as in Drosophila melanogaster and Caenorhabditis elegans, or in 
response to inductive signals, as for mice and probably all mammals. 
 
1.10 Origin of Primordial Germ Cells 
In D. melanogaster and C. elegans, founder PGCs are set aside at the outset of 
embryogenesis from the totipotent cells and prevented from differentiating into somatic 
cells by repression of the global transcriptional machinery (Strome and Lehmann 2007). 
Determinants of somatic cells and germ cells are already segregated in specific regions of 
the oocyte. In mammals however, no such determinants are already set aside in the oocyte;  40
the germ cell fate is imposed on pluripotent cells of the epiblast, induced by signals from 
extraembryonic tissues. 
 
 
 
Figure 1.7 The germ cell life cycle  
Fertilisation (top) is the point at which the gametes (sperm and oocyte) fuse; this 
generates a diploid zygote, which undergoes differentiation and mitosis, forms a 
blastocyst and implants into the uterine endometrium. During gastrulation, the process 
by which germ layers become positioned in the embryo, germ cell precursors 
(primordial germ cells) are set aside, then migrate to the gonads, undergo meiosis, 
mature, and eventually form haploid spermatozoa and ova in the mature organism. 
[Reproduced from the NIH Stem Cell Information website 
(http://stemcells.nih.gov/info/scireport/appendixA.asp).] 
 
To describe PGC development, it is firstly necessary to briefly review early mouse 
embryonic development (aspects of which are depicted in Figure 1.8). At around the time 
of implantation (E4.0-4.5) the blastocyst is composed of trophoblast cells enclosing the 
undifferentiated ICM. The ICM subsequently differentiates into an inner epiblast, or 
embryonic ectoderm population, and an outer primitive, or extraembryonic visceral 
endoderm. After implantation, the trophoblast forms the extraembryonic ectoderm and the 
epiblast forms a ‘cup-shaped’ epithelium. Gastrulation, the formation of the germ layers  41
(Figure 1.3), begins around E6.0. Proximal epiblast cells move posteriorly, lose epithelial 
organisation, and give rise to unpolarised mesodermal cells. The first cells to delaminate 
from the epiblast give rise to extraembryonic mesoderm, whereas cells that drop out later 
give rise to embryonic mesoderm in the primitive streak [reviewed in Hogan (2001)].   
Germ cells originate in the pluripotent proximal epiblast at about E6.0 (Figure 1.8) 
when cells respond to signals from extraembryonic tissues and begin to express 
Fragilis/Interferon induced transmembrane protein 3 (Ifitm3) (Saitou et al. 2002). Fragilis 
is an interferon-inducible gene, and was thought to mediate migration (Tanaka et al. 2005) 
until the demonstration that knock-out mice show normal germline development (Lange et 
al. 2008). It is only expressed transiently, being down-regulated as the cells migrate, 
although it is re-expressed later. At E6.25, about six of these cells begin to show 
expression of Blimp1: these cells are PGC precursors (Ohinata et al. 2005), although 
further cells are recruited to become PGCs before E7.25 (Saitou et al. 2002; McLaren and 
Lawson 2005; Ohinata et al. 2005). Blimp1 is a transcriptional repressor which is partially 
responsible for repressing the somatic program in PGCs while allowing establishment of 
germ cell character (Ohinata et al. 2005; Vincent et al. 2005). Blimp1 expression confers 
competent cell lineage restriction on a PGC, but not yet specification. At around E7.0, the 
PGCs express Stella, which they retain during migration toward and into the genital ridges 
(Saitou et al. 2002). 
 
1.10.1 Signals for Specification 
BMP4 and 8b from the extraembryonic ectoderm and BMP2 from the visceral 
endoderm are critical for PGC specification: loss of any of these signalling molecules leads 
to partial or complete loss of PGCs (Lawson et al. 1999; Ying et al. 2000; Ying and Zhao 
2001). BMP4 acts via Alk2, a type 1 BMP receptor in the visceral endoderm surrounding 
the proximal epiblast (de Sousa Lopes et al. 2004). Activation leads to the phosphorylation 
of serine residues on Smad1/5/8, causing translocation to the nucleus with Smad4. Loss of 
Smad1, 4 and 5 result in severe reduction in PGC number (Chang and Matzuk 2001; 
Tremblay et al. 2001; Hayashi et al. 2002). Along with the repression of somatic gene 
expression, the expression of genes which establish/maintain pluripotency are retained 
from the epiblast, including Sox2, Nanog, Oct4 and Embryonal stem cell
 gene 1 (Esg1) 
(Ohinata et al. 2005; Western et al. 2005; Yamaguchi et al. 2005; Yabuta et al. 2006; 
Chambers et al. 2007). However, despite the expression of these key pluripotency genes,  42
mouse PGCs are nullipotent: unlike pluripotent ESCs they do not contribute to any tissues, 
either somatic or germ line if they are transferred into blastocysts (Durcova-Hills et al. 
2006) 
 
 
Figure 1.8 Model for the development of PGCs in the mouse embryo 
At E4.5, the blastocyst consists of an outer layer of trophoblast (Troph) surrounding 
the epiblast (Ep; green) and the primitive or visceral endoderm (orange). By E5.5-6.0 
the epiblast has given rise to the embryonic ectoderm (Ect) and the trophoblast has 
formed the extraembryonic ectoderm (Xe). Signals from the Xe, including bone 
morphogenetic protein 4 (BMP4) and BMP8b (blue arrows) induce PGC precursors 
(open circles) in the proximal epiblast. These move from anterior to posterior (A-P; 
green arrow). By E7.5, mesoderm has been generated (red) in the primitive streak and 
extraembryonic region (Xm). Descendants of the PGC precursors are allocated to 
either the extraembryonic mesoderm or PGC (filled circles) lineages. [Reproduced 
from Hogan (2001).] 
 
Following establishment of the germ cell lineage, there is an extensive 
reprogramming of the genome, i.e. erasure of epigenetic marks and establishment of new 
marks (Surani 2001; Hajkova et al. 2002). Imprinting must be reprogrammed in the germ 
line, as a maternal allele in one generation may be a paternal allele in the next. PGCs do 
initially acquire genome wide de novo methylation; however, following entry into the 
gonadal ridge, there is rapid demethylation, simultaneously in male and females, prior to 
their sex-specific differentiation. The timing of erasure in humans is not known, but in 
mice it begins between E10.5 and E11.5, i.e. after arrival in the gonadal ridge (Lee et al. 
2002).   43
1.10.2 PGC Migration 
PGCs migrate from the allantois through the gut mesentery to the genital ridges of 
the developing gonad (Figure 1.7). This migration occurs at approximately E10.5 in the 
mouse and between weeks 5 and 8 of human gestation, and has been followed in the mouse 
using germ cells which express green fluorescent protein (GFP) (Molyneaux et al. 2001). 
Studies in mice have identified various molecules involved in the migratory process. The 
chemokine stromal-cell derived factor 1 (Sdf1), expressed in high levels in the gonad and 
genital ridge, is released from somatic cells and acts on the chemokine (C-X-C motif), 
receptor 4b (Cxcr4b), on the germ cell surface (Guardavaccaro et al. 2000; Stebler et al. 
2004). The importance of the Sdf1-Cxcr4b signal was demonstrated in mice lacking the 
ligand or the receptor; fewer germ cells were able to reach the gonadal ridge and total PGC 
number was reduced. In addition, Sdf1 influenced the migration of PGCs expressing GFP. 
A second Sdf receptor, Cxcr7, has been identified as being required for migration in 
zebrafish: interestingly, it does not function as a signalling receptor, but sequesters Sdf1 
thereby reducing levels in the extracellular environment (Boldajipour et al. 2008).  
Additional molecules thought to be involved in migration include the c-Kit receptor 
tyrosine kinase, expressed by PGCs, and its ligand, stem cell factor (SCF)
7, expressed by 
somatic cells along the migratory route. An interaction between these molecules may 
support the migration and survival of the PGCs, as disruption leads to germ cell apoptosis 
and reduced numbers reaching the gonadal ridge (De Miguel et al. 2002). Mutations in 
either  Steel (which codes for SCF) or W (which codes for c-Kit) interfere with PGC 
proliferation and migration (Mintz and Russell 1957; Donovan 1994), and in extreme 
mutants few PGCs, if any, reach the gonadal ridge (Buehr et al. 1993). However, the 
reduced number of germ cells do become distributed along the hindgut, which may be a 
passive mechanism. Knock-out/mutation of β2 integrin (Anderson et al. 1999), Fgf8 (Sun 
et al. 1999) and the germ cell deficient (gcd) locus (Pellas et al. 1991) also interfere with 
germ cell migration indicating these gene products are also involved. 
 
                                                 
7 Also known as steel factor (SF), mastocyte growth factor (MGF) or kit ligand (KL).  44
1.10.3 PGCs in the Gonad: Sex Determination 
By E11.5-12.5 in the mouse, PGCs which have not reached the gonads undergo 
apoptosis (Stallock et al. 2003). The altered environment of the gonad induces several 
changes in the germ cells: they acquire a more rounded morphology, and the dead-box 
transcription factor Deadbox 4 (Ddx4) is expressed. Ddx4 is the mouse orthologue of the 
Drosophila Vasa gene, also known as mouse Vasa homologue (Mvh), which encodes an 
ATP-dependent RNA
 helicase essential for male germ cell proliferation and subsequent 
differentiation (Tanaka et al. 2000). After entering the genital ridges, the cells continue to 
proliferate for two days with a doubling time of approximately 16 hours. By E12.5, germ 
cells in female and male embryos enter a pre-meiotic stage and up-regulate meiotic genes 
such as Synaptonemal complex protein 3 (Scp3) (Di Carlo et al. 2000; Chuma and 
Nakatsuji 2001). At about E13.5, the germ cells in the female gonad proceed into prophase 
of the first meiotic division, progressing through leptonema, zygonema, pachynema and 
diplonema, and they enter a prolonged arrest stage termed dictyate around the time of birth 
(Speed 1982). They remain in this stage until just before ovulation, when they complete the 
first meiotic division, begin the second, and arrest again; meiosis is completed only at 
fertilisation. Germ cells enter meiotic prophase at about the same time even if outside the 
genital ridge, for example in the adrenal gland (Zamboni and Upadhyay 1983; McLaren 
1995), or on a feeder layer in vitro (Chuma and Nakatsuji 2001); therefore, it appears that 
the default pathway for a germ cell is to develop as an oocyte, unless in the male genital 
ridge. 
In the developing testis, germ cells down-regulate meiotic genes and enter mitotic 
arrest in G0/G1 as prospermatogonia between E12.5 and E14.5 (Western et al. 2008), 
resuming mitosis after birth (McLaren 1984), with meiosis delayed until well after birth 
(McLaren 1988). At 5 days postnatum in the mouse, primary spermatocytes can be seen, 
indicating some spermatogonia have entered meiosis. This is the equivalent stage to 
puberty in humans. Primary spermatocytes then complete both meiotic divisions promptly 
to generate spermatids, which mature further into spermatozoa (for a detailed description, 
see Chapter 4, Figure 4.1). Waves of meiosis continue throughout life, generating sperm 
from spermatogonial stem cells which reside at the periphery of the testis cords. 
Exposure to retinoic acid and the function of the Stimulated by retinoic acid gene 8 
(Stra8) cause female germ cells in the fetal ovary to enter meiosis (Baltus et al. 2006; 
Bowles et al. 2006; Koubova et al. 2006), whereas in males mitotic arrest is induced by  45
somatic cells, probably the Sertoli cells (Adams and McLaren 2002). Male specific 
expression of Cyp26b1, a P450 enzyme that degrades all-trans retinoic acid, inhibits 
meiosis in the fetal testis (Bowles et al. 2006; MacLean et al. 2007). Completion of 
meiosis and formation of functional gametes are influenced by the sex chromosome 
composition of the germ cell (McLaren 1981; Bradbury 1983; Burgoyne 1987; Taketo-
Hosotani et al. 1989; Amleh et al. 2000; Park and Taketo 2003). Retinoic acid may also 
regulate meiotic progression in the pubertal testis (Bowles and Koopman 2007). 
 
1.11 Human PGCs  
Human PGC (hPGC) development is less well understood but is presumed to 
mirror that in mice. During the fifth week of human embryonic development, PGCs are 
apparent in the genital ridges and gut mesentery, and can be marked by alkaline 
phosphatase (AP) activity. The route of germ cell migration in the developing human 
embryo is depicted in Figure 1.9. 
 
 
Figure 1.9 PGC migration in the developing human embryo  
A. Path of PGC migration in the human embryo, from the allantois to the gonadal 
ridge. B. PGC migration through the gut mesentery within the dissected abdomen at 6 
weeks post-conception (wpc). The gonadal ridge (G) has developed on the medial 
surface of the mesonephros (M) adjacent to the adrenal gland (A) and superior to the 
kidney (K). C. Human embryo section corresponding to panel B showing PGCs darkly 
stained for alkaline phosphatase activity in the gonad (G) and throughout the folds of 
the gut mesentery (white arrow). Size bar represents 250 μm. [Reproduced from 
Turnpenny et al. (2006).] 
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PGC number increases rapidly in the gonad: the number of oogonia per ovary 
increases from ~26,000 in week six to ~250,000 in week nine (Bendsen et al. 2006), and 
germ cells per testis increases from ~3000 in week six to ~30,000 in week nine (Bendsen et 
al. 2003). At around 41-44 days post-conception (dpc; Carnegie Stage [CS] 17-18) male 
PGCs begin to undergo mitotic arrest, associated with Sertoli cell differentiation and 
testicular cord formation, whereas female PGCs increase in number until approximately 12 
weeks post-conception (wpc), when they undergo meiotic prophase (Gondos and Hobel 
1971). 
 
1.12 Derivation of Pluripotent ESCs from PGCs 
1.12.1 Mouse EGCs 
Early attempts at long-term mouse PGC (mPGC) culture had little success, even 
with feeder layers as had been used successfully for mESC culture. mPGCs (from 8.5-10.5 
dpc) could only be grown in culture for three to five days with feeder layers (Donovan et 
al. 1986; Godin et al. 1990; De Felici and Dolci 1991). Certain agents were found to 
enhance PGC survival and/or proliferation, including LIF, which enhances survival (De 
Felici and Dolci 1991) and forskolin, which increases intracellular cyclic adenosine 
monophosphate (cAMP), thereby promoting proliferation (De Felici et al. 1993). In 
addition, a number of groups reported that SCF was essential for PGC survival, and that 
the PGC life-supporting effect of STO feeder layers
8 was partly due to the production of 
this growth factor (Dolci et al. 1991; Godin et al. 1991; Matsui et al. 1991). SCF was also 
found to promote PGC proliferation (Matsui et al. 1991). SCF and LIF promote PGC 
survival by suppressing apoptosis (Pesce et al. 1993), and SCF activates telomerase (Dolci 
et al. 2002). However, these in vitro cultures had a finite proliferative capacity (Donovan 
et al. 1986; De Felici and Dolci 1991; Dolci et al. 1991; Godin et al. 1991; Matsui et al. 
1991), which correlated with the timing of their mitotic arrest (male) or the beginning of 
meiosis (female) in vivo.   
In 1992, two groups found that the addition of FGF2 to PGC cultures already 
containing LIF and membrane-bound SCF enhanced the growth of PGCs and allowed their 
continued proliferation beyond the time when they normally stopped dividing in vivo 
                                                 
8 STO is a mouse embryonic fibroblast cell line (S, SIM; T, 6-thioguanine resistant; O, ouabain  
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(Matsui  et al. 1992; Resnick et al. 1992). The cells formed colonies of AP-, SSEA1-
positive cells, that resembled ESCs and differentiated in vitro and in vivo, contributing to a 
variety of tissues in chimaeras, including the germ line (Labosky et al. 1994; Stewart et al. 
1994). These cells, termed embryonic germ cells (EGCs), have since been derived from 
PGCs before and during migration (E8.5-9.5), and from PGCs in the genital ridge up to 
E13.5 (Matsui et al. 1992; Resnick et al. 1992; Labosky et al. 1994; Stewart et al. 1994; 
Tada et al. 1998; Durcova-Hills et al. 2001; Shim et al. 2008). It is presumed that after this 
point mitotic arrest in males and the entry into the first stage of meiosis in females prevents 
successful EGC derivation.  
The major difference between ESCs and EGCs is that the PGCs from which EGCs 
are derived may have undergone the epigenetic changes that characterise the germ cell 
lineage, including demethylation and erasure of epigenetic marks. However, recent studies 
have indicated that the methylation pattern of imprinted genes in EGCs do not accurately 
reflect those of their parental PGCs (Durcova-Hills et al. 2001; Hajkova et al. 2002). 
During EGC derivation, de novo methylation occurs in the Igf2 and H19 genes in EGCs, 
with EGCs from the male gonad showing higher levels of methylation (Tada et al. 1998; 
Shim et al. 2008).  
 
1.12.2 Human EGCs 
Human EGCs (hEGCs) were first derived in 1998 by Shamblott et al., and 
subsequently by additional groups (Turnpenny et al. 2003; Liu et al. 2004; Aflatoonian and 
Moore 2005; Pan et al. 2005). Material is obtained from first trimester termination, 
specifically human fetuses aged 5-9 wpc. PGCs are prepared for culture by mechanical 
disaggregation of the fetal gonad, with or without additional enzymatic digestion, and cells 
are plated onto a feeder layer of STO. Compared to mEGC derivation, the efficiency for 
generating hEGCs is low. hEGCs fulfill some criteria for pluripotency; they differentiate in 
vitro as EBs, containing derivatives of all three germ layers (Shamblott et al. 1998; 
Turnpenny et al. 2003; Aflatoonian and Moore 2005; Pan et al. 2005); however, no group 
has reported teratomas in immunocompromised mice following injection of hEGCs, 
attempted within our group (Turnpenny et al. 2006).  
Despite the reprogramming which occurs in the germ line, monoallelic expression 
and methylation of imprinted genes has been observed in hEGC derivatives, and hEGCs 
derived from the gonadal ridge do not appear to have undergone epigenetic erasure  48
(Onyango et al. 2002). This indicates that imprinting may not be a significant barrier to 
hEGC transplantation. Encouragingly, hEGCs show therapeutic potential in transplantation 
therapy: hEGC-derived neural stem cells can successfully engraft, differentiate, and 
replace cells in the damaged neonatal mouse brain (Mueller et al. 2005), and hEGC-
derived EB cells differentiate towards a musculoskeletal lineage in vitro (Kim et al. 2005). 
In addition, hEGC derivatives facilitate motor recovery of rats with diffuse motor neuron 
injury by enhancing host neuron survival and function (Kerr et al. 2003). 
 
1.12.3 Mechanisms Underlying PGC-EGC Conversion   
 Relatively  little  is known regarding the mechanism behind the conversion of PGCs 
to EGCs. Knock-out of the tumour suppressor gene phosphatase and tensin homologue 
(PTEN) results in mice whose PGCs convert more readily to EGCs, although LIF, FGF2 
and SCF are still required. This may increase
 signals for PI3K, a downstream molecule
 for 
signalling via LIF, FGF2 and SCF (Kimura et al. 2003). Further investigations 
demonstrated that Akt activation increases EGC formation in a similar manner (Kimura et 
al. 2008). Akt is a serine/threonine kinase, one of the downstream effectors of PI3K: this 
signalling pathway plays an important role in the regulation of ESC pluripotency [(Paling 
et al. 2004; Ivanova et al. 2006; Watanabe et al. 2006) and Section 1.8.3].  49
1.13 This Thesis 
Compared to mouse and human ESCs, and mEGCs, hEGCs are notoriously 
difficult to derive and culture. Work delineating the mechanisms governing pluripotency, 
maintenance and differentiation in human stem cells has been conducted in hESCs. 
Continued research into hEGCs might provide further insights into these mechanisms,   
which may differ among different cell populations and/or between species. As well as 
having potential therapeutic benefit, research may provide insights into testicular germ cell 
tumours (TGCTs), which are of increasing frequency in the Western world. Studies may 
also provide useful information for the in vitro generation of gametes from human stem 
cells for future fertility treatments. For these reasons, the chapters of this thesis investigate:  
 
•  Chapter 3: Expression of ‘pluripotency regulators’ within the human germ 
cell  lineage 
hEGCs, while demonstrating pluripotency, fail to maintain this in long-term culture. 
This contrasts with mEGCs, and human and mouse ESCs. In addition, teratoma formation 
in vivo from hEGCs, a criterion for pluripotency, has not been described. Work within this 
chapter examines the expression of the key regulators of pluripotency, OCT4, SOX2 and 
NANOG, and their proposed target genes, in hEGCs and their starting population, hPGCs, 
in comparison with the other pluripotent cell types. 
 
•  Chapter 4: SOX2 expression in normal and neoplastic germ cell derivatives 
and its association with pluripotency 
Despite varying phenotypes, all TGCTs originate from a common precursor, the 
carcinoma in situ (CIS) cell, which is of germ cell antecedence. Previous studies have 
demonstrated that the transcription factor SOX2 is expressed by nonseminomas (which 
contain a pluripotent stem cell component) but is absent from seminomas. This chapter 
seeks to verify these findings and also extends analysis to examine SOX2 expression in 
CIS cells and during normal testicular development. 
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•  Chapter 5: Investigation of the role of the OCT4-SOX2-NANOG transcription 
factor complex in pluripotency 
The transcription factors OCT4, SOX2 and NANOG have been proposed to 
maintain pluripotency in human and mouse ESCs. Whilst expression of OCT4 and 
NANOG is restricted to PGCs after gastrulation, SOX2 is also expressed in embryonic and 
fetal tissues during development. In work described within this chapter, SOX2-positive 
cells are isolated from the human embryo/early fetus and culture methods optimised to 
grow the cells in vitro with retention of SOX2 expression. The expression of SOX2 target 
genes is examined, and attempts made to introduce OCT4 and NANOG, to determine 
whether establishing expression of the SOX2-OCT4-NANOG transcription factor complex 
in the cells induced pluripotency.   
   
•  Chapter 6: Identification of candidate genes for germ cell proliferation 
This chapter describes efforts to identify factors which promote germ cell 
proliferation, by performing an expression microarray on RNA isolated from developing 
ovary and testes aged approximately eight weeks post-conception. At this stage of 
development, male germ cells have entered mitotic arrest whereas female germ cells are 
still proliferating. It is hypothesised that genes showing higher expression in the 
developing ovary may be involved in promoting germ cell proliferation. An initial RT-
PCR screen is conducted to confirm differential gene expression, in order to draw up a 
short-list of likely candidate genes for further investigation. 
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CHAPTER 2: Methods  52
2.1 Preparation of Tissue Sections   
2.1.1 Carnegie Staging of Human Embryos   
The collection and use of human embryonic and fetal material was carried out 
following ethical approval from the Southampton & South West Hampshire Local 
Research Ethics Committee [Appendix 3 (i)-(iii)], under guidelines issued by the 
Polkinghorne committee (Polkinghorne 1989). Written consent for the use of embryos was 
obtained from women undergoing termination of pregnancy. Human embryos were 
collected following surgical termination of pregnancy and staged by stereomicroscopy 
according to the Carnegie classification [Table 2.1; O’Rahilly and Muller (1987); Bullen 
and Wilson (1997)]. Fetal material was also staged as weeks post-conception (wpc) by 
measuring foot length. 
 
Carnegie 
stage (CS) 
Human days post-
ovulation  
Equivalent mouse 
embryonic days (E) 
8 18  7.5 
9 20  7.5-8.5 
10 22  8.5-9.0 
11 24  9.0-9.5 
12 26  9.5-10.25 
13 28  10.25-10.5 
14 32  10.5-11.0 
15 33  11.0-11.5 
16 37  11.5-12.0 
17 41  12.0-12.5 
18 44  12.5-13.0 
19 48  13.0-13.5 
20 50  13.5-14.0 
21 52  13.5-14.0 
22 54  13.5-14.0 
23 56  13.5-14.0 
 
Table 2.1 The Carnegie Classification - a precise staging of human gestation age 
[Adapted from O’Rahilly and Muller (1987); Bullen and Wilson (1997).] 
 
2.1.2 Tissue Fixation and Embedding   
Immediately following dissection, human embryos and fetal material were placed 
in RNase-free bottles, containing 4% paraformaldehyde (PFA; Sigma Chemical Co., St. 
Louis, MO, US) in phosphate buffered saline (PBS; Sigma) overnight with gentle 
agitation. Samples were dehydrated by passing sequentially through 70%, 80%, 90% and 
100% RNase-free ethanol (Fisher Scientific, Leicestershire, UK) for 2 hours each, at room  53
temperature with gentle agitation. The embryonic and fetal tissues were treated with 
chloroform (Fisher) for 16 hours to remove ethanol, followed by three changes of molten 
paraffin (2 hours each) at 72°C, the final change being under vacuum. Embryos and fetal 
tissue were embedded in paraffin (BDH, Dorset, UK), in the desired orientation and 
allowed to solidify. Embedded samples were stored at 4°C until required. 
 
2.1.3 Slide Coating   
Glass slides (22 × 60 mm; Fisher) were coated with 3-aminopropyltriethoxysilane 
(TESPA; Sigma). Batches of 24 glass slides were placed in polyacetal racks, and RNases 
inactivated by dipping in 0.1% diethyl pyrocarbonate (DEPC; Sigma) treated H2O (DEPC- 
H2O), followed by two washes in 0.1% DEPC in 96% ethanol for 5 minutes each. Slides 
were dried in a filtered air stream for 30 minutes. Slides were washed in 10% hydrochloric 
acid (HCl; Fisher) in 70% ethanol, DEPC-H2O and 96% ethanol for 1 minute each, 
followed by drying in a filtered air stream for 1 hour. Coating was carried out by 
immersion for 45 seconds in ‘dry’ acetone (Fisher) containing 2% TESPA. The RNase-free 
coated slides were rinsed six times in 0.1% DEPC-H2O, dried for 1 hour in a filtered air 
stream and then transferred to an oven overnight at 37°C. Coated slides were stored in 
RNase-free slide boxes at room temperature. 
 
2.1.4 Tissue Sectioning and Slide Mounting 
Paraffin blocks were mounted onto a dry microtome (Leica RM 2135, Leica 
Instruments, Wetzlar, Germany) in the required orientation for sectioning. Sections were 
cut at 5 μm intervals, as continuous ribbons, and placed onto RNase-free trays. Four serial 
sections were mounted onto RNase-free coated glass slides by floating on 0.1% DEPC-
H2O, heating to 45°C to expand the paraffin wax and aspirating the H2O from underneath 
the embryo section. Slides were dried in an oven at 37°C overnight and then transferred to 
RNase-free slide boxes for storage at 4°C. 
 
2.1.5 Haematoxylin & Eosin Staining   
Every ninth section (40 μm intervals) cut from paraffin blocks was taken for 
histological staining. Paraffin was removed from the slides by immersion in xylene  54
(Fisher) for 5 minutes, followed by rehydration for 3 minutes each in 100% ethanol, 70% 
ethanol and H2O. Slides were stained in Harris haematoxylin (ThermoShandon, PA, 
Pittsburgh, US) for 2-3 minutes, depending on the age of the solution, rinsed in H2O and 
immersed in acid alcohol (95% ethanol, 1% HCl) and bluing solution (0.24 M NaHCO3, 14 
mM MgSO4) for 10 seconds each. Counter-staining with eosin (ThermoShandon) for 30-40 
seconds was followed by graded dehydration for 3 minutes in 50%, 70%, then 100% 
ethanol. Slides were placed in xylene for 5 minutes before mounting in Entellan (Merck 
Laboratories, Darmstadt, Germany). 
 
2.2 Immunohistochemistry  
A modified method of indirect immunohistochemistry (IHC) was used (Figure 2.1). 
Slides were dewaxed in xylene for 5 minutes, rehydrated in 100%, 70%, then 50% ethanol, 
followed by H2O, for 3 minutes each, followed by washing in PBS. For the use of 
biotinylated HRP secondary antibody, sections were pretreated with 3% (v/v) hydrogen 
peroxide (Sigma) in PBS to quench endogenous peroxidase. Antigen unmasking was 
achieved by immersing slides in 10 mM sodium citrate buffer heated at 95°C, for 10-20 
minutes, depending on the antibody. Sections were washed once more in PBS for 5 
minutes. The primary antibody (Table 2.2) was diluted in buffer (PBS/0.1% Triton X-100) 
containing 3% serum (from the species in which the secondary antibody was raised; Vector 
Laboratories, Burlingame, CA, US), to reduce background and subsequent non-specific 
binding by secondary antibody. Sections were incubated with primary antibody in 
buffer/serum overnight at 4°C. 
Sections were washed in PBS and biotin- or fluorescently-labelled secondary 
antibodies (Figure 2.1) applied in buffer (PBS/0.1% Triton X-100) for 2 hours at 4°C, at 
appropriate dilutions as listed in Table 2.3. For biotinylated secondary antibodies, further 
washing was followed by incubation for 1 hour at 4°C with the appropriate antibody (Table 
2.3). 
Dual immunofluorescence labelling was carried out sequentially (Figure 2.1), and 
sections were coverslip-mounted using Vectashield mounting medium containing 4',6-
diamidino-2-phenylindole (DAPI; Vector Laboratories). For bright-field 
immunohistochemistry, the colour reaction was developed with diaminobenzidine (DAB; 
Merck) containing 0.1% hydrogen peroxidase for 3 minutes, then counter-stained with  55
toluidine blue and coverslip-mounted using Entellan (Merck). Image analysis utilised a 
Zeiss Axiovert/Axiovision imaging system and Adobe Photoshop processing. 
 
Figure 2.1 Indirect methods of immunohistochemistry 
The antigen was detected using a primary antibody. The protein of interest was then 
visualised either using a secondary antibody conjugated to a fluorochrome (A), or 
using biotinylated secondary antibodies followed by streptavidin detection conjugated 
to a fluorochrome (e.g. FITC; Fluorescein Isothiocyanate; TR, Texas red), or horse 
radish peroxidase (HRP) which is detected enzymatically (B). A and B techniques 
were used sequentially to achieve dual expression profiles of two antigens in the same 
cell. 
 
 
A 
Cell or tissue with 
exposed antigen 
Primary antibody 
Secondary antibody 
conjugated to fluorochrome 
(FITC, TR) 
exposed antigen 
B 
Primary antibody  Biotinylated 
secondary antibody  
Streptavidin complex conjugated to enzyme or 
fluorochrome (HRP, FITC, TR) 
exposed antigen 
Cell or tissue with 
exposed antigen  56
 
Primary antibody  Raised in  Dilution Source 
Monoclonal anti-β tubulin III  Mouse  1:500  Covance Research Products, Inc., Berkeley, 
CA, US 
Monoclonal  anti-CK19  Mouse  1:100  Novocastra Laboratories Ltd., Newcastle 
upon Tyne, UK 
Monoclonal anti-EMA1  Mouse  1:20  Developmental Studies Hybridoma Bank 
(DSHB), Iowa University, IA, US 
Monoclonal anti-GFAP  Mouse  1:500  Novocastra Laboratories Ltd. 
Monoclonal anti-OCT4  Mouse  1:100  Santa  Cruz Biotech. Inc., Santa Cruz, CA, 
US 
Monoclonal anti-SSEA1  Mouse  1:20  DSHB 
Monoclonal anti-SSEA3  Rat  1:5  DSHB 
Monoclonal anti-SSEA4  Mouse  1:5  DSHB 
Monoclonal anti-TDGF1  Mouse  1:50  R&D Systems, Abingdon, UK 
Monoclonal anti-TRA-1-60  Mouse  1:5  Gift from Prof. Peter Andrews, University of 
Sheffield, UK 
Monoclonal anti-TRA-1-81  Mouse  1:20  Gift from Prof. Peter Andrews, University of 
Sheffield, UK 
Monoclonal anti-Vimentin  Mouse  1:50  DSHB 
Polyclonal anti-CX43  Rabbit  1:200  Sigma Chemical Co., St. Louis, MO, US 
Polyclonal anti-DPPA4  Sheep  1:500  R&D Systems 
Polyclonal anti-FGF4  Rabbit  1:50  Abcam Ltd., Cambridge, UK 
Polyclonal anti-Ki67  Rabbit  1:200  Novocastra Laboratories Ltd. 
Polyclonal anti-Nanog  Goat  1:20  R&D Systems 
Polyclonal  anti-Nestin  Rabbit  1:50  Gift from Dr. Ron McKay, NIH, Bethesda, 
MD, US 
Polyclonal anti-OCT4  Goat  1:150  Santa Cruz Biotech. Inc. 
Polyclonal anti-PLAP  Rabbit   1:2000  Neomarkers, Fremont, CA, US 
Polyclonal  anti-SOX2  Rabbit  1:500  Chemicon International Inc., Temecula, CA, 
US 
 
Table 2.2 Primary antibodies used in IHC experiments 
Optimal antibody concentrations were determined by titration. 
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Secondary antibody  Dilution Source 
Biotinylated anti-rabbit  1:800  Vector Laboratories, Burlingame, CA, US 
Biotinylated anti-goat  1:300  Vector Laboratories 
Biotinylated anti-sheep  1:300  Vector Laboratories 
Biotinylated anti-mouse  1:500  Vector Laboratories 
Biotinylated anti-rat  1:100  Vector Laboratories 
FITC anti-mouse  1:64  Sigma Chemical Co., St. Louis, MO, US 
FITC anti-goat  1:64  Sigma 
Texas red anti-rat  1:100  Vector Laboratories 
Alexa Fluor 594 anti-rabbit  1:200  Molecular Probes, Inc, Invitrogen Life 
Technologies, Paisley, UK 
Alexa Fluor 594 anti-mouse  1:200  Molecular Probes, Inc 
Streptavidin horseradish 
peroxidase (SA-HRP) 
1:200 Vector  Laboratories 
SA-FITC 1:150  Sigma 
SA-Texas Red   1:200  Vector Laboratories 
 
Table 2.3 Secondary antibodies used in IHC experiments 
 
2.2.1 Germ Cell Tumour Stainings  
The Regional Committee for Medical Research Ethics in Denmark approved the 
use of human tissue for this project. The tissue samples from adults with testicular 
neoplasms were obtained directly after orchidectomy and macroscopic pathological 
evaluation. Testicular samples were fixed overnight at 4
oC in formalin or PFA (both 
Sigma), and subsequently embedded in paraffin. A series of 20 overt testicular tumours 
were analysed by IHC, including six classical seminomas (mean age 32 years / range 28-
37), nine nonseminomatous tumour components (mean age 29 years / range 24-35), four 
spermatocytic seminomas (mean age 66 years / range 42-87) and a testicular B-cell 
lymphoma (58 years). Eleven samples of testicular CIS were analysed (mean age 30 years / 
range 26-37). The seven normal fetal tissue samples [four testicular (14-39 wpc) and 21 
ovarian 15-38 wpc) specimens] were obtained from spontaneous or induced abortions or 
autopsies of stillbirths mainly due to placental or maternal problems. The developmental 
age was calculated from the date of the last menstrual bleeding, supported by the foot size 
of the fetus. The six samples of infantile and prepubertal tissues (ranging from 2 months to 
10 years) were obtained either from autopsies of infants who died suddenly of causes 
unrelated to the reproductive system or as testicular biopsies performed in boys with acute 
leukaemia for monitoring the spread of disease. Finally, normal adult testis was examined  58
using nine specimens of tissue removed because of TGCT, where there were normal 
preserved tubules with complete spermatogenesis (mean age 31 years / range 26-37).   
IHC was carried out as per the protocol for bright-field IHC (Section 2.2), apart from 
the following amendment: the bound antibody was visualised using aminoethyl carbazole 
substrate (Zymed, San Francisco, CA, US). Sections were lightly counterstained with 
Mayer’s haematoxylin to mark unstained cell nuclei. 
The sections were examined under a light microscope (Zeiss, Oberkochen, 
Germany) and scored systematically by two investigators (RMP and SBS). The staining 
was assessed using an arbitrary, semi-quantitative score of the proportion of cells stained: 
+++: nearly all cells stained, ++: approximately half of the cells stained, +: a low 
percentage of cells stained, +/-: only single cells stained, -: no positive cells detected. The 
staining intensity was furthermore evaluated as strong, medium, weak, very weak or no 
staining. 
 
2.3 Immunoblotting 
2.3.1 Preparation of Cell Lysates 
Tissues and cells were rinsed with PBS, and ice-cold lysis buffer (50 mM Tris-HCl 
[pH 7.4], 150 mM sodium chloride, 0.5% Triton X-100; all Sigma), containing a set of 
protease inhibitors (‘Complete’; Roche Applied Science, West Sussex, UK), was added for 
30 minutes with gentle trituration. Lysates were stored at -80
oC. Protein was quantified by 
the Bio-Rad Protein Assay (Bio-Rad, Hertfordshire, UK), based on the Bradford dye-
binding procedure (Bradford 1976). This utilises the colour change of Coomassie Brilliant 
Blue G-250 dye in response to various concentrations of protein; the absorbance maximum 
shifts from 465 nm to 595 nm when protein binding occurs. A range of dilutions of a 
bovine serum albumin (BSA) standard was produced in water, and dilutions of the cell 
lysate were also made in water. 180 μl of the diluted standard or sample was added to 20 μl 
of the concentrated reagent in a 96-well plate (Bibby Sterilin Ltd., Stone, UK) in triplicate. 
The absorbances were read at 595 nm on a microplate reader (Bio-Rad Model 680). The 
readings for the standard dilutions were used to plot a standard curve to enable an 
estimation of the protein concentration of the extract. The protein extracts were then 
equalised. 
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2.3.2 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Single dimension SDS-PAGE was carried out vertically using the Laemmli 
discontinuous buffer system, in a Mini-Protean 3 Cell (Bio-Rad), assembled according to 
the manufacturer’s instructions. Stacking gels comprised 5% bisacrylamide, 125 mM Tris-
HCl [pH 6.8], 0.1% sodium dodecyl sulphate (SDS), 0.1% ammonium persulphate (APS) 
and 0.1% N,N,N’,N’-tetramethylethylenediamine (TEMED). Resolving gels comprised 
10% bisacrylamide, 375 mM Tris-HCl [pH 8.8], 0.1% SDS, 0.1% APS and 0.05% 
TEMED. The resolving gel was poured first, overlaid with isopropanol, and allowed to set. 
The isopropanol was poured off and any unpolymerised acrylamide removed by rinsing 
with distilled deionised H2O (ddH2O). The stacking gel was then poured onto the resolving 
gel and Teflon well combs inserted. The gel was allowed to set at room temperature. 
15 μg of protein, prepared as described (Section 2.3.1), was combined with an 
equal volume of 2 × SDS gel-loading (Laemmli) buffer (100 mM Tris-HCl [pH 6.8], 200 
mM DTT, 4% SDS, 20% glycerol and 0.2% bromophenol blue) and heated at 95
oC for 5 
minutes. A prestained protein marker (Broad-range; New England Biolabs Inc., Beverly, 
MA, US) was also heated for 95
oC for 5 minutes before gel loading. The gel combs were 
removed and unpolymerised acrylamide removed from the wells by flushing with ddH2O. 
Gels were mounted vertically in the electrophoresis apparatus and 1 × SDS-PAGE buffer 
(25 mM Tris-HCl [pH 8.3], 250 mM glycine, 0.1% SDS) added to the top and bottom 
reservoirs. Prepared samples were then loaded, with any unused wells being loaded with 1 
× Laemmli buffer. A current of 55 mA was applied by connection to a Bio-Rad Power Pac 
300 power supply and ran until proteins were sufficiently resolved as determined by the 
separation of the prestained marker. 
 
2.3.3 Immunoblotting 
Immunoblotting or Western blotting of proteins in SDS-PAGE gels was carried out 
by electrophoretic transfer onto nitrocellulose membrane (Hybond-C Extra, Amersham 
Biosciences, Piscataway, NJ, US). A piece of nitrocellulose was soaked in ddH2O, then 
equilibrated in transfer buffer (48 mM Tris-HCl [pH 8.3], 39 mM glycine, 20% methanol). 
The gel was sandwiched between layers of Whatman 3MM paper and two porous pads, put 
in a Trans-Blot electrophoresis tank (Bio-Rad) filled with transfer buffer, and proteins 
transferred by applying a current of 250 mA for 2 hours.  
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2.3.4 Immunodetection 
Following immunoblotting, success of protein transfer was confirmed by staining 
with a solution of Ponceau S (0.1% Ponceau S and 5% glacial acetic acid; Sigma) for 1 
minute, followed by washes in ddH2O until all red stain was removed.  Blocking of non-
specific binding sites was carried out by immersing the membrane in PBS containing 5% 
non-fat powdered milk and 0.1% Tween-20 (Sigma) for 2 hours at room temperature. The 
membrane was washed three times
9 in PBS containing 0.1% Tween-20, and then incubated 
with the selected primary antibody at a suitable dilution (determined by preliminary 
titration experiments) in blocking buffer overnight at 4°C. Membranes were washed three 
times in PBS containing 0.1% Tween-20, and then incubated with either peroxidase 
labelled anti-rabbit antibody (1:50,000; Amersham), anti-goat antibody (1:200,000; 
Sigma), or anti-sheep antibody (1:2000; Dako, Glostrup, Denmark) in blocking buffer for 1 
hour at room temperature. β-actin was detected by 1 hour incubation with mouse anti-β-
actin peroxidase conjugated antibody (1:50,000; Sigma) at room temperature. Membranes 
were washed three times in PBS / 0.1% Tween-20 and once in PBS, followed by detection. 
 
2.3.5 Detection of Antibody-Immobilised Antigen Complexes 
Location of antibody bound to antigen on nitrocellulose membranes was detected 
by luminescence, using either Standard or Advanced Enhanced Chemiluminescence (ECL) 
reagents (Amersham), depending on the quantity of target protein present. Equal volumes 
of the two chemical detection solutions were combined, sufficient to cover the membrane. 
The membranes were drained of excess wash buffer and laid protein side up on polythene 
wrap. The detection mixture was applied to the surface of the blots, ensuring complete 
coverage, for one (Standard) or five minutes (Advanced). The excess chemical was 
drained, and blots overlaid with polythene, placed in a film cassette, and under dark room 
conditions overlaid with photographic film (Kodak Scientific Imaging Film) with exposure 
for 30 seconds. Subsequent exposures were carried out for time periods (10 seconds to 30 
minutes), according to the intensity of the signal observed on the first developed film. 
 
                                                 
9 Each wash lasted 10 minutes and was carried out on a rotating platform at room temperature.  61
2.4 Polymerase Chain Reaction (PCR)  
2.4.1 Primer Design   
DNA sequences were obtained from the National Centre for Biotechnology 
Information website (NCBI; http://www.ncbi.nlm.nih.gov/) and downloaded into the 
Primer Select programme (DNASTAR Inc., Madison, WI, US). A sorted list of primers 
was generated based on the thermodynamic properties of the annealing reactions. Primer 
pairs were chosen according to product length, position within the target sequence, 
annealing temperature and the absence of hairpin loops. Where possible, primers that 
spanned introns were chosen so that any amplification from contaminating genomic DNA 
within the PCR reaction could be distinguished. Primers were ordered from Operon 
Biotechnologies, Inc. (Cologne, Germany). 
 
2.4.2 Amplification of PCR Products   
A typical PCR reaction contained 50-100 ng template DNA, along with DNA 
polymerase reaction buffer (50 mM KCl, 10 mM Tris-HCl [pH 8.3], 1.5 mM MgCl2; 
Promega Corporation, Madison, WI, US), 200 μM dNTPs (Roche), 0.2 μM of the relevant 
primer and 1 unit of Thermus aquaticus (Taq) DNA polymerase (Promega). For GC rich 
template DNA, 1M betaine (Sigma) or 5% dimethyl sulphoxide (DMSO; Sigma) was often 
included. To optimise conditions where necessary, the annealing temperature and MgCl2 
concentration were varied by using a DNA polymerase reaction buffer without MgCl2 
(Promega) and adding varying concentrations of MgCl2 (provided as a 25mM stock 
[Promega], concentration range of 0.5-3.5 mM used). Reactions were carried out on a MJ 
Research DNA Engine Tetrad. A typical PCR cycle began with denaturation at 94
oC for 3 
minutes, followed by 30-40 cycles of: 1 minute at 94
oC (denaturation); 1 minute at 55-
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oC (annealing) and 1 minute at 72
oC (extension). The reaction was completed by a final 
extension step at 72
oC for 10 minutes. Products were identified by running on an agarose 
gel and recovered by gel extraction (see Section 2.5). 
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2.5 Agarose Gel Electrophoresis   
DNA samples in the size range of 75 bp – 10 kb were analysed on 0.8 – 3% agarose 
gels. Agarose (Sigma) was dissolved in 1 × TAE buffer (40 mM Tris-acetate and 1 mM 
EDTA [pH 8.0]), and approximately 200 μg/ml of ethidium bromide (Roche) added to 
visualise reaction products under UV light. The gel was poured into casting apparatus 
containing a comb to mould wells for sample application. Once solidified, the gel was 
submerged in 1 × TAE running buffer in an electrophoresis tank (Bio-Rad Sub-Cell GT). 
DNA and 1 × Ficoll orange (0.25% orange G, 15% Ficoll and 0.5 M EDTA at [pH 7.0], all 
Sigma) were electrophoresed in parallel with 100 bp and 1 kb DNA step ladders 
(Promega), or in-house DNA ladders, at 80 V for 1-2 hours. The separated samples and 
markers were observed under UV light (High Performance UV Transilluminator, UVP, 
Cambridge, UK) and photographed using Doc-It software (UVP). 
 
2.5.1 Gel Extraction 
DNA was separated by gel electrophoresis and purified by QIAquick gel extraction 
(QIAGEN, West Sussex, UK). This entailed excising selected product bands from agarose 
gels with a scalpel, dissolving the agarose in Buffer QG (containing guanidine thiocyanate) 
at 50
oC for 10 minutes before mixing with isopropanol. This mixture was applied to a 
QIAquick column and the DNA bound to the silica-gel membrane by centrifugation at 
12,000 g. Residual agarose was eliminated by adding further Buffer QG and centrifuging 
at 12,000 g, before washing with Buffer PE (tris-hydroxy amino-methane-buffered 80% 
ethanol). DNA was eluted in ddH2O.  
 
2.6 DNA Cloning: General Principles   
2.6.1 Preparation of Insert DNA   
Generally, insert DNA was amplified using primers incorporating the recognition 
sequences for restriction endonucleases (see Section 2.7.4 and 2.7.5), allowing subsequent 
cloning into appropriate vectors [Appendix 2(i)-(ii)]. Following amplification, products 
were gel purified, digested with the relevant restriction enzyme, and re-purified via gel 
extraction. The resultant DNA was cloned into the vector of choice.  63
2.6.2 Preparation of Vectors   
The vector was digested with the appropriate restriction enzymes. To avoid self-
annealing, vectors were dephosphorylated by adding 1 μl of calf intestinal phosphatase 
(CIP; New England Biolabs) directly into the digestion reaction, and incubating at 37°C for 
15 minutes. The vector DNA was then purified by gel electrophoresis and extraction. 
 
2.6.3 Ligation of DNA Inserts into Vectors   
Ligations were carried out in a 10 μl volume containing 1 × DNA ligase buffer (50 
mM Tris-HCl [pH 7.8], 10 mM MgCl2, 1 mM DTT, 1 mM ATP, 5% polyethylene glycol), 
dephosphorylated vector, digested insert DNA, and 1 unit of T4 DNA ligase (Promega). 
Vector:insert ratios were estimated for efficient ligation using the following calculation: 
 
 
For most ligations <100 ng of vector DNA was sufficient, with vector:insert ratios 
optimised at 1:1 or 1:3. Ligations were carried out at room temperature overnight. 
 
2.7 Transformation of Plasmids into Bacterial Cells   
2.7.1 ‘Heat-Shock’ Transformation  
50 μl of chemically competent cells (JM109; Promega) were thawed on ice, mixed 
with 1-5 μl of recombinant DNA and incubated on ice for 10 minutes. The DNA cell mix 
was heat shocked by incubation in a H2O bath at 42°C for 45 seconds. Cells were 
immediately chilled on ice for a further 2 minutes, rescued with 950 μl of warmed SOC 
media (SOB
10 media [0.5% yeast extract, 2.0% tryptone, 10mM NaCl, 2.5mM KCl, 10mM 
MgCl2, 10mM MgSO4] with 20 mM glucose) and incubated at 37°C for 1 hour with 
                                                 
10 SOB stands for Super Optimal Broth. SOC had the 'B' in SOB changed to 'C' , for catobolite repression, 
reflective of the added glucose. 
ng insert =  X desired ratio of 
vector 
insert  ng vector x kb size of insert 
kb size of vector   64
shaking. The transformed cells were plated out onto LB
11 agar containing 50 μg/ml of 
carbenicillin (Sigma), and grown overnight at 37°C. 
 
2.7.2 Growth of Bacterial Cultures and Plasmid Preparation 
Individual colonies from LB/carbenicillin agar plates were picked with a sterile 
loop and inoculated into an appropriate volume of LB medium
11 containing 50 μg/ml 
carbenicillin (Sigma). To prepare smaller amounts of plasmid DNA, 3 ml cultures were 
incubated overnight at 37°C /  225 rpm. Cells were harvested by centrifugation at 2000 g 
for 10 minutes. High-copy recombinant plasmids were purified from pelleted cells by the 
alkaline lysis method, employing the QIAGEN QIAprep Miniprep kit. Following 
resuspension in 250 μl of Buffer P1 (50 mM Tris-Cl, 10 mM EDTA, 100 μg/ml RNase A 
[pH 8.0]), cells were lysed by the addition of 250 μl of Buffer P2 (200 mM NaOH, 1% 
SDS)
12 and gentle mixing. The lysis reaction was limited to 5 minutes
13, before 
neutralisation by gentle mixing with 350 μl of Buffer P3 (3.0 M potassium acetate [pH 
5.5])
14. The precipitate was compacted by centrifuging for 10 minutes at 12,000 g and the 
supernatant applied to a QIAprep silica-gel membrane column placed in a 2 ml collection 
tube. Following centrifugation for 1 minute at 12,000 g, the flow-through was discarded. 
The membrane-bound plasmid DNA was then washed by applying 0.75 ml of ethanol-
containing Buffer PE and centrifuging for 1 minute at 12,000 g. After discarding the flow-
through, residual ethanol was removed by a repeat centrifugation. The column was then 
transferred to a clean microcentrifuge tube and the purified plasmid DNA eluted in 50 μl 
ddH2O by centrifuging again at 12,000 g for 1 minute.  
To prepare larger amounts of plasmid DNA for transfection into mammalian cells, 
5 ml starter cultures were grown for 8 hours at 37°C / 225 rpm. The starter cultures were 
then used to inoculate larger overnight cultures (100 ml of LB/carbenicillin) at a dilution of 
1:100. Cells were harvested by centrifugation at 6000 g for 15 minutes at 4°C. The alkaline 
lysis method was again used to purify high-copy recombinant plasmids from pelleted cells, 
                                                 
11 LB stands for Lysogeny broth, also known as Luria Bertani medium or Luria broth. LB medium comprises 
0.5 % yeast extract; 1% tryptone and 171mM NaCl. LB agar is LB medium plus 1.5% agar. 
12 Contains SDS,which disrupts the cell membrane, releasing the cell contents, and NaOH for the 
denaturation of the exposed DNA and proteins. 
13 Prevents release of chromosomal DNA, but permits optimum release of plasmid DNA while minimising 
denaturation. 
14 This high-salt buffer precipitates denatured proteins, chromosomal DNA, cellular debris and SDS, while 
the plasmid DNA renatures and remains in solution. The high-salt conditions also enable selective adsorption 
of plasmid DNA to the membrane of the QIAprep column.  65
employing the QIAGEN Plasmid Maxi Kit. Following resuspension in 10 ml Buffer P1, 
cells were lysed by adding 10 ml Buffer P2, mixed thoroughly, and incubated at room 
temperature for 5 minutes, before neutralisation by the addition of 10 ml of chilled Buffer 
P3. The lysate was poured into the barrel of a QIAfilter cartridge, and incubated at room 
temperature for 10 minutes. The cell lysate was then filtered into a QIAGEN-tip previously 
equilibrated with Buffer QBT (750 mM NaCl, 50 mM MOPS [pH 7.0], 15% isopropanol 
and 0.15% Triton X-100); as the lysate gravitates through the tip, DNA binds to the 
QIAGEN resin. The QIAGEN-tip was washed twice with Buffer QC (1.0 M NaCl, 50 mM 
MOPS [pH 7.0], 15% isopropanol), and DNA eluted with 15 ml Buffer QF (1.25 M NaCl, 
50 mM Tris-Cl [pH 8.5] and 15% isopropanol). DNA was precipitated by adding 0.7 
volumes (10.5 ml) room temperature isopropanol, and centrifuged at 15,000 g for 30 
minutes at 4°C. The DNA pellet was washed with 5 ml room temperature 70% ethanol, 
and centrifuged at 15,000 g for 10 minutes, followed by drying and redissolving in ddH2O.  
 
2.7.3 DNA Quality and Concentration   
Plasmid DNA was analysed on an agarose gel. The separated samples and markers 
were observed under UV and photographed. Pure plasmid DNA was found as two separate 
bands, one for relaxed (nicked) DNA and the other for supercoiled DNA, which migrates 
more rapidly due to its compact form. DNA was quantified by measuring the A260 using a 
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, US). 
 
 
The quality of plasmid DNA was estimated by the ratio between A260:A280, to 
ensure the solution was relatively free from proteins. For a pure DNA solution the 
A260:A280 ratio should be at least 1.8, with the A260:280 ratio at ≥1.8 indicative of DNA 
of sufficient purity. 
 
1 A260 Unit of double stranded DNA ~50 μg/ml  66
2.7.4 Expression Vector Constructs 
The coding sequences for the human (h) OCT4, NANOG, and SOX2 genes were 
amplified by PCR
15 and cloned into the expression vector pcDNA 3.1 Zeo(+) [see 
Appendix 2(i), Invitrogen] which drives expression from a CMV promoter. The primers in 
Table 2.4 were used to amplify insert DNA for cloning into the pcDNA 3.1 Zeo(+) vector. 
All reverse primers contained an EcoRI recognition sequence, the OCT4 and SOX2 
forward primers contained a BamHI site, and the NANOG forward primer a BglII site. 
 
  Forward primer  Reverse primer 
hNANOG 5’  GAAGATCTTTTTTCCTCCTCTTCCTCTAT 3’  5’ GGAATTCATGGGAGGAGGGGAGAGGAAGGAT 3’ 
hOCT4 5’  CGGGATCCGCTTGGGGCGCCTTCCTTCC 3’  5’ GGAATTCCCCTCCCCCTGTCCCCCATTCCTA 3’ 
hSOX2 5’  GGGATCCCGCCCGCCTCCCCTCCTCCTCTC 3’  5’ GGAATTCTGCACCCCTCCCATTTCCCTCGTT 3’ 
 
Table 2.4 Primers used for generating expression vector constructs 
Restriction sites are underlined. 
 
2.7.5 Short Interfering RNA Constructs 
Short interfering RNA (siRNA) constructs were cloned into pSUPER.gfp/neo [see 
Appendix 2(ii), Oligoengine, Seattle, WA, US], a mammalian expression vector which 
directs intracellular synthesis of siRNAs 19 nucleotides in length, and which also contains 
a neomycin resistance gene and the gene for green fluorescent protein (GFP). A 19 
nucleotide region of the hSOX2 gene was selected using the Wistar Institute siRNA 
Selector (from http://hydra1.wistar.upenn.edu/Projects/siRNA/siRNAdescrip.htm). A 
BLAST search was performed on the highest scoring sequences, and one selected with 
fewer than 15 nucleotides matching with any other human gene. Complementary forward 
and reverse oligonucleotides were designed containing the 19 nucleotide regions and 
restriction enzyme recognition sequences at either end. These were annealed, digested and 
ligated into the BglII and HindIII sites of the vector. The oligonucleotides used are shown 
in Table 2.5 (siRNA 1). In addition, a second 19 nucleotide region (Table 2.5, siRNA 2) 
was chosen to which siRNA has been directed and shown to reduce the level of SOX2 
transcripts by 50% (Chew et al. 2005). This sequence also shows less than 15 base pair 
                                                 
15 For SOX2, genomic DNA could be used as template, as the gene contains no introns. However, for the 
intron-containing genes OCT4 and NANOG, cDNA clones were used, obtained from the I.M.A.G.E. 
Consortium (Geneservice Ltd., Cambridge, UK)   67
match with other human genes. This was cloned into the XhoI and BgII sites of the 
plasmid. A control sequence directed against the luciferase gene was also used.  
 
  Forward primer  Reverse primer 
hSOX2 
siRNA1 
5’GATCCCCACCAGCGCATGGACAGTTATTCAAG
AGATAACTGTCCATGCGCTGGTTTTTTGGAAA 3’ 
5’AGCTTTTCCAAAAAACCAGCGCATGGACAGTTAT
CTCTTGAATAACTGTCCATGCGCTGGTGGG 3’ 
hSOX2 
siRNA2 
5’GATCCCCGAAGGAGCACCCGGATTATTTCAAG
AGAATAATCCGGGTGCTCCTTCTTTTTC 3’ 
5’TCGCGAAAAAGAAGGAGCACCCGGATTATTCTC
TTGAAATAATCCGGGTGCTCCTTCGGG 3’ 
 
Table 2.5 Primers used for generating siRNA constructs 
19 nucleotide regions complementary to the hSOX2 gene are underlined. Restriction 
enzyme sequences flank these regions (BglII and HindIII for siRNA 1, BgIII and XhoI 
for siRNA 2). 
 
2.8 DNA Sequencing   
All plasmid sequences were verified by sequencing, using the Beckman Coulter 
CEQ 8000 Genetic Analysis System (Human Genetics Division, University of 
Southampton). This is a dye terminator cycle sequencing process which involves a PCR 
reaction containing the DNA, primer and DTCS Quick Start Master Mix, followed by 
ethanol precipitation. The sample is resuspended in loading solution, run on the CEQ 
Machine and analysed using CEQ Analysis Software.  
 
2.9 RNA Extraction and Analysis   
2.9.1 Total RNA Extraction   
All RNA work was carried out using baked glassware (180°C for 4 hours) and 
DEPC-treated reagents, to ensure work was carried out in RNase-free conditions. Total 
RNA was extracted using Tri reagent (Sigma). 1 ml of reagent was added to tissue or cells 
and pipetted up and down to dissociate the material. This was left at room temperature for 
5 minutes to allow complete dissociation of nucleoprotein complexes. 200 μl of chloroform 
was added and the solution mixed vigorously for 15 seconds and allowed to stand at room 
temperature for 15 minutes. The sample was then centrifuged at 10,000 rpm for 15 minutes 
at 4°C. This separated the mixture into 3 phases: a red organic phase (containing protein), 
an interphase (containing DNA), and a colourless upper aqueous phase (containing RNA). 
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precipitated by adding 500 μl of isopropanol, with incubation at room temperature for 10 
minutes, followed by centrifugation at 10,000 rpm for 10 minutes at 4°C; the RNA forms a 
precipitate on the side and bottom of the tube. The supernatant was removed, the pellet 
washed with 75% ethanol, centrifuged at 7,000 rpm for 5 minutes at 4°C, air-dried and 
resuspended in DEPC-H2O for storage at -80°C. 
 
2.9.2 RNA Quality and Concentration 
RNA was quantified by measuring the A260 using a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies). 
 
 
 
The quality of the RNA was estimated by the ratio between A260:A280, to ensure 
the solution was relatively free from proteins. An A260:A280 ratio of 1.8 is indicative of 
highly purified RNA. 
 
2.9.3 First Strand cDNA Synthesis   
This procedure converts 1-5 μg of total RNA into first strand cDNA using an 
oligo(dT) primer, which hybridises to the 3’ poly(A) tail sequences found in most 
eukaryotic mRNAs (Figure 2.2). An RNA/primer mixture was prepared in a 10 μl volume 
containing 1-5 μg of total RNA, 0.5 mM dNTP, 0.5 μg oligo(dT) primer, and DEPC-H2O. 
The RNA mixture was denatured at 65°C for 5 minutes. During this step a reaction mixture 
(maximum volume 7 μl) was prepared containing 1 × first strand buffer (50 mM Tris-HCl 
[pH 8.3], 75 mM KCl, 3 mM MgCl2), 10 mM DTT, and 4 U RNase inhibitor (Promega). 
The reaction mixture was added to the denatured RNA mixture, followed by an annealing 
step at 42°C for 2 minutes. 200 U of Superscript III Reverse Transcriptase (RT; Invitrogen) 
was added to the solution and cDNA synthesised at 42°C for 50 minutes. The reaction was 
terminated at 70°C for 15 minutes and stored at -20°C. 
As a control for genomic contamination in subsequent PCR reactions, ‘minus RT’ 
controls were prepared, containing DEPC-H2O in place of Superscript III Reverse 
Transcriptase enzyme. 
 
1 A260 Unit of single stranded RNA ~40 μg/ml  69
 
Figure 2.2 RT-PCR 
Total RNA was extracted from tissue or cells using Tri reagent. First strand cDNA was 
synthesised using an oligo(dT) primer, which hybridises to 3’ poly(A) tails found in the 
RNA. This cDNA can then be used to carry out conventional PCRs to identify 
expression of genes of interest. 
 
2.10 Expression Microarray 
2.10.1 RNA Extraction and Clean-up 
RNA was extracted from male and female gonads as described (Section 2.9.1)  and 
purified using the RNeasy MinElute Cleanup Kit (QIAGEN). The sample was adjusted to a 
volume of 100 μl with RNase-free water, and 350 μl Buffer RLT (containing 25-50% 
guanidinium thiocyanate and 143 mM β-mercaptoethanol)
16 added. 250 μl 96-100% 
ethanol
17 was added, an the solution applied to an RNease MinElute Spin Column in a 2 
ml collection tube, and centrifuged for 15 seconds at 8000 g, and the flow-through 
discarded. The spin column was transferred into a new 2 ml collection tube, and 500 μl 
Buffer RPE (wash buffer containing ethanol) added, followed by centrifugation at 8000 g 
for 15 seconds. Further washing was performed by adding 500 μl 80% ethanol, and 
centrifuged for 8000 g for 2 minutes, followed by a further centrifugation at 5 minutes at 
                                                 
16 β-mercaptoethanol irreversibly denatures RNases by reducing disulfide bonds and destroying the native 
conformation required for enzyme functionality. Guanidinium isothiocyanate (GITC) is a strong but 
temporary denaturing agent, therefore the action of both these agents is to inactivate RNases. 
17 Ethanol is added to provide appropriate binding conditions. 
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full speed to remove residual ethanol. RNA was eluted in RNase-free water by 
centrifugation for 1 minute at maximum speed.     
 
2.10.2 RNA Quality and Concentration 
The quality and concentration of the RNA were analysed on an Agilent 2100 
Bioanalyzer.  
 
2.10.3 Expression Microarray 
The expression microarray was conducted 
using the Amersham CodeLink Uniset Human 20K I 
Bioarray, which targets 21,000 transcripts using 30-
mer probes. The expression microarray assay process 
is summarised in Figure 2.3. This work was performed 
by Dr. Feng Lin (Cancer Sciences Division, University 
of Southampton). Results were analysed using 
Amersham CodeLink Expression Analysis v4.1 and 
GeneSifter software. 
 
 
Figure 2.3 Summary of expression microarray 
procedure 
Double stranded cDNA is synthesised from the RNA 
sample. This cDNA serves as a template in an in 
vitro transcription reaction that produces amplified 
amounts of biotinylated labelled antisense (copy) 
mRNA (cRNA). The cRNA is fragmented reducing it 
to 25-200 bp fragments and hybridised to the gene 
chip. The chip is then stained with streptavidin-
phycoerythrin which binds to the biotin, scanned with 
a confocal laser and the fluorescent signal from 
phycoerythrin recorded.   71
2.11 Cell Culture and Transfections    
2.11.1 Culture Conditions and Cell Maintenance 
2.11.1(i) Human Embryonal and Pancreatic Carcinoma Cell Lines  
The hECC line NTERA2 clone D1 (NT2) and the human pancreatic carcinoma cell 
line PANC1 were obtained from European Collection of Cell Cultures (ECCAC numbers 
01071221 and 87092802 respectively). The hECC lines TERA1 and 2102Ep were a gift 
from Professor Peter Andrews (University of Sheffield). All cell lines were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM; PAA Laboratories, Somerset, UK), 
supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin
  and 100 μg/ml 
streptomycin (all PAA Laboratories) in 5% CO2/95% humidity
 at 37°C in a Heto-Holten 
Cell house incubator. NT2 cells were subcultured using sterile glass beads (VWR 
International Ltd., Poole, UK). Other cell lines were subcultured using sufficient 
Trypsin/EDTA (0.05%/0.02% in D-PBS; PAA Laboratories) to cover the bottom of the 
culture vessel and placed at 37°C until adherent cells detached (2-5 minutes). Trypsin was 
inactivated by adding horse serum (PAA Laboratories) and the contents transferred to a 50 
ml tube. Further medium was added and the cells centrifuged at 1,000 rpm for 4 minutes. 
The pellet was resuspended in fresh culture medium and diluted to the appropriate density 
(~1:3 dilution for routine passaging) in fresh 75 cm
2 culture flasks.
 
 
2.11.1(ii) Human Embryonic Stem Cell Lines  
The hESC lines HUES1 and HUES7 were obtained under MTA from Harvard 
University (Cowan et al. 2004) and maintained in Knockout (KO)-DMEM containing 1% 
penicillin/streptomycin, 1% Gluta-MAX, 0.1 mM non-essential amino acids, 10% KO-
Serum Replacement (KO-SR; all Invitrogen), 10 ng/ml human recombinant fibroblast 
growth factor 2 (FGF2; Peprotech Ltd, London, UK) and 0.1 mM β-mercaptoethanol 
(Sigma) in 5% CO2/95% humidity
 at 37°C. hESCs were cultured on mitotically-inactivated 
primary mouse embryonic fibroblasts (pMEFs; C5BL6 background; a gift from Dr. Neil 
Smyth, University of Southampton) and passaged using 1 mg/ml type IV collagenase 
(GIBCO, Invitrogen) with mechanical disaggregation using a cell scraper (Greiner Bio-
One, Stonehouse, UK).
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2.11.1(iii) Human Embryonic Germ Cells  
•  Embryo Collection, Gonadal Dissection, and Disaggregation 
With local research ethics committee approval [Appendix 3 (i)-(iii)] and written 
informed
 consent, following Polkinghorne guidelines (Polkinghorne 1989), human fetuses
 
at 7-9 wpc were collected at surgical termination of
 pregnancy. In total, 25 gonadal cell 
cultures were initiated. Dissection was carried out using stereomicroscopy,
 and gonads 
were washed in Hanks’ Balanced Salt Solution
 (HBSS; PAA Laboratories).
 Gonads were 
mechanically disaggregated using hypodermic needles (0.4 ×  40 mm; Sterican, Braun, 
Melsungen, Germany) and trituration, and then plated. Puncturing the intact organ is 
equally effective as enzymatic dissociation in generating hEGC cultures (Turnpenny et al. 
2006), and avoids protracted washing and resuspension, along with any possible (although 
theoretical) damage caused to cell surface markers and receptors caused by proteolytic 
enzymes. 
 
•  Cell Culture 
  Mouse STO fibroblasts (American Type Culture Collection CRL-1503)
  were 
mitotically inactivated by exposure to 50 Gy of γ-radiation
  and plated in DMEM 
containing 10% FCS, 100 U/ml penicillin,
  and 100 μg/ml streptomycin (all PAA 
Laboratories). Dissociated
  PGCs were plated onto this feeder layer in KO-DMEM
 
(Invitrogen), containing either 15% KO-SR (Invitrogen) or ESC-tested FCS (PAA 
Laboratories), 1 mM L-glutamine, 0.1 mM β-mercaptoethanol
  (both Sigma), 0.1 mM 
nonessential amino acids (Invitrogen),
 and antibiotics as above. To promote their survival, 
proliferation,
 and maintenance in the undifferentiated state, PGCs/EGCs were cultured in 
the presence of 10 μM forskolin (Sigma),
 4 ng/ml human recombinant FGF2 (Peprotech) 
and
  1,000 U/ml human recombinant leukaemia inhibitory factor (LIF; Chemicon 
International Inc., Temecula, CA, US).
 During the first 14 days, cultures were sacrificed or 
sampled
  for characterisation (see below). Cells were passaged
  using Trypsin/EDTA 
(0.05%/0.02% in D-PBS; PAA Laboratories) onto fresh feeder layers, and samples were 
taken for additional
  characterisation. All cultures were maintained in 5% CO2/95% 
humidity
 at 37°C.
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•  Characterisation of PGCs and EGCs 
Cells were fixed in 4% PFA in PBS (both Sigma), and dehydrated via 2 minute 
sequential steps in 50%, 70% and 100% ethanol. Alkaline phosphatase (AP) activity was 
detected using the colour substrates nitro-blue tetrazolium chloride (NBT) and 5-bromo-4-
chloro-3'-indolyphosphate p-toluidine salt (BCIP; both Roche). 4.5 μl of each chemical 
was added per ml of detection buffer (100 mM Tris-HCl [pH 9.5], 50 mM MgCl2, 100 mM 
NaCl), the solution added to the fixed cells and left in the dark for 2 hours at room 
temperature. Cells were washed and mounted with glass cover slips using Aquamount 
(VWR). 
 
2.11.2 Freezing and Thawing Cells  
Cells were trypsinised and pelleted as described. The cell pellet was resuspended at 
a density of ~6 x 10
6 cells/ml in media containing 50% FCS, 40% DMEM (both PAA 
Laboratories) and 10% DMSO (Sigma) and aliquoted into cryotubes (Greiner Bio-one). 
Cells were frozen at a rate of 1°C/minute to -80°C in a Nalgene Cryo 1
oC freezing 
container and then transferred to storage in liquid nitrogen. 
Frozen cells were thawed rapidly at 37°C, diluted with prewarmed medium and 
centrifuged at 1,000 rpm for 4 minutes. The cell pellet was resuspended in medium and 
transferred to a culture vessel. 
 
2.11.3 Transient Transfections 
OCT4 and NANOG expression vectors (3 μg total DNA) were transfected into 
primary cells (stomach epithelial cells and neuroprogenitors) by nucleofection (Amaxa 
GmbH, Cologne, Germany). Cells were pelleted by centrifugation, resuspended in 100 μl 
Nucleofector Solution V, DNA added, put into a cuvette and nucleofected using the X-05 
program
18 on The Nucleofector (Amaxa). Media was added, and cells were plated directly 
into 8-well Lab-Tek chamber slides (Nalge Nunc International, Naperville, IL, US), with 
media being changed 24 hours later, and the cells being fixed with 4% PFA after 48 hours. 
                                                 
18 A selection of programs and Nucleofector solutions were tested with the pmaxGFP vector (GFP expression 
vector [3.49 kb] provided in the Nucleofector kit). The X-05 program was found to transfect the most 
primary cells (neuroprogenitors).  74
Cells were either plated on pMEFs in hESC medium (Section 2.11.1[ii]); or directly onto 
glass in NT2 conditioned medium
19, to mimic ESC-like growth conditions. 
 
2.11.4 G418 Titration (‘Kill Curve Analysis’) 
Cells successfully transfected with pSUPER.neo/gfp can be selected using the 
antibiotic G418 (PAA Laboratories), as the plasmid contains a neomycin resistance gene
20. 
The optimal concentration of G418 for the selection of stable NT2 clones was determined 
by titration. NT2 cells were plated at ~80% confluency onto 6-well plates (Iwaki Glass Co. 
Ltd., Tokyo, Japan) and incubated with varying concentrations of G418 (0, 25, 50, 100, 
150, 200, 300, 400, 500 μg/ml) for two weeks. The concentration of selection agent chosen 
was the least amount which caused total cell death in this period: 200 μg/ml G418. 
 
2.11.5 Generation of Stable Transfectants using Calcium Phosphate-
Mediated Transfection 
24 hours prior to transfection, NT2 cells were trypsinised and plated at 8 ×10
5 cells 
per 100 mm culture plate. Three hours prior to transfection, the medium was removed from 
the cells and replaced with fresh growth medium. Cells were transfected with DNA using 
the ProFection Mammalian Transfection System (Promega). 15 μg of DNA 
(pSUPER.neo/gfp) was added to 62 μl 2M CaCl2 and sterile, deionised water added to 500 
μl. This solution was added dropwise to 500 μl of 2 × HEPES-Buffered Saline (HBS), and 
incubated at room temperature for 30 minutes
21. The solution was vortexed and added to 
cells; 5 hours later the culture medium was replaced with fresh growth medium to 
minimise cell toxicity. After 24 hours, 200 μg/ml G418 was added, and 48 hours later the 
cells were subcultured 1:2 and maintained in medium containing 200 μg/ml G418. Media 
was changed every 3 days, and approximately 2 weeks later, green colonies were visible; 
these were trypsinised using cloning cylinders and transferred to multiwell plates for 
further propagation in selective growth medium.   
 
 
                                                 
19 Collected after 24 hours and filter-sterilised. 
20 The gene for aminoglycoside 3’-phosphotransferase. 
21 The solution appears cloudy due to the formation of a fine calcium phosphate-DNA coprecipitate.  75
CHAPTER 3: Expression of SOX2 within the Human 
Germ Cell Lineage  76
3.1 ABSTRACT 
OCT4, NANOG and SOX2 act cooperatively to maintain pluripotency in cells of 
the inner cell mass (ICM) of human and mouse blastocysts, and in the derived embryonic 
stem cells (ESCs). Knock-out/down-regulation of any one of these transcription factors 
causes loss of pluripotency. Pluripotent mouse embryonic germ cells (mEGCs), and their 
founder cells, mouse primordial germ cells (mPGCs), also express Oct4, Nanog and Sox2. 
Thus, a similar expression profile could be anticipated for human PGCs (hPGCs) and 
hEGCs. However, by RT-PCR, immunoblotting and immunohistochemistry, hPGCs were 
found to express OCT4 and NANOG, but not SOX2, with no evidence of redundancy 
within the Group B family of human SOX genes. Although lacking SOX2, proliferative 
human germ cells can still be identified in situ during early development and can be 
cultured  in vitro. Upon conversion to the hEGC state, which fulfills some but not all 
criteria for pluripotency, cells remain SOX2-negative, indicating SOX2 expression is not 
required for conversion to EGC. Surprisingly, with the exception of FGF4, many stem 
cell-restricted SOX2 target genes remained detected within the human SOX2-negative 
germ cell lineage. The hPGC is the first primary cell-type described to express OCT4 and 
NANOG but not SOX2,  exemplifying a striking difference in gene expression between 
human and mouse. The data also provide a new reference point for studies attempting to 
turn human stem cells into gametes by normal developmental pathways, for the treatment 
of infertility.  77
3.2 INTRODUCTION 
3.2.1 Mouse ESCs and EGCs 
Original experiments in mice have demonstrated that ESCs and EGCs are, 
unequivocally, two types of pluripotent stem cell. The former are derived from the ICM of 
the blastocyst taken into laboratory culture; the latter are presumed to represent an 
analogous in vitro conversion of the PGC, the diploid precursor of the male and female 
gametes. The criteria which mark the derivation of EGCs from PGCs are a suspension of 
meiosis and a state of rapid self-renewing proliferation. Mouse EGCs (mEGCs) were first 
derived in 1992 independently by two groups (Matsui et al. 1992; Resnick et al. 1992). 
Derivation is most successful from earlier stages of development, including from PGCs 
still migrating (McLaren and Durcova-Hills 2001). Derivation efficiency is high: around 
95% of cultures initiated generate EGC lines (Shamblott et al. 2004). In many respects, 
mEGCs resemble mESCs, derived eleven years earlier. Both satisfy all criteria for 
pluripotency in vitro and in vivo. Both their precursor cells (i.e. cells of the ICM/PGCs) 
and their derived cell types (ESCs/EGCs) are diploid and express the pluripotency related 
genes Oct4, Nanog and Esg1 (Western et al. 2005), and share AP activity (Ginsburg et al. 
1990) and SSEA1 expression (Solter and Knowles 1978), along with that of other markers 
(Table 3.1).  
Both mESCs and mEGCs grow rapidly and indefinitely in vitro while retaining 
pluripotency and tumourigenic capability (Matsui et al. 1992; Stewart et al. 1994). They 
both show comparable cell cycle phase distribution (Rohwedel et al. 1996), and cell cycle-
related gene transcripts and proteomic signatures are indistinguishable based on global 
gene expression alone (Kurosaki et al. 2007; Sorrentino et al. 2007); although detailed 
comparison identified some differences (Sharova et al. 2007). In addition, minor 
dissimilarities in differentiation capabilities have been noted: in the presence of retinoic 
acid, EGCs show lower expression of muscle- and cardiac-related genes and a higher 
expression of gonad-related genes (Sharova et al. 2007). EGCs differentiate more 
efficiently to neuronal cells and less efficiently to cardiac and skeletal muscle cells than 
ESCs (Rohwedel et al. 1996), and fail to differentiate in co-culture with lung tissue 
(Durcova-Hills et al. 2003). Another difference between the cells is the DNA methylation 
patterns of some imprinted genes. During migration and maturation of PGCs, the somatic 
status of imprinted genes is progressively erased (Yamazaki et al. 2003), and EGCs can  78
retain some of these differences, for example reduced methylation of many imprinted 
genes, including H19 and Snrpn (Hajkova et al. 2002).  
 
Gene  Species ESCs Early GCs Late GCs  ICM 
Oct4 (Pesce and Scholer 2001)  M +  +  +  + 
Nanog (Chambers et al. 2003)  M +  +  +  + 
Stella
22 (Saitou et al. 2002)  M +  +  +  + 
Fragilis (Saitou et al. 2002)  M +  +  +  + 
c-Kit (Horie et al. 1991)  M +  +  +  - 
Dazl (Pan et al. 2008)  H +  +  +  - 
Ddx4 (Toyooka et al. 2003)  M -  -  +  - 
Akp2
23
 (Chiquoine 1954)  M +  +  +  + 
Rex1
24 (Rogers et al. 1991)  H +  -  +  + 
 
Table 3.1 Comparison of marker expression between embryonic stem cells 
(ESCs), early and late germ cells (GCs), and the inner cell mass (ICM) 
+ denotes expression at that developmental stage; – denotes no expression. 
Abbreviations; Dazl, deleted in azoospermia-like; Ddx4, Dead (Asp-Glu-Ala-Asp) box 
polypeptide 4; Akp2, alkaline phosphatase 2, liver; Rex1, reduced expression 1; H, 
human; M, mouse. [Adapted from Zwaka and Thomson (2005).] 
 
The similarities between ESCs and EGCs have led to the hypothesis that ESCs are 
derived from PGC precursors that originated from the ICM (Zwaka and Thomson 2005). 
This theory is further supported by data which demonstrate that the SCF-KIT signal 
transduction pathway is required for ESC differentiation in vitro: there is no pre-
implantation defect in mice lacking either KIT or SCF function, indicating this pathway is 
not essential for ICM differentiation in vivo. Therefore, ESCs in vitro may not accurately 
reflect their in vivo counterpart, the ICM (Chambers and Smith 2004), and may have more 
resemblance to PGCs where the SCF-KIT pathway plays an important role in survival and 
differentiation (Godin et al. 1991; Matsui 1998; Kissel et al. 2000). 
 
                                                 
22 Also known as Dppa3 (Developmental pluripotency associated 3). 
23 Also known as Tnap (Tissue non-specific alkaline phosphatase). 
24 Also known as Zfp42 (Zinc finger protein 42).  79
3.2.2 Human ESCs and EGCs 
Human EGC (hEGC) derivation has been less frequently reported, by only a 
handful of groups (Shamblott et al. 1998; Turnpenny et al. 2003; Liu et al. 2004; 
Aflatoonian and Moore 2005; Pan et al. 2005). This is due, in part, to the limited 
availability of human embryonic/fetal material. However, it also reflects the difficulties 
encountered with hEGC culture: the cells are difficult to derive, in our experience only 
approximately one-eighth (≥14%) of cultures demonstrate ‘EG-like’ properties, and they 
are difficult to maintain over prolonged passaging (Turnpenny et al. 2003). No groups 
have maintained hEGCs indefinitely in culture; our experience is that loss occurs after 10-
12 passages, and is exacerbated by freeze-thaw routines (Turnpenny et al. 2003; 
Turnpenny et al. 2006). No lines have been banked in public depositories, and the cells 
have not been clonally expanded thus far. The only report describing continuous culture of 
hEGCs for over a year (Park et al. 2004) was subsequently retracted. It is possible that the 
ease of mEGC derivation is related to the high susceptibility of the 129/sv strain to 
spontaneously developing teratocarcinomas
25, due to a recessive mutation in the ter gene 
(Noguchi and Noguchi 1985). Human TGCTs do not have this tendency towards 
embryonal carcinomas: half of human TGCTs are seminomas, which lack a stem cell 
component and are difficult to culture in vitro: only one human seminoma cell line has 
been grown, likely facilitated by an activating mutation in the BRAF oncogene (de Jong et 
al. 2008). 
Germ cells could potentially be of therapeutic benefit, if pure populations could be 
isolated. In addition, further research might provide insight into cancer cell biology. 
TGCTs, which originate from a precursor cell, the carcinoma in situ cell, are of germ cell 
antecedence  (Skakkebaek 1972), and have increased in incidence over the last several 
decades; they now constitute the most prevalent malignant cancer among young male 
adults in Northern and Western Europe (Richiardi et al., 2004). 
In addition, hEGCs may provide a comparator with which to study hESC 
pluripotency, offering the opportunity to define important factors, markers and signalling 
pathways. They could provide an additional tool with which to study aspects of human 
development. Relatively little is known regarding human development from 14 days (the 
time limit for human embryo culture under the Human Fertilisation and Embryology Act) 
                                                 
25 Teratocarcinomas are comprised of teratoma and embryonal carcinoma; the stem cell component is 
contained within the embryonal carcinoma compartment.  80
to the receipt of material from social (or voluntary) termination of pregnancy at 
approximately 7-12 weeks of gestation, and hEGCs provide another pluripotent cell type 
with which to mimic these events, and provide a comparator to hESCs. 
Information gleaned from studying the human germ line will provide a reference 
point for studies aiming to replicate normal development for the in vitro generation of 
gametes from human stem cell populations for future fertility treatment (Nagano 2007). 
Germ cell induction from mESCs has been reported by a number of groups (Hubner et al. 
2003; Toyooka et al. 2003; Geijsen et al. 2004), with one reporting the successful 
production of offspring (Nayernia et al. 2006). Furthermore, hESCs can differentiate to 
cells expressing PGC and meiotic markers (Clark et al. 2004; Aflatoonian and Moore 
2006; Clark and Reijo Pera 2006). However, germ cell induction from ESCs is currently a 
rare event. In addition, it is not clear whether the in vitro process follows the same pathway 
as that of normal germ cell development in vivo. 
 
Work described within this chapter sought to further characterise aspects of the 
human germ cell lineage, specifically comparing hEGCs to PGCs, the ICM, ESCs and 
ECCs. The difficulties in initiating hEGC cultures and maintaining them in the long-term 
led to the postulation that they may lack some factor present in mEGCs, or they may fail to 
induce expression of a factor which would maintain their pluripotency.   81
3.3 SPECIFIC AIMS 
3.3.1 To characterise hEGCs in comparison to PGCs, ESCs and ECCs. 
OCT4, SOX2 and NANOG are proposed to maintain pluripotency in human and 
mouse ESCs (Boyer et al. 2005; Loh et al. 2006). The expression of these transcription 
factors was examined in hEGCs and their precursors, hPGCs, and in hESCs, by RT-PCR, 
immunohistochemistry and immunoblotting, and also compared to the mouse germ cell 
lineage. 
 
3.3.2 To characterise the expression of transcription factors central to 
maintaining pluripotency in pluripotent and nullipotent hECC lines. 
This involved determining whether pluripotency/nullipotency of hECC lines 
correlated with expression of key transcription factors involved in maintaining 
pluripotency.  
 
3.3.3 To analyse the expression of OCT4, NANOG and SOX2 target 
genes in the various pluripotent stem cells and their starting cell 
types. 
OCT4, SOX2 and NANOG are proposed to co-occupy over 350 gene promoters in 
hESCs, activating transcription from those which maintain pluripotency and repressing   
those which promote differentiation (Boyer et al. 2005). OCT4 and SOX2 are known to act 
cooperatively in up-regulating FGF4 (Ambrosetti et al. 1997), UTF1 (Nishimoto et al. 
1999) and FBX15 (Tokuzawa et al. 2003) transcription. Expression of these genes, and a 
further 13 genes which are expressed in ESCs when their respective promoter regions are 
bound by OCT4, NANOG and SOX2 (Boyer et al. 2005), were analysed by RT-PCR in 
human fetal gonads, hESCs and hECCs. 
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3.4 RESULTS 
3.4.1 Primordial Germ Cell Expression of SOX2 Differs between Human 
and Mouse 
The human fetal gonad is apparent as a distinct structure from 32 dpc with sex 
determination marked by the expression of SRY and SOX9 at ~41-44 dpc. Thereafter, sex 
cords comprised of Sertoli cells and germ cells become increasingly apparent within the 
testis during late embryonic (up to 56 dpc) and early fetal (thereafter) development 
(Hanley et al. 2000). OCT4, NANOG and SOX2 are known as three critical transcription 
factors in hESCs (Boyer et al. 2005) and were expressed accordingly (Figure 3.1 A). 
Nuclear OCT4 and NANOG proteins were clearly detected within germ cells in the gonad 
of the embryonic ovary and testis ranging from Carnegie stages 19-23 (48-56 dpc), and in 
the early fetus (56-73 dpc; Figure 3.1 B, D-H). In sharp contrast, SOX2 was not detected 
within the human female or male gonad either prior to sex determination or later during the 
first trimester (48-73 dpc; Figure 3.1 B, D-H). The expression of some genes, such as 
Ddx4, is altered upon the arrival of the PGC to the gonadal ridge in mice (Tanaka et al. 
2000). Therefore, PGCs were also studied within the gut mesentery at 48 dpc, a location 
consistent with their migration from yolk sac wall to gonadal ridge. Nuclear OCT4 and 
NANOG were again robustly detected; however, SOX2 was absent (Figure 3.1 C). 
Figure 3.1 OCT4, NANOG and SOX2 expression in hESCs and late 
embryonic/early fetal ovary and testis 
A. hESCs (HUES1); B. 48 dpc testis; C. Immunohistochemistry [IHC] combined with 
AP staining; D. 48 dpc gut mesentery; E. 54 dpc ovary; F. 68 dpc ovary; G. 72 dpc 
ovary; H. 72 dpc testis; I. 73 dpc testis. Abbreviation: gut mes, gut mesentery. Size 
bars represent 50 μm (A,B,D-I) and 20 μm (C). 
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[For legend see facing page]  84
Sox2 transcripts have been demonstrated in the gonadal ridge of mouse embryos 
(Western et al. 2005). Consistent with this finding, nuclear Sox2 protein was present in 
PGCs within the mouse embryonic testis and ovary (E13.5 and E12.5 respectively; Figure 
3.2 A, B). As the PGC is the precursor to the EGC, the ICM is the starting cell-type for 
ESC derivation. Nuclear Sox2 was also clearly detected within the ICM of mouse 
blastocysts (Figure 3.2 D) (Avilion et al. 2003). In human blastocysts, SOX2 detection was 
more diffuse but included nuclear localisation within the ICM (Figure 3.2 C). These data, 
demonstrating an inter-species difference in PGC SOX2/Sox2 expression, were further 
validated by immunoblotting of protein isolated from fetal gonads (Figure 3.2 E). SOX2 
was present as a 35 kDa band in protein isolates from mouse gonads at E14 but not from 
the corresponding human organs. OCT4 detection is shown as a positive control for the 
presence of PGCs. 
 
3.4.2 SOX2-Negative Germ Cells are Proliferative in situ 
The SOX2-negative human germ cells included ones that were proliferative in situ, 
as demonstrated by dual immunoreactivity for OCT4 and the proliferative marker MK167, 
marked by the Ki67 antibody
26 (Figure 3.3). There were more of these double-stained cells 
in the embryonic ovary (Figure 3.3 A) than in the embryonic testis (Figure 3.3 B), 
consistent with male PGCs entering mitotic arrest following testicular cord formation. 
                                                 
26 Ki-67 is a commercially available monoclonal antibody that reacts with a nuclear antigen expressed in 
proliferating cells but not in quiescent cells. Expression of this antigen occurs preferentially during late G1, 
S, G2, and M phases of the cell cycle, while in cells in G0 phase the antigen cannot be detected.  85
 
Figure 3.2 SOX2 expression in human and mouse embryonic gonads and 
blastocysts 
Immunocyto/histochemistry for SOX2 in mouse embryonic testis (A; E13.5), ovary (B; 
E12.5; insets show IHC combined with AP staining), and human (C) and mouse (D) 
blastocysts. Size bars represent 50 μm. E. Immunoblotting for the detection of SOX2, 
OCT4 and β-actin in mouse and human embryonic gonads. Positive control, NTERA-2 
D1 hECCs; negative control, PANC1 cells. Ovarian and testicular samples were 
prepared from at least three human fetuses. [Parts C and D Dr. Judith Eckert, 
Developmental Origins of Health and Disease Division, University of Southampton.] 
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Figure 3.3 PGCs are proliferative in situ during early human development 
Dual IHC for OCT4 and the proliferation marker MK167, identified using the Ki67 
antibody, in human embryonic ovary (A) and testis (B). Arrows point to examples of 
PGCs that are dual stained. From left to right, individual band pass images are shown 
for FITC (OCT4), Texas Red (Ki67), dual band pass image (OCT4 and Ki67) and 
DAPI. Size bar represents 100 μm. 
 
3.4.3 Redundancy is Unlikely to Compensate for Absence of SOX2 in 
Human Germ Cells 
One potential explanation for this species difference is redundancy for SOX2 
within Group B of the SOX  gene family, which comprises SOX1,  SOX2,  SOX3 (the 
SOXB1 group), and SOX14 and SOX21 (SOXB2). This group shows significant homology 
both between and within the B1 and B2 groups (Figure 3.4). 
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Figure 3.4 Comparison of the domain organisation of chick SOXB proteins 
Conserved subdomains within the B1 and B2 subgroups are indicated. Between 
subgroups B1 and B2, homology is found within the Group B homology domain, 
depicted in red, in addition to the HMG domain. [Adapted from Kamachi et al. (2000).] 
 
By RT-PCR for 35 cycles (Figure 3.5), SOX2, SOX3, SOX14 and SOX21 transcripts 
were detected robustly in both hESCs (HUES1) and hECCs (NTERA-2 D1). The weak 
detection of SOX1 in hESCs may represent low level expression per se or, feasibly, minor 
spontaneous ectodermal differentiation as is commonly encountered in hESC culture. 
However, all transcripts were absent in four samples of human testes collected during the 
late embryonic and early fetal periods (51-59 dpc). Only SOX14, encoding a putative 
repressor of SOX2 function (Uchikawa et al. 1999), was clearly detected within the ovary 
after amplification for 35 cycles. In four ovarian samples ranging from 51 to 61 dpc, 
expression of SOX1 and SOX21 was weakly discernable in some samples. The failure to 
detect SOX2 transcripts within these testicular and ovarian samples following extensive 
PCR cycles corroborates the protein data from immunohistochemistry and immunoblotting 
(Figure 3.1 and Figure 3.2). 
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Figure 3.5 The potential for SOX2 redundancy in the human germ cell lineage 
RT-PCR panel is shown for members of the Group B SOX  gene family in hESCs 
(HUES1), hECCs (NTERA-2 D1 cells), and one of four samples each of human fetal 
testis and fetal ovary at 8 wpc, following PCR for 35 cycles. Abbreviations: c, control - 
the housekeeping gene HPRT  (hypoxanthine-guanine phosphoribosyl-transferase); 
ECC, embryonal carcinoma cell; ESC, embryonic stem cell. For primer sequences see 
Appendix 1. 
 
3.4.4 SOX2 in Human Embryonal Carcinoma Cell Lines 
The ECC represents malignant transformation of the PGC. SOX2 expression was 
examined in different ECC lines. In contrast to NTERA-2 D1 cells, once taken into culture 
some ECs have yielded nullipotent cell lines that are no longer capable of differentiation to 
derivatives of all three germ layers, for example TERA-1 and 2102Ep cells (Damjanov 
1990; Harrison et al. 2007). However SOX2 expression did not correlate with pluripotency 
versus nullipotency: it was clearly expressed equivalently in both pluripotent and 
nullipotent hECCs localising indistinguishably to the nucleus in all lines tested (Figure 3.6 
A-C), and confirmed by immunoblotting (Figure 3.6 D).  89
 
Figure 3.6 OCT4 and SOX2 expression in hECCs 
A-C: Immunocytochemistry for OCT4 and SOX2 in hECC lines fixed after culture on 
fibronectin-coated glass slide. A. pluripotent hECC line, NTERA-2 D1 and nullipotent 
hECC lines B. TERA-1 and C. 2102Ep. Individual band pass images are shown for 
FITC (left: OCT4), DAPI, and Texas Red (right: SOX2). Size bar represents 40 μm. D. 
Immunoblotting for the detection for SOX2, OCT4 and β-actin in NTERA-2 D1, TERA-
1 and 2102Ep hECC lines.  90
3.4.5 Human Germ Cells Persisting in Culture in vitro Remain SOX2-
Negative 
Human germ cell cultures have been previously assigned as ‘poorly proliferative’ 
(‘PP’) or ‘vigorously proliferative’ (‘VP’), according to their growth characteristics, with 
the latter taken as indicative of conversion to the EGC state (Turnpenny et al. 2003). Akin 
to ESCs, hEGCs demonstrate expression of the nuclear transcription factor OCT4 and AP 
activity (Turnpenny et al. 2006). However, SOX2, required for the maintenance of 
pluripotent ESCs (Avilion et al. 2003), was not expressed in the human germ line in situ. 
In order to test whether SOX2 expression was induced in culture, numerous human gonad-
derived cultures were established and samples of both PP and VP/EGC cultures were 
analysed. OCT4/OCT4 and AP activity served as positive controls for the presence of the 
germ cell lineage. Neither SOX2 protein nor SOX2 transcripts were detected by 
immunoblotting or RT-PCR, respectively, in either early, PP or VP/EGC cultures (Figure 
3.7). 
 
3.4.6 SOX2 is Dispensable for the Expression of Genes Previously 
Identified to Require OCT-SOX Interaction or Cooperative OCT4-SOX2-
NANOG Function 
Given the absence of SOX2 in human germ cells, yet the presence of both OCT4 and 
NANOG, a selection of genes which are recognised as targets of these critical transcription 
factors were investigated. OCT4 and SOX2 are known to act cooperatively in up-
regulating  FGF4 (Ambrosetti et al. 1997), UTF1 (Nishimoto  et al. 1999) and FBX15 
(Tokuzawa  et al. 2003). However, despite the absence of SOX2, UTF1 and FBX15 
transcripts were detected in the human fetal ovary and testis. In contrast, FGF4 was absent 
(Figure 3.8 A). A further set of 13 genes were analysed, which are expressed in ESCs 
when the respective promoter regions are bound by OCT4, NANOG and SOX2 (Boyer et 
al. 2005). All 13 stem cell-restricted transcripts were detected in fetal gonads, albeit more 
weakly for DKK1, SET, ZIC3 and STAT3 in the human fetal ovary (Figure 3.8 B).  91
 
Figure 3.7 SOX2 is not detected in human germ cell cultures 
A. Image of germ cell-derived culture showing colonies after one week that were 
positive for AP activity. Size bar represents 2 mm. B. Immunoblotting for the detection 
of SOX2, OCT4 and β-actin. Left column, germ cell culture; positive control, NTERA-2 
D1 cells; negative control, PANC1 cells. Four OCT4-positive/AP-positive cultures were 
analysed after one week and SOX2 was not detected in any of them. C. Image of a 
passaged germ cell culture fulfilling VP/EGC criteria. Size bar represents 250 μm. D. 
RT (+) of mRNA isolated from the EGC culture shown in C after 3.5 weeks and PCR 
for 32 cycles. NTERA-2 D1 cells (NT2) and ESCs are shown as positive controls. 
Omission of RT (-) is shown as negative control. The same results were obtained from 
another EGC culture. [Parts C and D Dr. Lee Turnpenny, Human Genetics Division, 
University of Southampton.] For primer sequences see Appendix 1. 
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Figure 3.8 RT-PCR analysis of genes regulated by SOX-OCT enhancers and 
those identified by bioinformatic analysis as targets of OCT4, NANOG and SOX2, 
following PCR for 35 cycles 
A. Genes previously recognised as targets of OCT4 and SOX2 (Ambrosetti et al. 
1997; Nishimoto et al. 1999; Tokuzawa et al. 2003) and B. genes previously described 
to be expressed in human ESCs when OCT4, NANOG and SOX2 are bound to the 
respective promoter regions (Boyer et al. 2005). NANOG and HPRT are shown in A as 
controls. Abbreviations
27. For primer sequences see Appendix 1. 
                                                 
27 FGF4, fibroblast growth factor 4; UTF1, undifferentiated embryonic cell transcription factor 1; FBX15, F-box only 
protein 15; HPRT, hypoxanthine-guanine phosphoribosyl-transferase; TDGF1, teratocarcinoma-derived growth factor 
1; DKK1, Dickkopf Xenopus, homolog of 1; SKIL, SKI-like; DPPA4, developmental pluripotency associated gene 4; 
CMYC, myelocytomatosis oncogene;  GJA1, gap junction protein, alpha 1; REST, RE-1 silencing transcription factor; 
MYST3, MYST histone acetyltransferase; SMARCAD1, SWI/SNF-related, matrix-associated actin-dependent 
regulator of chromatin, subfamily a, containing DEAD/H box 1; HESX1, homeobox gene expressed in ESCs; SET, 
suppressor of variegation, enhancer of zeste and Trithorax; ZIC3, zinc finger protein of cerebellum; STAT3, signal 
transducer and activator of transcription 3; ECC, embryonal carcinoma cell;  ESC, embryonic stem cell.  93
3.5 DISCUSSION 
Studies have demonstrated that pluripotent stem cells share gene and marker 
expression, growth characteristics and tumourigenic capability. hEGCs share some of these 
characteristics: these cells express the transcription factors OCT4 and NANOG, the surface 
markers SSEA4, TRA1-60 and TRA1-81, AP activity, and differentiate in vitro (Shamblott 
et al. 1998; Turnpenny et al. 2003; Liu et al. 2004; Aflatoonian and Moore 2005; Pan et al. 
2005). However, hEGCs have not been demonstrated, thus far, to generate teratomas upon 
engraftment or injection into nude mice (Turnpenny et al. 2006), a criterion for 
pluripotency. The cells do not remain undifferentiated long-term in vitro, and clonal 
expansion has not been shown. 
This study sought to determine whether hEGCs lacked a critical factor(s), or 
whether attempts to derive hEGCs fail to induce and/or retain the expression of a key 
gene(s) required for the maintenance of self-renewal and pluripotency. 
 
3.5.1 The Human Germ Cell Lineage Does Not Express SOX2 
Data herein demonstrate that hPGCs within the embryonic/early fetal (48-73 dpc) 
testis and ovary do not express SOX2, a gene identified as fundamental to stem cell 
pluripotency (Avilion et al. 2003; Boyer et al. 2006). In addition, hPGCs and hEGCs in 
culture also fail to express SOX2. This contrasts with the germ cell lineage in the mouse: 
mPGCs (data herein) and mEGCs (Western et al. 2005; Sharova et al. 2007) express 
SOX2. This difference in gene expression is contrary to predictions from previous studies 
(Western et al. 2005), or previously presumed conservation (Clark 2007). The absence of 
SOX2 in the early human germ cell lineage was confirmed as a lack of both transcripts and 
protein. In contrast, SOX2 was present in the human ICM, ESCs, and various ECCs. 
Levels of Sox2 and Oct4 are known to alter in cells derived from different stages of mouse 
development; mouse germline stem cells, which are cultured spermatogonial stem cells of 
highly restricted developmental potential, express abundant transcripts, but limited Sox2 
and Oct4 protein (Imamura et al. 2006). However, mPGCs clearly express Sox2 (Western 
et al. 2005 and data herein). These data make the human early germ cell lineage unique in 
expressing OCT4 and NANOG, yet lacking SOX2, both in vivo and in in vitro culture. 
The regulation of SOX2 in germ cells must differ from that in ESCs (and 
presumably the epiblast) where an upstream enhancer is bound by OCT4 and a further 
downstream composite element by both OCT4 and SOX2 (Catena et al. 2004; Chew et al.  94
2005). The high inter-species sequence conservation of these elements and the wider SOX2 
locus suggest that alternative factors, such as epigenetic mechanisms, may be responsible 
for divergent SOX2 expression (Katoh and Katoh 2005; Zhan et al. 2005). Although the 
earliest germ cell lineage is inaccessible in humans (i.e. prior to those cells in the gut 
mesentery at 6-7 weeks), the failure to detect SOX2 within the earliest specimens (48 dpc) 
implies that SOX2 must be extinguished during germ cell specification from cells of the 
SOX2-positive epiblast or soon afterwards. As reports unfold of hESCs differentiated 
towards functional germ cells (Clark et al. 2004; Aflatoonian and Moore 2006), it will be 
interesting to observe whether SOX2 disappears in mimicry of normal human 
development. 
Redundancy amongst Group B SOX family members would limit functional 
consequences of absent SOX2 for the hPGC, however, this appears unlikely, as only 
SOX14 was detected clearly in fetal ovary samples and only after relatively high numbers 
of PCR cycles. Furthermore, to date, this transcription factor has been recognised to 
counteract, rather than substitute for the role of SOX2 (Uchikawa et al. 1999). 
 
3.5.2 SOX2: Necessary but not Sufficient for Pluripotency 
The collective data infer that, alongside OCT4 and NANOG, SOX2 is necessary 
but not sufficient for pluripotency. The epiblast from Sox2-null mice fails to progress in 
vivo and Sox2-null blastocyst outgrowths fail to generate ESCs in vitro (Avilion et al. 
2003); however, whereas mPGCs give rise to robust pluripotent EGC lines, the Sox2-
positive PGCs themselves are nullipotent (Donovan and de Miguel 2003). Similarly, 
although previous data on nullipotent hECC lines were largely limited to analysis of 
transcripts (Sperger et al. 2003), this study reveals relatively equivalent quantities of 
correctly localised nuclear SOX2 protein regardless of an ability for broad differentiation. 
The few groups to record hEGC derivation to date have all demonstrated 
differentiation in vitro to cells that represent the three germ layers. However, none has 
reported teratoma formation in vivo; although this was attempted within our group 
(Turnpenny et al. 2006). Stable transfection of hSOX2 cDNA into cultured human germ 
cells has also been attempted; however, no teratomas formed upon engraftment of these 
cells into immunocompromised mice, and reliable long-term SOX2-positive cultures were 
not generated (Dr. Marie Best, Human Genetics Division, University of Southampton; 
pers. comm.). Aside from the graft environment being foreign, human germ cell  95
proliferation would be expected as, distinct from the mouse epiblast (Avilion et al. 2003), 
SOX2 is dispensable for hPGC and EGC proliferation in vitro. Furthermore, germ cells 
were proliferative in situ during development. Discovery of ways to induce SOX2 
expression in cultured human germ cells will be important to facilitate further work in this 
area. Indeed, with the initiation of neoplastic transformation of human germ cells proposed 
to occur in utero (Rajpert-De Meyts 2006), the absence of SOX2 in proliferative hPGCs 
may explain the predilection for testicular seminomas in humans compared to mice. 
Further experiments to investigate the role of SOX2 in pluripotent cells included attempts 
to generate long-term clones of NTERA-2 cells with reduced SOX2 expression using two 
SOX2 siRNA vectors; however, such clones could not be established, despite clones being 
obtained with the control vector (containing siRNA directed against the luciferase gene). 
This may indicate a fundamental requirement for SOX2 in pluripotent cells.  
 
3.5.3 Expression of OCT4-SOX2-NANOG Target Genes in Human PGCs 
Identifying the consequences of missing SOX2 offers comparative insight into its 
role when present in other cell types. Where co-expressed, SOX2 is considered to act 
cooperatively with OCT4 and NANOG in regulating critical cohorts of target genes. From 
bioinformatic studies, their collective association with gene promoters is proposed to 
induce the expression of genes that determine self-renewal, whilst repressing those 
associated with differentiation (Boyer et al. 2005). Data herein suggest that SOX2 is 
dispensable in the former function as in its absence all 13 of the arbitrarily selected ‘ESC-
restricted’ target genes from Boyer and colleagues, as well as UTF1 and FBX15, were 
expressed in the fetal ovary and testis. Indeed, most recently, evidence has been published 
that the major role for Sox2 in mESCs is in maintaining Oct4 expression (Masui et al. 
2007). This implies that the regulation of both OCT4 and SOX2 is different in human germ 
cells; SOX2 on account of its absence, and OCT4 due its independence from SOX2 protein. 
In contrast, the data do support a pivotal role for SOX2 in promoting FGF4 expression 
(Yuan et al. 1995; Ambrosetti et al. 1997); FGF4 transcripts were undetected in the SOX2-
negative germ cell lineage. The difference between FBX15 (present) and FGF4 (absent) is 
interesting as both have been shown hypermethylated and correspondingly absent in mouse 
germline stem cells (Imamura et al. 2006). 
These findings suggest that exogenous FGF addition to the media might be able to 
compensate for the lack of SOX2 in cultured human germ cells. Although FGF2 has been  96
added to human germ cell cultures by all groups reporting derivation, definitive evidence 
for the roles of any FGF family member in human equivalents is lacking (Turnpenny et al. 
2006). 
Finally, it has been discussed whether, on the basis of gene expression profiles, the 
closest equivalent of the hESC is an early germ cell and, indeed, whether ESC derivation 
arises from an early germ cell phenotype (Zwaka and Thomson 2005). On the basis that the 
earliest human germ cells detected are SOX2-negative, and remain so – including in 
culture – this theory appears unlikely. 
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3.5.4 Summary 
Studies described in this chapter analysed the expression of OCT4, NANOG and 
SOX2 during early human germ cell development in comparison with that in hESCs, 
various ECCs, EGCs and mPGCs. The data highlight a stark human-mouse species 
difference, confounding previous predictions of human development (Western et al. 2005) 
and demonstrating the limitations of inter-species extrapolation. Surprisingly, despite the 
absence of SOX2, many of the stem cell-restricted target genes reported to require OCT4 
and SOX2 (Ambrosetti et al. 1997; Nishimoto et al. 1999; Tokuzawa et al. 2003) or 
OCT4, NANOG and SOX2 (Boyer et al. 2005) remained expressed in the human fetal 
gonad. Furthermore, in contrast to the epiblast of Sox2-null mice (Avilion et al. 2003), 
SOX2-negative germ cells were able to grow in culture with retained expression of 
pluripotent markers. These data highlight SOX2 as an important transcription factor for 
further investigation in attempts to understand the relationship between hPGCs, GCTs and 
the derivation, self-renewal and pluripotency of hEGCs. The information is also instructive 
to attempts at generating human gametes from stem cell sources for ambitious fertility 
treatments.  
Taken together, the data demonstrate a striking inter-species difference in the 
transcription factor determinants of pluripotency and a lack of stringency regarding their 
collective presence to elicit characteristic gene expression ‘signatures’. 
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CHAPTER 4: SOX2 Expression in Normal and 
Neoplastic Germ Cell Derivatives and its 
Association with Pluripotency 
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4.1 ABSTRACT 
The transcriptional regulators of pluripotency, OCT4, NANOG and SOX2, are 
highly expressed in embryonal carcinoma (EC). In contrast to OCT4 and NANOG, SOX2 
has not been demonstrated in seminoma and in carcinoma in situ (CIS), a common 
precursor of these testicular germ cell tumours (TGCTs). This study sought to clarify this 
unusual pattern and examined SOX2 expression at the mRNA and protein level in CIS and 
a panel of TGCTs, and compared this to the developmental ontogeny of SOX2 in normal 
testes.  
In contrast to earlier studies, SOX2 expression was found in CIS and normal fetal, 
neonatal and adult testes. Cytoplasmic immunoreactivity was detected in fetal 
prespermatogonia and nuclear staining in a subset of adult spermatogonia and 
spermatocytes. Nuclear SOX2 protein was abundant in EC, absent in seminoma, but 
detected in a small subset of CIS cells as well as in a subset of Sertoli cells. However, 
SOX2 mRNA was detected in most CIS cells and in focal areas of seminomas. SOX2 was 
also detected in spermatocytic seminoma, a tumour not derived from CIS.  
Changes in subcellular protein localisation during germ cell maturation are likely 
related to differing regulation of SOX2 during development and in adult spermatogenesis. 
The presence of SOX2 mRNA in seminoma, despite the absence of protein, suggests post-
transcriptional regulation linked to the germ cell phenotype. The expression of SOX2 
protein in a subset of CIS cells may be linked to re-programming towards a pluripotent 
phenotype. 
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4.2 INTRODUCTION 
4.2.1 Human Testicular Germ Cell Development: An Overview 
The migration of germ cells into the developing gonad has already been described 
(Section 1.10.2). However, the subsequent development of germ cells into gonocytes and 
eventually functional spermatozoa, has not. In the developing testis gonocytes begin to 
migrate towards the periphery of the cords during the 14
th week of development. Once in 
close contact with the basal lamina, they are referred to as prespermatogonia. By the 20
th 
week, prespermatogonial germ cells make up the majority of germ cells in the fetal testis 
(Gondos and Hobel 1971). During infancy the testis is not quiescent (Chemes 2001): at 
around 2-4½ months, a transient increase in the production of testicular hormones occurs, 
known as the ‘mini-puberty’ (Forest et al. 1973), which coincides with the final stage of 
differentiation of gonocytes into infantile spermatogonia (Hadziselimovic et al. 1986). The 
newborn period is characterised by a higher rate of germ cell proliferation and a lower rate 
of germ cell apoptosis than in the rest of prepuberty (Berensztein et al. 2002). During 
infancy, there are abortive attempts at spermatogenic maturation, ending with the 
degeneration of newly developed spermatocytes, similar to the first waves of incomplete 
spermatogenesis that occur during puberty. These initial waves of incomplete 
spermatogenesis mean that 2-4 years pass between the onset of puberty and the acquisition 
of fertility, equivalent to 20-30 spermatogenic waves (Rey et al. 1993). Fertility is acquired 
when spermatogonia undergo meiotic divisions and successfully mature to form 
spermatozoa. Figure 4.1 depicts the stages of spermatogenesis in the adult human testis. 
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Figure 4.1 Spermatogenesis in the adult human testis 
A. Bright-field image of a transverse section of a seminiferous tubule within normal 
adult testis; black box surrounds spermatogonium in contact with basal lamina, 
primary spermatocyte and spermatids. Size bar represents 20 μm. B. Summary of 
spermatogenesis. Diploid primordial germ cells migrate to the genital ridge and 
undergo mitosis forming spermatogonia. These self-renew as stem cells via mitosis or 
undergo two stages of meiosis to form haploid spermatids, which then differentiate 
(spermiogenesis) to form sperm. This process takes about 72 days in man. 
 
4.2.2 Heterogeneous Subpopulations of Germ Cells Exist During 
Development 
In mice,
 PGCs within the testis cords differentiate into a single population
 of fetal 
germ cells, usually referred to as ‘gonocytes’, that
 actively proliferate until about 15.5 dpc, 
and then remain
 arrested in G1 until day 1.5 postpartum, when they resume mitotic
 activity 
(Vergouwen et al. 1991; Nagano et al. 2000). Two days before they resume reproliferation,
 
gonocytes relocate to the periphery of the cord, make contact
 with the basement membrane, 
and thereafter undergo further
 differentiation.  
In contrast, germ cell maturation in humans is a gradual process, with a 
heterogeneous population of germ cells existing at any one time. In the second trimester all 
germ cells in the testis express DAZL (Ruggiu et al. 2000), VASA (Castrillon et al. 2000) 
and CHKD (Bartkova et al. 2001). However, other proteins are only expressed by 
subpopulations of these cells. Gaskell et al. (2004) identified three populations of germ 
cells: gonocytes (OCT4
pos/c-KIT
pos/MAGE-A4
neg),
 intermediate germ cells (OCT4
low/neg/c-
A B  102
KIT
neg/MAGE-A4
neg), and
 prespermatogonia (OCT4
neg/c-KIT
neg/MAGE-A4
pos). In the first
 
trimester, most germ cells have a gonocyte phenotype; however,
  from 18 weeks of 
gestation, prespermatogonia are the most abundant
 cell type. Pauls et al. (2006) described 
fetal male germ cells as being comprised of two groups with distinct immunohistochemical
 
phenotypes: germ cells predominantly found before week
 25 of gestation co-express the 
proteins OCT4, c-KIT,
 M2A and AP2γ. After week 25, most germ cells have lost their
 
pluripotent potential and acquire a spermatogonial phenotype
  defined by expression of 
MAGE-A4. Kerr et al. (2008) demonstrated that PGCs initially express SSEA1, SSEA4, 
OCT4, NANOG, AP, and c-KIT but during early differentiation prior to mitotic arrest they 
gradually loose OCT4, AP and NANOG expression while retaining that of c-KIT and 
VASA. 
Pluripotent stem cells have been isolated from neonatal mouse testis; termed 
multipotent germline stem cells (Kanatsu-Shinohara et al. 2004). These ES-like cells are 
phenotypically similar to ESCs/EGCs except in their genomic imprinting pattern. A subset 
of spermatogonial stem cells in adult mouse testes retain the embryonic phenotype of 
PGCs and gonocytes; these spermatogonial stem cells [termed multipotent adult germline 
stem cells (Nayernia 2007)] have been isolated and exhibit properties similar to ESCs; they 
are pluripotent and express Oct4, Sox2 and Nanog (Guan et al. 2006; Seandel et al. 2007). 
No cells retaining such an embryonic phenotype are present in adult human testes; germ 
cells expressing NANOG and OCT4 (together with c-KIT and AP2γ) are rapidly down-
regulated from the second half of pregnancy until 2-4½ months of postnatal age (Rajpert-
de Meyts et al., 2004; Hoei-Hansen et al., 2005). However downstream factors identified 
in ESCs, UTF1 and REX1 (Niwa, 2001; Nishimoto et al., 2005), continue to be expressed 
throughout the male development in spermatogonia and are still present in the adult testes 
(Kristensen et al. 2008). Therefore a partial embryonic phenotype of the germ cells is still 
evident in the mature human testes. 
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4.2.3 TGCTs: A Classification 
TGCTs that occur in young adults are subdivided into two histologically distinct 
groups; seminomas (also called classical seminoma to distinguish from spermatocytic 
seminoma) and nonseminomatous GCTs, each constituting approximately 50%. Whereas 
the seminoma is generally a uniform tumour and resembles early fetal germ cells, the 
nonseminomas are very heterogeneous and encompass embryonal carcinoma (EC), 
choriocarcinoma (CC), teratomas (TER), yolk sac tumour (YST), and can also contain 
elements of seminoma (SEM) (Ulbright et al., 1999). These tumours mimic different 
stages of embryogenesis; ECs are pluripotent and undifferentiated like the ICM, TERs 
contain the differentiated somatic cells found in the embryo, and CCs and YSTs show 
extraembryonic differentiation (see Table 1.2 for a summary). 
The carcinoma in situ (CIS) cell, also known as intratubular germ cell neoplasia 
(ITGCN) or testicular intraepithelial neoplasia (TIN), was first identified in 1972 and is the 
preinvasive stage of TGCTs of adolescents and young adults (Skakkebaek 1972). 
Spermatocytic seminomas in elderly men and infantile germ cell tumours are additional 
types of TGCT which do not arise from CIS cells (Muller et al. 1987). Both of these 
tumour types are rare and have remained at a steady low incidence level (Visfeldt et al. 
1994). The opposite is true for the TGCTs in young adults, which have increased in 
incidence over the last several decades and now constitute the most prevalent malignant 
cancer among young male adults in Northern and Western Europe (Richiardi et al. 2004).  
 
4.2.4 CIS Cells Express both Fetal and Pluripotent Markers 
    CIS cells have many morphological similarities with PGCs and early gonocytes 
(Nielsen  et al., 1974; Albrechtsen et al., 1982; Skakkebaek et al., 1987). They share 
expression of immunohistochemical markers such as placental-like alkaline phosphatase 
(PLAP) and the stem cell factor receptor c-KIT (Giwercman et al. 1991; Rajpert-De Meyts 
and Skakkebaek 1994; Jorgensen et al. 1995). These markers are commonly used in the 
clinical setting to help identify CIS in surgical biopsies. A fetal origin is also supported by 
the identification of CIS cells in prepubertal patients who later developed TGCTs, 
indicating that the cells had originated prior to puberty (Muller et al. 1984). More recently, 
the expression profiles of CIS cells studied by microarrays (Almstrup et al. 2004; 
Skotheim  et al. 2006) provided a series of candidate marker genes, such as TFAP2C  104
(Transcription factor activator protein-2C; AP2γ) (Hoei-Hansen et al. 2004), which has 
shown promising results as a possible marker of CIS cells in semen samples (Hoei-Hansen 
et al. 2007). 
    Studies in mouse and human ESCs indicate that the transcription factors OCT4, 
SOX2 and NANOG are crucial in maintaining pluripotency, and do so by acting 
cooperatively (Boyer et al. 2005; Loh et al. 2006). The three factors are co-expressed 
simultaneously in the pluripotent cells in the embryo and homozygous knock-out of any of 
them in the mouse causes failure of the epiblast to form (Nichols et al. 1998; Avilion et al. 
2003; Mitsui et al. 2003). Nuclear OCT4 and NANOG proteins have also been identified 
in fetal PGCs, gonocytes, seminoma, gonadoblastoma and in overt TGCTs derived from 
CIS except for fully differentiated TERs (Avilion et al. 2003; Gidekel et al. 2003; 
Looijenga et al. 2003; Honecker et al. 2004; Jones et al. 2004; Rajpert-De Meyts et al. 
2004; Hart et al. 2005; Western et al. 2005; Kerr et al. 2008; Perrett et al. 2008).  
Genome-wide expression profiling has revealed that the genes expressed by CIS 
cells and hESCs may overlap by as much as 50% (Almstrup et al. 2004). In particular, 
OCT4 and NANOG were amongst the highest expressed genes in testes containing CIS 
compared to normal adult testes. Indeed, the expression of these transcription factors and 
other fetal germ cell markers by CIS cells can be viewed as support for the origin of CIS 
cells from gonocytes that failed to mature to spermatogonia (Rajpert-De Meyts 2006).  
In comparison, the expression profile of SOX2 is less clear. The gene was not 
among those significantly up-regulated in testes with CIS (Almstrup et al. 2004) instead, 
increased expression of SOX17 has been reported (Almstrup et al. 2007). In contrast, 
nuclear SOX2 has been described in nonseminomatous TGCTs but not in CIS (Korkola et 
al. 2006) and is absent in seminomas (Santagata et al. 2007). It has also been reported 
negative in germ cells during later development but positive in Sertoli cells surrounding 
CIS (de Jong et al. 2008). Although SOX2 is present in mPGCs as both transcripts and 
protein (Western et al. 2005), the gene is not expressed in hPGCs (Perrett et al. 2008). 
Thus, compared to studies in mouse, SOX2 expression is divergent from that of OCT4 and 
NANOG in the untransformed human germ cell lineage. However, all three transcription 
factors appear present in EC, which is considered a pluripotent TGCT type (Skotheim et al. 
2005). 
 
From these studies it is evident that molecular understanding of the phenotypic 
differences amongst TGCT types and their relationship to CIS is incomplete. This study  105
sought to extend these previous studies and clarify the expression of SOX2, OCT4 and 
NANOG by systematic analyses of over thirty samples of TGCTs and CIS, and a broader 
range of TGCT types than previously reported. 
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4.3 SPECIFIC AIMS 
4.3.1 To characterise the spatiotemporal expression profile of SOX2 
during human testicular development from the second and third 
trimester until adulthood. 
Immunohistochemistry (IHC) was used to determine the spatiotemporal expression 
profile of SOX2 in samples of fetal (mid-gestation: 14, 23, 29 and 39 wpc); postnatal (2, 3 
and 4 months after birth) and prepubertal testis (1, 2.5, 8 and 10 years); and fetal ovarian 
(mid-gestation: 15, 25 and 38 wpc) samples held at the Department of Growth and 
Reproduction, Copenhagen University Hospital, Denmark. 
 
4.3.2 To characterise the expression profile of SOX2 in various types 
of TGCTs, and their precursors, CIS cells. 
A substantial selection of carcinoma samples were analysed using IHC for SOX2 
(along with OCT4, NANOG and PLAP), utilising the collection held at the Department of 
Growth and Reproduction, Copenhagen University Hospital, Denmark. Eleven samples of 
CIS (comprising CIS-only samples and also those adjacent to seminoma, nonseminoma 
and mixed tumours); nine nonseminomatous tumour components (comprising four EC, 
three mixed tumours and two teratomas), and six samples of seminoma (three seminoma-
only and three mixed) were examined. In situ hybridisation (ISH) was used to validate 
SOX2 expression in three samples each of seminoma and nonseminoma (EC), two samples 
of CIS and three of normal testicular tissue. 
 
4.3.3 To characterise SOX2 expression in testicular tumours not 
derived from CIS. 
IHC was used to determine whether SOX2 was expressed in spermatocytic 
seminoma (four samples) and testicular B-cell lymphoma (one sample).  107
4.4 RESULTS 
The results obtained for SOX2 IHC and ISH in the normal and neoplastic 
specimens are summarised in Table 4.1. 
 
4.4.1 Testicular SOX2 Expression During Mid- to Late-Gestation and 
After Birth 
SOX2, in stark contrast to OCT4 and NANOG, is absent from PGCs/gonocytes in 
specimens from the first trimester of human development (Perrett et al. 2008 and Chapter 
3). Here, by IHC, SOX2 was not detected in a sample of fetal testis at 14 wpc (Figure 4.2 
A). The majority of germ cells at this stage express OCT4 and NANOG (Honecker et al. 
2004; Rajpert-De Meyts et al. 2004; Hoei-Hansen et al. 2005). By 23 wpc, expression of 
OCT4 and NANOG is only observed in approximately 0-2% of cells (Honecker et al. 
2004; Rajpert-De Meyts et al. 2004; Hoei-Hansen et al. 2005). At this stage, 
immunoreactivity against SOX2 was apparent, localised to the cytoplasm of a few germ 
cells (arrowheads in Figure 4.2 B). Counts of ten fields of vision demonstrated 56% of 
tubules contained at least one SOX2-positive germ cell in testis of this age. Fewer germ 
cells demonstrated immunoreactivity at 29 and 39 wpc (approximately 50% of tubules 
contained at least one SOX2-positive germ cell), when staining was predominantly 
perinuclear, although some cytoplasmic staining was still visible (arrowheads in Figure 4.2 
C for 29 wpc).  
Postnatally, at 2 and 4 months of age (Figure 4.2 D and E respectively), some weak 
staining was observed in presumed prespermatogonia, which was frequently cytoplasmic 
(arrowhead in Figure 4.2 E) but occasionally included nuclear localisation (arrowhead in 
Figure 4.2 D), again with approximately 50% of tubules containing a SOX2-positive germ 
cell. At these stages, some staining was also observed in undifferentiated Sertoli cells. 
Weak cytoplasmic staining for SOX2 within germ cells was observed in testis 12 months 
of age (arrowheads on Figure 4.2 F), with only 8% of tubules containing a positive cell. 
Weak nuclear staining in some cells at the base of the tubules was observed in a testis 
specimen of 2.5 years of age (Figure 4.2 G; marked with arrowheads); 27% of tubules 
contained a positive cell. 
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IHC ISH 
Tissue and cell type   Age  N 
Staining  Intensity and location 
N 
Staining  Intensity and location 
    Fetal and prepubertal testis 
Gonocytes   14 wpc  1  -  None  ND 
Prespermatogonia 23  wpc  1  +/- Weak  cytoplasmic  ND 
Prespermatogonia 29  wpc  1  +/- Weak 
cytoplasmic/perinuclear  ND 
Prespermatogonia 39  wpc  1  +/- Weak 
cytoplasmic/perinuclear  ND 
Infantile spermatogonia  2 m  1  +/-  Weak 
cytoplasmic/perinuclear  ND 
Infantile spermatogonia  3 m  1  +/-  Weak 
cytoplasmic/perinuclear  ND 
Infantile spermatogonia  4 m  1  +/-  Weak 
cytoplasmic/perinuclear  ND 
Infantile spermatogonia  1 y  1  +/- (very 
occasional)  Weak cytoplasmic  ND 
Infantile spermatogonia  2.5 y  1  +/- (very 
occasional)  Weak nuclear  ND 
Prepubertal spermatogonia  8 y  1  -  None  ND 
Prepubertal spermatogonia  10 y  1  -  None  ND 
   Ovary 
Oogonia 15  wpc  1  -  None  ND 
Oocytes  25 wpc  1  +/-  Weak cytoplasmic   ND 
Oocytes  38 wpc  1  +/-  Weak cytoplasmic   ND 
    Adult testis (including normal tubules in vicinity of CIS) 
Spermatogonia Adult  9  ++  Medium  nuclear 3  +  Medium  cytoplasmic 
Sertoli, undifferentiated in 
CIS tubules  Adult  9 ++  Medium  nuclear    2 ++  Weak  cytoplasmic 
Spermatocytes Adult  9  +/-  Weak  nuclear 3  ++  Weak  cytoplasmic 
Spermatids Adult  9  -  None 3  +  Weak  cytoplasmic 
   Testicular neoplasms 
CIS Adult  11  ++  Weak  nuclear  2 ++  Strong/weak  cytoplasmic 
Seminoma  Adult  6 -  None  3 ++  Medium  cytoplasmic 
Lymphocytes (infiltrating 
seminomas)  Adult 4  +/-  Weak  -  ND  Lymphocytes 
Embryonal carcinoma  Adult  5  +++ 
Strong nuclear; 
overlaps with OCT4 
and NANOG positive 
areas 
3 +++  Strong  cytoplasmic 
Teratoma Adult  4  ++  Strong  nuclear  -  ND 
Spermatocytic seminoma  66 y 
(42-87)  4 +/-  Weak  cytoplasmic  -  ND 
Testicular B-cell lymphoma  58 y  1  -  None  -  ND 
 
Table 4.1 Summary of the SOX2 expression data by IHC and ISH during normal 
human testicular development, in fetal ovaries, and TGCTs 
The proportion of cells stained was assessed using a semi-quantitative score: +++, nearly 
all cells stained; ++, approximately half of the cells stained; +, a low percentage of cells 
stained; +/-, only single cells stained; -, no positive cells detected. The staining intensity 
was furthermore evaluated as strong, medium, weak, very weak or none, along with 
cellular location (nuclear, perinuclear or cytoplasmic). All fetal, infantile and prepuburtal 
sections were from formalin-fixed archival tissues not suitable for ISH. Abbreviations: wpc, 
weeks post-conception; m, months; y, years; N, number; ND, not done.  109
SOX2 staining was not apparent in older testicular specimens prior to puberty (8-10 
years of age; Figure 4.2 H-I respectively). Within the fetal ovary, SOX2 was not detected 
in oogonia at 15 wpc (Figure 4.2 J), whereas some weak expression was observed in the 
cytoplasm of oocytes, identified by their large nuclei, at 25 wpc (arrowhead in Figure 4.2 
K), and more pronounced expression at 38 wpc (Figure 4.2 L). These results are 
summarised in Table 4.1.  
 
4.4.2 SOX2 Expression in Adult Testes 
Nuclear SOX2 protein was clearly detected in a subset of spermatogonial cells at 
the base of the normal adult testicular tubules (SPG on Figure 4.3 A-C). Expression within 
spermatogonia was heterogeneous, with some appearing strongly positive, some 
moderately so, and some negative. It was less robustly detected in some primary 
spermatocytes (SPC on Figure 4.3 A-C) and was not apparent in spermatids (SPT on 
Figure 4.3 A, C). SOX2 protein was not identified in adult Sertoli cells from normal 
tubules. A similar profile was observed by ISH, except that the strongest reaction was 
observed in spermatocytes (Figure 4.3 D, summarised in Table 4.1). In keeping with its 
detection in normal testis, SOX2 transcripts were detected weakly by RT-PCR in  a sample 
of whole normal testis (Figure 4.4).  
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Figure 4.2 Localisation of SOX2 protein during human testicular development  
Bright-field images of human testicular and ovarian sections counter-stained with 
Mayer’s haematoxylin following IHC for SOX2. Fetal testis A. 14 wpc (arrow points to 
negative germ cell); B. 23 wpc; C. 29 wpc (arrowheads in B and C point to positive 
germ cells). SOX2 expression in postnatal testis aged D. 2 months (arrowhead points 
to positive germ cell, arrows to negative germ cells and positive Sertoli cells); E. 4 
months (arrowhead points to positive germ cell, arrows to negative germ cells and 
weak staining in Sertoli cells); F. 12 months (arrowhead points to positive germ cells, 
arrows to negative germ cells); G. 2.5 years (arrowhead points to positive germ cells, 
arrows to negative germ cells, note nuclear staining); H. 8 years; and I. 10 years 
(arrows to negative germ cells). Ovarian expression at J. 15 wpc; K. 25 wpc (arrow 
depicts cytoplasmic staining) and L. 38 wpc. Abbreviations: GC, germ cell; m, month; 
SER, Sertoli cell; wpc, weeks post-conception; y, years. Size bars represent 20 μm.  111
 
Figure 4.3 Localisation of SOX2, OCT4 and NANOG protein and SOX2 mRNA in 
normal adult testes 
Bright-field images of human adult testicular sections counter-stained with Mayer’s 
haematoxylin. A-C. Immunohistochemistry (IHC) panels are shown for SOX2, OCT4 
and NANOG in normal adult testis. Serial (6 μm) sections are shown from three 
different patients. PLAP-negativity demonstrates the absence of CIS cells (normal 
tissue was obtained from CIS-containing testes). Arrows indicate Sertoli cells (SER), 
spermatids (SPT), spermatocytes (SPC) and spermatogonia (SPG). ** signify 
spermatogonia showing strong SOX2 expression, * moderate, - none. D-E. mRNA in 
situ hybridisation (ISH) with SOX2 antisense (D) and sense (E) riboprobes. Serial (6 
μm) sections of the same tubule are shown. Size bars represent 20 μm. 
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Figure 4.4 Expression of SOX2 in normal and neoplastic human testes 
RT-PCR panel is shown for SOX2 and the housekeeping gene β-ACTIN in a range of 
TGCT types following PCR for 35 cycles. Abbreviations: SEM, seminoma; TER, 
teratoma; EC, embryonal carcinoma; CIS, carcinoma in situ; NORM, normal testis; 
SCO, Sertoli cell-only testis; NT2, NTERA2 cells (positive control) and –RT, negative 
control containing RNA but not reverse transcriptase (RT) (shown in this case for EC, 
but performed for all RNA samples with no SOX2 detection). For primer sequences 
see Appendix 1. 
 
4.4.3 SOX2 Expression in CIS 
PLAP staining was used in order to distinguish CIS-containing tubules (PLAP-
positive) from normal tubules (PLAP-negative). By staining serial sections, it could be 
concluded that whilst CIS cells were OCT4- and NANOG-positive to a similar degree, 
regardless of phenotypic proximity to a specific type of TGCT, SOX2 expression in CIS 
cells was very heterogeneous. Only a few CIS cells exhibited positive nuclear staining 
(arrows on Figure 4.5 A, C-E), with some CIS cells being negative (arrowheads on Figure 
4.5 A-E). There was no difference in the relative expression between CIS cells adjacent to 
seminomas and those adjacent to nonseminomas. Comparable findings were observed at 
the RNA level; ISH showed a relatively strong signal in CIS (Figure 4.5 F). RT-PCR 
detected  SOX2 weakly to moderately in four out of five CIS samples, presumably 
reflecting the variable numbers of CIS cells and normal germ cells present (Figure 4.4). 
Transcripts were very weakly expressed in a Sertoli cell-only sample (Figure 4.4); also 
called germ cell aplasia, a condition of the testes in which only Sertoli cells line the 
seminiferous tubules. 
In addition, nuclear SOX2 expression was observed in some Sertoli cells within 
CIS tubules (Figure 4.5 A-B, D), but not in others (Figure 4.5 E). SOX2 expression was 
also detected in Sertoli cells by ISH (arrows on Figure 4.5 F), but not at the protein level  113
(Figure 4.3 A, C), although some staining was apparent during fetal testicular development 
(Figure 4.2 D-E). 
Figure 4.5 Localisation of SOX2, OCT4 and NANOG protein and SOX2 mRNA in 
carcinoma in situ 
Bright-field images of carcinoma in situ sections counter-stained with Mayer’s 
haematoxylin. A-E. IHC panels are shown for SOX2, OCT4 and NANOG in carcinoma 
in situ. Serial (6 μm) sections are shown from five different patients. Arrows point to 
SOX2-positive CIS and Sertoli cells; arrowheads to SOX2 negative CIS cells. PLAP 
positivity demonstrates the presence of CIS cells. F-G. mRNA in situ hybridisation with 
SOX2 antisense (F) and sense (G) riboprobes. Serial (6 μm) sections of the same 
tubule are shown. Abbreviations: CIS: carcinoma in situ, IHC: immunohistochemistry, 
ISH: in situ hybridisation, SER: Sertoli cell. Size bars represent 20 μm. 
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4.4.4 SOX2 Expression in TGCTs Derived From CIS 
4.4.4(i) Nonseminomas 
SOX2 protein co-localised with OCT4 and NANOG to the same areas of ECs. All 
three proteins showed clear nuclear localisation (Figure 4.6 A-D). Strong expression of 
SOX2 was detected by both RT-PCR (Figure 4.4) and ISH (Figure 4.6 G) in EC. In 
addition, SOX2 was expressed within some differentiated areas of teratomas (Figure 4.6 E-
F), particularly in papillary structures, which were OCT4- and NANOG-negative; data that 
are consistent with known SOX2 expression in neural and gut epithelial cells (Ishii et al. 
1998; Wood and Episkopou 1999; Sakamoto et al. 2000; Graham et al. 2003). A very faint 
band could be detected by RT-PCR in teratoma (Figure 4.4), although protein detection 
was very strong. SOX2 expression was stronger in EC/teratoma than in CIS or normal 
adult testis; both at the mRNA and protein level. 
 
4.4.4(ii) Seminomas 
In contrast to nonseminomas, SOX2 protein was not detected by IHC in OCT4-
positive/NANOG-positive seminomas (Figure 4.7 A-D), consistent with previous reports 
(Korkola  et al. 2006; Santagata et al. 2007). However, by ISH, SOX2 expression was 
detected in all samples, with focal or heterogeneous staining (Figure 4.7 E). In keeping 
with this finding, of three seminoma samples tested by RT-PCR, weak expression was 
detected in two samples (Figure 4.4). This discrepancy between mRNA and protein 
expression could be due to the presence of low level untranslated mRNA. 
 
Figure 4.6 Localisation of SOX2, OCT4 and NANOG protein and SOX2 mRNA in 
nonseminoma 
Bright-field images of nonseminoma sections counter-stained with Mayer’s haematoxylin. 
A-F. IHC panels are shown for SOX2, OCT4, NANOG and PLAP in embryonal carcinoma 
(A-D) and SOX2 positive areas of teratoma (E-F). Serial (6 μm) sections are shown from 
six different patients. G-H. mRNA in situ hybridisation with SOX2 antisense (G) and sense 
(H) riboprobes. Serial (6 μm) sections of the same tubule are shown. Abbreviations: EC: 
embryonal carcinoma, IHC: immunohistochemistry, ISH: in situ hybridisation, TER: 
teratoma. Size bars represent 20 μm.  116
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Figure 4.7 Localisation of SOX2, OCT4 and NANOG protein and SOX2 mRNA in 
seminoma 
Bright-field images of seminoma sections counter-stained with Mayer’s haematoxylin. 
A-D. IHC panels are shown for SOX2, OCT4, NANOG and PLAP. Serial (6 μm) 
sections are shown from four different patients. E-F. mRNA in situ hybridisation (ISH) 
with SOX2 antisense (E) and sense (F) probes. Serial (6 μm) sections of the same 
tubule are shown. Size bars represent 20 μm.  118
4.4.5 SOX2 Expression in TGCTs Not Derived From CIS 
4.4.5(i) Spermatocytic Seminoma 
Of four samples of spermatocytic seminoma tested, weak cytoplasmic staining was 
detected in two (arrows in Figure 4.8 A and B), albeit infrequently. A third sample showed 
nuclear staining in stromal cells (arrows in Figure 4.8 C), and a fourth was negative 
(Figure 4.8 D). 
 
4.4.5(ii) Testicular B-Cell Lymphoma 
Testicular B-cell lymphoma was negative for SOX2 (Figure 4.8 E). 
 
 
Figure 4.8 Localisation of SOX2 protein in spermatocytic seminoma and 
testicular B-cell lymphoma 
Bright-field images of testicular carcinoma sections counter-stained with Mayer’s 
haematoxylin.  A-D. IHC staining for SOX2 in spermatocytic seminoma from four 
different patients. Arrows indicate cytoplasmic staining (A-B) and nuclear staining (C). 
E. IHC staining for SOX2 in testicular B-cell lymphoma. Size bars represent 20 μm. 
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4.5 DISCUSSION 
4.5.1 Temporal Expression Profile of SOX2 During Human Testicular 
Development 
This study, coupled with Chapter 3, provides a comprehensive analysis of SOX2 
expression during testicular development. The temporal expression profile of SOX2 is 
depicted in Figure 4.9: nuclear localisation indicated by a solid line and cytoplasmic by a 
dashed line. The earliest germ cells detectable in the indifferent gonad (around 5 wpc) are 
positive for OCT4 and NANOG (Honecker et al. 2004; Rajpert-De Meyts et al. 2004; 
Hoei-Hansen  et al. 2005). All germ cells express these transcription factors until both 
number stained and staining intensity begins to decline at around 13 wpc. At 17 wpc, 
around 50% are positive for OCT4. At 18 wpc, expression declines more rapidly, with 5-
10% positive at week 20. Subsequently only single cells are positive. Expression of 
NANOG mirrors that of OCT4 but declines slightly later, being expressed in all germ cells 
at 17 wpc, then declining rapidly, becoming expressed by only a subset of gonocytes until 
3-4 months (Honecker et al. 2004; Rajpert-De Meyts et al. 2004; Hoei-Hansen et al. 2005).  
No SOX2 staining was detected in samples up to 14 wpc (Perrett et al. 2008 and 
Chapter 3); however, positive cells were detected in 23, 29 and 39 wpc testes. Germ cells 
in 2, 3, 4 and 12 month postnatal testis were also positive, with SOX2 localised to the 
cytoplasm in all; however, the number of germ cells positive in 12 month old testis was 
lower. Numbers increased again in 2.5 year old testis but expression was nuclear rather 
than cytoplasmic. The percentage of germ cells positive for SOX2 is an estimate at all 
stages (at 50% on the graph). Total germ cell number was unknown; however, it appeared, 
by identifying cells with large nuclei as being germ cells, that 50% or less were positive for 
SOX2 at each age. At 8 years there was no SOX2 expression; the unavailability of samples 
between 2.5 and 8 years means it is unclear at what stage during testicular maturation 
SOX2 expression declines. Nuclear expression was detected in adult spermatogonia and 
spermatocytes; although it is unclear at what stage expression is initiated, it is possibly 
pubertal. Analysis of more specimens would help to clarify the exact expression profile of 
SOX2 during testicular development.  120
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Figure 4.9 Schematic overview of the temporal expression profile of OCT4, 
NANOG and SOX2 in germ cells during human testicular development 
The image shows approximately smoothed curves based on the combined results of 
several studies (Gaskell et al. 2004; Honecker et al. 2004; Rajpert-De Meyts et al. 
2004; Hoei-Hansen et al. 2005; Anderson et al. 2007; Perrett et al. 2008) and this 
work. Nuclear SOX2 expression is indicated by a solid line, cytoplasmic expression by 
a dashed line. 
 
4.5.2 SOX2 Expression in Infantile and Adult Spermatogonia 
Cytoplasmic (along with perinuclear/nuclear) expression of SOX2 was visible in 
infantile spermatogonia in both fetal (23-39 wpc) and infantile (2-12 months) testes. 
Expression at 2.5 years was nuclear. Cytoplasmic detection of SOX2 has been reported 
previously: unlike OCT4 and NANOG which are exclusively nuclear in the ICM, SOX2 is 
localised in both the nuclei
 and cytoplasm in pre-implantation embryos from the human, 
but is solely nuclear in the mouse (Perrett et al. 2008 and Chapter 3). Other SOX proteins 
are regulated by subcellular localisation: for example, the lack of Sox9 nuclear 
translocation induces a sex-reversed phenotype in male gonads (Gasca et al. 2002); and, 
interestingly, continuous nucleocytoplasmic shuttling appears to be essential to the 
transactivation function of Sox10 (Rehberg et al. 2002). SOX2 has recently been shown to 
contain two nuclear localisation signals (NLSs; depicted for hSOX2 in Figure 4.10), which  121
it uses to shuttle between the nucleus and cytoplasm in mESCs (Li et al. 2007). These 
NLSs are contained within the HMG domain and are well conserved amongst other SOX 
proteins. In addition, the nuclear export signal (NES) essential for Sox9 subcellular 
localisation (Gasca et al. 2002), and required for Sox10 shuttling and subsequent 
transactivation (Rehberg et al. 2002), is also conserved within the SOX2 HMG domain 
(Figure 4.10), the only difference being the presence of isoleucine in place of leucine at the 
first residue (both hydrophobic). The existence of these NLSs and a NES within the HMG 
domain of SOX2 is further evidence for its cytoplasmic/perinuclear/nuclear location during 
testicular development. 
Figure 4.10 Conservation of nuclear localisation signals (NLS) and a nuclear 
export signal (NES) in human SOX proteins 
A. The 318 amino acid (aa) SOX2 protein contains two NLSs positioned at either end 
of the HMG domain, originally identified for SRY and SOX9 (Sudbeck and Scherer 
1997), but conserved in many if not all the SOX proteins. The HMG domain also 
contains a leucine-rich NES sequence (detailed in B), similar, but not identical to that 
conserved within the SOXE subgroup and required for Sox9 and Sox10 translocation 
(Gasca et al. 2002; Rehberg et al. 2002). 
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Akin to its putative role in maintaining adult neural stem cells (Rex et al. 1997; 
Graham et al. 2003), the identification of SOX2 in selected adult spermatogonial cells may 
be marking their stem cell population. This is supported by the recent discovery of UTF1 
protein in spermatogonia (Kristensen et al. 2008). UTF1 is a transcription factor linked to 
pluripotency in ESCs (van den Boom et al. 2007), but apparently involved in proliferation 
of spermatogonia in the adult (Kristensen et al. 2008). The expression of these presumed 
pluripotency factors in mature spermatogonia suggests a different biological role, as 
indicated in the case of SOX2 by a shift from a cytoplasmic to nuclear location during 
testis development. This finding warrants further studies, also in view of the fact that SOX2 
transcripts were more abundant in primary spermatocytes than in spermatogonia. It is 
possible that ISH staining may detect the presence of several types of single stranded 
RNA, which germ cells may use to selectively silence transcripts that are no longer needed 
after stem spermatogonia commit to enter meiosis (Novotny et al. 2007).   
In humans, it is proposed that there are two species of spermatogonia in the adult 
testes [Figure 4.11 C (Clermont 1966; Clermont 1966)], similar to the monkey (Figure 4.11 
B). This contrasts the seven types of A spermatogonia described in the mouse [Figure 4.11 
A (de Rooij 1998; Dettin et al. 2003)]. Adark spermatogonia are testicular stem cells and 
function as regenerative reserve, they show low proliferative activity during normal 
spermatogenic activity, but are active during pubertal expansion (Simorangkir et al. 2005). 
Apale spermatogonia are self-renewing progenitors which proliferate continuously during 
each spermatogenic cycle. Apale spermatogonia generate B spermatogonia, which then 
generate spermatocytes (depicted in Figure 4.11).  
It is unclear in which population of spermatogonia SOX2 is expressed. If expressed 
by Adark spermatogonia, SOX2 may be functioning to maintain the testicular stem cell 
population, whereas if expressed by Apale spermatogonia, it may be maintaining 
spermatogonia in an undifferentiated progenitor state, so called ‘transit-amplifying cells’. 
When SOX2 is expressed in the absence of the pluripotency-maintaining transcription 
factors OCT4 and NANOG in neural stem cells, it maintains a state of proneural 
commitment and the capacity for self-renewal, its activity being down-regulated during 
terminal division (Graham et al. 2003). Forced expression of SOX2 inhibits neuronal 
differentiation preserving a naïve progenitor state. However, the requirement for Sox2 in 
the conversion of somatic cells to induced pluripotent stem cells (iPS cells), first reported  123
by Takahashi and Yamanaka (2006), suggests it more likely has a stem cell-specific role 
than simply a transit-amplifying role. 
Figure 4.11 Schematic overview of the premeiotic steps of spermatogenesis in 
different species of mammals  
Premeiotic steps of spermatogenesis are shown for A. mouse, B. rhesus monkey and 
C. man. The number given in brackets indicates the total number of daughter cells 
derived from any one progenitor cell that enters differentiation. Abbreviations: As, 
Asingle; Apr, Apaired; Aal, Aaligned; Spc, spermatocyte. [Adapted from Ehmcke et al. (2006).] 
 
A role for SOX2 in spermatogenesis is supported by the phenotype of Sox2
βgeo 
heterozygous mice, which show reduced male fertility (Kelberman et al. 2006). These 
animals occasionally have smaller testes with sperm blockage in the seminiferous tubules, 
however the infertility is thought to be more likely due to a primary defect in developing 
sperm that compromises their motility and/or ability to fertilise the oocyte. However, in the 
mouse, undifferentiated spermatogonia also express Sox3, required for spermatogenesis 
(Raverot et al. 2005), which, as a member of the B1 group of SOX proteins, may function 
redundantly with Sox2 (Wegner and Stolt 2005). 
SOX2 functions with partner proteins to activate transcription of target genes; for 
example with the class III POU factor Brain 2 (Brn2) to drive Nestin expression in the 
nervous system (Tanaka et al. 2004) and with Paired box gene 6 (Pax6) to activate the δ-
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crystallin enhancer DC5 in the eye (Kamachi et al. 2001); thus it may have an, as yet 
unknown, partner protein in spermatogonia. 
 
4.5.3 SOX2 Expression in CIS 
SOX2 functions in concert with OCT4 and NANOG to maintain pluripotency in 
human and mouse ESCs (Boyer et al. 2005; Loh et al. 2006). However, only OCT4 and 
NANOG have been shown to be up-regulated in CIS compared to normal testes (Almstrup 
et al. 2004). Work described in this chapter involved a more comprehensive analysis of 
both the transcription factor and its associated transcript in human CIS and TGCTs. A 
differential pattern of SOX2/SOX2 expression was found: in concert with other studies 
(Korkola et al. 2006; Santagata et al. 2007), clear expression was detected at both the 
mRNA and protein level in EC cells. However, variable SOX2 expression was detected at 
the mRNA and protein level in germ cells, CIS cells and seminomatous TGCTs. The latter 
was in concert with Santagata et al. (2007) who also noticed SOX2-positivity in a small 
subset of seminoma cells (<1%). In this study, weak staining was also observed in 
undifferentiated Sertoli cells in some CIS tubules, as with the fetal testes, consistent with 
tubules containing CIS demonstrating an arrest of development (Rajpert-De Meyts et al. 
1998; Rajpert-De Meyts 2006). The presence of immature Sertoli cells could explain the 
weak SOX2 expression observed in a Sertoli cell-only specimen by RT-PCR. 
The heterogeneous expression of SOX2 in CIS cells, with occasional positive cells, 
is reminiscent of a pattern previously noted for another marker, TRA-1-60 (Rajpert-De 
Meyts et al. 1996). Human PGCs and fetal gonocytes are SOX2-negative (Perrett et al. 
2008 and data herein); nonseminomatous TGCTs, derived from CIS, are SOX2-positive. It 
is possible that SOX2 (and TRA-1-60) expression in CIS may mark those cells in a process 
of re-programming towards malignancy associated with a stem cell compartment and a 
capacity for differentiation (i.e. an EC, CC or YST phenotype). The factors that affect this 
process can be considered extrinsically or intrinsically: it is perhaps noteworthy that CIS 
cells lie within a variable microenvironment consisting of several cell-types that secrete 
hormones and growth factors. The fact that Sertoli cells within CIS tubules are sometimes 
SOX2-positive along with the CIS cells themselves indicates that a diffusible growth factor 
may induce SOX2 expression, and therefore may not be intrinsic to the tumour cell per se. 
Conversely, an up-regulation of SOX2 gene expression may be caused by altered  125
epigenetic status. Methylation changes are a common feature in somatic cancers and may 
be indicative of increased malignant potential. SOX2 expression has been associated with 
poorly-differentiated tumours (Sanada et al. 2006; Rodriguez-Pinilla et al. 2007) and has 
been reported in a range of tumours derived from cells that are ordinarily SOX2-negative, 
such as sporadic breast cancer (Rodriguez-Pinilla et al. 2007) and pancreatic carcinoma 
(Sanada et al. 2006), as well as SOX2-positive parent cells, malignant glioma (Schmitz et 
al. 2007) and stomach adenocarcinomas (Tsukamoto et al. 2005). Alternatively, SOX2 
expression by a subset of CIS cells could indicate derivation from postnatal SOX2-positive 
prespermatogonia.  
While this study was in progress, SOX2 was reported to be absent in CIS cells 
(Korkola et al. 2006; Biermann et al. 2007), along with gonocytes and normal adult testis 
(de Jong et al. 2008). This inconsistency with results herein possibly relate to the use of a 
different antibody (Korkola, Biermann and de Jong used a monoclonal antibody from 
R&D Systems, while Santagata et al. used the same antibody used here) and problems of 
cross-reactivity with other epitopes or variable sensitivity of SOX2 detection. Therefore, 
findings were corroborated at the RNA level by ISH and RT-PCR. In accordance with the 
findings of de Jong et al. (2008), weak staining was observed in undifferentiated Sertoli 
cells in some CIS tubules, consistent with tubules containing CIS demonstrating an arrest 
of development (Rajpert-De Meyts et al. 1998; Rajpert-De Meyts 2006). 
 
4.5.4 SOX2 Expression in TGCTs Derived From CIS 
Findings regarding SOX2 expression in TGCTs were in accordance with other 
studies (Korkola et al. 2006; Santagata et al. 2007; de Jong et al. 2008): SOX2 protein was 
expressed in OCT4-, NANOG-positive ECs, in overlapping areas, but was absent from 
OCT4-, NANOG-positive seminomas. Contrastingly, by ISH, seminomas were all positive 
for  SOX2 expression with focal or heterogeneous staining. The lack of SOX2 protein 
expression, but presence of mRNA, suggests some form of post-transcriptional repression. 
Interestingly, mouse germline stem cells derived from newborn mouse testes (Kanatsu-
Shinohara et al. 2003) express abundant transcripts but limited Sox2 protein (Imamura et 
al. 2006). Post-transcriptional suppression of Sox2 is implicated in their loss of 
pluripotency.  126
The only human seminoma cell line isolated, TCam-2, does not express SOX2 
protein (de Jong et al. 2008; Eckert et al. 2008). In addition, microarray expression 
analysis demonstrated a lack of SOX2 expression in TCam-2 along with three seminoma 
tumour samples (de Jong et al. 2008) This contrasts findings herein of SOX2 expression in 
seminoma. Interestingly, high expression of miRNAs 145 and 324-5p were found in 
TCam-2 versus EC (de Jong et al. 2008); these target SOX2 and may be responsible for 
preventing its translation. miRNA could therefore be the mechanism of post-transcriptional 
repression of SOX2 expression within these tumours. 
Gene expression studies in seminoma are consistent with the OCT4-SOX2-
NANOG transcription factor complex being absent compared to EC and thus being unable 
to activate expression of target genes. One such target in mouse is Fgf4, activated by the 
Sox2-Oct4 complex (Yuan et al. 1995). A study examining FGF4 expression in TGCTs 
found all nonseminomas (excluding teratomas) expressed FGF4, compared with a much 
lower incidence in seminomas (Suzuki et al. 2001). In addition TDGF1, a gene whose 
transcription is putatively activated by OCT4, SOX2 and NANOG in hESCs (Boyer et al. 
2005), was expressed in all nonseminomas compared with a lower incidence in seminomas 
and with no expression in normal testes tissue (Baldassarre et al. 1997). 
 
4.5.5 SOX2 Expression in TGCTs Not Derived From CIS 
This study is the first described to examine SOX2 expression in tumours not 
derived from CIS cells - spermatocytic seminomas - where moderate expression of SOX2 
protein was detected. These tumours are OCT4- and NANOG-negative and are believed to 
originate from adult spermatogonia (Rajpert-De Meyts et al. 2003) or spermatocytes 
(Looijenga et al. 2006). Interestingly, SOX2 expression in spermatocytic seminomas was 
predominantly cytoplasmic, in contrast to the nuclear localisation in normal adult germ 
cells, implying an inability to function as a transcription factor in this tumour.   127
4.5.6 Summary 
This study describes SOX2 expression during testicular development, illustrating 
previously undescribed expression within infantile and adult spermatogonia. Here, SOX2 
is expressed independently from its usual transcriptional activating partners OCT4 and 
NANOG, as is also the case in developing nervous and sensory systems and gut (Ishii et al. 
1998; Wood and Episkopou 1999; Sakamoto et al. 2000; Graham et al. 2000; Kondoh et 
al. 2004; Kiernan et al. 2005; Okubo et al. 2006; Taranova et al. 2006; Donner et al. 2007 
and Chapter 5). In these tissues it preserves progenitor cell identity; both by maintaining 
proliferative capacity and inhibiting differentiation. SOX2 functions in adult tissues: for 
example, in mouse brain (Ferri et al. 2004; Suh et al. 2007) and ear (Oesterle et al. 2008). 
The presence of SOX2 in selected adult spermatogonia may be indicative of the adult 
spermatogonial stem cell population that underpins male gametogenesis. 
This study has demonstrated that a hitherto unappreciated subset of CIS cells 
express SOX2, at the RNA and protein level. This expression may be linked to invasive 
CIS progression towards a malignant pluripotent phenotype. Conversely, SOX2-negative 
CIS cells may be forerunners of SOX2-negative seminomas; a larger specimen study 
would help to determine this. The absence of SOX2 from seminomas, and thus absence of 
the pluripotency maintaining OCT4-SOX2-NANOG transcription factor complex, may 
explain the homogeneity of seminomas as compared to pluripotent nonseminomas, which 
in many respects resemble a developing embryo. In addition, the expression of SOX2 in 
seminoma, but absence of protein, in contrast to the detection of SOX2 protein in EC, 
suggest differential regulation of SOX2 expression at the post-transcriptional level likely 
related to different roles in germ cells during testis development and adult 
spermatogenesis. 
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CHAPTER 5: Investigating the Association of the 
OCT4-SOX2-NANOG Transcription Factor Complex 
with Pluripotency 
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5.1 ABSTRACT 
As well as being expressed in pluripotent cells, SOX2 is also expressed in 
progenitor cells during development, in the epithelial lining of foregut-derived organs, 
including the lung and stomach, and within the nervous and sensory systems. In order to 
study SOX2 independently from OCT4 and NANOG, SOX2-positive cells 
(neuroprogenitors and stomach epithelial cells) were isolated from the human embryo/early 
fetus and cultured in vitro. These cells were found to express 13 arbitrarily selected OCT4-
SOX2-NANOG target genes, despite the absence of OCT4 and NANOG. Expression of 
two of these genes, TDGF1 and DPPA4, was analysed at the protein level. TDGF1 was 
detected in neuroprogenitors, but not in stomach epithelial cells in vitro. DPPA4 was 
present in neuroprogenitors and stomach epithelial cells, in vitro and in vivo. It was also 
expressed by germ cells, which are OCT4- and NANOG-positive, but SOX2-negative, and 
in mesonephros (negative for all three transcription factors). Therefore, in the case of 
TDGF and DPPA4, the combined presence of OCT4, SOX2 and NANOG is not required 
for gene expression. The expression of genes demonstrated to be direct targets of OCT4 
and SOX2, namely FGF4 and UTF1, correlated better with the combined presence of 
OCT4, SOX2 and NANOG, and were not expressed in the absence of OCT4 and NANOG. 
The transduction of a few key transcription factors into somatic cells reverts them 
to ES-like cells, termed induced pluripotent stem (iPS) cells. Prior to publication of this 
recent discovery, OCT4 and NANOG were transduced into SOX2-positive cells; however, 
pluripotent cells were not generated. It has since been discovered that somatic cells require 
10-12 days exposure to the exogenous factors to be reprogrammed, achieved using 
lentiviral vectors, whereas experiments herein used transient (48 hour) transfection. 
In addition, it was discovered that the expression of cell surface antigens commonly 
used to confirm pluripotency in human embryonic stem cells; stage-specific antigen 3 
(SSEA3), SSEA4, TRA-1-60 and TRA-1-81, were not specific to pluripotent cells, being 
expressed by neuroprogenitors and stomach epithelial cells. This highlights some 
limitations for their use as pluripotent markers; a combination of markers including those 
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5.2 INTRODUCTION 
5.2.1 The  OCT4-SOX2-NANOG  Transcription Factor Complex: 
Indispensable or Dispensable for Pluripotency? 
Numerous studies have implicated the OCT4-SOX2-NANOG transcription factor 
complex as crucial in maintaining pluripotency. Knock-out of any one alone is embryonic-
lethal (Nichols et al. 1998; Avilion et al. 2003; Mitsui et al. 2003). The OCT4-SOX2 
complex, sometimes in combination with NANOG, activates transcription of a number of 
genes which either promote pluripotency, are essential for embryonic development, or 
both: for example, FGF4 (Yuan et al. 1995) and UTF1 (Nishimoto et al. 1999). The wide 
encompassing roles of the transcription factor complex were revealed in an elegant study 
by Boyer et al. (2005) which used genome-scale location analysis (chromatin 
immunoprecipitation [ChIP] coupled with DNA microarrays) to identify promoters 
(defined as within 8 kb upstream and 2 kb downstream of the transcript start site) bound by 
the transcription factor complex in hESCs. Numerous promoters were bound by all three, 
and the identity of these - genes which promoted pluripotency and proliferation and 
inhibited differentiation - suggested that these occupancies were functionally significant 
(Figure 1.6). Loh et al. (2006) reproduced these findings in mESCs, although with 
relatively little overlap with the target genes identified in hESCs. 
Studies by the group of Shinya Yamanaka have to some extent disputed the 
essential role of the transcription factor complex, at least in the initial conversion to 
pluripotency. In August 2006 the group published a landmark paper in which they 
demonstrated that pluripotent stem cells (termed induced pluripotent stem [iPS] cells), 
could be generated from mouse embryonic or adult fibroblasts by introducing four factors - 
Oct4, Sox2, c-Myc and Klf4 - under ESC culture conditions (Takahashi and Yamanaka 
2006). Unexpectedly, Nanog was dispensable, although selection for Nanog expression 
rather than Fbx15 (both targets of Oct4 and Sox2) gave iPS cells which were more similar 
to ESCs, and notably were able to form adult chimaeras (Okita et al. 2007). Recently it has 
been found that the role of Nanog in pluripotent cells is more in resisting or reversing 
alternative gene expression states rather than in the housekeeping machinery of 
pluripotency (Chambers et al. 2007).  
This technique has been reproduced by others (Wernig et al. 2007), also in human 
adult fibroblasts (Takahashi et al. 2007) and in fetal, neonatal and adult human primary  131
cells (Lowry et al. 2008; Park et al. 2008). The cells sequentially express pluripotency 
markers during the reprogramming process: AP first, followed by SSEA1, then Oct4, Sox2 
and Nanog later (Brambrink et al. 2008; Stadtfeld et al. 2008). The reprogrammed 
fibroblasts show global epigenetic remodelling from the somatic epigenome to an ES-like 
state (Maherali et al. 2007). Three groups have since demonstrated that tumourigenic c-
Myc is not required when transducing cells with Oct4, Sox2 and Klf4 (Blelloch et al. 2007; 
Nakagawa et al. 2008; Wernig et al. 2008). In addition, drug selection is not necessary 
(Blelloch et al. 2007; Meissner et al. 2007; Wernig et al. 2007). OCT4, NANOG, SOX2 
and LIN28 reprogram human somatic cells to pluripotent stem cells (Yu et al. 2007). The 
only two transcription factors common to all studies were OCT4 and SOX2, although the 
transduction of these two alone was not sufficient to induce pluripotency in any study. 
Terminally differentiated mature B lymphocytes could also be reprogrammed, however 
along with Oct4, Sox2, Klf4, and c-Myc they also required either ectopic expression of the 
myeloid transcription factor CCAAT/enhancer-binding-protein-alpha (C/EBPalpha), or 
specific knockdown of the B-cell transcription factor Pax5 (Hanna et al. 2008). Most 
recently, it has been demonstrated that Sox2-positive neural progenitors isolated from 
neonatal mouse brains can be reprogrammed with Oct4, Klf4 and c-Myc, however the 
overall efficiency at generating iPS cells was 100-fold lower than when transducing the 
four factors into mouse fibroblasts (Eminli et al. 2008). In addition, iPS cells can be 
generated from adult mouse neural stem cells, which express higher endogenous levels of 
Sox2 and c-Myc than ESCs, with exogenous Oct4 and either Klf4 or c-Myc (Kim et al. 
2008). 
The OCT4-SOX2-NANOG transcription factor complex is not always co-expressed 
during human development; whilst all three transcription factors are co-expressed in the 
ICM and ESCs, hPGCs express OCT4 and NANOG without SOX2 (Perrett et al. 2008). 
This is the first cell type demonstrated thus far to do so and is fascinating given this 
transcription factor complex’s proposed ability to act in a feed-forward loop activating its 
own transcription (Boyer et al. 2005). The major role for Sox2 in ESCs is proposed to be 
in maintaining Oct4  expression (Masui et al. 2007). Therefore, Oct4 must be 
activated/maintained by a different mechanism in hPGCs, possibly via Lrh1 (Gu et al. 
2005), or Sall4 (Zhang et al. 2006), which maintains Nanog expression (Wu et al. 2006). 
SOX2 appears dispensable in the ability to activate target genes with OCT4 and NANOG, 
as without it, all 13 of the arbitrarily selected ‘ESC-restricted’ target genes from Boyer and  132
colleagues, as well as UTF1  and  FBX15, were expressed in the fetal ovary and testis 
(Perrett et al. 2008 and Chapter 3). In contrast, the data do support a pivotal role for SOX2 
in promoting FGF4  expression (Yuan et al. 1995; Ambrosetti et al. 1997): FGF4 
transcripts were undetected in the SOX2-negative germ cell lineage. hPGCs are 
nullipotent, and lack of SOX2 could be deemed a cause of this. However, upon hEGC 
derivation, with associated ‘VP’ (‘vigorously proliferative’) growth, SOX2 expression was 
not activated. Whilst hEGCs do differentiate in vitro to derivatives of all three germ layers, 
they have not been reported to generate teratomas in mice. Whether this is associated with 
lack of SOX2 expression is unknown. 
 
5.2.2 SOX2: Not Just a Regulator of Pluripotency 
Whilst hPGCs are the only cells identified so far to express OCT4 and NANOG 
without SOX2, SOX2 is expressed by a variety of cells later on in development in the 
absence of OCT4 and NANOG, where, rather than maintaining pluripotency, it plays 
important roles in the regulation of organ development and cell-type specification, both 
during embryogenesis and in the adult. 
 
5.2.2 (i) SOX2 in Foregut Derived Organs 
The foregut of the embryo is initially an epithelial tube of endoderm surrounded by 
mesoderm. During development, the foregut gives rise to separate organs, including the 
trachea, esophagus, stomach and lungs. Sox2 is expressed at varying levels in epithelial 
cells of these organs in a variety of species (Ishii et al. 1998; Wood and Episkopou 1999; 
Park  et al. 2006; Que et al. 2007). Here it may function to conserve progenitor cell 
characteristics. In the developing chick stomach, Sox2 expression is switched off in 
epithelia that are actively changing their morphology (Ishii et al. 1998), possibly linked to 
its ability to regulate the transcription and expression of gastric differentiation-related 
genes, for example, Pepsinogen A (Tani et al. 2007) and gastric foveolar mucin, MUC5AC 
(Li et al. 2004; Park et al. 2008). Heterozygosity for SOX2 in humans is associated with 
anophthalmia-esophageal-genital (AEG) syndrome (Williamson et al. 2006), which in 
some instances is associated with failure of normal tracheo-esophageal separation, with the 
trachea being connected to the stomach by an abnormal distal esophagus. Using compound 
mutant mouse embryos in which the level of Sox2 varies below 50%, Que et al. (2007)  133
proposed that Sox2 regulates two independent processes in the developing foregut 
endoderm: 1. The early dorsal/ventral patterning of the anterior foregut that is coupled to 
the specification and morphogenesis of the trachea and eosophagus; 2. The patterning and 
differentiation of the foregut into keratinised, squamous eosophagus/forestomach versus 
posterior glandular hindstomach. 
SOX2 is important for branching morphogenesis and epithelial cell differentiation 
in mouse and chick lung (Ishii et al. 1998; Gontan et al. 2008). In addition, SOX2 
expression has been detected in a stem cell population in the adult human pancreas (Zhao 
et al. 2007). 
 
5.2.2(ii) SOX2 in the Nervous System  
The expression profile and function of SOX2 in the nervous system of many 
species, including Drosophila,  Xenopus, zebrafish and chick, has been relatively well 
characterised (for reviews, see Pevny and Placzek 2005; Wegner and Stolt 2005). In the 
mouse nervous
 system, Sox2 is expressed in stem cells and early precursors,
 and in a few 
mature neurons (Zappone et al. 2000; Ferri et al. 2004). The role of Sox2 in maintaining 
neural progenitor identity extends from embryogenesis into adulthood: adult Sox2-
deficient mice, in which Sox2 expression is
  decreased by about 70%, exhibit neural 
stem/precursor cell proliferative
 defects in the hippocampus and periventricular zone (Ferri 
et al. 2004). Sox2 is thought to play an important role in maintaining the neural stem cell 
pool in the adult mouse brain (Suh et al. 2007) and adult human spinal cord (Dromard et 
al. 2008).  
Heterozygous SOX2 mutations in humans cause hippocampal defects and forebrain
 
abnormalities, associated with anophthalmia (Fantes et al. 2003; Kelberman et al. 2006; 
Sisodiya et al. 2006). SOX2 functions to maintain neural progenitor identity in the chick 
(Graham et al. 2003), and conversion of rat oligodendrocyte precursor cells (OPCs) to 
neural stem cells depends on the reactivation of Sox2 (Kondo and Raff 2004). It is also 
thought to have an additional function in early precursors committing themselves to 
neurogenesis: in ‘programming’ later neural differentiation events, and suppressing 
alternative (glial-specific) lineage markers (Cavallaro et al. 2008).  
The mechanism of action of Sox2 in the nervous system has not yet been 
elucidated, it possibly counteracts neurogenic genes - the ability of basic-helix-loop-helix 
(bHLH) proteins to direct neuronal differentiation depends on their ability to suppress  134
Sox1-3 expression in chick CNS progenitors (Bylund et al. 2003). SoxNeuro, a putative 
Drosophila orthologue of the vertebrate Sox1, Sox2 and Sox3 proteins, acts upstream and 
in parallel to the proneural genes of the achaete-scute gene complex (Buescher et al. 2002; 
Overton et al. 2002). Alternatively, it may maintain neural progenitors in the cell cycle - 
inhibition of Sox2 in chick neural progenitor cells results in cell cycle exit (Bylund et al. 
2003; Graham et al. 2003) and rat OPCs (Kondo and Raff 2004).  
Nestin is the only known nervous system target of Sox2; the transcription of this 
intermediate filament protein is activated by the binding of Sox2 and the POU domain 
factor Brn2 to the Nestin enhancer (Tanaka et al. 2004). Sox2 expression in turn is 
regulated by neural induction signals. An enhancer of chick Sox2, conserved in mammals, 
responds directly to neural inducing signals (Uchikawa et al. 2003). In both Xenopus and 
Drosophila, Sox2 (or the ortholog SoxNeuro in Drosophila) is suppressed by BMP (dpp in 
Drosophila) or up-regulated by Chordin (sog) (Mizuseki et al. 1998; Cremazy et al. 2000; 
Buescher et al. 2002). Pax6 activates Sox2 expression in neuroprogenitors of the cortical 
subventricular zone late on in mouse embryonic development (Wen et al. 2008). In 
addition, Stat3 directly regulates the Sox2 promoter thereby initiating commitment to the 
neural precursor cell fate (Foshay and Gallicano 2008). Recently, a mechanism governing 
the onset of Sox2 expression in the chick embryonic neural plate has been described 
(Papanayotou  et al. 2008), involving the recruitment of transcriptional repressors to 
chromatin-remodelling complexes. The neural plate generates the entire nervous system, 
and one of its earliest molecular markers is Sox2. 
 
5.2.2 (iii) SOX2 in the Sensory System 
Mutations in SOX2 cause anophthalmia (Fantes et al. 2003) and hearing loss 
(Hagstrom et al. 2005). Sox2 is expressed at all stages of eye development within zebrafish 
and chick in the optic vesicle, head surface ectoderm and derived lens placode (chick) or 
eye field (zebrafish) through to the neural retina (Kamachi et al. 1998). Here it activates 
the transcription of the αB- and δ1-crystallin genes, the latter in cooperation with Pax6 
(Kamachi et al. 2001; Ijichi et al. 2004; Kondoh et al. 2004). It also acts with Oct1 to 
maintain Pax6 expression during lens and nasal placode induction (Donner et al. 2007), 
and with Pax6 to regulate its own transcription (Inoue et al. 2007). Alterations in the levels 
of Sox2 regulate
 the choice between maintenance of retinal progenitor cell identity and
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differentiation. Sox2 mediates its effects by directly regulating the expression
 levels of 
Notch1 (Taranova et al. 2006). 
Levels of Sox2 regulate the differentiation of endodermal progenitor cells of the 
mouse tongue into taste bud sensory cells versus keratinocytes (Kiernan et al. 2005). In the 
mouse inner ear, alteration or loss of expression of Sox2 correlates with abnormal/absent 
hair and supporting cell differentiation, indicating a role for Sox2 in establishing sensory 
progenitors (Okubo et al. 2006). Sox2 is also expressed by some highly differentiated 
vestibular hair cells in the mature mouse ear, and given their limited proliferative 
capability, a role for maintaining a stem cell-like state appears unlikely (Oesterle et al. 
2008). In the chick, Sox2 is proposed to specify a population of otic progenitors committed 
to a neural fate, giving rise to neurons and hair cells (Neves et al. 2007). 
 
To summarise, therefore, when expressed in the absence of OCT4 and NANOG, 
SOX2 maintains progenitor cells during development, and occasionally in the adult, it has 
additional uncharacterised functions in some differentiated cells. To investigate these three 
regulators of pluripotency further, SOX2-positive, OCT4- and NANOG-negative cells 
were isolated and cultured from the human embryo/early fetus, providing the opportunity 
to study SOX2 in isolation from OCT4 and NANOG, with the following aims: 
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5.3 SPECIFIC AIMS 
5.3.1 To determine the expression profile of SOX2 during human 
embryonic development. 
SOX2 is reportedly expressed in a number of sites during human embryonic 
development, including neuroprogenitors and the stomach epithelial lining; this expression 
will be verified by RT-PCR and immunohistochemistry. 
 
5.3.2 To successfully isolate, culture and characterise SOX2-positive, 
OCT4- and NANOG-negative cells from the human embryo/early fetus. 
This will involve the dissection of the spinal cord and stomach from the human 
embryo/early fetus, isolation and in vitro culture of neuroprogenitors and stomach 
epithelial cells. Cells will be tested for SOX2 expression and also for neuroprogenitor 
markers (e.g. the intermediate filament protein Nestin) or stomach epithelial markers (e.g. 
cytokeratin 19 [CK19]). 
 
5.3.3 To determine the expression profile of genes which reportedly 
rely on the presence of the OCT4-SOX2-NANOG transcription factor 
complex in these SOX2-positive cells.  
  The expression of genes previously recognised as targets of OCT4 and SOX2, and 
of those reported to be expressed in hESCs when OCT4, SOX2 and NANOG are bound to 
the respective promoter regions, will be examined in neuroprogenitors and stomach 
epithelial cells. 
 
5.3.4 To determine whether inducing expression of the OCT4-SOX2-
NANOG transcription factor complex causes cells to become 
pluripotent. 
  This will be determined by transfecting SOX2-positive cells with OCT4 and 
NANOG expression vectors and examining subsequent expression of 
neuroprogenitor/stomach epithelial and stem cell-specific markers.  137
5.4 RESULTS 
5.4.1 SOX2 Expression in the Human Embryo 
By RT-PCR, SOX2 expression was detected in human fetal (56 dpc) brain, spinal 
cord, eye and stomach (Figure 5.1), consistent with reports in other species (Ishii et al. 
1998; Kamachi et al. 1998; Wood and Episkopou 1999; Zappone et al. 2000; Graham et al. 
2003; Que et al. 2007). It was absent from lung, contrasting previous findings in mouse 
and chick (Ishii et al. 1998; Gontan et al. 2008), and from pancreas. Embryonic mouse 
pancreas does not appear to contain
 Sox2-expressing stem cells, although mRNA has been 
detected at low levels (Wilson et al. 2005), and it is proposed to mark a stem cell 
population in the adult human pancreas (Zhao et al. 2007).  
 
Figure 5.1 Expression of SOX2 in human fetal tissues 
RT-PCR panel for SOX2 and the housekeeping gene HPRT in a range of human fetal 
(56 dpc) tissues following PCR for 35 cycles. NT2: NTERA2 cells (positive control for 
SOX2 expression). Testis and ovary represent negative controls (Perrett et al. 2008 
and Chapter 3). For primer sequences see Appendix 1. 
 
By immunohistochemistry, strong nuclear SOX2 protein was detected in the 
developing spinal cord in a 48 dpc embryo (Figure 5.2) and in older embryonic and fetal 
sections (data not shown), throughout the progenitor domains (in the ventricular region 
close to the midline) from the roof plate to the floor plate. Strong nuclear staining was also 
detected throughout the epithelial lining of the stomach. At this stage of embryogenesis, 
the human gastric epithelium is stratified, composed of undifferentiated cells (Montgomery 
et al. 1999).  138
 
Figure 5.2 SOX2 expression during human embryogenesis at 48 dpc/CS19 
A. Bright-field image of human embryo at 48 dpc/CS19. White line indicates plane of 
transverse section shown in B. B.  Bright-field image of transverse section. SOX2 
immunohistochemistry is shown for the boxed areas in C and D. C-D. 
Immunohistochemical staining of SOX2 in C. spinal cord and D. stomach. Size bars 
represent 2 mm (A), 250 μm (B) and 50 μm (C). 
 
5.4.2 Isolation and Culture of SOX2-Expressing Cells from the Human 
Embryo/Early Fetus 
With confirmation that embryonic and fetal neuroprogenitors and stomach 
epithelial cells expressed SOX2, they were isolated from human embryonic/fetal material 
and culture methods employed aiming to retain SOX2 and cell-specific marker expression 
in vitro. 
 
5.4.2(i) Neuroprogenitors 
Freshly collected spinal cord (6-10 wpc) was isolated and immediately processed. 
A modified protocol from Austin Smith’s group was used to culture the cells (Conti et al. 
2005; Pollard et al. 2006). Under a dissecting microscope, the spinal cord was isolated,  139
separated from associated material (Figure 5.3 B), and the meninges removed (Figure 5.3 
C). Tissue was repeatedly pipetted with a P1000 pipette until completely homogenised, and 
then plated in ‘expansion’ media, comprising DMEM/Ham’s F-12 containing N2 and B27 
supplements and 10ng/ml of FGF2 and epidermal growth factor ([EGF], all Invitrogen). 
The combination of FGF2 and EGF is sufficient for the derivation and continuous 
expansion of pure cultures of neural stem cells (Suslov et al. 2002; Bez et al. 2003). Cells 
were left for approximately 3-4 days, until neurospheres became visible (Figure 5.3 D). 
Neurospheres contain a mixture of stem cells, committed progenitors, and differentiated 
cells (Aleksandrova et al. 2005); however, when grown under adherent conditions, only 
neural stem cells remain (Pollard et al. 2006). These spheres were allowed to settle for 10 
minutes, then plated onto a dish pre-coated in 0.1% gelatin. Attachment and outgrowth 
occurred within 4-5 days. At 70% confluence, cells were passaged 1:3 to 1:5 using trypsin 
and grown under adherent conditions. 
 
Figure 5.3 Dissection and culture of human embryonic/early fetal spinal cord 
A.  Collected embryo at 52 dpc/CS21. B. Isolated spinal cord. C. Spinal cord with 
meninges removed (arrow). D. Phase-contrast of spinal cord following mechanical 
disaggregation and culture for 2 days in suspension. Note formation of small 
neurosphere.  E. Neurosphere after culture for 2 days on gelatin-coated plastic. 
Neurosphere has enlarged and attached to growth surface with outgrowths. F. 
Neurosphere following culture for 7 days on gelatin-coated plastic. Outgrowths have 
extended across growth surface. G. Neuroprogenitors 1 day following trypsinisation 
and culture on gelatin-coated plastic. H. The same culture following 5 days of growth. 
Size bars represent 3 mm (A) 1 mm (B-C) and 200 μm (D-H). The dissection was 
performed by Prof. Neil Hanley (Human Genetics Division, University of 
Southampton).  140
 
5.4.2(ii) Stomach Epithelial Cells 
Freshly collected material (6-10 wpc) was immediately processed. Under a 
dissecting microscope, an incision was made that completely exposed the abdominal 
cavity, confirming the anatomical orientations of the liver, stomach, gall bladder and 
spleen (Figure 5.4 B). The entire stomach was removed from the associated organs (Figure 
5.4 C and D). The white dashed lines indicate the location of the incision made to gain 
access to the inner lining of the stomach (Figure 5.4 E) and the stomach flattened out 
(Figure 5.4 F) to expose the inner surface, which was then gently scraped, removing the 
epithelial layer of cells (Figure 5.4 G). 
Increasing cell density arrests epithelial cell proliferation
  by a process termed 
contact inhibition. As the initial dissection of cells provided them as a layer (Figure 5.4 G), 
cells were incubated in a cell
 dissociation mix, consisting of 0.25% collagenase, 20 U/ml 
DNase
  I, 60 µg/ml CaCl2 (all Sigma), 2% heat-inactivated newborn calf serum
 
(Invitrogen),
 in HBSS (PAA Laboratories) at 37°C for 1 hour,
 with repeated trituration, to 
encourage dispersion of cells. They were then plated in DMEM containing 10% FCS 
[media used by Basque et al. (1999) in their culture of human fetal stomach epithelium on 
plastic, with resultant retention of all gastric epithelial cell-types for one week]. Although 
cells attached and proliferated as ‘plaques’ (Figure 5.4 H), growth ceased after 
approximately 7 days, with detachment from the growth surface. Trypsinisation and 
subsequent replating did not encourage any further growth.  141
 
 
Figure 5.4 Dissection and culture of human embryonic/early fetal stomach 
A. Collected embryo at 52 dpc/CS21. B. Posterior view of preliminary dissection. C. 
Further dissection has removed associated organs. Dotted line indicates site of 
incision. D. View from the top of the stomach. E. Dotted line has been opened up. F. 
Further opening and flattening. G. Inner lining of stomach has been scraped leaving 
epithelial cells (arrow) which were enzymatically digested before plating. H. Phase-
contrast morphology of stomach epithelial cells following 4 days in culture. Gb, gall 
bladder; st, stomach; sp, spleen. Size bars represent 3 mm (A), 1 mm (B-G) and 200 
μm (H). The dissection was performed by Prof. Neil Hanley (Human Genetics Division, 
University of Southampton). 
 
5.4.3 Expression of SOX2 and Cell-Specific Markers in Human Fetal 
Neuroprogenitors and Stomach Epithelial Cells in vitro 
The cultured cells were tested to ensure that they retained SOX2 and cell-specific 
marker expression in vitro. 
 
5.4.3 (i) Neuroprogenitors 
Cells were isolated, cultured under non-adherent then adherent conditions, and then 
plated onto chamber slides coated with fibronectin and fixed with 4% PFA three days later. 
Therefore, all cells had been ex vivo for approximately thirteen days when characterised. 
Approximately 80% of cells expressed SOX2, β-tubulin, nestin and vimentin (Figure 5.5 
A-E). Between 10-20% of cells expressed glial fibrillary acidic protein (GFAP), in some 
cases co-expressing SOX2 (Figure 5.5 F). The expression of vimentin and nestin is  142
consistent with the cells being neural precursors/stem cells; however, expression of β-
tubulin III, a marker for newly-formed neurons, is indicative of differentiation towards a 
neuronal fate. In addition, SOX2 marks neural precursors, whereas GFAP marks glial 
cells; therefore, dual expression seems paradoxical (Figure 5.5 F). However, a population 
of GFAP-positive cells have been derived from human fetal brain, which, during their 
initial proliferative phase, co-express GFAP, nestin, vimentin and β-tubulin III. These cells 
differentiate into two distinct populations of cells, either restricted glial precursors 
(GFAP
+/nestin
+) or neuronal precursors (β-tubulin III
+/nestin
+) (Rieske et al. 2007). In 
addition, neurospheres obtained from human embryonic brain were found to co-express 
nestin and β-tubulin III (Aleksandrova et al. 2005). As well as being expressed by 
precursors, SOX2 is expressed in differentiating neural cells in vitro (Cavallaro et al. 2008)  
and in vivo (Bani-Yaghoub et al. 2006). Therefore, the cell type boundaries drawn by 
marker expression may not be distinct and it appears that some neural cells co-express a 
combination of precursor, neuronal and glial markers before final commitment. Despite the 
protocol for generation of neural stem cells being used (Conti et al. 2005; Pollard et al. 
2006), expression of β-tubulin III indicates further commitment down the neuronal lineage. 
Therefore, the cells isolated here are referred to as ‘neuroprogenitors’ rather than neural 
stem cells. 
 
5.4.3 (ii) Stomach Epithelial Cells 
Stomach epithelial cells were isolated, enzymatically digested, directly plated onto 
fibronectin coated chamber slides, and fixed four days later with 4% PFA. Approximately 
70% of cells expressed nuclear SOX2 (Figure 5.6 A-B), although diffuse cytoplasmic 
staining was also apparent, and all cells were positive for the epithelial cell marker CK19 
(Figure 5.6 C) and the gap junction protein Connexin 43 (CX43) (Figure 5.6 D).  143
 
Figure 5.5 Expression of neural markers in cultured human fetal 
neuroprogenitors 
Immunocytochemistry for  A-B. SOX2, C. β-tubulin III, D. nestin, E. vimentin in fetal 
neuroprogenitors. A-E. Individual band pass images are shown for Texas Red or FITC 
(left panel), DAPI (middle panel); with dual band pass imaging (right panel). F. SOX2 
(red)/GFAP (green); individual band pass images are shown for Texas Red (left 
panel), FITC (middle panel), with dual band pass imaging (right panel). Arrows point to 
cells exhibiting dual expression. Cells were cultured for 13 days before staining. Size 
bars represent 20 μm.  144
 
Figure 5.6 SOX2, CK19 and CX43 immunoreactivity in cultured human fetal 
stomach epithelial cells 
Immunocytochemistry for A-B. SOX2, C. CK19 and D. CX43 in cultured human fetal 
stomach epithelial cells. Individual band pass images are shown for Texas Red or 
FITC (left panel), DAPI (middle panel), with dual band pass imaging (right panel). Cells 
were cultured for 4 days before staining. Size bars represent 20 μm. 
 
5.4.4 Expression of OCT4-SOX2-NANOG Target Genes in Human Fetal 
Neuroprogenitors and Stomach Epithelial Cells in vitro and in vivo 
Boyer et al. (2005) identified a number of genes expressed in hESCs when OCT4, 
NANOG and SOX2 were collectively bound to their respective promoter regions. Thirteen 
were arbitrarily selected, and, along with genes known to be up-regulated by OCT4 and 
SOX2 (Yuan et al. 1995; Nishimoto et al. 1999; Tokuzawa et al. 2003), their expression 
tested for by RT-PCR in hPGCs (Perrett et al. 2008 and Chapter 3). Surprisingly, despite 
the absence of SOX2, all genes were expressed in fetal ovary and testis, indicating OCT4 
and NANOG expression may be sufficient to maintain expression of these genes. Here, the  145
expression of these target genes was also tested in neuroprogenitors and stomach epithelial 
cells. RT-PCR confirmed the presence of SOX2 and absence of OCT4 and NANOG in the 
cells (Figure 5.7 A). FGF4 and UTF1, transcriptional targets of the OCT4-SOX2 complex 
(Yuan et al. 1995; Nishimoto et al. 1999), were not expressed; however, FBX15, also a 
target (Tokuzawa et al. 2003), was (Figure 5.7 A), along with the 13 arbitrarily selected 
genes proposed to be targets of OCT4, SOX2 and NANOG in hESCs (Figure 5.7 B). 
Extending this analysis to protein expression, TDGF1 was detected in 
neuroprogenitors (Figure 5.8 A), but not stomach epithelial cells (Figure 5.8 B), despite 
TDGF1 expression being detected by RT-PCR in stomach epithelial cells (Figure 5.7 B). It 
is possible that protein levels were too low for detection by immunohistochemistry, or 
translation of the transcript is repressed. 
Nuclear DPPA4 protein was detected, consistent with DPPA4 expression, in 
neuroprogenitors (Figure 5.9 A), with expression stronger in some cells (arrows) than 
others (arrowheads). Weak expression was detected in stomach epithelial cells (Figure 5.9 
B), with a distinct subnuclear localisation, presumably nucleolar (arrows), similar to the 
staining pattern observed in NTERA-2 D1 cells (arrows Figure 5.9 D).  146
 
Figure 5.7 RT-PCR analysis for expression of genes regulated by OCT-SOX 
enhancers and those identified by bioinformatic analysis as targets of OCT4, 
SOX2 and NANOG in human fetal neuroprogenitors and stomach epithelial cells 
A. OCT4, SOX2, NANOG and genes previously recognised as targets of OCT4 and 
SOX2 (Yuan et al. 1995; Nishimoto et al. 1999; Tokuzawa et al. 2003), and B. genes 
previously described to be expressed in hESCs when OCT4, NANOG and SOX2 are 
bound to the respective promoter regions (Boyer et al. 2005) following PCR for 35 
cycles. Abbreviations
28. For primer sequences see Appendix 1. 
                                                 
28 FGF4, fibroblast growth factor 4; UTF1, undifferentiated embryonic cell transcription factor 1; FBX15, F-box only 
protein 15; HPRT, hypoxanthine-guanine phosphoribosyl-transferase; TDGF1, teratocarcinoma-derived growth factor 
1; DKK1, Dickkopf Xenopus, homolog of 1; SKIL, SKI-like; DPPA4, developmental pluripotency associated gene 4; 
CMYC, myelocytomatosis oncogene;  GJA1, gap junction protein, alpha 1; REST, RE-1 silencing transcription factor; 
MYST3, MYST histone acetyltransferase; SMARCAD1, SWI/SNF-related, matrix-associated actin-dependent 
regulator of chromatin, subfamily a, containing DEAD/H box 1; HESX1, homeobox gene expressed in ESCs; SET, 
suppressor of variegation, enhancer of zeste and Trithorax; ZIC3, zinc finger protein of cerebellum; STAT3, signal 
transducer and activator of transcription 3; ECC, embryonal carcinoma cell;  ESC, embryonic stem cell.  147
 
Figure 5.8 TDGF1 immunoreactivity in cultured human fetal neuroprogenitors 
and stomach epithelial cells 
Immunocytochemistry for TDGF1 in A. cultured fetal neuroprogenitors, B. cultured 
fetal stomach epithelial cells, C. hESCs (HUES1) and D. hECCs (NTERA-2 D1 cells, 
both positive controls). Individual band pass images are shown for FITC (left panel), 
DAPI (middle panel), with dual band pass imaging (right panel). Size bar represents 20 
μm. 
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Figure 5.9 DPPA4 immunoreactivity in cultured human fetal neuroprogenitors 
and stomach epithelial cells 
Immunocytochemistry for DPPA4 in A. cultured fetal neuroprogenitors (arrows indicate 
cells demonstrating strong expression, arrowheads weaker), B. cultured fetal stomach 
epithelial cells (arrows indicate presumed nucleolar expression), C. hESCs (HUES1) 
and D. hECCs (NTERA-2 D1 cells, arrows indicate presumed nucleolar expression). 
hESCs and hECCs are positive controls. Individual band pass images are shown for 
FITC (left panel), DAPI (middle panel), with dual band pass imaging (right panel). Size 
bar represents 20 μm. 
 
For comparison with these in vitro expression profiles, DPPA4 expression was 
investigated in situ in the human embryo at 48 dpc/CS19. Nuclear DPPA4 protein was 
detected in OCT4- and NANOG-positive germ cells in the ovary and testis (Figure 5.10 B-
C) and gut mesentery (Figure 5.10 D). Significant expression was noted in the 
mesonephros (Figure 5.10 E), which was negative for OCT4, NANOG and SOX2. Nuclear 
DPPA4 expression was apparent in the stomach (Figure 5.10 F, enlarged in H). Although 
this is a site of SOX2 expression, the pattern of DPPA4 expression was not identical, being 
expressed in a proportion of epithelial cells only and additionally in some cells of the  149
underlying mesenchyme. DPPA4 was expressed in the spinal cord (Figure 5.10 G, 
enlarged in I). Again, expression did not match that of SOX2 (Figure 5.11): SOX2 was 
expressed by all neuroprogenitors, whereas DPPA4 was specifically expressed in some 
dorsal progenitors in regions 3-6 (marked with the upper bracket in Figure 5.11), and also 
ventral progenitors in region 3 and in the motor neuron precursors (marked with the lower 
bracket in Figure 5.11). Overall, therefore, DPPA4 expression overlapped but did not 
exclusively correlate with expression of either OCT4, NANOG or SOX2. 
DPPA4 expression in situ was validated by immunoblotting of protein isolated 
from the human embryo (54 dpc; Figure 5.12). DPPA4 was present as a band of 34 kDa in 
gonads, with more detected in ovary presumably due to increased germ cell number, and 
also detected in mesonephros and hESCs (positive control). Weak expression was detected 
in spinal cord, cultured stomach and neuroprogenitors. 
 
Figure 5.10 DPPA4 expression during human embryogenesis at 48 dpc/CS19 
A. Bright-field image of transverse section of human embryo at 48 dpc/CS19. DPPA4 
immunohistochemistry is shown for the boxed areas in B-G. DPPA4-positive (OCT4-, 
NANOG-positive, SOX2-negative) germ cells in B. fetal ovary, C. testis and D. gut 
mesentery.  E. DPPA4-positive cells in mesonephros. The same cells are OCT4-, 
NANOG- and SOX2-negative. DPPA4 immunoreactivity is observed in fetal stomach 
(F, boxed area magnified in H) and spinal cord (G, boxed area magnified in I), but 
does not directly overlap with SOX2 expression. Size bars represent 250 μm (A), 50 
μm (B-G) and 20 μm (H-I). 
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Figure 5.11 DPPA4 and SOX2 expression in the developing human spinal cord at 
48 dpc/CS19 
A. SOX2 and B. DPPA4 immunoreactivity in spinal cord. Upper and lower brackets 
indicate areas of co-expression; however, whilst all neuroprogenitors in these regions 
are SOX2-positive, only approximately 30% are DPPA4-positive. Size bar represents 
50 μm. C. Diagram showing the regionalisation of the 6 types of dorsal neurons (dl1–
dl6) and the 5 types of ventral neurons (v0–v3 + mn) in the developing spinal cord 
(from Wilson and Maden 2005). On the left are the gene and protein markers used to 
identify the progenitor domains (in the ventricular region close to the midline) of these 
different dorsoventral regions. On the right are the gene and protein markers which are 
used to identify the neuronal types (in the mantle region where neurons differentiate). 
A B
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Figure 5.12 Immunoblot for DPPA4 in human embryonic tissues 
Immunoblot for DPPA4 and β-actin in protein extracted from human embryonic (54 
dpc) tissues (spinal cord, testis, ovary and mesonephros), hESCs (HUES1, positive 
control), and cultured fetal stomach and neuroprogenitors.  
 
5.4.5 Introduction of OCT4 and NANOG Does Not Induce Pluripotency 
in SOX2-Positive Neuroprogenitors/Stomach Epithelial Cells 
Recent studies have reported success in the reprogramming of somatic cells to 
pluripotency through the transduction of a combination of key transcription factors, 
including OCT4, SOX2 and NANOG, although most studies have found that NANOG is 
dispensable (Takahashi and Yamanaka 2006; Meissner et al. 2007; Okita et al. 2007; 
Takahashi et al. 2007; Wernig et al. 2007; Yu et al. 2007; Eminli et al. 2008; Kim et al. 
2008; Nakagawa et al. 2008; Park et al. 2008). The coding regions of OCT4 and NANOG 
were amplified from I.M.A.G.E. clones and cloned into the expression vector 
pcDNA3.1Zeo+ [Invitrogen; Appendix 3 (i)]. 
To select a ‘read-out’ pluripotent stem cell marker which would indicate reversion 
of neuroprogenitors/stomach epithelial cells to pluripotency, the expression profile of so-
called ‘pluripotent’ cell surface markers was firstly determined. Surprisingly, many of 
these surface antigens were already expressed by the differentiated cells (Figure 5.13). 
Neuroprogenitors were SSEA
+, EMA1
weak, SSEA3
weak, SSEA4
+, TRA-1-60
+ and TRA-1-
81
+ (Figure 5.13 A). Stomach epithelial cells were SSEA1
+, EMA1
+, SSEA3
-, SSEA4
-, 
TRA-1-60
weak and TRA-1-81
+ (Figure 5.13 B). hESCs were SSEA1
-, EMA1
-, SSEA3
+, 
SSEA4
+, TRA-1-60
+ and TRA-1-81
+ (Figure 5.13 C); hECCs SSEA1
weak (possibly due to  153
low level differentiation), EMA1
-, SSEA3
weak (again possibly due to early differentiation), 
SSEA4
weak, TRA-1-60
+ and TRA-1-81
+ (Figure 5.13 D). 
 
 
Figure 5.13 Immunocytochemistry for pluripotent stem cell markers in cultured 
human fetal neuroprogenitors and stomach epithelial cells 
Immunocytochemistry for SSEA1, EMA1, SSEA3, SSEA4, TRA-1-60 and TRA-1-81 in 
cultured A. fetal neuroprogenitors, B. fetal stomach epithelial cells, C. hESCs (HUES1) 
and D. hECCs (NTERA2 D1 cells). Dual band pass images are shown for Texas Red 
and DAPI (to mark nuclei). Abbreviations; hECC, human embryonal carcinoma cell; 
hESC, human embryonic stem cell, NP; neuroprogenitors, ST; stomach epithelial cells. 
Size bar represents 20 μm. 
 
As the neuroprogenitors and stomach epithelial cells already expressed pluripotent 
cell surface markers, another marker was selected. FGF4 was chosen, a SOX2-OCT4 
target gene (Yuan et al. 1995) which is expressed by hESCs and hECCs (Figure 5.14 A-B) 
but not neuroprogenitors and stomach epithelial cells (Figure 5.14 C-D). Cells were co-
transfected with OCT4 and NANOG expression vectors by nucleofection and plated onto 
fibronectin-coated chamber slides for 48 hours. Cells were then fixed with 4% PFA, and 
immunocytochemistry carried out. One chamber was always tested to confirm SOX2  154
expression (not shown). Dual immunocytochemistry for OCT4 and NANOG revealed 
nuclear co-staining of both transcription factors in the majority of transfected cells (Figure 
5.14 E-F); although some cells only expressed one protein. However, dual 
immunocytochemistry demonstrated that no OCT4-positive cells expressed FGF4 (Figure 
5.14 G-H). In addition, OCT4-positive cells still expressed differentiation markers: β-
tubulin III for neuroprogenitors (Figure 5.14 I), and CK19 for stomach epithelial cells 
(Figure 5.14 J). Therefore, in these experiments, expression of the OCT4-SOX2-NANOG 
transcription factor complex in cultured neuroprogenitors and stomach epithelial cells did 
not induce pluripotency. Interestingly, though, cells expressing OCT4 and NANOG were 
often present as groups of cells rather than single cells, particularly notable for stomach 
epithelial cells, indicating a possible effect on cell proliferation worthy of further 
investigation.  155
 
Figure 5.14 Immunocytochemistry for stem cell/tissue-specific markers in 
cultured human fetal neuroprogenitors and stomach epithelial cells 48 hours 
after co-transfection with OCT4 and NANOG expression vectors 
A-D. Immunofluorescence staining of FGF4 in cultured hESCs (A), hECCs (B), 
neuroprogenitors (C) and stomach epithelial cells (D).  E-F. Staining for OCT4 and 
NANOG in cultured neuroprogenitors (E) and stomach epithelial cells (F) 48 hours 
after co-transfection with OCT4- and NANOG-pcDNA3.1Zeo+. Note nuclear and 
overlapping staining for both. G-H. Staining for OCT4 and FGF4 in cultured 
neuroprogenitors (G) and stomach epithelial cells (H) 48 hours after co-transfection 
with OCT4- and NANOG-pcDNA3.1Zeo+. All cells were negative for FGF4 despite 
OCT4-positive cells being present. I-J. Staining for OCT4 and tissue-specific markers 
in cultured neuroprogenitors (I. β-tubulin III) and stomach epithelial cells (J. CK19) 48 
hours after co-transfection with OCT4- and NANOG-pcDNA3.1Zeo+. Cells remained 
positive for tissue-specific markers despite acquired immunoreactivity for OCT4. Size 
bars represent 20 μm.  156
5.5 DISCUSSION 
5.5.1 Successful Isolation and Culture of Human Fetal Stomach 
Epithelial Cells 
Stomach epithelial cells were successfully isolated from human embryonic and 
early fetal (6-10 wpc) stomach and cultured with retention of SOX2, CK19 and CX43 
expression for one week, with the avoidance of any obvious mesenchymal contamination. 
This is the first report of undifferentiated, stratified gastric epithelial cell culture from 
human embryonic and early fetal stomach, with retention of undifferentiated status, as 
marked by SOX2 expression. Stomach epithelium has been successfully cultured from 
human fetal material aged 15-18 wpc, again only for one week (Basque et al. 1999). 
However, Basque et al. used older fetal material: the epithelia at this age are differentiated 
simple columnar, which begins to replace stratified epithelium at around 9-10 wpc, with 
total replacement occurring at 13-15 wpc (Basque and Menard 2000). By 13 wpc, the 
human fetal stomach is representative of the adult stomach with all differentiated epithelial 
cell types being present (Menard et al. 1995; Tremblay and Menard 1996; Tremblay et al. 
1997). Previous reports have not had success in culturing gastric epithelium using a 
scraping technique, as used here, with overgrowth by mucous cells occurring within a few 
days (Terano et al. 1983; Fukamachi et al. 1994). The success in this study is likely due to 
a homogenous starting cell population; the late fetal and adult specimens used in other 
studies contain differentiated cells which can contaminate the culture. The cessation of 
proliferation observed after approximately one week of culture found in this study and by 
Basque et al. is likely due to contact inhibition. 
 
5.5.2 The OCT4-SOX2-NANOG Transcription Factor Complex is Not 
Required for Expression of Genes Identified as Targets by 
Bioinformatic Analysis 
OCT4, NANOG and SOX2 are thought to establish the initial genomic state from 
which all other gene expression patterns are derived during development (Boyer et al. 
2006). However, somatic cells do not require induction of NANOG to reprogram, whereas 
OCT4 and SOX2, along with KLF4 or LIN28 are required (Yu et al. 2007; Nakagawa et 
al. 2008). This suggests that the action of OCT4 and SOX2 is sufficient to generate a 
cascade of events which induce NANOG expression and pluripotency. Consistent with this  157
notion, Nanog is dispensable for pluripotency in mESCs; it acts primarily in the 
construction of the ICM, and stabilises mESCs in culture rather than playing a primary role 
in maintaining pluripotency (Chambers et al. 2007). 
All 13 of the arbitrarily selected OCT4-SOX2-NANOG target genes proposed by 
Boyer et al. were expressed in neuroprogenitors and stomach epithelial cells, and in SOX2-
negative hPGCs (Perrett et al. 2008 and Chapter 3). It is likely, therefore, that these genes 
are regulated by additional transcription factors. The analysis of target gene expression was 
extended to the protein level for DPPA4 and TDGF1. DPPA4 has recently been confirmed 
to be a direct target of Oct4 and Sox2 in mESCs (Chakravarthy et al. 2008), and is 
proposed to be a direct target of OCT4 (Babaie et al. 2007), and SOX2 and NANOG 
according to bioinformatic studies in hESCs (Boyer et al. 2005). DPPA4 is expressed in 
human and mouse ESCs, PGCs and ECCs (Maldonado-Saldivia et al. 2007). Consistent 
with these findings, it was detected in OCT4-positive hESCs, hECCs and hPGCs. 
However, DPPA4 was also detected in human tissues during embryonic development in 
the absence of OCT4, SOX2 and NANOG, indicating differences in transcriptional 
regulation between ESCs and cell types that arise later in embryogenesis. This is similar to 
SOX2 itself: within ESCs, expression is in part maintained by OCT4, but it is also 
expressed in differentiated tissues, where its regulators are currently unknown. DPPA4 was 
expressed within neuroprogenitors, however expression within the spinal cord has not been 
previously described, and the functional significance is unclear. Indeed, Dppa4 function in 
ESCs has not been characterised. One study found it inhibited differentiation into an 
ectoderm lineage in mESCs (Masaki et al. 2007); however, another found that over- or 
under-expression had no effect on differentiation (Ivanova et al. 2006). 
The promoter of TDGF1 was also bound by OCT4, SOX2 and NANOG in hESCs 
(Boyer et al. 2005). Expression was detected in cultured neuroprogenitors in this study. 
Although Tdgf1 (also known as Cripto1) is required for commitment of ESCs to a cardiac 
fate (Parisi et al. 2003), Tdgf1 protein expression has been widely detected in the primate 
nervous system (Stephens et al. 2006), and knock-out mice have a disordered 
neuroepithelium and fail to produce a recognisable spinal cord or head-fold (Xu et al. 
1999). This indicates a role in neurogenesis. 
Of the genes demonstrated to be regulated by OCT-SOX enhancers, two were 
absent from cultured neuroprogenitors and stomach epithelial cells: UTF1 and FGF4 
(Yuan et al. 1995; Nishimoto et al. 1999), indicating a requirement for OCT4 in their 
transcription. UTF1 was detected in SOX2-negative, OCT4-positive hPGCs (Perrett et al.  158
2008 and Chapter 3), indicating SOX2 is dispensable for its activation. However, FGF4 
was also absent from hPGCs, indicating that both OCT4 and SOX2 need to be present for 
transcription (Yuan et al. 1995). FBX15, a SOX2/OCT4 target gene (Tokuzawa et al. 
2003), was detected in neuroprogenitors and stomach epithelial cells. This is surprising as, 
in mice, the expression
 profile of Fbx15 is nearly identical to that of Oct4, restricted to 
ESCs, early embryos and testis tissue (Tokuzawa et al. 2003). Fbx15 is not required for 
mESC pluripotency or differentiation. Its role is unknown, but may function as an E3 
ubiquitin ligase and play a role in determining the expression levels of regulatory proteins 
necessary for pluripotency. Its expression during human development has not been 
examined. 
 
5.5.3 Neuroprogenitors and Stomach Epithelial Cells Express ‘Stem 
Cell-Specific’ Markers: Implications for Stem Cell Research 
The glycolipids SSEA3 and SSEA4 and the keratan sulfate antigens TRA-1-60 and 
TRA-1-81 are the cell surface antigens widely used in the ESC research community as 
indicators of pluripotent cells (for example Henderson et al. 2002), and to isolate 
pluripotent cells using cell sorting (for example SSEA4: Schulz et al. 2004; SSEA3: Enver 
et al. 2005). They were recently used in the characterisation of 59 hESC lines from 17 
laboratories worldwide by the International Stem Cell Initiative (Adewumi et al. 2007). 
Immunoreactivity was detected in all lines, with the conclusion that they are thus valuable 
markers of undifferentiated cells. Whilst this is true, the finding that differentiated cells 
during development express these markers advises some caution for their use in marking a 
cell as undifferentiated. Specifically, neuroprogenitors were SSEA3
weak, SSEA4
+, TRA-1-
60
+, TRA-1-80
+, and stomach epithelial cells SSEA3
-, SSEA4
-, TRA-1-60
weak and TRA-1-
81
+. SSEA-3 and SSEA-4 are epitopes on related glycosphingolipids, termed GL-5 and 
GL-7 (Kannagi et al. 1983). They were recently shown not to be required for hESC 
pluripotency as their depletion using glycolipid biosynthesis inhibitors had no effect on 
retention of an undifferentiated state (Brimble et al. 2007). The exact molecular identity of 
the epitopes of TRA-1-60 and TRA-1-81 are unknown, but they have been shown to 
recognise a keratan-sulphated proteoglycan in neuraminidase-sensitive and neuraminidase-
insensitive fashion, respectively (Badcock et al. 1999). The search for the carrier of the 
TRA family antigens in ECC has led to the identification of podocalyxin, a heavily 
sialylated membrane protein structurally similar to CD34. EC expresses two distinct forms  159
of podocalyxin, and the larger version is a molecular carrier of the TRA-1-60 and TRA-1-
81 antigens (Schopperle and DeWolf 2007).  
Given these data, it is candid to use other, more functionally relevant, markers to 
denote pluripotency. A combination of genes expressed in hESCs is required. Recently, 
quantitative RT-PCR using 12 selected genes was demonstrated to reliably distinguish 
differentiated cells from undifferentiated hESC populations (Cai et al. 2006). 
 
5.5.4 Induction of the OCT4-SOX2-NANOG Transcription Factor 
Complex in Neuroprogenitors/Stomach Epithelial Cells Did Not Induce 
Pluripotency 
The technique of converting somatic cells to iPS cells holds great promise 
therapeutically and ethically. Using a mouse model of sickle cell anaemia, mice could be 
rescued after transplantation with haematopoietic progenitors generated in vitro from 
autologous iPS cells (Hanna et al. 2007). Although the tumourigenic c-Myc was used, the 
mice did not show any evidence of tumour formation. iPS cells can now be generated 
without the use of c-Myc (Nakagawa et al. 2008; Wernig et al. 2008). The requirement for 
Klf4 is surprising: knock-out mice have no abnormalities in their pluripotent cell 
population during embryogenesis, and die within 15 hours of birth due to a skin barrier 
defect (Segre et al. 1999). In fact, iPS cells generated from human fibroblasts did not 
require KLF4, but rather SOX2, OCT4, NANOG, and LIN28, although the latter was not 
absolutely required for initial reprogramming or stable expansion. In addition, NANOG 
was not required for initial reprogramming, providing a beneficial effect in clone recovery  
(Yu et al. 2007).  
Despite this evidence suggesting that introduction of OCT4, NANOG and SOX2 
would be sufficient to reprogram somatic cells, the transduction of OCT4 and NANOG 
into SOX2-positive cells in this study proved insufficient. Differences in methodology may 
explain the lack of success. It has since been proven that the exogenous factors are required 
for at least 10-12 days in order to generate iPS cells (Brambrink et al. 2008; Stadtfeld et al. 
2008). Experiments herein involved only transient expression with testing 48 hours later. 
Studies by Yamankana’s group obtained iPS cells from only a small portion of cells that 
expressed the four factors. Too few cells may have been transfected, and only 
approximately 30% of cells were transfected with both vectors. In addition, the levels of 
OCT4 and NANOG generated from the vectors, or even the endogenous SOX2, may not  160
have been ‘correct’. A two-fold increase in Oct4 levels causes mESCs to differentiate
 into 
endoderm and mesoderm, whereas knockdown of Oct4 causes
  differentiation into 
trophectoderm-like cells (Niwa et al. 2000). Elevating the levels of Sox2 inhibits 
expression of Sox2-Oct4 target genes (Boer et al. 2007), and increasing or decreasing 
levels causes mESC differentiation (Chew et al. 2005; Kopp et al. 2008). Over-expression 
of Nanog in mESCs negates their need
 for LIF (Mitsui et al. 2003), and suppression results 
in differentiation to endoderm (Mitsui et al. 2003; Hough et al. 2006). Therefore, levels are 
precise and those generated by the pcDNAZeo3.1+ vector, with gene transcription under 
the control of the cytomegalovirus enhancer-promoter which gives high-level expression, 
may have been too high. 
Another possibility is that SOX2 in the differentiated cells may be in an alternate 
‘form’ or ‘state’, for example due to different post-translation modifications, which may 
render it incapable of complexing with the introduced OCT4 or NANOG. The mere 
presence of OCT4, SOX2 and NANOG in the transfected cells did not correlate with FGF4 
expression, indicating that this was not enough to initiate target gene expression.   
 
5.5.5 Fetal Tissue Culture Provides Insight into Developmental 
Pathways for ESC Differentiation Purposes 
  hESCs and hEGCs hold great promise therapeutically; however, only if they can be 
successfully differentiated in culture to specific cell types. The work and culture 
methodologies elucidated here provide insights into the normal developmental pathways 
for these cells, and thus provide clues as to the methodologies required to differentiate 
ESCs to these lineages.  
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5.5.6 Summary 
This study describes the successful isolation and culture for one week of human 
fetal gastric epithelial cells. The starting cells were undifferentiated stratified epithelia, 
rather than differentiated epithelial cells, which have been isolated later in fetal 
development (Basque et al. 1999). Data within this chapter and Chapter 3 have 
demonstrated that the expression of the OCT4-SOX2-NANOG transcription factor 
complex is not required for expression of target genes identified by biometric analysis 
(Boyer et al. 2005). SOX2
-, OCT4
+, NANOG
+ germ cells and SOX2
+, OCT4
-, NANOG
- 
neuroprogenitors and stomach epithelial cells expressed all 13 genes arbitrarily selected 
from this study. Expression of genes identified from functional studies as being activated 
by the SOX2-OCT4 complex showed better correlation with OCT4, SOX2 and NANOG 
expression: FGF4 was not expressed within SOX2
-, OCT4
+, NANOG
+ germ cells and 
SOX2
+, OCT4
-, NANOG
- neuroprogenitors and stomach epithelial cells, consistent with 
the absence of OCT4 and SOX2 (Ambrosetti et al. 1997). UTF1, also activated by OCT4 
and SOX2 (Nishimoto et al. 1999), was expressed in SOX2
-, OCT4
+, NANOG
+ germ cells 
but not in SOX2
+, OCT4
-, NANOG
- neuroprogenitors and stomach epithelial cells. 
Therefore, conclusions drawn regarding transcriptional activation of genes based on 
promoter binding require extensive validation by in vitro studies. 
The potential shortcomings of the use of SSEA3, SSEA4, TRA-1-60 and TRA-1-81 
to mark pluripotent cells have been identified by data presented within this chapter. 
Differentiated cells also express these markers. Therefore their use to characterise stem cell 
lines is limited and a combination of functionally relevant markers would perhaps prove 
more robust. In addition, initial experiments attempting to transduce OCT4 and NANOG 
into SOX2-positive neuroprogenitors and stomach epithelial cells did not reprogram the 
cells to a pluripotent state, contrasting subsequent reports using the same factors 
(Takahashi and Yamanaka 2006; Takahashi et al. 2007; Wernig et al. 2007; Yu et al. 2007; 
Lowry et al. 2008; Park et al. 2008).  162
CHAPTER 6: Identification of Candidate Genes for 
Germ Cell Proliferation 
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6.1 ABSTRACT 
Alongside ESCs and ECCs, EGCs are a third pluripotent stem cell type which can 
be derived from the embryo. Human EGCs are poorly characterised, having only been 
derived by a handful of groups to date. Relative to hESCs, in vitro culture of hEGCs is 
problematic, with cells only remaining undifferentiated for a limited period. Mouse EGCs, 
on the other hand, remain undifferentiated long-term and in many respects resemble 
mESCs. However, the same culture conditions do not also maintain hEGCs indefinitely. 
This chapter aimed to identify factors which might promote human germ cell proliferation 
and thus which could aid in prolonging hEGC culture. Expression microarray was 
conducted on RNA isolated from developing ovaries and testes at the stage of mitotic 
arrest in the male; at this point female germ cells are still proliferating. Genes more highly 
expressed in female samples might promote germ cell proliferation, and those with higher 
expression in the male may be involved in inducing or maintaining mitotic arrest. Of the 
20,000 genes analysed in the microarray, thirty genes were chosen from the microarray 
data and an initial screen performed by RT-PCR to confirm differential expression between 
ovary and testis. A number of interesting genes were identified which may potentially play 
a role in promoting germ cell proliferation, and could provide clues as to new factors to 
add to the media to improve hEGC culture.  164
6.2 INTRODUCTION 
 
6.2.1 PGC Proliferation and Survival 
Genetic studies in Drosophila and mice, along with cellular investigations using 
germ cell culture models, have revealed a number of genes and signalling molecules 
involved in promoting PGC proliferation and survival.  
  
6.2.1(i) Genetic Analysis – Mouse Mutants 
A number of mouse mutants are sterile or have reduced fertility, and the 
identification of the affected genes has implicated their corresponding products as playing 
important roles in PGC proliferation and/or survival. As described [previously in Section 
1.10.2 and in Section 6.2.1(iv) of this chapter], mutants of W and Sl, which affect the genes 
encoding c-Kit and SCF, respectively, are sterile with reduced PGC number at 9-10 dpc 
(Godin et al. 1991). The an mutation (Hertwig’s anaemia) causes sterility, with reduced 
germ cell number at 12 dpc (Russell et al. 1985). It is not clear whether this is due to a 
defect in migration, proliferation or survival, although no PGC proliferation is observed 
from 12 to 15 dpc. The identity of the affected gene(s) is not known.  
The  ter (teratoma) mutation inactivates the Dead-end 1 (Dnd1) gene on 
chromosome 18 and causes sterility, due to a defect in PGC proliferation which begins at 8 
dpc (Sakurai et al. 1994); (Youngren et al. 2005). Dnd1 binds to the 3’ UTR of mRNAs to 
displace miRNAs that bind to adjacent sites on the same mRNA (Kedde et al. 2007). 
Mouse Dnd1 protein shows highest homology to APOBEC1 complementation factor 
(ACF) (Youngren et al. 2005; Matin 2007). ACF is the RNA-binding co-factor of 
APOBEC1 and together they comprise the RNA editing enzyme complex (editosome) 
(Lellek et al. 2000; Mehta et al. 2000). Mouse Dnd1 interacts with APOBEC3; both are 
expressed in germ cells, and, in common with Dnd1, APOBEC3 can inhibit miRNA-
mediated repression of mRNA (Huang et al. 2007).  
The gcd (germ cell deficient) mutant is sterile with reduced PGC number at 11.5 
dpc (Pellas et al. 1991). It is caused by an insertational mutation which disrupts two genes 
on chromosome 11: Proliferation of germ cells (Pog) and Vaccinia virus-related protein 
kinase 2 (Vrk2) (Agoulnik et al. 2002). Pog expression is required for mPGC proliferation 
starting between E9.5-10.25, just as germ cells begin to enter the gonadal ridge (Agoulnik  165
et al. 2002). Vrk2 is highly expressed in actively proliferating
 cells (Nezu et al. 1997). 
Finally, the at (atrichosis) mutation causes depletion of germ cells (Handel and Eppig 
1979), however, it is not known which gene(s) is affected. 
 
6.2.1(ii) Genetic Analysis – Knock-out Mice 
Along with the sterile mouse mutants, the phenotypes of various knock-out mice 
have also unearthed further genes involved in germ cell proliferation. Pin1, a peptidyl-
prolyl isomerase, regulates the timing of PGC proliferation during mouse embryonic 
development (Atchison et al. 2003; Atchison and Means 2004). It promotes the 
degradation of proteins phosphorylated at Ser/Thr-Pro motifs, and is implicated in control 
of the cell cycle (Lu et al. 1996; Yaffe et al. 1997). PGCs have a prolonged cell cycle in 
the absence
 of Pin1, therefore there are fewer cell divisions and thus fewer Pin1
-/- PGCs by 
the end of the proliferative phase. An inhibitor of Pin1 - PinB - reduces mPGC growth in 
culture (De Felici et al. 2004). Knock-out of the Zfx gene, which encodes a zinc finger 
protein, results in reduced PGC number at 11.5 dpc, with no defect in migration (Luoh et 
al. 1997). Therefore the gene may act to promote PGC proliferation and/or prevent PGC 
death.  
Knock-out/reduction of Pten increases mPGC proliferation (Kimura et al. 2003; 
Moe-Behrens et al. 2003). Pten induces G1 arrest through suppression of the PI3K-Akt 
pathway (Li and Sun 1998; Ramaswamy et al. 1999; Sun et al. 1999). Disruption of the 
RNA-binding protein Tiar (T-cell restricted intracellular antigen-related protein) causes 
adult sterility; PGCs are reduced at 11.5 dpc and completely absent by 13.5 dpc (Beck et 
al. 1998). This is not due to a defect in migration. Tiar-deficient mESCs do not proliferate 
in the absence of LIF, supporting a role for Tiar in regulating cell proliferation (Beck et al. 
1998).  
  Dazl knock-out mice are infertile, with a reduction in germ cells by 19 dpc, and a 
failure to progress from Aaligned to A1 spermatogonia (Ruggiu et al. 1997; Schrans-Stassen 
et al. 2001). Dazl binds to mRNA in the cytoplasm, and this mRNA might be 
translationally active (Tsui et al. 2000; Maegawa et al. 2002; Collier et al. 2005). It 
interacts with Pum2, a translational repressor (Moore et al. 2003), and may play a role in 
RNA transport (Lee et al. 2006).  
Knock-out of Desert hedgehog (Dhh), a cell-signalling molecule first discovered in 
Drosophila, causes sterility, with a reduction in testis size from 18.5 dpc (Bitgood et al.  166
1996). The source of Dhh is the Sertoli cells, with receptors on peritubular cells and 
possibly Leydig cells (Pierucci-Alves et al. 2001). Inactivation of Cx43, the predominant 
testicular gap junction protein (Steger et al. 1999), causes a severe depletion in germ cell 
number in fetuses and neonates, beginning at 11.5 dpc (Juneja et al. 1999). 
 
6.2.1(iii) TGFβ Family 
TGFβ family members have been implicated in PGC and gonocyte development in 
a number of studies, reviewed in (Itman et al. 2006; Knight and Glister 2006). In 
Drosophila, two homologues of mammalian BMPs, decapentaplegic (dpp) and glass 
bottom boat  (gbb, also called 60A), function in the maintenance and proliferation of 
germline stem cells (Xie and Spradling 1998; Shivdasani and Ingham 2003; Kawase et al. 
2004). As previously described (Section 1.10.1), Bmp2, 4 and 8b are all involved in mouse 
germ cell specification in vivo (Lawson et al. 1999; Ying et al. 2000; Ying and Zhao 
2001). Bmp4 promotes mPGC proliferation in culture, through Smad1/4 signalling (Pesce 
et al. 2002). Disruption of Bmp8b causes male infertility due to a reduction in germ cell 
proliferation followed by an increase in death (Zhao et al. 1996). In addition, Bmp7 is 
required for mPGC proliferation between E10.5-11.5 (Ross et al. 2007). Knock-out mice 
for Smad1 (Tremblay et al. 2001) or Smad5 (Chang and Matzuk 2001) show reduced PGC 
number. Exogenous Activin and Tgfβ limit mPGC proliferation (Richards et al. 1999), and 
Tgfβ2 suppresses chick PGC proliferation (Fujioka et al. 2004). 
 
6.2.1(iv) Role of c-Kit and Stem Cell Factor 
The sterile mouse mutants Sl (Steel) and W (Dominant White Spotting) arose from 
mutations affecting SCF and its receptor, c-Kit, respectively, and revealed a role for SCF 
in the proliferation and maintenance of mPGCs (Godin et al. 1991). c-Kit is present on the 
surface of mPGCs and its ligand SCF can either exist as a membrane-bound (mbSCF) or a 
soluble (sSCF) isoform. mbSCF is required for mPGC proliferation and migration in vivo 
(Lev et al. 1994; Runyan et al. 2006), and in vitro it promotes survival for longer than 
sSCF (Dolci et al. 1991; Pesce et al. 1993; Yan et al. 2000; De Miguel et al. 2002). 
However, the latter increases telomerase activity in vitro (Dolci et al. 2002).  
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6.2.1(v) Role of LIF and Related Factors 
LIF increases the number and mitotic activity of mPGCs (De Felici and Dolci 
1991; Matsui et al. 1991; Resnick et al. 1992; Dolci et al. 1993; Koshimizu et al. 1996), 
and enhances the survival of mouse fetal gonocytes (Cheng et al. 1994) by reducing 
apoptosis (Pesce et al. 1993). LIF acts on the LIF receptor (LIFR) and the gp130 subunit 
(Cheng et al. 1994), which are both expressed in mouse gonads (Koshimizu et al. 1996). 
Addition of anti-LIFR or anti-gp130 antibodies to mPGC culture medium reduces PGC 
number (Cheng et al. 1994; Koshimizu et al. 1996). However, PGC development in LIF- 
or LIFR-deficient mice is normal (Stewart et al. 1992; Li et al. 1995; Ware et al. 1995). It 
is likely there is redundancy between related cytokines, which may be able to bind to 
gp130 and not require the presence of LIFR: inactivation of gp130 does reduce PGC 
number (Hara et al. 1998). Indeed, oncostatin M (OSM) can substitute for LIF in affecting 
survival and/or proliferation of mPGCs in culture (Cheng et al. 1994; Koshimizu et al. 
1996; Hara et al. 1998). Therefore, LIF itself may be dispensable. LIF maintains mESCs in 
the absence of feeders (Smith et al. 1988; Williams et al. 1988), but not hESCs (Daheron 
et al. 2004; Humphrey et al. 2004). Although all groups culturing hEGCs have included 
LIF, none has proven its necessity in derivation/growth. 
Knock-out mice for ciliary neurotrophic receptor (CNTF), another gp130 ligand, 
show no defects in germline development (Masu et al. 1993). In vitro CNTF promotes the 
survival of fetal gonocytes, and enhances the formation of germ cell colonies in neonatal 
mouse testis culture, but has no effect on mPGCs (Cheng et al. 1994; De Miguel et al. 
1996; Koshimizu et al. 1996; Kanatsu-Shinohara et al. 2007). Interleukin 6 (IL6), also a 
gp130 ligand, has no effect on mPGC or gonocyte proliferation in vitro (De Felici and 
Dolci 1991; De Miguel et al. 1996; Koshimizu et al. 1996), although it, IL2, IL4 and IL11 
enhance mPGC survival (Cooke et al. 1996; Koshimizu et al. 1996; Eguizabal et al. 2007).   
 
6.2.1(vi) Other Local Factors 
FGF2 supplementation to mPGC cultures already containing LIF and SCF led to 
the first reports of mEGC derivation (Matsui et al. 1992; Resnick et al. 1992). Only 12 
hour exposure is required for conversion to mEGCs; such a short time-frame indicating a 
direct rather than indirect effect (i.e. via feeders) (Donovan and de Miguel 2003). Once 
mEGCs are established, FGF2 and SCF are no longer required (Matsui et al. 1992). In 
addition, some studies suggest that FGF2 can be replaced by retinoic acid or agents that  168
activate cAMP such as forskolin (Koshimizu et al. 1996). cAMP has a proliferative effect 
on mPGCs and gonocytes (De Felici et al. 1993; Dolci et al. 1993; Pesce et al. 1996). 
Pituitary adenylate cyclase-activating peptide (PACAP) promotes mPGC proliferation via 
the activation of adenylate cyclase (Pesce et al. 1996). Forskolin raises intracellular cAMP 
levels and stimulates mitosis in cultured mPGCs (Dolci et al. 1993), and has been included 
by all groups reporting hEGC derivation. Its effect in mEGCs does not substitute for the 
survival mediated by LIF and SCF (De Felici et al. 1993). 
Growth arrest-specific 6 (Gas6) is expressed in both female and male mouse genital 
ridges after 11.5 dpc and it promotes mPGC proliferation and/or survival in culture 
(Matsubara et al. 1996). It has no effect on mPGCs cultured on feeders lacking the SCF 
gene, indicating it enhances SCF-induced growth or survival of mPGCs. The Sdf1/Cxcr4 
interaction, as well as regulating mPGC migration (Section 1.10.2), also mediates germ 
cell growth and survival (Molyneaux et al. 2003).  
The receptor tyrosine kinase ErbB3, its coreceptor ErbB2 (named for their 
similarity to avian erythroblastosis oncogene B), and their ligand Neuregulin-β, are 
expressed in mouse genital ridges at 12.5 dpc, and downregulated at 14.5 dpc when germ 
cells undergo growth cessation. Neuregulin-β enhances mPGC proliferation at 12.5 dpc 
(Toyoda-Ohno  et al. 1999). Tumour necrosis factor α (TNFα) stimulates mPGC 
proliferation (extracted before and during migration) in vitro (Kawase et al. 1994). TNFα 
and its receptors TNFRI and TNFRII are expressed in most embryonic tissues (Kohchi et 
al. 1994), therefore a role in vivo could be anticipated. 
Suppression of Wnt/β-catenin signalling is required for normal mPGC 
development. Aberrant activation of Wnt/β-catenin signalling causes germ cell deficiency 
due to delayed cell cycle progression, followed by apoptosis (Kim et al. 2000; Kimura et 
al. 2006). The opposite is true in Drosophila, where Wingless (Wg) signalling initiates 
mitosis in PGCs (Sato et al. 2008). Finally, knock-out of the mouse Vasa homologue gene 
(Mvh, also known as Ddx4), which encodes a cytoplasmic RNA helicase, causes reduced 
male PGC proliferation and differentiation (Tanaka et al. 2000).  
 
6.2.1(vii) Human PGCs 
hEGCs can be derived using the same cocktail of factors as mEGCs, i.e. forskolin, 
FGF2, LIF and SCF (Shamblott et al. 1998). However, unlike mEGCs, hEGCs do not 
remain undifferentiated long-term in their presence, and their derivation efficiency is  169
lower. This indicates that while the mechanisms controlling initial PGC growth may be 
largely conserved between the two species, differences do exist, particularly relating to 
longer term growth.  
c-KIT, mbSCF and sSCF are expressed in human fetal gonads (Hoyer et al. 2005). 
However, in contrast to the mouse, mutations in c-KIT do not affect fertility, instead they 
are associated with mast cell neoplasms (Nagata et al. 1995) and GI stromal tumours 
(Hirota et al. 1998). c-KIT mutations are found in some types of TGCT (Tian et al. 1999), 
which are believed to originate from PGCs, suggesting that, in common with the mouse, c-
KIT plays a role in hPGC survival and/or proliferation. Individuals suffering from 
Fancoli’s anaemia exhibit reduced fertility (D'Andrea and Grompe 2003). Mice carrying 
one of the disease-causing mutations, within the Fanconi anaemia complementation group 
C locus (Fancc), show reduced mPGC proliferation, beginning at E12.5 (Nadler and Braun 
2000), again indicating similarities exist in the control of proliferation. In addition, a 
mouse model of Down’s syndrome (trisomy 16), human sufferers of which have reduced 
fertility, has fewer PGCs than normal (Leffler et al. 1999). 
 
Therefore, while there are some similarities in the genes and signalling molecules 
controlling mouse and human PGC proliferation, differences are apparent. Work 
undertaken in this chapter attempted to identify factors which might promote hPGC/hEGC 
proliferation, and thus extend culture, as detailed below.  170
6.3 SPECIFIC AIMS 
6.3.1 To identify endogenous factors which promote human primordial 
germ cell proliferation. 
hPGC-EGC cultures generally acquire one of two differing characteristics, 
designated either ‘PP’ (‘poorly proliferating’) or ‘VP’ (‘vigorously proliferating’) 
(Turnpenny et al. 2003). VP cultures arise from approximately 15% of cultures, in our 
group’s experience, and, along with fulfilment of other criteria, including pluripotent 
marker expression and in vitro pluripotency, are taken as conversion to hEGCs. However, 
they are difficult to maintain undifferentiated long-term. The proportion of cells 
maintaining expression of pluripotent markers, such as OCT4 and SSEA family members, 
declines over time and is exacerbated by freeze-thaw routines (Turnpenny et al. 2003). 
This study sought to identify endogenous factors promoting hPGC proliferation, which 
might potentially unearth factors which have the same effect in hEGCs. 
In the developing human testis, PGCs enter mitotic arrest around 7 wpc, whereas 
PGCs in the developing ovary increase in number until approximately 12 wpc (Gondos and 
Hobel 1971). Expression microarray was used to identify genes whose detection level 
differed between testis and ovary at the time of this mitotic arrest. Genes more strongly 
detected in the ovary could potentially be involved in promoting germ cell proliferation. 
RT-PCR verification of differential expression validated a number of interesting candidate 
genes selected from the microarray data.    171
6.4 RESULTS 
6.4.1 Selection of Appropriately Aged Material for Expression 
Microarray 
Before RNA was isolated from ovary and testis for the expression microarray, dual 
immunohistochemistry was undertaken on gonads from embryos of different stages using 
an OCT4 antibody, which marks germ cells, and a Ki67 antibody, which recognises the 
proliferation marker MK167, to determine at which age germ cells in the testis would be in 
mitotic arrest, but those in the ovary would still be proliferating. In 54 dpc ovary (Figure 
6.1 A-B), many dual stained cells were visible (cells with yellow nuclei, indicated by 
arrows), approximately 75% of germ cells were proliferating
29. However, in 56 dpc testis 
(Figure 6.1 C-D) and 64 dpc testis (Figure 6.1 E-F), fewer dual stained cells could be 
detected; 37% and 36% of germ cells were proliferating, respectively, indicating that germ 
cells were entering mitotic arrest at this stage.  
Therefore, for the purposes of RNA preparation, gonads were collected from 
embryos/early fetuses aged 50-60 dpc and stored in RNA later (QIAGEN) at -80
oC. Sex 
was determined by fluorescent in situ hybridisation (FISH) on placental tissue, using 
probes specific for the X and Y chromosomes (performed by Louise Williams, Human 
Genetics Division, University of Southampton; data not shown). Four ovaries (average age 
55 dpc) and four testes (average age 56 dpc) were separately pooled, RNA extracted, 
purified using the RNeasy MinElute Cleanup Kit (QIAGEN) and concentration and 
integrity determined using an Agilent 2100 Bioanalyzer (Figure 6.2). RNA yield and 
quality were deemed sufficient to proceed with the expression microarray. 
 
                                                 
29 Determined by counting the number of dual stained cells, and dividing it by the total number of germ cells 
(OCT4-positive cells) in ten fields of vision (× 20 magnification).   172
 
Figure 6.1 Dual immunohistochemistry for OCT4 (green) and the proliferation 
marker MK167, identified using the Ki67 antibody (red), in human embryonic 
ovary and embryonic/early fetal testes 
IHC was performed in 54 dpc ovary (A-B), 56 dpc testis (C-D) and 64 dpc testis (E-F). 
Arrows point to examples of PGCs that are dual stained and therefore proliferating. 
Size bar represents 50 μm (A, C, E) and 20 μm (B, D, F). From left to right, individual 
band pass images are shown for FITC (OCT4), Texas Red (Ki67), dual band pass 
imaging and DAPI, at low and high magnification for each stage.  173
 
Figure 6.2 Electropherogram summary from Agilent 2100 Bioanalyzer of RNA 
isolated from A. male and B. female gonads 
Characteristic 18 S and 28 S rRNA peaks are visible at 39 and 46 seconds with little 
evidence of RNA degradation. Although a 28 S:18 S of 2 is usually taken to indicate 
high quality RNA, RNA extracted from tissues has a lower ratio. 
 
6.4.2 Expression Microarray and Data Analysis 
The expression microarray was conducted using the Amersham CodeLink Uniset 
Human 20K I Bioarray, which targets 21,000 transcripts using 30-mer probes, and was 
performed by Dr. Feng Lin (Cancer Sciences Division, University of Southampton). Data 
was analysed using CodeLink Expression Analysis v4.1 (Amersham) and GeneSifter 
software (http://www.genesifter.net/web/). The data was normalised to remove background 
noise, and the detection level of genes compared between testis and ovary using the log2 
values of the normalised intensity. A cut-off intensity level of 0.3 was used to filter the 
data, which represented an approximate four-fold increase on the average intensity of all 
20K spots, so that only differences between the most differentially detected genes were 
compared. 
Figure 6.3 depicts the scatter plot obtained for the entire data set. This graph plots 
the log2 intensities against one another, with each point representing a gene. The majority 
of genes showed similar intensities within ovary and testis. A number of candidate 
differentially expressed genes are visible as lying far from the diagonal line.  174
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Scatterplot of the ratio of gene expression log2 intensities obtained 
from the Human 20K I Bioarray using RNA isolated from male and female 
gonads 
Diagonal line indicates a ratio of 1, i.e. equal detection in both RNA samples. Outliers 
from the diagonal line represent genes whose detection differed in either male (green) 
or female (red) RNA. 
 
The GeneSifter software was used to generate a list of the top 30 genes with the 
most differential intensity levels involved in cell proliferation (Figure 6.4). 
 
6.4.3 RT-PCR Validation 
The list of the top 30 genes involved in cell proliferation (Figure 6.4) and the raw 
data were examined and a number of genes selected for further analysis. These are listed in 
Table 6.1 along with the normalised intensities obtained for each gene and the fold 
induction in the female (F/M). In particular, cytokines were chosen, particularly 
interleukins, as these have been shown to promote germ cell proliferation in previous 
studies (Section 6.2.1). Three separate RT-PCR reactions were performed for each gene, 
on RNA extracted from different samples, aged 55-59 dpc (Figure 6.5). 
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Figure 6.4 The top 30 genes involved in cell proliferation (according to 
GeneSifter) identified by expression microarray as being most differentially 
detected in male or female gonads 
Genes in red were more highly detected in ovary; genes in green more highly detected 
in testis. Fold induction is listed on the left (female/male).  176
Name ACCN  # 
Normalised 
Intensity: 
Female 
Normalised 
Intensity: 
Male 
Ratio 
(F/M)  Reason chosen for RT-PCR 
small inducible cytokine 
subfamily A (Cys-Cys), 
member 20 (SCYA20) 
NM_004591  0.02  0.09  0.18  Control for low/no detection in both 
growth arrest-specific 11 
(GAS11) 
NM_001481  1.37  4.18  0.33  Higher detection in male; expressed in 
growth arrested cells 
colony stimulating factor 3 
(granulocyte) (CSF3) 
NM_000759  2.08  3.30  0.63  Acts on the CSF3 receptor which is 
similar to the IL6R 
cardiotrophin-like cytokine; 
neurotrophin-1/B-cell 
stimulating factor-3 (CLC) 
NM_013246  0.48  0.58  0.82  Acts on the CNTFR, LIFR and IL6R, the 
latter two being implicated in ESC 
pluripotency 
CNTF gene for ciliary 
neurotrophic factor 
X60542  0.90  1.10  0.82  Acts on the CNTFR, LIFR and IL6R, the 
latter two implicated in ESC pluripotency 
leukaemia inhibitory factor 
(LIF) 
NM_002309  4.30  4.60  0.93  Control for equal detection in both; LIF 
used for ESC/EGC derivation 
signal transducer and activator 
of transcription 5A (STAT5A) 
NM_003152  0.40  0.39  1.02  Phosphorylated upon SCF activation of c-
KIT 
interleukin 6 (IL6)  NM_000600  1.40  1.30  1.08  Control for equal detection in both; 
implicated in ESC pluripotency 
ciliary neurotrophic factor 
receptor (CNTFR) 
NM_001842  13.00  12.00  1.08  Control for equal detection in both; same 
member of family as IL6R 
interleukin 6 signal transducer 
(gp130, oncostatin M receptor) 
(IL6ST) 
NM_002184  0.45  0.41  1.10  Control for equal detection in both; 
implicated in ESC pluripotency 
bone morphogenetic protein 7 
(BMP7) 
NM_001719  0.54  0.44  1.23  Higher detection in female; BMPs 
promote PGC specification/proliferation 
transcription factor 8 (TCF8)  NM_030751  21.57  17.03  1.27  Higher detection in female; cytokine 
repressor 
interferon induced 
transmembrane protein 1 
(IFITM1) 
NM_003641  41.20  32.25  1.28  Higher detection in female; cytokine 
induced 
v-kit Hardy-Zuckerman 4 feline 
sarcoma viral oncogene 
homologue (KIT) 
NM_000222  6.66  5.20  1.28  Higher detection in female; receptor for 
SCF 
interleukin 1 receptor, type I 
(IL1R1) 
NM_000877  0.51  0.39  1.30  Higher detection in female; cytokine 
receptor 
bone morphogenetic protein 2 
(BMP2) 
NM_001200  0.68  0.53  1.30  Higher detection in female; BMPs 
promote PGC specification/proliferation 
FK506 binding protein 12-
rapamycin associated protein 1 
(FRAP1)/mTOR 
NM_004958  1.98  1.44  1.37  Higher detection in female; mediates AKT 
signalling (involved in PGC-EGC 
transition) 
signal transducer and activator 
of transcription 5B (STAT5B) 
NM_012448  1.10  0.78  1.41  Higher detection in female; 
phosphorylated upon SCF activation of c-
KIT 
bone morphogenetic protein 4 
(BMP4) 
NM_001202  2.19  0.83  2.65  Higher detection in female; BMPs 
promote PGC specification/proliferation 
interleukin 6 receptor (IL6R, 
gp80) 
NM_000565  0.10  0.03  2.76  Higher detection in female; cytokine 
receptor; implicated in ESC pluripotency 
interleukin 8 (IL8)  NM_000584  2.81  1.07  2.81  Higher detection in female; cytokine 
neuropeptide Y receptor Y1 
(NPY1R) 
NM_000909  0.95  0.21  4.56  Higher detection in female; receptor for 
NPY (see below) 
interleukin 1, beta (IL1B)  NM_000576  3.86  0.79  4.88  Higher detection in female; cytokine 
neuropeptide Y (NPY)  NM_000905  107.73  16.76  6.43  Higher detection in female; promotes 
neuroprogenitor proliferation 
cholecystokinin B receptor 
(CCKBR) 
NM_000731  1.76  0.24  7.38  Higher detection in female 
glutamate receptor, 
metabotropic 4 (GRM4) 
NM_000841  2.17  0.29  7.54  Higher detection in female; expressed in 
colonic neoplasms with a poor prognosis 
carboxypeptidase A2, 
pancreatic (CPA2) 
NM_001869  2.92  0.25  11.70  Much higher detection in female 
LIM homeobox protein 2 
(LHX2) 
NM_004789  2.68  0.14  19.66  Much higher detection in female; 
expressed in immortalised haematopoietic 
stem cells 
XIST, coding sequence 'd' 
mRNA (locus DXS399E) 
X56196  40.34  1.04  38.82  Positive control for high expression in 
female 
 
Table 6.1 Genes selected from expression microarray data for RT-PCR 
verification in ovary and testis 
Gene name, accession number, normalised intensity in ovary and testis, female:male 
ratio and a brief explanation for why the gene was selected are listed.  177
 
Figure 6.5 RT-PCR verification of genes selected from expression microarray 
data 
RT-PCR for selected genes in human embryonic/early fetal ovary and testis following 
35 cycles. Each repeat reaction was performed on RNA from a different gonad (55-59 
dpc). Genes are shown in the same order they are mentioned in the text (below). 
Abbreviations: M, male (i.e. testis); F, female (i.e. ovary). For full gene names, see 
Table 6.1. For primer sequences see Appendix 1.  178
6.5 DISCUSSION 
This chapter describes efforts to identify genes which may promote human germ 
cell proliferation. The comparison of gene expression within the fetal ovary while germ 
cell proliferation is still underway, with that in the testis where germ cells are entering 
mitotic arrest, has highlighted a number of genes which appear to be differentially 
expressed. Examining known functions of these genes may provide clues as to whether 
they may be mitogenic for germ cells. 
No cell-sorting was performed, so results are based on analysis of gene expression 
within the entire gonad. Whilst this is somewhat unspecific, it allows for the identification 
of important somatic factors, as well as germ cell-specific ones.  
 
6.5.1 Genes Potentially Involved in Germ Cell Proliferation Identified 
using Expression Microarray Analysis and RT-PCR 
6.5.1(i) Neuropeptide Y (NPY) and Neuropeptide Y Receptor Y1 (NPY1R) 
By microarray, NPY and one of its receptors, NPY1R, were 40-fold and 5-fold more 
highly detected in the ovary respectively. By RT-PCR, NPY was more strongly expressed 
in ovary than testis (Figure 6.5); however, this difference was only slight, likely because 
detection was relatively high in testis, with a normalised intensity of 17.  
NPY is a 36 amino acid neuropeptide broadly expressed in the central and 
peripheral nervous system during development and adulthood (Allen et al. 1983; Danger et 
al. 1990). It promotes the proliferation of neuroprogenitors, vascular smooth muscle and 
endothelial cells (Hansel et al. 2001; Lee et al. 2003; Pons et al. 2003), and it has been 
linked to cell proliferation in a number of cancers, including breast, prostate and neural 
crest tumours (Kitlinska 2007). It appears that its effects on proliferation are mediated 
through the Y1 receptor subtype (Magni and Motta 2001; Reubi et al. 2001; Kitlinska 
2007), which also showed higher expression in the ovary (Figure 6.5). It could be 
speculated, therefore, that NPY promotes germ cell proliferation by acting on the NPY1R 
within the developing ovary. 
  179
6.5.1(ii) LIM-homeobox 2 (LHX2) 
LHX2 showed 20-fold increased expression in ovary compared to testis. This higher 
expression was verified by RT-PCR (Figure 6.5). LHX2 is expressed in mouse fetal liver at 
the time of active haematopoiesis (Xu et al. 1993). Immortalised haematopoietic stem cell 
lines can be generated by expressing Lhx2 in haematopoietic progenitor cells derived from
 
mESCs (Pinto do et al. 1998). It maintains the growth and undifferentiated properties of 
mouse hair follicle progenitors (Rhee et al. 2006), and a similar role in germ cells within 
the ovary could be anticipated. 
 
6.5.1(iii) Cholecystokinin B receptor (CCKBR) 
Cholecystokinin B receptor (CCKBR) showed 7.5-fold increased expression in 
female compared to male gonad. By RT-PCR no transcript was detected in testis (Figure 
6.5; level was 0.24 in expression microarray). CCKBR is a gastrin receptor (Kopin et al. 
1992), which may promote the proliferation of gastric carcinoma cells (Eden and Taylor 
1993). Gastrin acts via the CCKBR to promote growth of the AR42J rat acinar cell line, 
acting via AKT, thereby inhibiting apoptosis (Todisco et al. 2001). Interestingly, AKT 
signalling has recently been shown to promote derivation of mEGCs from PGCs (Kimura 
et al. 2008). 
 
6.5.1(iv) Interleukins 
The expression of a number of genes involved in cytokine signalling, in particular 
members of the interleukin family, were increased in developing ovary compared to testis, 
for example, IL8 (2.7-fold), IL10 (1.5-fold) and the IL1R1 (1.3-fold). Despite these 
differences, RT-PCR for IL8, IL10 and IL1R1 detected approximately the same amounts of 
transcript in ovary and testis (Figure 6.5). It is likely that these small differences in gene 
expression level are not detectable by conventional RT-PCR. 
IL1β expression was 4.8-fold higher in ovary (3.9 compared to 0.8 in the testis), 
and RT-PCR also detected more transcript in ovary compared to testis (Figure 6.5). IL1β 
mediates proliferation and differentiation of multipotent rat neural precursor cells (Wang et 
al. 2007), and it promotes neuroepithelial proliferation and differentiation of the chick 
spinal cord during development (de la Mano et al. 2007).  180
Transcription factor 8 (TCF8) encodes a zinc finger transcription factor that 
represses the IL2 gene (Williams et al. 1991). Expression was 1.3-fold higher in ovary 
compared to testis; however, this slight difference in expression was not evident by RT-
PCR (Figure 6.5). A role in suppressing IL2 within the ovary is contradictory, however, as 
IL2 promotes proliferation of mPGCs in vitro (Eguizabal et al. 2007). 
 
6.5.1(v) LIF, SCF and related genes 
A number of genes were chosen from the LIF family for further investigation. LIF 
is included in the culture media during mEGC derivation as it promotes their survival; 
however, LIFR-knockout animals have normal numbers of PGCs (Stewart et al. 1992; 
Ware et al. 1995). This may be explained by the fact that LIF is a member of the IL6 
family of cytokines which exhibit overlapping functions (Taga and Kishimoto 1997). In 
the mouse there are six members of this family: IL6, IL11, LIF, OSM, CNTF and 
cardiotrophin 1 (CT1). Members of this family signal through
 receptor complexes that are 
dimers (or multimers) comprising
 high affinity growth factor-specific receptors (e.g. LIFR, 
OSMR, IL6R
 [gp80 also known as IL6Rα]) and a low affinity common receptor
 (gp130 
also known as IL6 signal transducer [IL6ST]). Surprisingly, given the role of LIF in 
promoting EGC survival, gp130-mediated signalling is not required for the early stages
 of 
mPGC development, but it is required late in oogenesis (Brizzi et al. 1999). In addition, the 
receptor for SCF (required for EGC derivation), c-KIT, was chosen for RT-PCR analysis, 
along with STAT5A and STAT5B. SCF stimulation of c-KIT results in tyrosine 
phosphorylation of STAT5A and STAT5B (Molyneaux et al. 2003). 
 
By expression microarray and RT-PCR, cytokines of the IL6 family were expressed 
at the same levels in ovary and testis (IL6, CNTFR, c-KIT, LIF, gp80, gp130, STAT5A 
and STAT5B), perhaps indicating that these factors are intrinsic to germ cells per se, rather 
than sex-specific. CNTF showed higher expression in the testis, in both the expression 
microarray and RT-PCR (Figure 6.5). CNTF promotes survival of mouse fetal gonocytes 
in vitro (De Miguel et al. 1996), and has recently been shown to enhance the formation of 
germ cell colonies in neonatal mouse testis culture (Kanatsu-Shinohara et al. 2007), 
therefore it may promote PGC proliferation in the testis: in 56 dpc and 64 dpc testes some 
PGCs were proliferative (Figure 6.1 D and F, arrows). Cardiotrophin-like cytokine (CLC) 
was detected at relatively low levels in both (0.48 and 0.58 in ovary and testis,  181
respectively). This cytokine acts on the IL6, CNTF and LIF receptors (Vlotides et al. 
2004). Interestingly, slightly higher expression of CLC was detected in ovary by RT-PCR 
(Figure 6.5). Conversely, colony stimulating factor 3 (CSF3) showed 1.6-fold higher 
expression in testis by microarray, and more transcript was detected in testis than ovary 
(Figure 6.5). This cytokine acts on the CSF receptor, which shares significant similarity 
with gp130 (Taga et al. 1989; Kishimoto et al. 1995). 
 
6.5.1(vi) Bone morphogenetic proteins 2 and 4 (BMP2 and BMP4) 
BMP2 and BMP4 showed 1.3- and 2.7-fold higher expression in ovary compared to 
testis, respectively, and higher expression of both in ovary was verified by RT-PCR 
(Figure 6.5). Signalling by endoderm-derived BMP2 and extraembryonic ectoderm-derived 
BMP4 is involved in mPGC specification (Lawson et al. 1999; Ying and Zhao 2001). In in 
vitro assays, BMP2 and BMP4 enhance juvenile spermatogonial proliferation (Pellegrini et 
al. 2003; Puglisi et al. 2004), and BMP4 can influence spermatogonial  differentiation 
(Pellegrini et al. 2003; Baleato et al. 2005). In organ culture, addition of BMP4 elevated 
PGC number in E9.5 gonads (Dudley et al. 2007), and, with a cocktail of other factors, 
BMP4 supported survival and self-renewal of mPGCs in the absence of somatic cells 
(Farini  et al. 2005). BMP4 has same effect in mESCs: the absence of serum, BMP4 
synergises with LIF to maintain self-renewal by inducing expression of Id (Inhibitor of 
differentiation) genes (Ying et al. 2003). However, in hESCs, BMP4 induces 
differentiation to trophoblast (Xu et al. 2002), and has been reported to induce germ cell 
differentiation from hESCs, in combination with BMP7 and BMP8b (Kee et al. 2006). 
BMP2 causes hESCs to differentiate to extra-embryonic endoderm (Pera et al. 2004). 
FGF2 represses BMP signalling in hESCs, and synergises with noggin, a BMP antagonist, 
to sustain undifferentiated proliferation of hESCs (Xu et al. 2005). In addition, BMP2, 4 
and 7 induce epithelial differentiation of hECCs (Caricasole et al. 2000). The effect of 
BMPs on hPGCs/EGCs is not known. 
 
6.5.1(vii) Glutamate receptor, metabotropic 4 (GRM4) 
GRM4 showed higher expression in female gonads (Figure 6.5), consistent with the 
7.5-fold higher expression in ovary detected in the expression microarray. GRM4 has been 
identified in the epithelial layer of a number of non-neuronal peripheral adult tissues, and  182
is absent from adult testis. GRM4 expression is frequently identified in colorectal 
carcinoma, followed by malignant melanoma, laryngeal carcinoma and breast carcinomas. 
It may play a role in tumour growth and progression, with expression associated with a 
poor prognosis in colorectal carcinoma (Chang et al. 2005). 
 
6.5.1(viii) Carboxypeptidase A2, pancreatic (CPA2) 
Expression of CPA2 was 12-fold higher in ovary in the expression microarray, and 
higher ovarian expression was verified by RT-PCR (Figure 6.5). The significance of this 
higher expression is unknown as expression in gonads has not been described, nor has a 
role in cell proliferation. 
 
6.5.1(ix) Interferon-induced transmembrane protein 1 (IFITM1) 
IFITM1 is a 17-kDa membrane protein induced on tumour cell lines by interferon-α 
and interferon-γ (Deblandre et al. 1995). It showed 1.3-fold higher expression in ovary, 
with relatively high expression in both ovary and testis (32 and 41 respectively). Mouse 
Ifitm1 and Ifitm3 are expressed on the cell surface of PGCs. Ifitm1 activity was 
demonstrated to be required for PGC transit from the mesoderm into the endoderm, acting 
via a repulsive mechanism, such that PGCs avoided Ifitm1-expressing tissues (Tanaka et 
al. 2005). However, a recent study has suggested that Ifitm genes are not required for 
development of the germline (Lange et al. 2008). Higher expression in ovary may 
therefore be due to increased germ cell number, rather than playing any specific role in 
proliferation, although this difference was unverifiable by conventional RT-PCR (Figure 
6.5). 
 
6.5.1(x) Mammalian target of rapamycin (mTOR) 
mTOR showed 1.4-fold higher expression in ovary. Also known as FKBP12-
rapamycin complex-associated protein 1 (FRAP1), this is one of a family of proteins 
involved in cell cycle progression, DNA recombination and damage detection (Hay and 
Sonenberg 2004). mTOR activation
  promotes cell growth and proliferation, and it is 
frequently up-regulated in many
  cancers (Feng et al. 2005). PI3K, PTEN and the 
downstream effector Akt mediate mTOR activity, and are involved in maintaining hESC  183
pluripotency (Armstrong et al. 2006). Akt signalling promotes derivation of mEGCs from 
PGCs (Kimura et al. 2008). Given these functions, and although no difference in 
expression was verifiable by RT-PCR (Figure 6.5), mTOR remains a possible candidate for 
a role in germ cell proliferation within the ovary. 
 
6.5.1(xi) Growth arrest-specific 11 (GAS11) 
Growth arrest-specific genes are a group of genes which are up-regulated in the 
murine 3T3 cell line by serum starvation and contact inhibition. It is speculated that the 
gene products are involved directly in reversible growth arrest, and they may be tumour 
suppressor genes (Schneider et al. 1988). The expression microarray detected three-fold 
higher expression of GAS11 in testis; however, no difference was apparent by RT-PCR 
(Figure 6.5). GAS11 is also known as Gas8 in mouse, and is expressed in testes during 
postmeiotic development
 of male germ cells, with its gene product proposed to play a role 
in sperm motility. However, only low levels of expression are detected before puberty 
(Yeh et al. 2002). Expression and function in human testes have not yet been examined. 
Another member of the growth arrest-specific gene family, Gas6, promotes SCF-induced 
growth and/or survival of mPGCs (Matsubara et al. 1996). 
 
6.5.1(xii) Controls 
β-actin expression was approximately equal in both samples by RT-PCR (Figure 
6.5), indicating equal amounts of RNA for each reaction. XIST served as a control for high 
expression in ovary, where 40-fold higher expression was detected by microarray. Low 
levels were detected in male by expression microarray and RT-PCR (Figure 6.5). SCYA20 
(small inducible cytokine subfamily A, member 20) was used as a control for low level 
expression in both (0.02 in ovary compared to 0.09 in testis), with consistent RT-PCR 
verification of absent or very weak expression.  
 
6.5.2 Accounting for Increased Germ Cell Number 
It is unclear what cells in the gonad the genes identified here are expressed in, and, 
if expressed by germ cells, higher expression may merely reflect the increased number of 
germ cells within the ovary. POU5F1, the gene for OCT4 which is expressed exclusively  184
by germ cells within the gonad, showed 1.6-fold higher expression in ovary: a difference, 
therefore, likely due to increased germ cell number. Consistently, IFITM1, expressed on 
PGC surface, showed 1.3-fold higher expression in ovary compared to testis. This 
approximate figure could be used as a reference ratio; i.e. genes with a fold-induction value 
above 1.6 could be taken as having  a ‘real’ increase in expression and be worthy of 
investigating further, for example, BMP7 (2.7) rather than BMP2 (1.3). 
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6.5.3 Summary 
This chapter aimed to identify genes which could promote hPGC - and therefore 
hEGC - proliferation. Comparing gene expression levels by expression microarray and RT-
PCR in developing ovary and testis has highlighted a number of genes which are more 
highly expressed in ovary, and which also promote proliferation in other tissues, including 
NPY (and its receptor NPY1R),  CCKBR,  GRM4,  CPA2 and LHX2. NPY promotes 
neuroprogenitor proliferation acting through the NPY1R; CCKBR promotes proliferation 
of gastric carcinoma cells; GRM4 signalling may promote tumour growth, and LHX2 
maintains the growth of hair follicle progenitors.  
To progress this study, further investigations could use real-time PCR to quantify 
expression levels of candidate genes. This would provide a higher level of sensitivity than 
that provided by the initial RT-PCR screen. Protein expression and localisation could be 
confirmed by immunohistochemistry, and any candidate mitogenic cytokines could be 
added to the media during hPGC culture. For example, NPY could be added, and any 
effect on hEGC derivation monitored by, for example, using a BrdU assay or Ki67 
immunohistochemistry. 
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CHAPTER 7: Summary and Future Work/Directions  187
7.1 The Starting Point - Objectives and Strategies  
  Embryonic stem cell research has progressed markedly since their first description 
in the mouse in 1981 and the human in 1998. While no ESCs have been used in human 
therapy, the group of Yamanaka has demonstrated that induced pluripotent stem cells can 
be generated by transducing somatic cells with Oct4, Sox2 and Klf4; allowing for the 
theoretical generation of ESCs, and thus tissues, which would circumvent immune 
rejection and limited source cells. In fact, a mouse model for sickle cell anaemia has been 
cured using such a technique. 
  This work has only been made possible by research into molecules governing 
pluripotency in ESCs. Embryonic germ cells (EGCs), another pluripotent stem cell, 
provide a further avenue for research into pluripotency. Insights into the germ cell lineage 
give clues into the origins and development of testicular germ cell tumours. In addition, 
further investigations might provide details of the developmental pathway which should be 
mimicked during the in vitro generation of gametes from ESCs. For these reasons, this 
thesis investigated the human germ cell lineage and associated aspects of pluripotency. 
 
7.2 The Human Germ Cell Lineage: in vivo and in vitro  
  hEGCs are notoriously difficult to derive and culture, compared with the relative 
ease of that for their mouse equivalents. mEGCs in many respects resemble mESCs, in 
terms of growth characteristics and gene expression. Conditions used for hEGC derivation 
and culture currently mimic those used for mEGCs. However, hEGCs do not remain 
pluripotent, indicating that these cells may have different requirements. Chapter 3 sought 
to determine whether the difference in behaviour between hEGCs and hESCs/mEGCs 
could be due to a difference in gene expression. Whilst all pluripotent cell types tested 
expressed OCT4 and NANOG, the early human germ cell lineage was found not to express 
SOX2, either in vivo as hPGCs, or upon conversion to hEGCs in culture, in contrast with 
hESCs and mPGCs/EGCs. SOX2 is proposed to act with OCT4 and NANOG in initiating 
and maintaining the expression of genes which promote pluripotency. Interestingly, many 
of these genes were expressed by hPGCs, despite the absence of SOX2. Of all genes tested, 
only the presence of FGF4 correlated with presence/absence of SOX2: being absent in the 
hPGCs but expressed in hESCs. Unlike ESCs and mEGCs, hEGCs have not been reported 
to lead to teratocarcinoma formation in immunocompromised mice. Whether this is due to  188
the lack of SOX2 is an interesting question, and one which was pursued. Transfection of a 
SOX2 expression vector into gonad-derived cells and subsequent transplantation into mice 
did not generate teratomas; however, proliferation would have been expected, given that 
the SOX2-negative germ cells were proliferative in situ. Further attempts at this 
experiment, and attempting transfection of hPGCs with a SOX2 expression vector in vitro, 
are warranted.  
 
7.3 Expression of Pluripotency Determinants in Testicular Germ Cell 
Neoplasia  
Chapter 4 sought to investigate the expression profile of the three major 
determinants of pluripotency in the transformed human germ cell lineage, in vitro and in 
vivo. Germ cell tumours were the first source of pluripotent stem cells: once isolated some 
cell lines have retained pluripotency and some have become nullipotent. Regardless of 
differentiation capability, ECCs expressed OCT4, SOX2 and NANOG in vitro. However, 
in vivo, expression of SOX2 correlated with pluripotency status of the TGCT: the 
pluripotent compartments of EC tumours expressed OCT4, SOX2 and NANOG, whereas 
seminomas, which resemble germ cells, only expressed OCT4 and NANOG. The role of 
SOX2 in pluripotency is contentious, therefore, given that SOX2-negative hEGCs are 
considered pluripotent, but fail to remain so indefinitely and have not been shown to 
generate teratomas in vivo. Nuclear SOX2 was detected in a subset of CIS cells, the 
precursors of TGCTs, where expression may indicate progression towards a malignant 
phenotype. It was also expressed in infantile and adult spermatogonia, localised to the 
cytoplasm and nucleus respectively; here it may maintain progenitor cell characteristics, a 
role fulfilled in other cell types. SOX2 was found to be expressed by some Sertoli cells in 
CIS tubules, but not in Sertoli cells of normal tubules, indicating perhaps a soluble factor 
may induce SOX2 expression. If this were true it may prove advantageous if such a factor 
could be identified, and could do so in hEGC cultures.   
The results of this study conflicted reports of SOX2-negative CIS cells (Korkola et 
al. 2006; Biermann et al. 2007), and gonocytes and normal adult testis (de Jong et al. 
2008), using a monoclonal SOX2 antibody. It will be important to perform immunoblotting 
to ensure SOX2 is being recognised by the polyclonal antibody used here, and also to 
perform stainings using the monoclonal SOX2 antibody used in these other studies, to see 
if the same staining pattern is observed. In addition, as there is a heterogeneous population  189
of germ cells in both the testis and ovary during development, it would be interesting to 
determine whether SOX2 expression in early specimens co-localises with OCT4 (first 
trimester) or VASA (second trimester) (Anderson et al. 2007). This work is currently being 
conducted at the University of Copenhagen, Denmark. 
 
7.4 Investigating the Association of the OCT4-SOX2-NANOG 
Transcription Factor Complex with Pluripotency 
The expression of OCT4, SOX2 and NANOG was not sufficient to reprogram a 
cell to pluripotency in this study, as shown by transfection of the two transcription factors 
into SOX2-positive neuroprogenitors and stomach epithelial cells as described in Chapter 
5. Cells retained expression of differentiation markers and did not induce expression of 
FGF4, a gene whose expression is activated by OCT4 and SOX2. Surprisingly the OCT4
-, 
NANOG
-, SOX2
+ neuroprogenitors and stomach epithelial cells expressed genes which are 
proposed to be targets of the transcription factor complex in hESCs. In addition, 
neuroprogenitors and stomach epithelial cells expressed cell surface markers commonly 
used to denote pluripotency, namely SSEA3, SSEA4, TRA-1-60 and TRA-1-81. This 
indicates that the expression of such markers should be interpreted with some caution 
when being used to assess pluripotency. It would be interesting to determine whether other 
differentiated cells express these ‘pluripotent’ genes and markers. 
 
7.5 Identification of Candidate Genes for Germ Cell Proliferation 
  In Chapter 6, a number of factors which were more highly expressed in female 
compared to male gonads were identified by expression microarray as candidate genes 
involved in promoting germ cell proliferation. This differential expression was verified by 
RT-PCR for selected genes. Of particular interest are Neuropeptide Y and its receptor 
NPY1R, the Cholecystokinin B receptor and LIM-homeobox 2, which all have proven roles 
in promoting cell proliferation in other cell types. Further verification will need to be 
performed, including quantification of gene expression by real-time PCR. 
Immunohistochemistry could be used to identify which particular cells in the gonad 
express these factors, and soluble factors, for example NPY itself, could be added to the 
culture medium of germ cells to determine whether they promote derivation and improve 
duration in culture. Preliminary immunohistochemistry results indicate that the  190
Cholecystokinin B receptor is expressed by germ cells specifically in both ovary and testis, 
however, no difference in protein abundance was detected (Martin McDonnell, Human 
Genetics Division, University of Southampton; pers. comm.). In addition, preliminary 
culture experiments did not identify NPY as having any effect on hEGC derivation when 
added to the culture medium (Dr. Marie Best, Human Genetics Division, University of 
Southampton; pers. comm.), however, this will be re-investigated using a 96-well counting 
method to quantify any effect on hPGC survival or proliferation. 
 
It is hoped that the information provided here, and future studies which emanate 
from it, will prove instructive for improving human germ cell culture in vitro and also 
provide insights into cancer cell biology. The differences between hESCs and hEGCs in 
terms of gene expression indicate that there may be different mechanisms governing 
pluripotency in these cell types.  191
Appendix 1. RT-PCR Primer Sequences 
 
 
Primer Sequence 
  Gene 
Forward (5'-3')  Reverse (5'-3') 
  
Annealing 
Temperature (
oC) 
  
Product 
Size (bp) 
β-ACTIN   TTCTACAATGAGCTGCGTGTGGCT TCTCCTTAATGTCACGCACGA 60  376 
BMP2  CTCCCCCTGCTCGCTGTTGTTGTG TGCTGGGGGTGGGTCTCTGTTTCA 64  573 
BMP4  AGACGCCGCTGCTGCTC CTCCCGCGTGGCCCTGAATCTC  59  435 
CCKBR  CCGCCGGGTCGAGCTGAGTAAG TGACGGTGCCAAAGATGAATGTGC 63  419 
CKIT  GGACACCGGGCCAGTATCTA ACGGCCACAGTTCTCTAAATG 57  551 
CLC  TGGGCCTGGCGGATGGGATTATTA TGGGTCAGCCGCAGTTTGTCATTG 64  423 
CMYC  GCCCACCACCAGCAGCGACTCT CCTTGGGGGCCTTTTCATTGTTTT 60  442 
CNTF   CCGGGGCTGGCGTAGTAGTAGGAC AGCGAGGATGGGCAAGGACAGTTC 58  533 
CNTFRα  AAGGGCTTCTACTGCAGCT TCACTCCATGTCCCAATCTCA 55  508 
CPA2  CAAAAATCGTATGTGGCGGAAGAC TGACGGGCTGGCAAGAGGA 58  492 
CSF3  AGCGGCCTTTTCCTCTACCAG ACAGCGGCTCATCCCAGTGC 60  561 
DKK1  ACGGTCATTTTCTCTTTCTTTCTC AGTAATTCCCGGGGCAGCACATAG  60  439 
DPPA4  CGAGGCTCCGCTTCTTCTAC ATTTTGGCCTCTTTTGCTGTGCTA 55  416 
FBX15  TTGGGCAATTATACTGAAAGAAAA TACTCGGGGCTATCATCCAAAAAG  54  456 
FGF4  CCTCGGGCCGGGATGTCG AGGCGTTGTAGTTGTTGGGAAGGA  64  517 
GAS11  CCCGCAAGCTGGAGGATGTT GAGAAGGTGCCGCCGACTGTGGT  61  514 
GJA1  CGCCCCACGGAGAAAACCAT ATCGGGGAAATCAAAAGGCTGTG  55  413 
gp80  GAGCACCCCATCCCTGACGA CGCCTTGCCCGAACTCCTC  60  493 
gp130  GCTGTATGAAGGAAGATGGTAAGG GAAAGTCACAGGCAGGGATAGTTA  60  366 
GRM4  CTGGGCGCCCGCATTCTGG CCTTGGGCTCCCGTGGTATCTTCA 63  484 
HESX1  CGCTCAGCTCGGGGAAAAC TCGCCATTAGAAACTGTGATT  53  503 
HPRT  CCTGGCGTCGTGATTAGTGATGAT  AGCTTGCGACCTTGACCA 60  472 
IFITM1  CGCTCCACGCAGAAAACCACACT AGGGGGCAGGGGCAACAGC  60  522 
IL1β  CAGGCCGCGTCAGTTGTTGT TTATATCCTGGCCGCCTTTGGTC 57  592 
IL1R1  ACCGGCCAGTTGAGTGACA GGTAGACCCTTCCCCAACAGT 53  450 
IL6  CCCAGTACCCCCAGGAGAAGATT GTTGGGTCAGGGGTGGTTATTG  60  425 
IL8  ACCGGAAGGAACCATCTCACTG  GCATCTGGCAACCCTACAACA 55  445 
IL10  AAGGCCGTGGAGCAGGTGAAGAAT GAAGCCCCAAGCCCAGAGACAAGA  57  571 
LHX2  CGCGCTCGGGACTTGGTTTATCAC ATGCGCTTGGTCTTCTGGCTGCTC 57  418 
LIF   ATGTCACAACAACCTCATGAA GATCTGCTTATACTTCCCCAG 60  465 
mTOR  GCCTCCCGGATCATTCACCCTATT GTCTCAGCCATTCCAGCCAGTCAT 59  403 
MYST3  GATCCGCCACTCACCCGTATG TCCTGTTGCCCCTCTTTCTGATTC 56  456 
NANOG  GCGCGGTCTTGGCTCACTGC GCCTCCCAATCCCAAACAATACGA 63  426 
NPY  TGCTAGGTAACAAGCGACTG CTGCATGCATTGGTAGGATG 55  386 
NPY1R  TTTGGTGAGGCGATGTGTAAG GTAAGAGGGAGCCAGCAGACT  54  518 
OCT4A  GATCGGATCCATGGCGGGACACCTGGCT CCTTCCCAAATAGAACCC  60  532 
REST  AGGGCCCCATTCGCTGTGAC AAGAGGTTTAGGCCCATTGTGA  58  445 
SCYA20  GTGCGCAAATCCAAAACAGAC CAAAACAATATAAACAAAAGAATG 49  465 
SET  AACTCCGCCAACCATTTTT CCATATCGGGAACCAAGTAGTA  55  491 
SKIL  GCCGCTTCATCTCCGCTTCT TCTTGCTTCCCGTTCCTGTCTG  54  452  192
SMARCAD1  AATAACCGTTTGCTGCTCAC TTGGCGATGTAATAAAGGATG 52  429 
SOX1  CCGGGGAATGGGAGGACAGGAT ACGCGGGGGAGGGTGATGG 60  526 
SOX2  GGCACCCCTGGCATGGCTCTTG TTCTTGTCGGCATCGCGGTTTTTG  60  484 
SOX3  GACCGCGCCGCAAGACCAAGACG GGCGGCCGCGGCTGCTGTG 68  413 
SOX14  GCGCAAGATGGCCCAGGAAAAC CAGAGCGCCGGTAGCCAAGGTGTG 63  424 
SOX21  GGGGGCCCGGTTTGTATGTA AGATTCGAGCCGGTCACTGGTC  59  561 
STAT3  CCCCCGCACTTTAGATTCATTG AGGCACCAGGAGGCACTTGTCTAA 57  510 
STAT5A  CCCCGGAACGCAACCTGTGGAACC GGGGGCGAGAGGCGGGAGTCAAG 63  442 
STAT5B  CCCCGGCCCAGTGGAGGAGAT CAGTGGCCGTCGCATTGTTGTC  61  530 
TCF8  CGCAGTCTGGGTGTAATCGTAAAT  CATGCCCTGAGGAGAACTGG 55  476 
TDGF1  ACGATGTGCGCAAAGAGAAC GAGGGCAGGGCAAAGAAGTAAGAA  58  434 
UTF1  CGCGCTGGGGGAACTCG AGCGGGGTGGCGTCTGG  66  432 
XIST  AAGAAGATTGCAGTAAAACGAT AGCCTAAGGAGACATGACTACTAA  51  548 
ZIC3  TCAGCTGAGCCGGCCCAAGAAGA AGGGAGCTCGGGTGCGTGTAGGAC 60  415 
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Appendix 2. Commercial Vector Maps 
(i) pcDNA3.1Zeo+ (Invitrogen, Carlsbad, CA, US) 
   
From http://www.invitrogen.com/manuals.html. 
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(ii) pSuper.gfp/neo (Oligoengine, Inc., Seattle, WA, US) 
 
From http://www.oligoengine.com/products/psuper.html#maps. 
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ABSTRACT
NANOG, POU5F1, and SOX2 are required by the inner cell
mass of the blastocyst and act cooperatively to maintain
pluripotency in both mouse and human embryonic stem cells.
Inadequacy of any one of them causes loss of the undifferenti-
ated state. Mouse primordial germ cells (PGCs), from which
pluripotent embryonic germ cells (EGCs) are derived, also
express POU5F1, NANOG, and SOX2. Thus, a similar expression
profile has been predicted for human PGCs. Here we show by
RT-PCR, immunoblotting, and immunohistochemistry that hu-
man PGCs express POU5F1 and NANOG but not SOX2, with no
evidence of redundancy within the group B family of human
SOX genes. Although lacking SOX2, proliferative human germ
cells can still be identified in situ during early development and
are capable of culture in vitro. Surprisingly, with the exception
of FGF4, many stem cell-restricted SOX2 target genes remained
detected within the human SOX2-negative germ cell lineage.
These studies demonstrate an unexpected difference in gene
expression between human and mouse. The human PGC is the
first primary cell type described to express POU5F1 and
NANOG but not SOX2. The data also provide a new reference
point for studies attempting to turn human stem cells into
gametes by normal developmental pathways for the treatment of
infertility.
embryonic, gamete biology, gene regulation, human, human
development, human stem cell biology, primordial germ cells,
SOX2
INTRODUCTION
From original experiments in mice, embryonic stem cells
(ESCs) and embryonic germ cells (EGCs) are, unequivocally,
two types of pluripotent stem cell [1]. The former are derived
from the inner cell mass (ICM) taken into laboratory culture;
the latter are presumed to represent an analogous in vitro
conversion of the primordial germ cell (PGC), the diploid
precursor of the male and female gametes. A third pluripotent
stem cell, the embryonal carcinoma cell (ECC), arises from in
vivo malignant transformation of the PGC. Comparative
studies of these different cell types and their respective parent
cells offer a collective view on the derivation and maintenance
of pluripotent stem cells. In addition, improved knowledge of
the germ cell lineage can benefit research into the different
types of germ cell tumor (GCT), particularly those affecting the
testis, which are of increasing frequency in the Western world
[2]. Information will also provide a reference point for studies
aiming to replicate normal development for the in vitro
generation of gametes from human stem cell populations for
future fertility treatment.
Studying the development of human germ cells is hampered
by restricted access to appropriately aged material and by their
intractability in culture [3]. Human embryonic material is
inaccessible from 14 days (UK legal limit for in vitro culture of
the preimplantation embryo) until potential access to material
with appropriate consent at social/voluntary termination of
pregnancy (rarely earlier than 4 wk postconception) [4]. Thus,
researchers have extrapolated heavily from other species, most
notably the mouse, with implicit and, where analysis has
permitted, mostly correct assumption of high interspecies
conservation [5, 6]. Mouse PGCs become apparent during
gastrulation and over the following days migrate via the gut
mesentery to the gonadal ridge [7]. This same path seems to be
followed in human embryos, as first-trimester material, stained
for alkaline phosphatase (AP) activity, identifies germ cells in
the gut mesentery and gonad [1]. A few groups, including our
own, have taken these cells into culture to generate cells that
have been termed human EGCs [3, 8, 9]. In our experience,
derivation is defined by acquiring highly proliferative cells
positive for AP activity and cell surface antigens, such as
SSEA4, TRA1–60, and TRA1–81, commonly used as markers
of pluripotent cell types [3]. However, contrary to the
equivalent mouse cell type, common experience has indicated
a difficulty maintaining this cell state over numerous passages
in prolonged culture, suggesting value in further characterizing
the human germ cell lineage.
Three of the main transcription factors identified in the ICM
and ESC are POU5F1 (previously known as OCT4), NANOG,
and SOX2 [10]. They have been suggested to act collabora-
tively in the promoter region of genes encoding two sets of
transcription factors: activating expression of those that
maintain pluripotency, while repressing transcription from
those that enact differentiation [11]. In this study, we have
analyzed the expression of POU5F1, NANOG, and SOX2
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852during early human germ cell development and compared the
data to those acquired from human ESCs and various ECCs.
We have also studied the expression in the fetal gonad of many
genes described as stem cell restricted [11] and that have been
reported to require POU5F1 and SOX2 [12–14] or POU5F1,
NANOG, and SOX2 [11] for their expression.
MATERIALS AND METHODS
Collection of Human Embryonic and Fetal Material and
Germ Cell Tumor Samples
Ethical approval, collection, and staging of human embryonic and fetal
material was carried out as described previously, using the Carnegie
classification and fetal foot length to provide a direct assessment of gestational
age as days or weeks postconception (dpc or wpc) [15–17]. Human
preimplantation embryos were obtained with ethical permission and informed
consent under a licence from the UK Human Fertilisation and Embryology
Authority (RO142). Table 1 details the numbers and ages of human fetal
material used in this study. The Regional Committee for Medical Research
Ethics in Denmark approved the use of human germ cell tumor material. The
tissue samples from adults with testicular neoplasms were obtained directly
after orchidectomy and macroscopic pathological evaluation.
Immunohistochemistry/Immunocytochemistry and
Alkaline Phosphatase Activity Staining
Tissue processing of human embryonic and fetal samples, immunohisto-
chemistry (IHC), immunocytochemistry (ICC), and alkaline phosphatase (AP)
activity staining were performed as described previously [3, 17, 18]; primary
antibodies used are detailed in Supplemental Table 1 available online at www.
biolreprod.org. Adult testicular samples were fixed overnight at 48Ci n4 %
paraformaldehyde or formalin and subsequently embedded in paraffin. A series
of 12 testicular tumors were analyzed by IHC, including classical seminomas
and various nonseminomatous tumor components. Either biotin- or fluores-
cently labeled secondary antibodies were used according to the manufacturer’s
instructions. Anti-rabbit (1:800), anti-goat (1:300), and anti-mouse (1:100)
biotinylated antibodies were from Vector Laboratories. Fluorescently labeled
secondary antibodies were fluorescein isothiocyanate (FITC) anti-mouse (1:64)
or anti-goat (1:64) (both from Sigma-Aldrich). For biotinylated secondary
antibodies, either streptavidin horseradish peroxidase (SA-HRP; 1:200; Vector
Laboratories), SA-FITC (1:150; Sigma-Aldrich), or SA-Texas Red (1:200;
Vector Laboratories) conjugates were used according to the manufacturer’s
instructions. Controls omitted primary or secondary antibody. For bright-field
immunohistochemistry, the color reaction was developed using diaminobenzi-
dine (Merck) containing 0.1% hydrogen peroxidase (Sigma-Aldrich) with
toluidine blue counterstaining or, for the GCT samples, using aminoethyl
carbazole substrate (Zymed) counterstained with Mayer hematoxylin.
Protein Preparation, SDS-PAGE Electrophoresis, and
Western Blotting
Tissues and cells were rinsed with PBS and treated with ice-cold lysis
buffer (50 mM Tris-HCl [pH 7.4], 150 mM sodium chloride, 0.5% Triton X-
100 [Sigma-Aldrich]) containing a set of protease inhibitors (Complete; Roche
Diagnostics) for 30 min with gentle trituration. Lysates were stored at  808C.
Single-dimension SDS-PAGE was carried out vertically in buffer (25 mM Tris-
HCl [pH 8.3], 250 mM glycine, 0.1% SDS). Cell lysates containing 15 lgo f
protein were combined with an equal volume of 23 SDS gel-loading buffer
(100 mM Tris-HCl [pH 6.8], 200 mM DTT, 4% SDS, 20% glycerol, and 0.2%
bromophenol blue) and heated at 958C for 5 min before gel loading. Proteins
were electrotransferred onto a nitrocellulose membrane (Hybond-C Extra,
Amersham Biosciences) in transfer buffer (48 mM Tris-HCl [pH 8.3], 39 mM
TABLE 1. Numbers and ages of fetal material used in this study.
Experiment Age
a
Immunohistochemistry or
immunocytochemistry
(see Figs. 1 and 2)
Male: 48, 55, 56, 59, 63, and 73 dpc
Female: 48, 53, 54, 59, 63, and 73 dpc
Immunoblotting (see Fig. 3) Pooled sample of 3 male gonads 52, 56,
and 63 dpc
Pooled sample of 3 female gonads 52,
52, and 55 dpc
Pooled sample of 3 mouse male gonads
E14
Pooled sample of 6 mouse female
gonads E14
RT-PCR (see Figs. 4 and 7) Pooled sample of male gonads 51, 53,
59, and 61 dpc
Pooled sample of female gonads 51, 54,
55, 57, and 61 dpc
Germ cell culture (see Fig. 6) Cultures initiated from 11 male gonads
50–72 dpc (average age 58 dpc)
Cultures initiated from 14 female gonads
53–65 dpc (average age 57 dpc)
a All samples are derived from human material unless otherwise stated.
FIG. 1. Expression of POU5F1, NANOG, and SOX2. ICC and IHC
panels are shown for human ESCs (A) and the following human embryonic
sites: ovary (B), testis (C), gut mesentery (D), spinal cord (E), and stomach
(F). The example shown in B is at 54 dpc, in C–F at 48 dpc (insets in C also
include AP staining). SOX2 staining is shown in mouse embryonic testis
(E13.5; G) and ovary (E12.5; H) (insets show AP staining). I) Human and
mouse blastocysts counterstained with DAPI. Bars ¼ 40 lm( A and I) and
300 lm( B–H).
SOX2 AND THE HUMAN GERM CELL LINEAGE 853glycine, 20% methanol). Blocking of nonspecific binding sites was carried out
by immersion in PBS containing 5% nonfat powdered milk and 0.1% Tween-
20 (Sigma-Aldrich) for 1 h at room temperature. Primary antibodies were
diluted in blocking buffer and incubated with the membrane overnight at 48C.
Membranes were washed three times in PBS containing 0.1% Tween-20 and
then incubated with peroxidase labeled anti-rabbit antibody for SOX2
(Amersham Biosciences; 1:50000) or anti-goat antibody for POU5F1
(Sigma-Aldrich; 1:200000) in blocking buffer for 1 h at room temperature.
b-actin was detected by 1-h incubation with mouse anti-b-actin peroxidase
conjugated antibody (Sigma-Aldrich; 1:50000) at room temperature. Mem-
branes were washed three times in PBS/0.1% Tween-20 and once in PBS, and
developed using advanced enhanced chemiluminescence reagents (Amersham
Biosciences) according to the manufacturer’s instructions.
Reverse Transcriptase-PCR
Total RNA was isolated from tissues using Tri-Reagent (Sigma-Aldrich)
and cDNA synthesized from 1 lg per sample with Superscript III (Invitrogen).
Wherever possible, intron-spanning primer pairs were designed (Supplemental
Table 2 available online at www.biolreprod.org). Negative (water and
–RT) and positive (genomic) control reactions were performed concurrently.
Human Germ Cell, ESC, and ECC Culture
Human gonad-derived cells were processed, plated, and cultured as
described previously [3]; in total, 25 cultures were initiated, as detailed in
Table 1. The hECC lines NTERA-2 (clone D1 [ECCAC], TERA-1, and
2102Ep [both gifts from Peter Andrews, University of Sheffield] were cultured
in Dulbecco modified Eagle medium (DMEM; PAA Laboratories) containing
10% fetal calf serum (PAA Laboratories) and 1% penicillin/streptomycin
(Invitrogen) in 5% CO2 at 378C. Human ECCs were passaged using glass beads
(VWR International) and maintained at high density. The hESC lines HUES1
and HUES7 were obtained under MTA from Harvard University [19] and
maintained in KO-DMEM containing 1% penicillin/streptomycin, 1% Gluta-
MAX, 1% nonssential amino acids, 10% KO-Serum Replacement (all from
Invitrogen), 10 ng/ml FGF2 (Peprotech), and 0.1% 2-mercaptoethanol (Sigma-
Aldrich) in 5% CO2 at 378C. Human ESCs were cultured on mitotically
inactivated mouse embryonic fibroblasts and passaged using 0.05% Trypsin/
EDTA (PAA Laboratories).
RESULTS
Germ Cell Expression of SOX2 Differs Between Human and
Mouse
The human fetal gonad is apparent as a distinct structure
from 32 dpc with sex determination marked by the expression
of SRY and SOX9 at ;41–44 dpc in the male [18]. Thereafter,
sex cords comprised of Sertoli cells and germ cells become
increasingly apparent within the testis from 48 dpc during late
embryonic (up to 56 dpc) and early fetal (thereafter)
development [18]. POU5F1, NANOG, and SOX2 are known
as three critical transcription factors in human ESCs [11] (Fig.
1A). Nuclear POU5F1 and NANOG proteins were clearly
detected within germ cells in the gonad of the embryonic ovary
and testis at Carnegie stages 19–22 (48–54 dpc; Fig. 1, B and
C). In sharp contrast, SOX2 was not detected within the human
female or male gonad either prior to sex determination or later
during the first trimester (ranging from 48 to 73 dpc for both
sexes; Table 1, Fig 1, B and C; data not shown). The
expression of some genes, such as Ddx4, is altered on the
arrival of the PGC to the gonadal ridge in mice [20]. Therefore,
we also studied PGCs within the gut mesentery at 48 dpc, a
location consistent with their migration from yolk sac wall to
gonadal ridge. Nuclear POU5F1 and NANOG were again
clearly detected; however, SOX2 was not (Fig. 1D). The
validity of the SOX2 antibody within the same human
embryonic sections was confirmed by clear staining of the
neuroprogenitors in the spinal cord and stomach epithelial cells
(Fig. 1, E and F). Sox2 transcripts have been demonstrated in
the gonadal ridge of mouse embryos [6]. Consistent with this
finding, nuclear SOX2 protein was present in primordial germ
cells within the mouse embryonic testis and ovary (E13.5 and
E12.5, respectively; Fig. 1, G and H). Nuclear SOX2 was also
clearly detected within the ICM of mouse blastocysts (Fig. 1I)
[21]. In human blastocysts, SOX2 detection was more diffuse
but included nuclear localization within the ICM.
The SOX2-negative human germ cells included ones that
were proliferative in situ as marked by dual immunoreactivity
for POU5F1 and the proliferative marker MK167 (recognized
by the Ki67 antibody; Fig. 2). There were more of these
double-stained cells in the embryonic ovary at 54–56 dpc than
in the embryonic testis of the same age, consistent with male
FIG. 2. PGCs are proliferative in situ
during human development. Dual IHC for
POU5F1 (green) and the proliferation
marker MK167, identified using the Ki67
antibody (red), shown for the human em-
bryonic ovary (A) and testis (B) at 54–56
dpc. Arrows point to examples of PGCs that
are dual stained. Bar ¼ 300 lm.
FIG. 3. SOX2 expression in human and mouse embryonic gonads.
Immunoblotting for the detection of SOX2, POU5F1, and b-actin. Positive
control, NTERA-2 D1 ECCs; negative control, PANC1 cells. Ovarian (o)
and testicular (t) samples were prepared from specimens listed in Table 1.
854 PERRETT ET AL.PGCs entering mitotic arrest following testicular cord forma-
tion.
These data, demonstrating an interspecies difference in PGC
SOX2 expression, were further validated by immunoblotting of
protein isolated from fetal gonads (Table 1, Fig. 3). SOX2 was
present as a 35-kDa band in protein isolates from mouse
gonads at E14 but not from the corresponding human organs.
POU5F1 detection is shown as a positive control for the
presence of PGCs.
Redundancy Is Unlikely to Compensate for Lack of SOX2 in
Human Germ Cells
One potential explanation for this species difference is
redundancy for SOX2 within group B of the SOX gene family,
which comprises SOX1, SOX2, SOX3, SOX14, and SOX21.B y
RT-PCR for 35 cycles, SOX2, SOX3, SOX14, and SOX21
transcripts were detected in both human ESCs and NTERA-2
D1 ECCs (Fig. 4). The weak identification of SOX1 in ESCs
may represent low-level expression per se or, feasibly, minor
spontaneous ectodermal differentiation as is commonly
encountered in human ESC culture. However, transcripts for
all SOX group B genes were undetected in four samples of
human testes collected during the late embryonic and early
fetal periods (51–61 dpc; Fig. 4, Table 1). In five ovarian
samples ranging from 51 to 61 dpc, a very faint band was just
discernible for SOX1 and SOX21 (Fig. 4, Table 1). Only
SOX14, encoding a putative repressor of SOX2 function [22],
was clearly detected within the ovary after amplification for 35
cycles (Fig. 4). The failure to detect SOX2 transcripts
convincingly within these testicular and ovarian samples
following extensive PCR cycles corroborates the protein data
from IHC and immunoblotting (Figs. 1 and 3).
SOX2 in Germ Cell Tumors and Embryonal Carcinoma Cell
Lines
The ECC represents malignant transformation of the PGC.
Our findings led us to interrogate SOX2 expression in different
GCTs in vivo and in vitro. Previously, SOX2 transcripts have
been reported in a ‘‘germ cell carcinoma’’ sample [6]. In
agreement with data from others [23–25], we did not detect
SOX2 in samples of seminoma, a nullipotent human GCT;
however, it was clearly visualized as nuclear protein in
pluripotent nonseminomatous embryonal carcinoma. Both
seminomas and pluripotent GCTs expressed nuclear POU5F1
FIG. 4. The potential for SOX2 redundancy in the human germ cell
lineage. RT-PCR panel is shown for members of the group B SOX gene
family in human ESCs, ECCs (NTERA-2 D1 cells), and the fetal gonad
(samples are listed in Table 1).
FIG. 5. Expression of POU5F1, NANOG, and SOX2 in germ cell tumor
cell types. Fixed sections of pluripotent embryonal carcinoma (A) and
fixed sections of nullipotent seminoma (B). C–E) Cells fixed after culture
on fibronectin-coated glass slide: pluripotent ECC line, NTERA-2 D1 (C)
and nullipotent ECC lines TERA-1 (D), and 2102Ep (E). F) Immunoblotting
is shown with detection for SOX2, POU5F1, and b-actin. Bars ¼ 40 lm.
SOX2 AND THE HUMAN GERM CELL LINEAGE 855and NANOG (Fig. 5, A and B). In contrast to NTERA-2 D1
cells, once taken into culture some embryonal carcinomas have
yielded nullipotent cell lines that are no longer capable of
differentiation to derivatives of all three germ layers (e.g.,
TERA-1 and 2102Ep cells). SOX2 was clearly expressed
equivalently in both pluripotent and nullipotent hECCs
localizing indistinguishably to the nucleus in all lines tested
(Fig. 5, C–F).
Human Germ Cells Persisting in Culture In Vitro Remain
SOX2 Negative
We have previously assigned germ cell cultures as ‘‘poorly
proliferative’’ (PP) or ‘‘vigorously proliferative’’ (VP), accord-
ing to their growth characteristics, with the latter taken as
indicative of conversion to the EGC state [3]. Akin to ESCs,
human EGCs demonstrate expression of the nuclear transcrip-
tion factor POU5F1 and AP activity [1]. However, SOX2,
required for the maintenance of pluripotent ESCs [21], was not
expressed in the human germ line in situ. These findings led us
to question whether SOX2 expression was induced in culture.
Numerous human PGC cultures were established, and samples
of both PP and VP/EGC cultures were analyzed. POU5F1
protein and POU5F1 transcripts and AP activity served as
positive controls for the presence of the germ cell lineage (Fig.
6). Neither SOX2 protein nor SOX2 transcripts were detected
by immunoblotting or RT-PCR, respectively, in either early,
PP, or VP/EGC cultures.
SOX2 Appears Dispensable for the Expression of Genes
Previously Identified to Require OCT-SOX Interaction or
Cooperative POU5F1-SOX2-NANOG Function
Given the lack of SOX2 in human germ cells yet the
presence of both POU5F1 and NANOG, we investigated a
selection of genes recognized as targets of these critical
transcription factors. POU5F1 and SOX2 are known to act
cooperatively in up-regulating FGF4 [12], UTF1 [13], and
FBX15 [14]. However, despite the absence of SOX2, UTF1,
and FBX15 transcripts were detected in the human fetal ovary
and testis. In contrast, FGF4 was not detected (Fig. 7A, Table
1). A further set of 13 genes were analyzed that are expressed
in ESCs when the respective promoter regions are bound by
POU5F1, NANOG, and SOX2 [11]. All 13 stem-cell-restricted
transcripts were detected in fetal gonads after RT-PCR for 35
cycles albeit for DKK1, SET, ZIC,a n dSTAT3 more weakly in
the human fetal ovary (Fig. 7B, Table 1).
DISCUSSION
Previous studies have revealed highly concordant gene
expression profiles across different pluripotent stem cells, the
cells of the ICM and PGCs [5, 24, 26]. Here, our analysis of the
human germ cell lineage was borne of recognized difficulties in
the long-term maintenance of human germ cell cultures [1]. We
hypothesized that the starting human PGCs lack a critical
factor(s) or fail to induce one in in vitro culture that is required
for maintained self-renewal and pluripotency. Contrary to
predictions from other studies [6] or previously presumed
conservation [5], we have identified that SOX2/SOX2
expression, identified as fundamental to stem cell pluripotency
[10], was not detected in human PGCs as either transcripts or
protein. In contrast, SOX2 was present in the human ICM,
ESCs, and various ECCs. Amounts of SOX2 and POU5F1 are
known to alter in cells derived from different stages of mouse
development; mouse germ-line stem cells, which are cultured
FIG. 6. SOX2 is not detected in human germ cell cultures. A) Image of
germ cell-derived culture showing colonies after 1 wk that were positive
for APactivity. Bar¼2 mm. B) Immunoblotting for the detection of SOX2,
POU5F1, and b-actin. Left column, germ cell culture; positive control,
NTERA-2 D1 cells; negative control, PANC1 cells. Four POU5F1-positive/
AP-positive cultures were analyzed after 1 wk, and SOX2 was not
detected in any of them. C) Image of a passaged germ cell culture fulfilling
VP/EGC criteria. Bar¼250 lm. D)R T( þ) of mRNA isolated from the EGC
culture shown in C after 3.5 wk and PCR for 32 cycles. NTERA-2 D1 cells
(NT2) and ESCs shown as positive controls. Omission of RT (–) is shown as
negative control. The same results were obtained from another EGC
culture.
FIG. 7. RT-PCR analysis of genes regulated by OCT-SOX enhancers and
those identified by bioinformatic analysis as targets of POU5F1, SOX2,
and NANOG. A) Genes previously recognized as targets of POU5F1 and
SOX2 [12–14]. B) Genes previously described to be expressed in human
ESCs when POU5F1, NANOG, and SOX2 are bound to the respective
promoter regions [11]. NANOG and HPRT are shown in A as controls.
Samples analyzed are shown in Table 1.
856 PERRETT ET AL.spermatogonial stem cells of highly restricted developmental
potential, express abundant Sox2 and Pou5f1 transcripts but
limited corresponding protein [27]. However, mouse PGCs
clearly express SOX2 [6 and herein]. At equivalent stages of
human development, human PGCs are distinguished by
expressing POU5F1 and NANOG but lacking SOX2.
Genome sequencing projects have revealed remarkable
conservation across seemingly diverse species. Therefore, a
likely explanation underlying cross-species differences in
phenotype is altered regulation of gene expression. Thus,
the regulation of SOX2 in human PGCs must differ from that
in ESCs (and presumably the epiblast) where an upstream
enhancer is bound by POU5F1 and a further downstream
composite element by both POU5F1 and SOX2 [28, 29]. The
high interspecies sequence conservation of these elements and
the wider SOX2 locus suggest that alternative factors, such as
epigenetic mechanisms, may be responsible for divergent
SOX2 expression [30, 31]. Although the earliest germ cell
lineage was inaccessible in our human specimens (i.e.. prior to
those cells in the gut mesentery at 6–7 wk postconception),
our data imply that SOX2 expression must cease either during
germ cell specification from cells of the SOX2-positive
epiblast or soon afterward. As reports unfold of human ESCs
differentiated toward functional germ cells [32], it will be
interesting to observe whether SOX2 disappears in mimicry of
normal human development. Redundancy among group B
SOX family members would limit functional consequences of
undetectable SOX2 for the human PGC. This appears unlikely
from our data. Only SOX14 transcripts were detected clearly
in fetal ovary samples and only after relatively high numbers
of PCR cycles. Furthermore, to date, SOX14 has been
recognized to counteract rather than substitute for the role of
SOX2 [22].
The collective data infer that, alongside POU5F1 and
NANOG, SOX2 is necessary but not sufficient for pluripoten-
cy. The epiblast of SOX2 null mice fails to progress in vivo,
and SOX2 null blastocyst outgrowths fail to generate ESCs in
vitro [21]; however, whereas mouse PGCs give rise to robust
pluripotent EGC lines, the SOX2-positive PGCs themselves are
nullipotent [33]. Similarly, although previous data on nullipo-
tent human ECC lines were limited largely to analysis of
transcripts [24], our data reveal relatively equivalent quantities
of correctly localized nuclear SOX2 protein regardless of a
capacity for broad differentiation. SOX2 expression, as
demonstrated here and by others [23–25], identifies patients
with a pluripotent GCT phenotype rather than a nullipotent
seminoma. Discovery of ways to induce SOX2 expression in
cultured human germ cells might allow improved models of
human GCTs. For instance, with the initiation of neoplastic
transformation of human germ cells proposed to occur in utero
[34], the lack of SOX2 in proliferative PGCs may explain the
predilection for SOX2-negative testicular seminomas in
humans compared to mice.
Identifying the consequences of missing SOX2 offers
comparative insight into its role when present in other cell
types. Where coexpressed, SOX2 is considered to act
cooperatively with POU5F1 and NANOG in regulating critical
cohorts of target genes. From bioinformatic studies, their
collective association with gene promoters is proposed to
induce the expression of genes that determine self-renewal,
while repressing those associated with differentiation [11]. Our
data suggest that SOX2 is dispensable in the former function,
as, without its detection, all 13 of our arbitrarily selected ‘‘ESC-
restricted’’ target genes from Boyer and colleagues, as well as
UTF1 and FBX15, were expressed in the fetal ovary and testis.
Indeed, most recently, evidence has been published that the
major role for SOX2 in ES cells is in maintaining POU5F1
expression [35]. This implies that the regulation of both
POU5F1 and SOX2 is different in human germ cells—SOX2
because of its apparent absence and POU5F1 because of its
independence from SOX2 protein. In contrast, our data do
support a pivotal role for SOX2 in promoting FGF4 expression
[12, 36]; FGF4 transcripts were undetected in the SOX2-
negative germ cell lineage. The difference between FBX15
(detected) and FGF4 (not detected) is interesting, as both have
been shown hypermethylated and correspondingly absent in
mouse germ-line stem cells [27].
Finally, it has been discussed whether, on the basis of gene
expression profiles, the closest equivalent of the human ESC is
an early germ cell and, indeed, whether ESC derivation arises
from an early germ cell phenotype [37]. On the basis that the
earliest human germ cells detected are SOX2 negative, this
hypothesis appears unlikely. In conclusion, we have discovered
a fundamental difference in gene expression between human
and mouse, demonstrating the limitations of interspecies
extrapolation. The data highlight SOX2 as an important
transcription factor for further investigation in attempts to
understand the relationship between human PGCs, GCTs, and
the derivation, self-renewal, and pluripotency of human EGCs.
The information is also instructive in attempts to generate
human gametes from stem cell sources for ambitious fertility
treatments.
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Steroidogenic factor 1 (SF1) is expressed in a time- and cell-
specific manner in the endocrine system. In this study we
present evidence to support that methylation of CpG sites
located in the proximal promoter of the gene encoding SF1
contributes to the restricted expression pattern of this nu-
clear receptor. DNA methylation analyses revealed a nearly
perfect correlation between the methylation status of the
proximal promoter and protein expression, such that it was
hypomethylated in cells that express SF1 but hypermethyl-
ated in nonexpressing cells. Moreover, in vitro methylation of
this region completely repressed reporter gene activity in
transfected steroidogenic cells. Bisulfite sequencing of DNA
from embryonic tissue demonstrated that the proximal pro-
moter was unmethylated in the developing testis and ovary,
whereasitwashypermethylatedintissuesthatdonotexpress
SF1.TogethertheseresultsindicatethattheDNAmethylation
patternisestablishedearlyintheembryoandstablyinherited
thereafter throughout development to confine SF1 expres-
sion to the appropriate tissues. Chromatin immunoprecipi-
tation analyses revealed that the transcriptional activator
upstream stimulatory factor 2 and RNA polymerase II were
specifically recruited to this DNA region in cells in which
the proximal promoter is hypomethylated, providing func-
tional support for the fact that lack of methylation corre-
sponds to a transcriptionally active gene. In conclusion, we
identified a region within the SF1/Sf1 gene that epigeneti-
cally directs cell-specific expression of SF1. (Endocrinology
149: 5599–5609, 2008)
D
NA METHYLATION IS a major epigenetic mechanism
that control developmental gene expression. Coordi-
nated waves of demethylation and de novo methylation es-
tablish the genome-wide methylation pattern during embry-
ogenesis, and function to maintain cellular phenotypes
through clonal inheritance of spatiotemporal expression of
key developmental genes (1). Mammalian cytosine DNA
methyl transferases (Dnmts) are divided into two groups
based on their preferred DNA substrate. Dnmt1 copies the
methylationpatternduringDNAreplication.Inconcordance
with this, Dnmt1 is expressed constitutively in proliferating
cells and is located at the replicating foci during S-phase (2).
De novo methylation is carried out by the DNA methyl trans-
ferases, Dnmt3a and Dnmt3b. These factors are highly ex-
pressedinthedevelopingmouseembryoinwhichtheycarry
out de novo methylation after implantation (3). Genetic ma-
nipulation of the Dnmt genes has demonstrated that appro-
priate DNA methylation is required for normal mammalian
development (4).
Steroidogenic factor 1 (SF1; also called adrenal-4 binding
protein and officially designated NR5A1) is a nuclear recep-
tor encoded by the Fushi tarazu factor-1 gene (Ftz-F1; for sim-
plicity we refer to the gene as SF1/Sf1). SF1 plays funda-
mental roles in the development and function of
steroidogenic organs, and targeted deletion of the Sf1 gene
causes adrenal and gonadal agenesis and nearly immediate
postnatal death due to respiratory distress caused by glu-
cocorticoiddeficiency(5).Duringmouseembryogenesis,SF1
is expressed from embryonic day (E) 9.0 in the adrenogo-
nadal primordium, a population of cells that arises from the
coelemic epithelium of the urogenital ridge (6). The adrenal
and gonadal anlagen progressively individualize and are
separate structures at E12.5. The adrenal cells form the outer
cortexwithinvasionbymigratoryneuralcrestcellsthatform
the inner adrenal medulla by E16–E16.5. SF1 expression is
confined to the cortical region of the adrenal gland (7). In this
location, it is maintained postnatally in which it transacti-
vates the genes encoding cytochrome P450 steroid hydroxy-
lases, the melanocortin type 2 receptor, which binds ACTH,
cholesterol transporters, and other genes responsible for the
steroidogenic phenotype (8). SF1 is expressed in the bipo-
tential gonad. In the developing testis, it is maintained in the
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Abbreviations: A2780, Human ovarian carcinoma cells; ChIP, chro-
matin immunoprecipitation; Dnmt, DNA methyl transferase; E, embry-
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erase; MA-10, mouse Leydig tumor cells; MeCP2, methyl-CpG-binding
domain protein 2; MSC-1, mouse Sertoli cells; NIH-3T3, mouse embry-
onic fibroblast cells; polII, RNA polymerase II; SDS, sodium dodecyl
sulfate; SF1, steroidogenic factor 1; SMAT-1, mouse prepubertal Sertoli
cells; USF, upstream stimulatory factor; VMH, ventromedial hypotha-
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entiationduetoitsrole,asintheadrenalcortex,inregulating
expression of the cytochrome P450 steroid hydroxylases
among other genes responsible for testosterone synthesis. In
Sertoli cells, SF1 regulates expression of the Mu ¨llerian inhib-
iting substance (MIS) and insulin-like factor 3 (Insl-3) genes.
After sex determination, SF1 is gradually down-regulated in
the ovary from E12.5 and reappears postnatally in theca and
granulosa cells and in the corpus luteum once folliculogen-
esis commences (9). SF1 is also expressed in the gonado-
trophs of the pituitary, ventromedial hypothalamic nucleus
(VMH), and spleen (8). A corresponding expression pattern
of SF1 is observed in human fetal and adult tissues (10, 11).
Several transcription factors have been implicated in the
regulation of the SF1/Sf1 gene: Sp1 (stimulatory protein-1)
(12, 13), GATA4 (14), Sox9 (SRY-type high-mobility-group-
box protein 9) (15), WT-1 (Wilms tumor suppressor) (16),
Lhx-9 (lim homeobox gene-9) (17) and Cited2 (CBP/p300
interacting transactivator with ED-rich tail-2) (18). In tran-
sient transfection experiments, expression also depends on a
conserved E-box motif in the proximal promoter (13, 19, 20),
bound with different consequences by two basic helix-loop-
helix factors. Upstream stimulatory factor (USF) family
membersactivatetranscription(21–23),whereasPod-1seem-
ingly represses SF1 expression (24). In Pod-1 knockout mice,
SF1 is expressed ectopically in cells that would normally
have expressed Pod-1, supporting a repressive role of this
factor (25). In the last few years, two studies using transgenic
mouse models have identified enhancer elements regulating
SF1 expression in a tissue-specific fashion. One of these stud-
iesidentifiedafetaladrenal-specificenhancerinintron4(26).
Transcription from this intronic enhancer is initiated by the
binding of heterodimeric complexes of Pbx1/Prep1 and
Pbx1/Hox. Subsequently when the expression of SF1 is es-
tablished, SF1 acts back on fetal adrenal-specific enhancer in
a positive autoregulatory manner (26). Furthermore, the
same group has also detected a VMH-specific enhancer in
intron 6 (27). Despite these advances, we are only starting to
reveal the mechanisms underlying tissue-specific expression
ofSF1,andlittleattentionhasfocusedonpotentialepigenetic
regulation of this gene.
In this study we demonstrate that the proximal promoter
of the SF1/Sf1 gene is subject to DNA methylation. It is
hypomethylated in cells and tissues that express SF1 but
hypermethylated in nonexpressing cells and tissues, indi-
cating that epigenetic mechanisms contribute to the re-
stricted expression of this factor. Analyses of fetal tissues
indicate that the DNA methylation pattern is established at
an early embryonic stage in structures that are determined to
express SF1 and faithfully conserved during development.
Materials and Methods
In vitro methylation of reporter plasmids
A fragment spanning 185/141 bp (ApaI/EcoRI) of the mouse Sf1
gene was inserted upstream of luciferase (lacking a minimal heterolo-
gous promoter) to create the reporter plasmid Sf1 (185/141)/lucif-
erase (Luc). Sf1 (185/141)/Luc was methylated in vitro by using the
SssI CpG methylase (New England Biolabs Inc., Beverly, MA).
Cell culture
Mouse adrenocortical tumor cells (Y1), human cervix epitheloid car-
cinoma cells (HeLa), mouse Sertoli cells (MSC-1), and mouse hepatoma
liver cells (Hepa-c1c6) were cultured in DMEM (high glucose) supple-
mented with 10% fetal calf serum. Human ovarian carcinoma cells
(A2780) were maintained in DMEM (low glucose) supplemented with
10%fetalcalfserum,andl-glutamine.Humanadrenocorticalcarcinoma
cells (H295R) were cultured in a 1:1 mixture of DMEM (high glucose):
HAM F12 supplemented with 2% ITS (Collaborative Research, Bed-
ford, MA) and 2% Nu-Serum (Collaborative Research). Mouse prepu-
bertal Sertoli cells (SMAT-1) were grown in DMEM (high glucose), 10%
fetalcalfserum,andaminoacids.Humanembryonickidneycells(HEK-
293 EBNA) were cultured in DMEM (high glucose), l-glutamine, 10%
fetal calf serum, and 25 mm HEPES. Mouse embryonic fibroblast cells
(NIH-3T3) were maintained in DMEM (high glucose), 10% fetal calf
serum, and 25 mm HEPES. Mouse Leydig tumor cells (MA-10) were
cultured in a 1:1 mixture of DMEM (high glucose):HAM F12, 15% horse
serum, 20 mm HEPES, and 40 g/ml gentamicin. All cells were main-
tained in 5% CO2 humidified atmosphere at 37 C, and growth medium
also contained penicillin (100 U/ml) and streptomycin (100 g/ml)
(except for MA-10 cells).
Transfection of cells and luciferase assay
Cells were plated in 12-well plates and transiently transfected the
following day using Superfect (QIAGEN, Valencia, Sweden). Cells were
transfected with reporter plasmid (Sf1(185/141)/Luc, 300 ng/well)
andaplasmidencoding-galactosidase(pCMV5/LacZ,100ng/well)to
controlfortransfectionefficiency.Twenty-fourhourslater,thecellswere
lysed in luciferase buffer 10 mm Tris-HCl (pH 8), 4 mm EDTA, 150 mm
NaCl, 0.65% Nonidet P-40, and total cell extracts were analyzed for
luciferase and -gal activity on a LUCY-3 luminometer (Anthos,
Salzburg, Austria) using the luciferase assay kit from BIO Thema AB
(Dalaro ¨, Sweden).
Immunoblotting
Total cell extracts were separated by SDS-PAGE and blotted to ni-
trocellulosemembranes.Themembraneswereincubatedwith6%milk/
primary antibodies/secondary antibodies, each incubation step per-
formed for1ha troom temperature. Antibody dilutions were 1:1000 for
the anti-SF1 antibody 06-431; Upstate Biotechnology, Lake Placid, NY;
28740 (H-60) from Santa Cruz Biotechnology (Santa Cruz, CA) for ver-
ification of SF1 in HeLa cells, whereas anti--actin (ab-6276; Abcam,
Cambridge, UK) and secondary horseradish peroxidase (HRP)-conju-
gated antibodies were used at 1:10000 antimouse conjugated to HRP
was from Santa Cruz Biotechnology; antirabbit HRP conjugated anti-
body was from Pierce (Rockford, IL). Chemiluminescence signals were
developed by using SuperSignal West Pico chemiluminescent substrate
(Pierce Biotechnology).
Genomic DNA preparation
GenomicDNAfromcelllines,paraffinsections,andhumanormouse
tissue was isolated using the QIAGEN DNeasy kit or with a standard
protocol using proteinase K. Mouse embryonic tissues were pooled
before DNA preparation. Mice used in this study were of C57/BL6
background. Ethical approval, collection, and staging of human fetal
material were carried out as described previously, using the Carnegie
classification and fetal foot length to provide a direct assessment of
gestational age as weeks after conception (28).
DNA methylation analysis by HpaII/MspI digestion
Genomic DNA (250 ng) from human and murine cell lines were
digested with HpaII (methylation sensitive restriction enzyme, recog-
nizing 5-CCGG-3) or its isoschizomer MspI (methylation insensitive).
All samples were codigested with NcoI (digests outside SF1 and control
PCR targets) to aid digestion and PCR. Digested samples were subjected
to PCR amplification using appropriate primers (see Table 1) and re-
solved ona2o r3 %agarose gel. Selected regions with no HpaII/MspI
restriction sites of human IGF-II exon 9 or mouse -globin genes were
used as internal controls in the PCRs.
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Genomic DNA (100–500 ng) was subjected to sodium bisulfite mod-
ificationwiththeEZDNAmethylationkit(ZymoResearch,Orange,CA)
according to the manufacturer‘s instructions. PCR amplification was
carried out using primers specific for bisulfite-converted DNA sequence
of the selected gene area to target either mouse or human origin (see
Table 1). The amplified PCR product was subcloned into the pGEM-T-
easy vector (Promega, Madison, WI) and subsequently sequenced and
analyzed. Only PCR clones with at least 95% C-to-T conversion outside
CpG sites were analyzed further.
Laser dissection from paraffin embedded tissues
Laser dissections were performed with a system comprised by an
inverted microscope (Axiovert 200; Zeiss, New York, NY) and an air-
cooled nitrogen laser (model VSL-337 ND-S) from P.A.L.M. Microlaser
Technologies GmbH (Munich, Germany). Microdissection was per-
formed on 7-m-thick paraffin sections. Paraffin embedding and sec-
tioning were performed according to standard protocols.
Chromatin immunoprecipitation (ChIP) assay
Cellsweregrownto95%confluenceona500-cm
2plate.Thecellswere
rinsed with PBS and fixed in 1% formaldehyde at room temperature for
10min,rinsedagaininPBS,andcollectedinto100mmTris-HCl(pH8.7),
10 mm dithiothreitol by scraping. Cells were collected by centrifugation
and sequentially washed in ice-cold PBS, buffer I 0.25% Triton X-100,
10 mm EDTA, 0.5 mm EGTA, 10 mm HEPES (pH 6.5) and buffer II 200
mm NaCl, 1 mm EDTA, 0.5 mm EGTA, 10 mm HEPES (pH 6.5). Nuclei
were resuspended in lysis buffer 1% sodium dodecyl sulfate (SDS), 10
mm EDTA, 50 mm Tris-HCl (pH 8.0), 1 protease inhibitor cocktail
(Roche,Indianapolis,IN)andsonicatedtoanaveragelengthof400–800
bp. The lysates were centrifuged at 14,000 rpm for 10 min and the
supernatant diluted 1:10 in dilution buffer 1% Triton X-100, 2 mm
EDTA, 150 mm NaCl, 20 mm Tris-HCl (pH 8.1), 1 protease inhibitor
cocktail(Roche).Onemilliliterofthechromatinsolutionwasprecleared
with the addition of recombinant protein G agarose (Invitrogen, Carls-
bad, CA), sheared herring sperm DNA (2 g), and normal rabbit IgG
(sc-2027; Santa Cruz). Precleared chromatin was then incubated with 5
gofspecificantibodyornormalrabbitIgGandrotatedat4Covernight.
Polyclonal antibodies for the ChIP experiment were against USF2 (N-18;
Santa Cruz), methyl-CpG-binding domain protein 2 (MeCP2; ab2828;
Abcam), Dnmt3a (H-295; Santa Cruz), and RNA polymerase II (ab5131,
Abcam). The beads were harvested by centrifugation at 3000 rpm for 15
sec and washed sequentially for 20 min with the following buffers:
low-salt buffer 0.1% SDS, 1% Triton X-100, 2 mm EDTA, 150 mm NaCl,
20 mm Tris-HCl (pH 8.1), high-salt buffer 0.1% SDS, 1% Triton X-100,
2m m EDTA, 500 mm NaCl, 20 mm Tris-HCl (pH 8.1) and buffer III 1%
Nonidet P-40, 1% deoxycholate, 1 mm EDTA, 0.25 m LiCl, 10 mm Tris-
HCl (pH 8.1) and four times with Tris/EDTA buffer. Immunoprecipi-
tates were eluted three times with 100 l 1% SDS and 0.1 m NaHCO3,
and the eluates were pooled. After dilution, 100 l of the supernatant
were saved as total input of chromatin and was processed with the
eluted immunoprecipitates beginning at the cross-link reversal step.
Reverse cross-linking of samples was performed by incubation at 65 C
overnight.After1hproteinaseKdigestion,sampleswerepurifiedusing
QIAquick PCR purification kit (QIAGEN), resuspended in 40 lo f
elution buffer 10 mm Tris-Cl (pH 8.5). Subsequently quantitative PCRs
were performed with 1 l of immunoprecipitate and serial dilution of
input material by using the iQ SYBR Green supermix (Bio-Rad Labo-
ratories, Hercules, CA) with primers spanning the SF1 proximal pro-
moter area (128/70) or an upstream region (8500/8305; see Table
1 for primers). The quantitative PCR was performed on an iQ5 real-time
PCR detection system (Bio-Rad).
Results
The proximal promoter contains CpG sites
The sequences analyzed in this study correspond to the
regions spanning 129/122 of the human SF1 gene and
123/125 of the mouse Sf1 gene containing the proximal
promoter region and part of exon 1 (Fig. 1, A and B; for
simplicity, these regions will hereafter be referred to as the
proximal promoter). The proximal promoter is conserved
among species, contains binding sites for several transcrip-
tion factors, and can promote reporter gene activity in vitro
(12, 13). Sequence analyses of the selected region revealed 14
putative CpG sites in the human sequence and 10 in the
corresponding mouse sequence. Many of the sites were con-
served between the two species including one that coincided
with the E-box motif (Fig. 1, A and B). Notably, according to
the cpgplot program (www.ebi.ac.uk/emboss/cpgplot), the
mouseandhumanproximalpromoterdoesnotresidewithin
CpG islands. A CpG island is frequently defined as a region
ofDNAofgreaterthan500bpwithaGCequaltoorgreater
than 55% and observed CpG/expected CpG of 0.65 (29).
TABLE 1. Overview of the PCR primers used in this study
Species Application Target region Primer sequence (5)
Human HpaII-dig PCR SF1 F CCACCCTCAGCCCCCAGATA
R GGGGGTAGCATGGTGGGAGG
IGF-II F CTTGGACTTTGAGTCAAATTGGCC
R GAGGGTCGTGCCAATTACATTTCA
Bisulfite PCR (nested) SF1 outer F AAAAAAAACTAACCATTAAAAACCTAAAC
R TTTTTATTTTTAGTTTTTAGATAGATAGGGGTATT
SF1 inner F GTAAATGAAGAGAAATATTAATAAAGAAGG
R AAAAATAACAATAAACACCAAAAATCC
Mouse HpaII-dig PCR SF1 F CCACCCTCAGCCCCCAGATA
R GGGGGTAGCATGGTGGGAGG
-Globin F ACACAGGATAGAGAGGGCAGGAG
R GTCTGTTTCTGGGGTTGTGAGTC
Bisulfite PCR (nested) SF1 outer F TAGTGTTTTGGTTTTTGTTTTTATTTAGG
R AATAAAAAAATAAATCTAAAAAAACCCCTAAC
SF1 inner F TGAAGAGAAATATTAATAAAGGAGGAGAAAG
R AAAAATAAACACTAAACACCAAAATCCTAAT
qChIP SF1 promoter F CCAAATGAAGAGAAACACCAACAAAG
R GCTAGCGGGCTCTCAGAAACTT
SF1 upstream F CTTGGGATTGGTACAGGTAGTGAGG
R AGCCTTCTCTCAAACTTCAAACTCCT
F, Forward; R, reverse; dig, digestion; qChIP, quantitative ChIP.
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To investigate whether the activity of the proximal pro-
moter is dependent on methylation status, we constructed a
reporter gene plasmid in which the fragment spanning
185/141 of the mouse Sf1 gene was inserted upstream of
luciferase Sf1(185/141)/Luc. The plasmid was propa-
gated in the Escherichia coli strain DH5 (which does not
contain CpG methylases) and subjected to in vitro methyl-
ation using the SssI CpG methylase. To verify that the orig-
inal reporter plasmid was indeed unmethylated and that in
vitro methylation had occurred, the plasmids were digested
with HpaII, which is sensitive to methylation, and with its
isoschizomerMspI,whichismethylationinsensitive(seeFig.
2A for HpaII/MspI sites). As demonstrated in Fig. 2B, HpaII
readily digested unmethylated Sf1 (185/141)/Luc (Fig.
2B, left panel), whereas it did not digest the methylated plas-
mid (Fig. 2B, right panel). As expected, MspI acted similarly
on both methylated and unmethylated plasmid (Fig. 2B). To
correlate methylation status with reporter gene activity, un-
methylated and in vitro methylated Sf1 (185/141)/Luc
were transfected into the steroidogenic cell lines H295R (hu-
man adrenocortical tumor cell line) and Y1 (mouse adreno-
cortical tumor cell line). As expected, based on the fact that
these cell lines express high levels of SF1, Sf1 (185/141)/
Luc gave rise to relatively high luciferase activity when un-
treated with SssI CpG methylase (Fig. 2C). In vitro methyl-
ation resulted in a 95.4 and 99.5% repression of luciferase
activity in H295R and Y1 cells, respectively (Fig. 2C). These
experiments thus suggest that the proximal promoter of the
Sf1 gene is inactive when methylated.
The proximal promoter is hypomethylated in cells and
tissues that express SF1
To determine whether the methylation status of the prox-
imalpromotercorrespondedtotheexpressionprofilesofSF1
in various cell lines of mouse and human origin, genomic
DNA was isolated and digested with HpaII/MseI followed
by PCR (see Fig. 2A for HpaII/MspI sites and positions of
PCR primers). The presence of a band on gel electrophoresis
afterPCRindicatesthatHpaIIisunabletodigestthetemplate
FIG. 1. Overview of the CpG sites in the proximal promoter. A, Overview of CpG sites (indicated as lollipops) in the proximal promoters of the
human (top) and mouse (bottom) SF1/Sf1 genes. The regions shown correspond to the region spanning 129/122 in the human gene and the
region spanning 123/125 in the mouse gene. The positions of DNA regulatory elements present in the proximal promoters are indicated
(12–16, 19, 20). A putative INR element (46) is present at the start site of transcription (1) (47, 48). B, Alignment of the human and mouse
SF1/Sf1 genes over the region selected for bisulfite sequencing. The CpG sites are indicated as circles, and the numbering corresponds to that
in A. As also shown in A, the positions of functional DNA-regulatory elements are indicated.
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Fig. 3A, the proximal promoter was unmethylated (i.e. no
PCR product was generated after HpaII digestion) in human
(Fig. 3A, left panel) and murine (Fig. 3A, right panel) cells of
steroidogenic origin (i.e. adrenocortical H295R and Y1 cells
and the mouse Leydig cell line, MA10). Furthermore, it was
unmethylated in the murine Sertoli-derived cell lines
SMAT-1 and MSC-1 (Fig. 3A, right panel). In contrast, PCR on
FIG.2 .In vitro methylation inhibits transcription from the proximal promoter. A and C, Overview of the positions of the primers used for the
HpaII/MspI digestion-based methylation analyses (arrows) and the bisulfite sequencing (arrowheads). The HpaII sites are indicated as
diamonds (six sites in the human promoter, four sites in the mouse promoter). Open symbols (top of gene diagram) indicate positions of primers
and HpaII sites in the human gene, and closed symbols (below gene diagram) denote HpaII sites and primers for the mouse gene. The
transcriptional start site is indicated as 1( bent arrow). B, Sf1 (185/141)/Luc was left untreated or methylated in vitro by the methyl-
transferase SssI and the methylation status confirmed by HpaII/MspI digestion. IVM, In vitro methylated; L, 1-kb DNA ladder; U, undigested
Sf1 (185/141)/Luc; MspI, MspI-digested Sf1 (185/141)/Luc; HpaII, HpaII-digested Sf1 (185/141)/Luc). C, H295R and Y1 cells were
transfected with Sf1 (185/141)/Luc (300 ng) or the same plasmid that had been methylated in vitro (IVM) (300 ng). Luciferase activity was
determined 24 h after transfection and normalized against -gal activity from LacZ/pCMV (100 ng) that was included in all transfection
experiments (n6). The experiment was repeated with different batches of in vitromethylatedSf1(185/141)/Luc, all giving the same result.
FIG. 3. DNA methylation analyses of the
proximal promoter by HpaII digestion. A,
Genomic DNA from cell lines of human (left
panel) and murine (right panel) origin was
submitted to HpaII/MspI digestion followed
byPCR.(PleaseseeMaterialsandMethodsfor
origin of cell lines.) Selected regions of the
human IGF-II and mouse -globin genes (con-
taining no HpaII sites) were used as controls.
U, Undigested DNA; MspI, MspI digested
DNA;HpaII,HpaIIdigestedDNA;,noDNA.
Representative data from two or three inde-
pendent sample preparations for each cell line
are shown. PCR analyses were performed
three times for each sample, and full repro-
ducibility was observed. B, Total cell lysates
was prepared from the human (left panel) and
mouse (right panel) cell lines and subjected to
Western blot analyses using an anti-SF1 an-
tibody. Equal protein loading was verified us-
ing an anti--actin antibody. The experiments
were performed three times with similar re-
sults and representative blots are shown. *,
Unspecific band.
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(human cervix epithelial carcinoma), A2780 cells (human
epithelial ovarian carcinoma), NIH-3T3 cells (mouse embry-
onic fibroblasts), and Hepa cells (mouse hepatoma cells)
generated PCR products indistinguishable from undigested
DNA. Thus, the proximal promoter was methylated in these
cell lines (Fig. 3A, left and right panels). By immunoblotting,
SF1 was detected in cells with hypomethylated proximal
promoter (Fig. 3B). In contrast, a hypermethylated proximal
promoter correlated with lack of SF1 expression with one
exception:HeLacellsexpressedlowlevelsofSF1(Fig.3B,left
panel). The presence of SF1 in HeLa cells was confirmed by
an antibody raised against a different epitope (data not
shown). The band corresponding to SF1 migrated at a
slightly higher molecular weight than observed for H295R
cells.Thereasonforthisisunknown.Searchingtheliterature,
we have not found other reports describing the expression of
SF1 in HeLa cells. However, SF1 is expressed in the uterus
(30) that, like the cervix, originates from the Mu ¨llerian ducts.
To investigate the precise methylation status of each in-
dividual putative CpG site, we performed bisulfite sequenc-
ing on genomic DNA isolated from the different cell lines. In
concordancewiththeresultsinFig.3,practicallyallpotential
sites in the human (Fig. 4A) and mouse (Fig. 4B) proximal
FIG. 4. Site-specific CpG methylation analyses of the proximal promoter in cell lines. Bisulfite sequencing was performed on DNA isolated from
the human (A) and murine (B) cell lines used in Fig. 3. The analysis covered 14 CpG sites (in the region spanning 129/122) in the human
gene and 10 CpG sites (in the region spanning 123/125) in the mouse gene. Filled circles indicate methylated CpG sites, and open circles
represent unmethylated CpG-sites. Horizontal lines represent individual analyzed clones. The CpG sites are numbered corresponding to the
overview in Fig. 1.
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to HpaII digestion and that expressed SF1 (i.e. H295R, Y1,
MA-10, SMAT-1 and MSC-1 cells). Similarly, the proximal
promoter was hypermethylated in cells that did not express
SF1 (i.e. HEK-293, A2870, NIH-3T3, and HeLa cells). Despite
the apparent presence of SF1 protein in Hela cells, the prox-
imal promoter was heavily methylated (Fig. 4A), in agree-
ment with the HpaII digestion analysis in Fig. 3A. However,
interestingly, all clones examined from this cell line were
demethylated at the CpG site at position 2 (Fig. 4A), located
within the E-box of the human proximal promoter (Fig. 1B).
Cell lines, especially those of tumorigenic origin, can ex-
hibitaberrantmethylationpatternsthatareunrepresentative
of the normal tissues from which they originate. Therefore,
we examined the methylation status of the proximal pro-
moter in adult mouse tissues. The adrenal gland consists of
a medulla and cortex, with only the cortical cells expressing
SF1. Thus, genomic DNA isolated from the whole gland
yielded clones that were either completely unmethylated or
completely methylated (Fig. 5A). Laser capture microdissec-
tion separated the cortex and medulla and established that
genomic DNA isolated from the cortex was responsible for
the unmethylated clones, whereas DNA from the medulla
was completely methylated (Fig. 5A). The capsule and sub-
capsular areas were avoided in the laser capture microdis-
section. Thus, capsular cells that are devoid of SF1 (31) and
cells in the subcapsular area that have been suggested to lack
SF1protein(7)werenotincludedinouranalyses.Intheadult
mouse ovary, SF1 is expressed in both granulosa and theca
cellsaswellasthecorpusluteum(32).Inagreementwiththis
expression pattern, we found 11 of 13 clones generated from
the ovary to be almost completely demethylated across the
proximal promoter (Fig. 5B, left panel). In the mouse adult
testis, SF1 expression is confined to Leydig and Sertoli cells
and is not expressed in germ cells or peritubular myoid cells
(31). In the adult rodent testis, Leydig and Sertoli cells con-
stitute approximately 10 and 8% of the total cell number,
respectively, whereas spermatogonia, spermatocytes, and
spermatids account for approximately 70% (33). When bisul-
fite sequencing was performed on adult mouse testis, it be-
came evident that approximately 24% of the CpG sites were
methylated (Fig. 5B, middle panel), which would suggest that
FIG. 5. Site-specific CpG methylation analyses of the proximal promoter in adult mouse tissue. A, B, and C, The analysis covered 10 CpG sites
(in the region spanning 123/125) in the mouse Sf1 gene. CpG sites are numbered corresponding to overview in Fig. 1. Filled circles indicate
methylated CpG-sites, and open circles represent unmethylated CpG sites. A, Paraffin sections of mouse adrenal glands were subjected to laser
capture microdissection to isolate cortical and medullary cells. Bisulfite sequencing was performed on whole sections (total adrenal; left panel)
or isolated cortical cells (cortex; middle panel) and medullary cells (medulla; right panel). B, Bisulfite sequencing on DNA isolated from mouse
ovary (left panel), testis (middle panel), and mature sperm (right panel). C, Bisulfite sequencing on DNA isolated from tail (left panel) and liver
(right panel). Horizontal lines represent individual analyzed clones. CpG sites are numbered corresponding to the overview in Fig. 1.
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of cells than could be accounted for by the Leydig and Sertoli
cell lineages. (In total 56 PCR clones, generated from four
testes, were analyzed; mean 24  8%; one representative
experiment is shown in Fig. 5B, middle panel.) Probably, de-
methylated promoter is present in cells of the germ cell
lineage because primordial germ cells become demethylated
around E10.5 and E13.5 and is not completely remethylated
until the pachytene stage (34). As expected, nearly complete
methylation was apparent in mature sperm (Fig. 5B, right
panel). The proximal promoter was hypermethylated in
genomic clones derived from the tail and liver (Fig. 5C).
Taken together, these results indicate that the methylation
status of the proximal promoter strongly correlates with the
expressionoftheproteininbothadultmousetissuesandcell
lines.
Methylation of the proximal promoter during development
As sexual differentiation occurs, SF1 expression is main-
tained in the developing testis but declines to undetectable
levels in the ovary (9). To determine whether this differential
expression is reflected in the methylation status, we per-
formed bisulfite sequencing on DNA isolated from murine
gonads at E13.5 and 16.5 (Fig. 6A). The proximal promoter
was virtually completely demethylated in both sexes at both
stages (Fig. 6A). The lack of methylated clones in the devel-
oping testis is in agreement with the fact that SF1-expressing
cells constitute the majority of the testicular cells and that the
germ cells contain mainly demethylated DNA at these de-
velopmental stages (34, 35). Because SF1 expression is un-
detectableintheovaryatthesetimepoints,ourresultswould
indicate that the Sf1 gene is demethylated in the proximal
promoter early in development and that it remains in this
state in cells programmed to express SF1 at later stages. As
expected, the proximal promoter was heavily methylated in
thedevelopingliver(Fig.6B).Asimilarpatternwasobserved
in the kidney at E13.5. However, at E16.5, a number of pu-
tative CpG sites were demethylated in the kidney, particu-
larly in the more distal part of the proximal promoter region
(Fig. 6B). Neither the developing nor adult kidney expresses
SF1 (Refs. 30, 36 and Hanley, N., unpublished data). The
observedlevelofdemethylationisthereforeunlikelytoallow
SF1 expression in this tissue.
During human development, as in the mouse, SF1 is ex-
pressed in the bipotential gonad and throughout testicular
development (10). At 9 wk after conception, when sex cords
haveformed,theproximalpromoterwasessentiallydemeth-
ylatedinthedevelopingtestis(Fig.7).Interestingly,similarly
to the mouse, DNA from human kidney also revealed rela-
tive low levels of methylation. SF1 is not expressed in the
human kidney (Hanley, N., unpublished data), and at
present it is not clear why the proximal promoter is partially
demethylated in this organ during development.
The unmethylated proximal promoter recruits transcriptional
activators. ChIP experiments were performed to determine
whether the methylation status affected the recruitment of
transcription factors to the proximal promoter. Occupation
of three factors was analyzed: USF2, which has previously
been demonstrated to interact with the unmethylated active
proximal promoter (23); MeCP2, which interacts with meth-
ylated DNA (37); and RNA polymerase II (polII). As evident
FIG. 6. Site-specific CpG methylation analyses of the proximal promoter in embryonic tissue. Bisulfite sequencing was performed on DNA
isolated from mouse testes, ovaries, kidney, and liver at E13.5 and E16.5 as indicated. The analysis covered 10 CpG sites (in the region spanning
123/125) of the Sf1 gene. Filled circles indicate methylated CpG sites, and open circles represent unmethylated CpG sites. Horizontal lines
represent individual analyzed clones. CpG sites are numbered corresponding to the overview in Fig. 1.
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tivator USF2 was specifically located at the proximal pro-
moter in Y1 cells, whereas no interaction above background
levels were detected in Hepa cells. Moreover, antibodies
against polII also specifically precipitated the proximal pro-
moter from Y1 cells (Fig. 8), further supporting that the
unmethylated status correlates with a transcriptionally ac-
tive promoter. As expected, MeCP2 interacted only with Sf1
in Hepa cells (Fig. 8, lower panel). We found that MeCP2 was
recruited to a region upstream of the proximal promoter.
This is partly in conflict with the study by Xue et al. (38), who
suggested that MeCP2 interacts with the proximal promoter
in SF1-negative endometrial stroma cells. The recruitment of
MeCP2 might differ between nonexpressing cells, but we
note that Xue at al. did not use upstream or downstream
primer pairs, hindering a direct comparison of the two
studies.
Discussion
Several studies have established that DNA methylation
plays regulatory roles in developmental gene expression
(39–43). We demonstrate a striking correlation between SF1
protein expression and methylation status of the proximal
promoter, indicating that DNA methylation is a major mech-
anism to regulate cell and tissue-specific expression of SF1.
Whereas our work was ongoing, Xue et al. (38) published a
study that links methylation and SF1 protein expression in
endometrial and endometriotic cells. In normal endometrial
cells that do not express SF1, the proximal promoter was
found to be hypermethylated, whereas DNA from endo-
metriotic cells, which do express SF1, was hypomethylated
over the same region (38). This study also revealed that
MeCP2, which contributes to the repressed state of methyl-
ated DNA, is recruited to the proximal promoter in endo-
metrial cells (38). Thus, together, these studies demonstrate
that methylation of the proximal promoter directs SF1 ex-
pression in both normal tissues and diseased tissue exhib-
iting aberrant levels of SF1 protein.
We observed low, but consistent, levels of SF1 in HeLa
cells (Fig. 3B). Interestingly, all PCR-generated clones from
HeLa cells were unmethylated at the CpG site located within
theE-box(Fig.4A).BecausethisDNAregulatoryelementhas
repeatedly been identified as crucial for SF1 expression, we
speculatethatthespecificlackofmethylationallowsbinding
ofafactorthatcandirectlowlevelsofSF1expressioninHeLa
cells, regardless of the overall hypermethylation of the prox-
imal promoter. Of specific interest in this regard is a recent
study suggesting that abnormal expression of USF2 and its
interaction with the E-box partly accounts for the aberrant
expression of SF1 in endometriosis (23). The demethylation/
remethylationprocessesthatoccuringermcellscomplicated
FIG. 7. Site-specific CpG methylation analyses of the proximal pro-
moter in fetal human tissue. Bisulfite sequencing was performed on
DNA isolated from the testis and kidney from a human embryo (8 mm
footlength,around9wkofdevelopment).Filledcirclesindicatemeth-
ylated CpG sites, and open circles represent unmethylated CpG sites.
Horizontal lines represent individual analyzed clones. CpG sites are
numbered corresponding to the overview in Fig. 1.
FIG. 8. Differential recruitment of transcriptional regulators to the
proximal promoter, depending on methylation status. ChIP experi-
ments were performed on Y1 and Hepa cell extracts using antibodies
against USF2, MeCP2, and RNA polII as indicated. The quantitative
PCR values were related to preimmune IgG control values and are
presented as relative fold enrichment in relation to 0.1% input ma-
terial. Statistical analyses were t tests with pooled variances. a, P 
0.015; b, P  0.005; c, P  0.012 (Y1: n  9; Hepa: n  6).
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and SF1 expression in the testis. DNA methylation patterns
are generally erased during gametogenesis, and complete
remethylation in the male is not evident until the pachytene
stage of meiosis (34). In line with this, our analyses of em-
bryonic testis demonstrated complete demethylation of
nearly all clones examined (Fig. 6), and furthermore, a far
greater number of clones than would be accounted for by the
Leydig and Sertoli lineages were demethylated in adult tes-
tes (Fig. 5B). To determine the methylation status of the
proximal promoter in SF1 expressing vs. nonexpressing cells
intheovaryandtestis,weperformedbisulfitesequencingon
cellssortedfrommiceexpressingenhancedgreenfluorescent
protein under the control of 50 kb of the 5 Sf1 promoter
region (44). However, these analyses demonstrated that the
methylation pattern of the transgenic construct differs from
that of the Sf1 gene, and the presence of multiple copies of
the transgenic construct in the SF1/enhanced green fluores-
cent protein mice impeded these analyses (Hoivik, E. A.,
M. Bakke, and K. L. Parker, unpublished results).
Although we did not analyze the methylation status at the
earliest time point of SF1 expression in the adrenogonadal
primordium (at E9.0 in mice), we hypothesize that the meth-
ylationpatternoftheproximalpromoterisestablishedatthis
stage and that it is maintained thereafter. Thus, as depicted
in Fig. 9, the proximal promoter will be demethylated in cells
that are programed to express SF1 continuously or in an
interrupted manner and methylated in other cells. In agree-
ment with this idea, the down-regulation of SF1 levels that
occurs in the ovary at the time of sexual differentiation is not
associated with a change in methylation status (Fig. 6). In-
stead, the change in SF1 expression during ovarian devel-
opment is more likely to be caused by the action of tran-
scription factors (although we cannot exclude epigenetic
modifications elsewhere in the gene). Genetic studies have
identified several transcription factors that appear to affect
SF1 expression in the developing mouse embryo. SF1 ex-
pressionisreducedtoaminimuminmicecarryingatargeted
deletion of Lhx9 (17). Similarly, the knockout models for
WT-1 (16) and the Pbx1 (45) exhibit undetectable levels of
SF1, clearly indicating that these factors act upstream of SF1.
Moreover, Pod1 most likely acts as a repressor of SF1 ex-
pression because loss of this factor leads to enhanced SF1
expression in the developing testis, followed by ectopic ex-
pression of SF1 and aberrant commitment of precursor cells
to the steroidogenic lineage (25). Thus, a number of tran-
scription factors, in addition to tissue-specific promoters (26,
27), and epigenetic regulatory mechanisms seemingly work
side by side to control the time and cell-specific expression
of SF1. Interestingly, in silico analyses suggest the presence
of CpG islands within the human and mouse SF1 genes.
Typically, CpG islands are associated with regions that are
involved in transcriptional regulation (1), and future exper-
iments should answer whether these regions confer epige-
netic regulation. According to our preliminary analyses, the
previously identified VMH-specific intronic enhancer (26,
27) resides within a CpG island.
In conclusion, our results clearly indicate that epigenetic
mechanisms control the expression of SF1 during embryonic
development, in adult tissues, and in cell lines. In this study
we have not investigated the mechanisms that direct the
cell-specific methylation pattern of the proximal promoter.
But because SF1 is a transcription factor associated with
embryonal lineage commitment, the SF1/Sf1 gene provides
an interesting candidate for future studies that aim to reveal
the mechanisms whereby CpG methylation contributes to
cell type-specific gene expression during development.
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FIG. 9. Proposed mechanism for tissue-specific expression of SF1 by DNA methylation. In SF1-negative tissues, DNA methylation of the proximal
promoter prevents expression of SF1. In contrast, the proximal promoter is hypomethylated in SF1-expressing tissues. We hypothesize that the
methylation pattern is established at the earliest time point of SF1 expression (E9 in the mouse) and maintained thereafter in a clonal manner. Both
cell lineages that express SF1 continuously and those that express SF1 periodically maintain a demethylated pattern. Various transcription factors
presumably interact with the hypomethylated promoter, controlling the level of SF1 expression. Unmethylated CpG sites are indicated by open
lollipops, whereas methylated CpG sites are shown as filled lollipops. Key time points are indicated. Expression profiles are based on a published
report (49).
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ABSTRACT
The realization of cell replacement therapy derived from
human pluripotent stem cells requires full knowledge of the
starting cell types as well as their differentiated progeny.
Alongside embryonic stem cells, embryonic germ cells
(EGCs) are an alternative source of pluripotent stem cell.
Since 1998, four groups have described the derivation of
human EGCs. This review analyzes the progress on deriva-
tion, culture, and differentiation, drawing comparison with
other pluripotent stem cell populations. STEM CELLS 2006;
24:212–220
INTRODUCTION
In mammalian biology, two clear sources of untransformed
pluripotent stem cell have been described (Fig. 1). The inner cell
mass (ICM) of the early embryo gives rise to the derivatives of
all three germ layers in the developing embryo. Taking the ICM
into in vitro culture offers the opportunity to derive embryonic
stem cells (ESCs). These cells, first attained from mouse em-
bryos by Evans and Kaufman [1] and, independently, by Martin
in 1981 [2], retain the ability for broad differentiation but also
undergo self-renewal. As such, they are the pluripotent stem cell
that has been the focus of most research. An alternative source
of pluripotent cells arises later in development. Germ cells are
the sole means of transmitting genetic information to the next
generation in their ultimate form as haploid gametes, sperma-
tozoa, and ova. However, before meiosis, these cells exist as
diploid primordial germ cells (PGCs). PGCs share significant
similarities to the cells of the ICM and, once taken into in vitro
culture, can lead to the generation of embryonic germ cells
(EGCs) (Fig. 1), the parallel of ESCs. The derivation of human
EGCs (hEGCs) has been reported now by several groups world-
wide [3–6]. This review brings together these experiences and
compares their emerging biology with that of human ESCs
(hESCs), beginning from the historical starting point of PGC-
EGC studies in mice.
Origin, Migration, and Proliferation of PGCs
To understand EGCs, it is first necessary to comprehend how
PGCs arise and proliferate [7, 8]. The mammalian germ cell
lineage is specified significantly later than in many other species
(e.g., Drosophila, Caenorhabditis, and Xenopus). Only after
blastocyst formation are the origins of mouse PGCs (mPGCs)
detected as a choice of cell fate during gastrulation among the
daughter cells of the proximal epiblast. Signaling from bone
morphogenetic proteins (Bmps), particularly Bmp4 and Bmp8b
acting via the type 2 activin receptor-like kinase [9–11], gen-
erates a population of cells that are maintained by Oct4 [12] and
distinguished from the surrounding somatic cells by a longer
cell cycle (16 versus 7 hours).
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 Understanding the biology and proliferation of mammalian
PGCs requires appreciation of a fascinating journey from their
origin in the epiblast, adjacent to the extraembryonic ectoderm,
through the gut mesentery, to their final destination in the
developing gonad (Fig. 2) [13]. Although the mechanisms reg-
ulating early mobilization are unclear, or even random, later
migration relies in part on the chemokine Sdf-1 released from
somatic cells. In mice, these signals act on the PGC surface
receptor Cxcr4b to activate phosphatidylinositol 3 kinase and
G-protein–coupled pathways that are responsible for PGC mo-
tility and direction, respectively [14–16]. In addition to che-
moattraction, migrating germ cells require other stimuli for their
maintenance, such as stem cell factor (SCF) (also known as steel
factor, mast cell growth factor, or Kit ligand), acting via its
receptor c-Kit. Disruption of this signaling pathway leads to
germ cell apoptosis and a failure of PGCs to reach the gonadal
ridge [17].
Between 10.5 and 12.5 days postconception (dpc) in mice,
PGCs arrive at the gonadal ridge, and those that fail regress [18].
The environment of the gonad and the opportunity for different
somatic cell interactions induce several changes, amongst which
cell shape condenses and the dead-box transcription factor,
Ddx4, is expressed. This homologue of the Drosophila vasa
gene is essential for male germ cell proliferation and subsequent
meiosis [19]. The early gonadal events coincide with sex deter-
mination, the process when chromosomal sex is translated into
either testis or ovary. Similar dimorphism becomes apparent
within the germ cell lineage [20]. Female germ cells reactivate
the second X chromosome before entering meiotic prophase at
13.5 dpc. The male germ cells enter mitotic arrest as prosper-
matogonia. Whereas the former mechanism seems largely in-
trinsic, the somatic signal from the testis is ill defined. It most
likely arises from the Sertoli cells that surround the germ cells
within the sex cords; a signal before 12.5 dpc can override the
meiotic tendency of female germ cells [21]. In both sexes,
arrival in the gonadal ridge also heralds the final erasure of
methylation patterns.
Knowledge of human PGCs (hPGCs) is more difficult be-
cause they are less amenable to study. Germ cells are apparent
in the gonadal ridge during the fifth and sixth week of devel-
opment, with further PGCs detected in the gut mesentery, most
likely in transit (Fig. 2). By 41 to 44 dpc (Carnegie stages 17 and
18), Sertoli cell differentiation and testicular cord formation is
associated with decreased numbers of PGCs in male compared
with female embryos, presumably due to mitotic arrest [22]. In
contrast, proliferation continues in the developing fetal ovary
during the remainder of the first trimester. This ability for
continued mitosis in female fetuses carries potential signifi-
cance. Female menopause results from an exhausted supply of
gametes and is considered premature if prior to 40 years. One
hypothesis to explain this untimely ovarian demise is inadequate
provision of germ cell number before meiosis. It becomes plau-
sible, therefore, that genes associated with premature ovarian
Figure 1. Cartoon of human embryonic stem cell and embryonic germ cell derivation. Abbreviations: hEGC, human embryonic germ cell; hESC,
human embryonic stem cell; ICM, inner cell mass; PGC, primordial germ cell.
Figure 2. Migration of human primordial germ cells. Representation of
human primordial germ cell (PGC) migration from the allantois to the
gonadal ridge in the intact embryo (A) and through the gut mesentery
within the dissected abdomen (B) at approximately 6 weeks after con-
ception. The gonadal ridge (G) has developed on the medial surface of
the mesonephros (M) adjacent to the adrenal gland (A) and superior to
the kidney (K). (C): Human embryo section corresponding to (B)
showing PGCs darkly stained for alkaline phosphatase activity in the
gonad (G) and throughout the folds of the gut mesentery (arrow). Bar 
250 m.
213 Turnpenny, Spalluto, Perrett et al.
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 failure are candidate regulators of PGC proliferation and vice
versa.
Mouse EGC Derivation
The identification of mPGCs fostered attempts to isolate and
study their properties in vitro. Survival depended on age:
PGCs from 13.5 dpc onwards could be cultured for days, with
female cells entering meiosis. In contrast, cells at 11.5 to 12.5
dpc did not survive unless temperature was reduced to 30°C,
favoring continued mitosis rather than meiosis of female
germ cells [23]. Even so, cells survived little more than 1
week, either succumbing to apoptosis or differentiating.
Problematic to these cultures was the apparent aversion of
germ cells to standard cell culture substrates (e.g., plastic,
glass, and gelatin). In contrast, gonad explant cultures dem-
onstrated greater survival of PGCs when supported by out-
growing, adherent somatic cells. Hence, growth-arrested, em-
bryo-derived feeder cell monolayers were adopted as an
effective adherent substratum for PGCs [24]. This more
reliable culture support system allowed distinction between
pregonadal migratory and gonadal postmigratory PGCs. Cul-
ture behavior mirrored events in vivo: later stages yielded
fewer motile PGCs, especially in male cells [25]. However, it
was evident that some migratory cells retained mitotic activ-
ity in culture, albeit for a limited period.
Survival and proliferation could be promoted by the syner-
gistic action of SCF and leukemia inhibitory factor (LIF), al-
though proliferation did not progress beyond that of their in vivo
counterparts [26–28]. Critically, extra supplementation with
fibroblast growth factor 2 (Fgf2) effected their continued pro-
liferation beyond normal in vivo cessation, a criterion in defin-
ing conversion or derivation from PGCs to EGCs [29, 30].
Remarkably, these more persistent cells possessed properties
redolent of the mouse ESC (mESC) lines first established 10
years earlier, satisfying all criteria for pluripotency, both in vitro
(giving rise to embryoid bodies [EBs] containing derivatives of
all three germ layers) and in vivo (contribution to all tissues and
the germ line of chimeric animals). Subsequently, derivation has
been proven most successful from PGCs before and during
migration but remains attainable from PGCs within the gonadal
ridge until 12.5 dpc [31]. After this time, presumably mitotic
arrest in male PGCs and the first stage of meiosis in female cells
renders them refractory to EGC derivation. This contrasts to a
population of multipotent germline stem (MGS) cells that has
been isolated recently from the mouse neonatal testis, most
probably derived from the diploid spermatogonial stem cell
population [32].
Human EGC Derivation
The knowledge acquired over the years from mPGC-mEGC
culture was a sensible starting point for attempts to derive
hEGCs. However, in contrast to the plethora of laboratories that
have derived hESC lines, reports of hEGC derivation remain
limited. The first report (soon after the initial description of
hESCs in 1998 [3, 33]) has been reinforced by three additional
groups (ourselves in 2003 and two other groups in 2004, the
latest group reporting twice with slightly varied methodology
[4–6, 34]). This restriction may be due in part to the compli-
cations in acquiring ethically approved, continued access to the
required starting material but also doubtless reflects the diffi-
culties in the derivation and culture management of hEGCs, as
acknowledged by some groups [4, 5, 35]. Nevertheless, this
progress demonstrates that the process is practically, rather than
just theoretically, possible.
The Starting Human PGC Population
The nature of acquiring human material from first-trimester
voluntary/social termination has restricted the age of the PGCs
available. This material spans 5 to 9 weeks after conception,
with no bias evident between groups from the use of the anti-
progestogen mifepristone/RU486 versus surgical termination of
pregnancy (Table 1). The earliest specimens would contain
PGCs shortly after arrival in the gonad, which might be ex-
pected to maintain proliferation better in culture; however, there
has been little evidence to support this. Whereas there is an
apparent upper age limit for mEGC derivation of 12.5 dpc in
both males and females, it is remarkable that an upper limit
related to sex cord formation cannot be applied to human male
PGCs, as all reports include derivation from the fetal testis after
this event. There are several potential explanations for this: male
PGCs might resume proliferative activity once freed from Ser-
toli cell influence; cord formation may not arrest all male PGCs
(i.e., a small cohort of proliferative PGCs might persist); or use
of the entire urogenital ridge, as reported by most groups [3, 5,
6, 34], might include a population of extragonadal PGCs. Our
continuing investigation considers both the retention of meso-
nephros, which contains some alkaline phosphatase (AP)-posi-
tive cells [4], and its removal from the fetal gonad. To date, no
significant difference is apparent.
Preparation of Human PGCs for Culture
Liu et al. [5] described a comparison of gonad cell dissociation
and plating combinations, confirming the optimal protocol as
essentially that used by the other groups—mechanical disaggre-
gation, enzymatic dissociation, and gentle trituration—before
plating on a monolayer of growth-arrested feeder cells (Table 1).
We have compared enzymatic dissociation with puncturing the
intact organ, as developed initially for the isolation of mPGCs
[36]. Equally effective at generating hEGC cultures, cells are
released directly into culture media, avoiding protracted wash-
ing and resuspension. At least theoretically, this avoidance of
proteolytic enzymes minimizes damage to cell-surface markers
and receptors during initial preparation and plating.
Basic In Vitro Culture Media
In reports to date, the basic composition of culture media has
shared many similarities to mEGC derivation methodology,
comprising a mix of Dulbecco’s modified Eagle’s medium
(DMEM) or knockout DMEM (KO-DMEM) with nonessential
amino acids, beta-mercaptoethanol, and L-glutamine. Choice of
serum varied between 10%–15% fetal bovine serum (FBS),
ESC-tested FBS, or knockout serum replacement (KO-SR) (Ta-
ble 1).
Whereas serum provides essential nutrients, its use is far
from ideal, being the primary source of unknown factors with
the potential to affect derivation or induce differentiation. Al-
ternatively, the serum-free supplement KO-SR can (in conjunc-
tion with KO-DMEM) decrease the propensity for spontaneous
differentiation of mESCs [37] and can improve the derivation
efficiency of mEGC, although growth is reduced [38]. Its effects
214 Human Embryonic Germ Cells
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 on the efficiency of hEGC derivation remain conjecture due to
the relatively unpredictable nature of these cells in culture, with
or without serum.
Feeder Layers
The reporting groups have predominantly used either mouse
STO fibroblasts or primary mouse embryonic fibroblasts
(pMEFs) as feeder layers (Table 1). Shamblott et al. [3] are the
only researchers to date who have reported the comparison of
feeder layers. Although in their experience STO cells were
preferable to either pMEFs, human fetal fibroblasts, or gelatin-
coated plates, further formal analyses of feeder layer character-
istics, such as via proteomic approaches [39], are required to
discern between the factor cohorts. This is particularly important
given the complexity of in vivo PGC-somatic cell interaction
within the fetal gonad and the consequences of alien interac-
tions, such as the in vitro meiotic influence of the fetal lung on
mPGCs [40]. Similar to this experience, it is conceivable that
different cell types, providing differing factor combinations,
will improve the sequential derivation and maintenance of
hEGCs.
Media Additives and Critical Factors
In addition to the influence of the basic media and feeder layers,
all groups reporting hEGC derivation and culture have included
other additives. Their use originates from mouse pluripotent
stem cell derivation and culture. Definitive requirements for any
in equivalent hEGC cultures have yet to be established conclu-
sively.
Stem Cell Factor. Perhaps the role of SCF is the most under-
standable. The sterile mouse mutants Sl (Steel) and W (Domi-
nant White Spotting) arose from mutations affecting SCF and its
receptor, c-Kit, respectively, and revealed a direct role in the
proliferation and maintenance of PGCs en route to the gonad
[41]. c-Kit is present on the cell surface of PGCs. Its ligand,
SCF, exists as two isoforms: a membrane-bound (mbSCF) fac-
tor and a soluble form (sSCF), produced by proteolytic cleav-
age. mbSCF is critical for the proliferation of PGCs in vivo [42].
In vitro, it promotes mPGC survival by inhibition of apoptosis
for longer than sSCF [17, 26, 43, 44]. The latter isoform,
however, increases telomerase activity in vitro [45]. It is there-
fore easy to envisage the benefit of both sSCF supplementation
combined with a feeder layer, such as STO, supplying mbSCF
[46]. As in the mouse, c-KIT and SCF are also present in human
fetal gonads [47] (our unpublished data).
Leukemia Inhibitory Factor. The role of LIF is intriguing.
PGC development in LIF-deficient mice is normal, suggesting
either no role or redundancy between related cytokines. Indeed,
oncostatin M can substitute for LIF in affecting survival and/or
proliferation of mPGCs in culture [46, 48, 49], although neither
can substitute for feeder support [46]. In contrast, LIF, originally
isolated from buffalo rat liver (BRL) cells for its differentiation
inhibiting activity [50], can obviate the requirement for feeder
layers in mESC culture, where signaling via the LIF receptor
(LIFR), gp130, and intracellular Stat3b has a proven role in
maintaining mESC pluripotency [51].
There are differences in pluripotent stem cells between mice
and humans. Despite activation of the LIFR/gp130-STAT3B
pathway, LIF (administered in human recombinant form) does
not maintain self-renewal of hESCs, which require feeder cells
or their conditioned media with an extracellular matrix [52, 53].
However, this highly pleiotropic cytokine may have earlier
effects. In LIF-deficient mice, blastocysts fail to implant [54].
The receptors LIFR and gp130, although dispensable for normal
early embryogenesis, are necessary for diapause, the suspension
of mouse development at the blastocyst stage in the event of
unfavorable conditions. Under these circumstances, the ICM
can maintain its undifferentiated state for months [55]. Although
Table 1. Methodology in published reports of human embryonic germ cell derivation
Report Collection Age
a Material Dissociation Feedeis Medium
b Additives
c Efficiency Duration
Shamblott et al.
[3, 77]
Surgical 5–9 Gonadal ridges
and
mesenteries
Mechanical and
enzymatic
(trypsin or
collagenase IV,
hyaluronidase V,
DNase I)
STO (irradiated) DMEM 
15% FBS
hrLIF,
forskolin, 1–2
ng/ml hrFGF2
Variable 20–25
passages
Turnpenny et
al. 4, 70
Surgical 7–9 Gonads EDTA treatment;
mechanical and
enzymatic
(collagenase IV,
DNase I)
STO (irradiated) KO-DMEM
 15%
KO-SR/ES-
FBS
hrLIF,
forskolin, 4 ng/
ml hrFGF2
8/56 
14%
10–12
passages
Park et al. 6 Surgical 9 Gonadal ridges
and
mesenteries
Mechanical and
enzymatic
(collagenase IV,
DNase I)
STO (mitomycin C) DMEM 
15% FBS
hrLIF,
forskolin, 1 ng/
ml hrFGF2
Unstated; 1
line
1 year
Liu et al. 5 RU486 6–8 Gonadal ridges
and
mesenteries
Mechanical or
mechanical and
enzymatic
(trypsin)
pMEFs (mitomycin C) DMEM 
15% FBS
hrLIF,
forskolin, 1 ng/
ml hrFGF2
Unstated;
multiple
specimens
pooled
6 months
Pan et al. 34 RU486 6–9 Gonadal ridges Mechanical and
enzymatic
(trypsin)
STO/pMEFs
(mitomycin C)
KO-DMEM
 15%
FBS/KO-
SR
hrLIF,
forskolin, 1 ng/
ml hrFGF2
2/40  5% 15 passages
aWeeks after conception.
bAll formulations included L-glutamine, -mercaptoethanol, nonessential amino acids, and sodium pyruvate.
cAll added hrLIF at 1,000 U/ml and forskolin at 10 M.
Abbreviations: DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; hrFGF2, human recombinant fibroblast growth
factor 2; hrLIF, human recombinant leukemia inhibitory factor; KO, knockout; pMEF, primary mouse embryonic fibroblast; SR, serum
replacement.
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 human embryos do not enter such a phase, LIF increases the
number and quality of human blastocysts in serum-free culture
[56], and medium conditioned by BRL cells potentially im-
proves hESC derivation [57].
In PGCs, however, the effects of LIF are debatable. LIFR/
gp130/Stat3b signaling inhibits the progression to meiosis of
cultured female mPGCs [58], but this has not been reported in
human cells. Similarly, although all groups have included LIF
during hEGC derivation and culture, none have systematically
proven its necessity. Certainly LIF, LIFR, gp130, and associated
signaling components are expressed in human fetal gonads [59]
(our unpublished data). Perhaps active LIFR/gp130/Stat3b sig-
naling in vivo sustains hPGCs in an undifferentiated suspended
state (akin to diapause). If this is the case, once removed and
exposed to myriad other, as-yet-undefined influences in vitro,
this effect may be overridden, resulting in the loss of hPGCs by
cell death and/or differentiation (including meiosis).
Fibroblast Growth Factor 2. As described earlier, Fgf2 was
the key addition that enabled mPGCs to continue proliferation in
cultures already containing LIF and SCF [60]. It is unclear
specifically which Fgf receptors transduce its effects, but the
receptivity of mPGCs is important. Potentially, only transient
(approximately 12-hour) exposure to Fgf2 is necessary for
mEGC derivation [41], after which its supplementation, along
with SCF, can be discontinued so long as cells are maintained on
feeders in the presence of serum [29]. However, after 11.5 dpc,
reduced Fgf receptor expression also correlates to diminished
derivation efficiency. This effect is more pronounced in fe-
males, perhaps due to the approach of meiosis [60, 61].
Fgf2 functions as a potent mitogen in many cell types and
induces telomerase activity in cultured mouse neural precursor
cells [62]. This suggests overlap or synergism with SCF in
maintaining telomerase activity of mPGCs when taken into
culture.
Forskolin. All groups deriving hEGCs have included forsko-
lin, which raises intracellular cAMP levels and stimulates mi-
tosis in cultured mPGCs [63]. Whether this action compensates
for an endogenous hormone is not known; however, in mEGCs
it does not substitute for the survival mediated by LIF and SCF
[64].
Although included by the groups reporting hEGC derivation,
systematic definition of optimal concentrations and time expo-
sures of all these and other growth factors remains a significant
challenge for hEGC researchers. Furthermore, the recent de-
scription of mouse MGS cells arose from cultures that primarily
maintained spermatogonial stem cells, i.e., the self-renewing
cells that give rise to spermatozoa [32]. These cultures included
glial-derived neurotrophic factor (GDNF) and epidermal growth
factor (EGF). Whereas MGS cells did not develop in standard
mEGC derivation media (LIF, SCF, and Fgf2) [32], the con-
verse effect of GDNF and EGF on mouse or human EGC
derivation and maintenance is unknown.
Growth Characteristics of Human PGCs and EGCs
The essence of hPGC-EGC basic biology can be summarized as
overcoming the in vitro sensitivity of PGCs that have been
removed from their specialized in vivo niche, the continuation
(or reacquisition) of proliferation, and the maintenance of self-
renewal and pluripotent properties in prolonged culture.
As with mouse, culture as gonadal explants mimics the
supportive in vivo environment for hPGCs, but outgrowth is
limited (Fig. 3). Dissociation and replating isolates the germ
cells, but the consequences are not all beneficial. The fetal
gonad is heterogeneous. In vivo, germ cells develop supportive
intercellular contacts with specialized somatic cells, such as
Sertoli (nurse) or granulosa cells. The loss of supportive in vivo
paracrine factors is detrimental, yet other somatic influences
(e.g., from the Sertoli cell) inhibit proliferation [20]. In stark
contrast, culturing the ICM benefits from maintained intercel-
lular contact with the same cell type.
mESCs and mEGCs are derived from inbred strains, such as
129/Sv mice, which display a high incidence (1%) of spontane-
ous teratocarcinoma and yield mEGCs with relative efficiency
[41, 65]. Conversely, hESCs and hEGCs are derived from
genetically heterogeneous sources, which prohibit such stan-
dardization and may restrict the frequency of derivation. In our
experience, hPGC-EGC cultures acquire one of two differing
characteristics, designated either PP (poorly proliferating) or VP
(vigorously proliferating) [4]. The latter arise from approxi-
mately 15% of starting cultures and comprise colonies of vary-
ing morphology and/or networks of proliferating migratory-like
cells (the term migratory is taken from the description by
Shamblott et al. [3]; Fig. 3). Neither resembles colonies of
hESCs. Although PP cultures have survived with AP
 cells
beyond 50 days, these cultures have never converted to intense
proliferation, despite factors such as Fgf2. The 15% of cultures
that rapidly proliferate tend to do so early—typically within the
first 2 weeks in culture. This suggests that the problem of
survival is less important than that of conversion to a cell with
Figure 3. Behavior of human primordial germ cells (PGCs) and em-
bryonic germ cells (EGCs) in culture. (A): Cultured gonadal explant
with limited outgrowth of alkaline phosphatase (AP)-positive PGCs.
Strong AP activity is preserved within the explant where contacts with
supporting somatic cells are maintained. (B): Colony containing AP

cells with a more tightly packed morphology, in contrast to (C), where
the cells have adopted a more open, migratory-like morphology, and
(D), an open network of vigorously proliferative AP
 cells that lack
obvious colony formation. Bar  500 m.
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 VP/hEGC characteristics. Information on the molecular differ-
ences between preconversion and postconversion germ cells
within the same and across different species would be instruc-
tive.
Several groups, including ourselves, have noted difficulty in
maintaining hEGCs undifferentiated long-term [4, 5, 35]. This
problem of undifferentiated status contrasts with other pluripo-
tent stem cell types: hESCs and human embryonal carcinoma
cells (hECCs) and mESCs and mEGCs, all of which have been
more extensively characterized. In our experience, VP hEGC
cultures have proliferated extensively; however, the proportion
of cells expressing pluripotent markers (e.g., OCT4 and stage-
specific embryonic antigen [SSEA] family members; see below)
declines over time, variably from 2 to 3 months onwards, and is
exacerbated by freeze-thaw routines [4]. In striking contrast, a
single report from Park et al. [6] described continuous, undif-
ferentiated culture of hEGCs for 12 months, despite similar
methodology and starting material (Table 1). All human pluri-
potent cell types are continuously prone to spontaneous differ-
entiation, and their properties, including karyotype, can alter
with high passage number [66]. This group’s experience needs
to be shared by other researchers, including characterization of
whether the properties of this line can be retained through
freeze-thaw cycles.
In Vitro and In Vivo Characterization of hEGCs
hEGCs have been subject to the same tests of stem cell status as
hESCs and hECCs. In addition, loss of pluripotent markers
merits greater consideration of meiotic progression as well as
normal somatic differentiation [58].
Gene Expression Analyses
The self-renewal of karyotypically normal hEGCs has been
assessed by the expression of characteristic markers (Table 2
and references therein). All groups report AP activity. SSEA1
and SSEA4 are present; however, groups either report variable
SSEA3 expression or its absence. It remains unclear what sig-
nificance should be attached to the expression of SSEA family
members. In hESCs and hECCs, SSEA1 is absent until the onset
of differentiation, whereas SSEA3 is readily detected. In con-
trast, hEGCs start out SSEA1-positive, with, at best, only weak
SSEA3 immunoreactivity (Table 2). Although this profile might
suggest early differentiation, the strongly SSEA1
/EMA-1

starting population of PGCs within the gonad argues against this
[4]. It is also difficult to be certain of the significance of these
differences when the genes under discussion perhaps mark, but
do not regulate, cell phenotype. Conversely, genes and proteins
with known function in pluripotent cells serve as more infor-
mative markers. Particular salient examples are the nuclear
transcription factors OCT4 and NANOG, which have key roles
in the maintenance of pluripotency [67–69] and are expressed in
hPGCs [4, 70]. All groups have identified OCT4 in hEGC by
reverse transcription–polymerase chain reaction and/or immu-
nocytochemistry. Some groups have identified telomerase ac-
tivity either by telomerase repeat-amplification protocol assay
or the expression of hTERT. Additional genes, such as SOX2,
FGF4, STELLAR, FRAGILIS,o rDDX4, highlighted in ESCs or
as orthologs in the germ cell lineage of other species, have not
been characterized in either hPGCs or hEGCs. The expression
of STELLAR is relevant as it forms part of the cluster at 12p13
that includes NANOG and GDF3, which is frequently overrep-
resented in teratocarcinogenesis and contained within 12p iso-
chromosomes in several aneuploid EC lines [71, 72].
Evidence for Pluripotency of hEGCs: In Vitro and
In Vivo
Self-renewal of hEGCs has been documented by continuous
cultures that retain markers such as OCT4 and SSEAs (Table 2).
The significance of hTERT, present within hPGCs and hEGCs,
is less clear. This catalytic component of the telomerase ribo-
nucleoprotein is a marker of nonsenescing cells, which maintain
telomere length. This includes stem cells, but also other cell
types, such as cancer cell lines or those from human fetal
development (i.e., postgastrulation) [73]. Nevertheless, loss of
Table 2. Characterization of pluripotency markers in published reports of human embryonic germ cell derivation
Report
Marker
Karyotype AP SSEA-1
a EMA-1
a SSEA-3 SSEA-4 TRA-1–60
b TRA-1–81 OCT4 NANOG hTERT
Shamblott et
al. 3, 77
 — 
c    —  Passages
8 and 10
Turnpenny
et al. 4, 70
  ND  ——    Passages
10 and 12
Park et al.
6
 —N D    ——  Passage
20
Liu et al.
5
 — 
c  ——  ——  Passage
15
Pan et al.
34
 —N D    —  Passages
7 and 13
hESC/hECC  ND —     
, positive test; —, not recorded.
aSSEA-1 and EMA-1 are very similar or identical antigens 81.
bAntibody recognizes the same epitope as GCTM2.
cStaining was weak and inconsistent.
Abbreviations: AP, alkaline phosphatase; hECC, human embryonal carcinoma cell; hESC, human embryonic stem cell; ND, not detected;
SSEA, stage-specific embryonic antigen.
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 this gene expression profile coincides with the onset of differ-
entiation via haphazard EB formation to ectodermal, endoder-
mal, and mesodermal end points. This satisfies in vitro criteria
for pluripotency and has been achieved by all four groups who
have derived hEGCs [3–6]. Unlike ESC-derived structures,
however, no spontaneous contractions consistent with mesoder-
mal differentiation toward cardiomyocytes have been reported.
Furthermore, since the original report, which maintained the
presence of LIF, Fgf2, and forskolin [3], the subsequent groups
have all withdrawn LIF and, in some instances, the other factors
from the culture medium [4–6]. These apparently conflicting
observations, possibly due to factors intrinsic or extrinsic to
hEGCs, or a combination of both, require clarification.
The issue of hEGC pluripotency becomes particularly inter-
esting with in vivo analyses, for which the only true test is the
ability to form chimeric embryos, not permitted with human
cells for ethical reasons. By these criteria, mouse ICM cells,
mESCs, mEGCs of either sex, and the recently derived mouse
multipotent germline cells (mMGCs) can give rise to all somatic
cell lineages, as well as functional gametes [32, 74–76]. In
contrast, mPGCs are nullipotent [41]. Without recourse to these
experiments for human cell types, teratoma formation is taken as
standard evidence of pluripotency in vivo and has been achieved
for hESC and hECC [41]. Further, this property (unlike effi-
ciency of derivation) is not dependent on genetic background
[74, 75]. Intriguingly, no group has reported teratomas from
hEGCs. Our experience has been to engraft early-passage
hEGCs into the thigh muscle of immunocompromised mice. The
cells expressed AP at the time of engraftment. Whereas the
positive control of human N-TERA2 ECCs, cultured in parallel,
yielded characteristic teratomas, no such tumors have been
observed from equivalent numbers of hEGCs, consistent with
findings elsewhere [77]. The multiple cell lineages within a
teratoma confirm pluripotency. However, failure to form a tu-
mor does not mean hEGCs lack pluripotency. Teratomas arise
from unrestricted local proliferation of the undifferentiated cells
that then differentiate to derivatives of all three germ layers. Our
preliminary evidence suggests that at least some human cells
persist within the immunocompromised mice, but their pheno-
type is, as yet, unclear. This insinuates that hEGC proliferation
was restrained sufficiently to avoid tumorigenesis, but poten-
tially in its place cells have differentiated (if so, presumably in
response to cues from their respective individual murine envi-
ronments).
So, at present, in the absence of the definitive chimeric
experiment, the in vivo pluripotency of hEGC remains unre-
solved. Two therapeutic considerations may lessen the im-
portance of this: first, in vivo transplantation of EGC-derived
cells has generated functional responses; second, lack of
teratoma formation is highly desirable for therapy in human
recipients.
Therapeutic Potential of Human EGCs
Important studies toward therapeutic exploitation of hEGCs
have progressed. The in vitro differentiation capacity of
hEGC, via ongoing culture of EB-differentiated (EBD) cells,
has been well described by the original deriving group [78],
including in vitro characterization in response to BMP2 and
transforming growth factor 3 of a musculoskeletal pheno-
type [79]. EBD cells, capable of significant expansion in
culture, also provided the material to demonstrate that im-
printing appears appropriate with monoallelic expression of
several relevant genes, a critical consideration for potential
therapeutic applications [35]. Further accumulating evidence
reflects a propensity for neuronal differentiation [6, 34] (our
unpublished data). Pan et al. [34] found that, as for hESCs,
retinoic acid or increases in intracellular cAMP signaling
enhanced neural differentiation of hEGC derivatives, includ-
ing tyrosine hydroxylase-positive cell types relevant to ther-
apy for Parkinson’s disease. Whereas this study was re-
stricted to in vitro investigation, cellular derivatives of
hEGCs have also improved motor function in rats in vivo.
Interestingly, after diffuse motor neurone injury, the grafts of
transplanted human cells did not directly reinnervate tissues;
instead, they appeared to support the survival and regrowth of
endogenous rat neurones [80]. Taken together, these studies
argue for the inclusion of hEGCs in stem cell research
programs.
Future Directions
Now that several groups have successfully established hEGC
cultures, an increase in protocols for directed differentiation is
likely to follow. The goals of these experiments are no different
from other aspects of human stem cell research: namely, to
generate physiologically normal cells with the desired function,
ideally by normal regenerative or developmental pathways. It
remains to be seen whether the undifferentiated cells ever pro-
duce teratomas. Potentially, this will be an unforeseen advan-
tage of hEGC research, in which case-comparative study of
hEGCs and hECCs also offers an informative model on the
origin of gonadal tumors.
Better understanding is needed of the derivation process and
long-term culture so that true robust hEGC lines can be banked
equivalently to hESCs. This needs to include transition to hu-
man feeder cells, or, ideally, their complete avoidance, and
gearing up of cell culture efforts toward good manufacturing
practice. To achieve these goals, our current focus is on trying
to understand the determinants of derivation. For this, better
knowledge of the starting hPGC population will allow definition
of the differences that arise between species and after derivation.
Unique to PGC-EGC research, this requires consideration of the
complex somatic-germ cell interactions that differ between male
and female and the propensity for meiotic differentiation. All of
this research will be hindered without refined methods for
isolating pure PGC populations away from their somatic neigh-
bors. Conversely, achieving this will allow better gene expres-
sion analyses and standardized culture experiments that enable
more thorough analysis of additive factors and comparison of
EGCs with ESCs and ECCs. It will be revealing to determine
whether the differences apparent at the cell surface, currently
demonstrated by the variable requirement for exogenous factors,
translate to intracellular differences or whether the same under-
lying molecular pathways are truly common to all human plu-
ripotent stem cells.
ACKNOWLEDGMENTS
We acknowledge all of the authors of the numerous publications
we were unable to cite due to space limitations. L.T. is a U.K.
Medical Research Council (MRC) Collaborative Career Devel-
218 Human Embryonic Germ Cells
 
a
t
 
S
O
U
T
H
A
M
P
T
O
N
 
G
E
N
E
R
A
L
 
H
O
S
P
I
T
A
L
 
o
n
 
N
o
v
e
m
b
e
r
 
3
,
 
2
0
0
8
 
w
w
w
.
S
t
e
m
C
e
l
l
s
.
c
o
m
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 opment Fellow in Stem Cell Research; R.P. is the recipient of a
U.K. MRC Ph.D. Studentship in Stem Cell Research; and
N.A.H. is a U.K. Department of Health Clinician Scientist. This
work was funded by project grants from the British Heart
Foundation (PG/03/021/15128 to D.I.W.) and Hope and the
Wellcome Trust (074320 to N.A.H.), the latter award and the
fellowship to L.T. generously partnered by the Juvenile Diabe-
tes Research Foundation (www.jdrf.org).
DISCLOSURES
The authors indicate no potential conflicts of interest.
NOTE ADDED IN PROOF
Since electronic publication of this article, a further group has
reported on aspects of the human PGC-EGC lineage [82] and
their use in cell therapy.
REFERENCES
1 Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells
from mouse embryos. Nature 1981;292:154–156.
2 Martin GR. Isolation of a pluripotent cell line from early mouse embryos
cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl
Acad SciUSA1981;78:7634–7638.
3 Shamblott MJ, Axelman J, Wang S et al. Derivation of pluripotent stem
cells from cultured human primordial germ cells. Proc Natl Acad Sci
U S A 1998;95:13726–13731.
4 Turnpenny L, Brickwood S, Spalluto CM et al. Derivation of human
embryonic germ cells: An alternative source of pluripotent stem cells.
STEM CELLS 2003;21:598–609.
5 Liu S, Liu H, Pan Y et al. Human embryonic germ cells isolation from
early stages of post-implantation embryos. Cell Tissue Res 2004;318:
525–531.
6 Park JH, Kim SJ, Lee JB et al. Establishment of a human embryonic
germ cell line and comparison with mouse and human embryonic stem
cells. Mol Cells 2004;17:309–315.
7 McLaren A. Primordial germ cells in the mouse. Dev Biol 2003;262:1–
15.
8 Zhao GQ, Garbers DL. Male germ cell specification and differentiation.
Dev Cell 2002;2:537–547.
9 de Sousa Lopes SM, Roelen BA, Monteiro RM et al. BMP signaling
mediated by ALK2 in the visceral endoderm is necessary for the gener-
ation of primordial germ cells in the mouse embryo. Genes Dev 2004;
18:1838–1849.
10 Ying Y, Liu XM, Marble A et al. Requirement of Bmp8b for the
generation of primordial germ cells in the mouse. Mol Endocrinol
2000;14:1053–1063.
11 Ying Y, Qi X, Zhao GQ. Induction of primordial germ cells from murine
epiblasts by synergistic action of BMP4 and BMP8B signaling pathways.
Proc Natl Acad SciUSA2001;98:7858–7862.
12 Kehler J, Tolkunova E, Koschorz B et al. Oct4 is required for primordial
germ cell survival. EMBO Rep 2004;5:1078–1083.
13 Molyneaux KA, Stallock J, Schaible K et al. Time-lapse analysis of
living mouse germ cell migration. Dev Biol 2001;240:488–498.
14 Dumstrei K, Mennecke R, Raz E et al. Signaling pathways controlling
primordial germ cell migration in zebrafish. J Cell Sci 2004;117:4787–
4795.
15 Molyneaux KA, Zinszner H, Kunwar PS et al. The chemokine SDF1/
CXCL12 and its receptor CXCR4 regulate mouse germ cell migration
and survival. Development 2003;130:4279–4286.
16 Doitsidou M, Reichman-Fried M, Stebler J et al. Guidance of primordial
germ cell migration by the chemokine SDF-1. Cell 2002;111:647–659.
17 De Miguel MP, Cheng L, Holland EC et al. Dissection of the c-Kit
signaling pathway in mouse primordial germ cells by retroviral-mediated
gene transfer. Proc Natl Acad SciUSA2002;99:10458–10463.
18 Stallock J, Molyneaux K, Schaible K et al. The pro-apoptotic gene Bax
is required for the death of ectopic primordial germ cells during their
migration in the mouse embryo. Development 2003;130:6589–6597.
19 Tanaka SS, Toyooka Y, Akasu R et al. The mouse homolog of Dro-
sophila vasa is required for the development of male germ cells. Genes
Dev 2000;14:841–853.
20 McLaren A. Primordial germ cells in mouse and human. In: Lanza R,
Gearhart J, Hogan BL et al., eds. Handbook of Stem Cells. New York:
Elsevier Academic Press, 2004:187–192.
21 Adams IR, McLaren A. Sexually dimorphic development of mouse
primordial germ cells: Switching from oogenesis to spermatogenesis.
Development 2002;129:1155–1164.
22 Hanley NA, Hagan DM, Clement-Jones M et al. SRY, SOX9, and DAX1
expression patterns during human sex determination and gonadal devel-
opment. Mech Dev 2000;91:403–407.
23 De Felici M, McLaren A. In vitro culture of mouse primordial germ cells.
Exp Cell Res 1983;144:417–427.
24 Donovan PJ, Stott D, Cairns LA et al. Migratory and postmigratory
mouse primordial germ cells behave differently in culture. Cell 1986;44:
831–838.
25 Durcova-Hills G, Ainscough J, McLaren A. Pluripotential stem cells
derived from migrating primordial germ cells. Differentiation 2001;68:
220–226.
26 Dolci S, Williams DE, Ernst MK et al. Requirement for mast cell growth
factor for primordial germ cell survival in culture. Nature 1991;352:809–
811.
27 Matsui Y, Toksoz D, Nishikawa S et al. Effect of Steel factor and
leukaemia inhibitory factor on murine primordial germ cells in culture.
Nature 1991;353:750–752.
28 Godin I, Deed R, Cooke J et al. Effects of the steel gene product on
mouse primordial germ cells in culture. Nature 1991;352:807–809.
29 Matsui Y, Zsebo K, Hogan BL et al. Derivation of pluripotential embry-
onic stem cells from murine primordial germ cells in culture. Cell
1992;70:841–847.
30 Resnick JL, Bixler LS, Cheng L et al. Long-term proliferation of mouse
primordial germ cells in culture. Nature 1992;359:550–551.
31 McLaren A, Durcova-Hills G. Germ cells and pluripotent stem cells in
the mouse. Reprod Fertil Dev 2001;13:661–664.
32 Kanatsu-Shinohara M, Inoue K, Lee J et al. Generation of pluripotent
stem cells from neonatal mouse testis. Cell 2004;119:1001–1012.
33 Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell
lines derived from human blastocysts. Science 1998;282:1145–1147.
34 Pan Y, Chen X, Wang S et al. In vitro neuronal differentiation of cultured
human embryonic germ cells. Biochem Biophys Res Commun 2005;327:
548–556.
35 Onyango P, Jiang S, Uejima H et al. Monoallelic expression and meth-
ylation of imprinted genes in human and mouse embryonic germ cell
lineages. Proc Natl Acad SciUSA2002;99:10599–10604.
36 De Felici M, McLaren A. Isolation of mouse primordial germ cells. Exp
Cell Res 1982;142:476–482.
37 Goldsborough TM, Price PJ, Lobo-Alfonso J et al. Serum-free culture of
murine embryonic stem (ES) cells. Focus 1998;20:8–12.
38 Horii T, Nagao Y, Tokunaga T et al. Serum-free culture of murine
primordial germ cells and embryonic germ cells. Theriogenology 2003;
59:1257–1264.
39 Lim JW, Bodnar A. Proteome analysis of conditioned medium from
mouse embryonic fibroblast feeder layers which support the growth of
human embryonic stem cells. Proteomics 2002;2:1187–1203.
219 Turnpenny, Spalluto, Perrett et al.
www.StemCells.com
 
a
t
 
S
O
U
T
H
A
M
P
T
O
N
 
G
E
N
E
R
A
L
 
H
O
S
P
I
T
A
L
 
o
n
 
N
o
v
e
m
b
e
r
 
3
,
 
2
0
0
8
 
w
w
w
.
S
t
e
m
C
e
l
l
s
.
c
o
m
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 40 McLaren A, Southee D. Entry of mouse embryonic germ cells into
meiosis. Dev Biol 1997;187:107–113.
41 Donovan PJ, de Miguel MP. Turning germ cells into stem cells. Curr
Opin Genet Dev 2003;13:463–471.
42 Lev S, Blechman JM, Givol D et al. Steel factor and c-kit protooncogene:
Genetic lessons in signal transduction. Crit Rev Oncog 1994;5:141–168.
43 Pesce M, Farrace MG, Piacentini M et al. Stem cell factor and leukemia
inhibitory factor promote primordial germ cell survival by suppressing
programmed cell death (apoptosis). Development 1993;118:1089–1094.
44 Yan W, Suominen J, Toppari J et al. Stem cell factor protects germ cells
from apoptosis in vitro. J Cell Sci 2000;113:161–168.
45 Dolci S, Levati L, Pellegrini M et al. Stem cell factor activates telom-
erase in mouse mitotic spermatogonia and in primordial germ cells.
J Cell Sci 2002;115:1643–1649.
46 Cheng L, Gearing DP, White LS et al. Role of leukemia inhibitory factor
and its receptor in mouse primordial germ cell growth. Development
1994;120:3145–3153.
47 Hoyer PE, Byskov AG, Mollgard K. Stem cell factor and c-Kit in human
primordial germ cells and fetal ovaries. Mol Cell Endocrinol 2005;234:
1–10.
48 Koshimizu U, Taga T, Watanabe M et al. Functional requirement of
gp130-mediated signaling for growth and survival of mouse primordial
germ cells in vitro and derivation of embryonic germ (EG) cells. Devel-
opment 1996;122:1235–1242.
49 Hara T, Tamura K, de Miguel MP et al. Distinct roles of oncostatin M
and leukemia inhibitory factor in the development of primordial germ
cells and sertoli cells in mice. Dev Biol 1998;201:144–153.
50 Smith AG, Heath JK, Donaldson DD et al. Inhibition of pluripotential
embryonic stem cell differentiation by purified polypeptides. Nature
1988;336:688–690.
51 Niwa H, Burdon T, Chambers I et al. Self-renewal of pluripotent em-
bryonic stem cells is mediated via activation of STAT3. Genes Dev
1998;12:2048–2060.
52 Xu C, Inokuma MS, Denham J et al. Feeder-free growth of undifferen-
tiated human embryonic stem cells. Nat Biotechnol 2001;19:971–974.
53 Daheron L, Opitz SL, Zaehres H et al. LIF/STAT3 signaling fails to
maintain self-renewal of human embryonic stem cells. STEM CELLS
2004;22:770–778.
54 Stewart CL, Kaspar P, Brunet LJ et al. Blastocyst implantation depends
on maternal expression of leukaemia inhibitory factor. Nature 1992;359:
76–79.
55 Nichols J, Chambers I, Taga T et al. Physiological rationale for respon-
siveness of mouse embryonic stem cells to gp130 cytokines. Develop-
ment 2001;128:2333–2339.
56 Dunglison GF, Barlow DH, Sargent IL et al. Leukaemia inhibitory factor
significantly enhances the blastocyst formation rates of human embryos
cultured in serum-free medium. Hum Reprod 1996;11:191–196.
57 Stojkovic M, Lako M, Stojkovic P et al. Derivation of human embryonic
stem cells from day-8 blastocysts recovered after three-step in vitro
culture. STEM CELLS 2004;22:790–797.
58 Chuma S, Nakatsuji N. Autonomous transition into meiosis of mouse
fetal germ cells in vitro and its inhibition by gp130-mediated signaling.
Dev Biol 2001;229:468–479.
59 Abir R, Fisch B, Jin S et al. Immunocytochemical detection and RT-PCR
expression of leukaemia inhibitory factor and its receptor in human fetal
and adult ovaries. Mol Hum Reprod 2004;10:313–319.
60 Resnick JL, Ortiz M, Keller JR et al. Role of fibroblast growth factors
and their receptors in mouse primordial germ cell growth. Biol Reprod
1998;59:1224–1229.
61 Manova K, Bachvarova RF. Expression of c-kit encoded at the W locus
of mice in developing embryonic germ cells and presumptive melano-
blasts. Dev Biol 1991;146:312–324.
62 Haik S, Gauthier LR. Granotier C et al. Fibroblast growth factor 2 up
regulates telomerase activity in neural precursor cells. Oncogene 2000;
19:2957–2966.
63 Dolci S, Pesce M, De Felici M. Combined action of stem cell factor,
leukemia inhibitory factor, and cAMP on in vitro proliferation of mouse
primordial germ cells. Mol Reprod Dev 1993;35:134–139.
64 De Felici M, Dolci S, Pesce M. Proliferation of mouse primordial germ
cells in vitro: A key role for cAMP. Dev Biol 1993;157:277–280.
65 Stevens LC. Genetic influences on teratocarcinogenesis and partheno-
genesis. Prog Clin Biol Res 1981;45:93–104.
66 Draper JS, Smith K, Gokhale P et al. Recurrent gain of chromosomes 17q
and 12 in cultured human embryonic stem cells. Nat Biotechnol 2004;
22:53–54.
67 Chambers I, Colby D, Robertson M et al. Functional expression cloning
of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell
2003;113:643–655.
68 Mitsui K, Tokuzawa Y, Itoh H et al. The homeoprotein Nanog is required
for maintenance of pluripotency in mouse epiblast and ES cells. Cell
2003;113:631–642.
69 Nichols J, Zevnik B, Anastassiadis K et al. Formation of pluripotent stem
cells in the mammalian embryo depends on the POU transcription factor
Oct4. Cell 1998;95:379–391.
70 Turnpenny L, Cameron IT, Spalluto CM et al. Human embryonic germ
cells for future neuronal replacement therapy. Brain Res Bull (in press).
71 Looijenga LH, de Munnik H, Oosterhuis JW et al, A molecular model for
the development of germ cell cancer. Int J Cancer 1999;83:809–814.
72 Clark AT, Rodriguez RT, Bodnar MS et al. Human STELLAR,
NANOG, and GDF3 genes are expressed in pluripotent cells and map to
chromosome 12p13, a hotspot for teratocarcinoma. STEM CELLS 2004;
22:169–179.
73 Wright WE, Piatyszek MA, Rainey WE et al. Telomerase activity in
human germline and embryonic tissues and cells. Dev Genet 1996;18:
173–179.
74 Stewart CL, Gadi I, Bhatt H et al. Stem cells from primordial germ cells
can reenter the germ line. Dev Biol 1994;161:626–628.
75 Labosky PA, Barlow DP, Hogan BL et al. Mouse embryonic germ (EG)
cell lines: Transmission through the germline and differences in the
methylation imprint of insulin-like growth factor 2 receptor (Igf2r) gene
compared with embryonic stem (ES) cell lines. Development 1994;120:
3197–3204.
76 Durcova-Hills G, Wianny F, Merriman J et al. Developmental fate of
embryonic germ cells (EGCs), in vivo and in vitro. Differentiation
2003;71:135–141.
77 Shamblott MJ, Kerr CL, Axelman J et al. Derivation and differentiation
of human embryonic germ cells. In: Lanza R, Gearhart J, Hogan BL et
al., eds. Handbook of Stem Cells. New York: Elsevier Academic Press,
2004:459–470.
78 Shamblott MJ, Axelman J, Littlefield JW et al. Human embryonic germ
cell derivatives express a broad range of developmentally distinct mark-
ers and proliferate extensively in vitro. Proc Natl Acad SciUSA
2001;98:113–118.
79 Kim MS, Hwang NS, Lee J et al. Musculoskeletal differentiation of cells
derived from human embryonic germ cells. STEM CELLS 2005;23:113–
123.
80 Kerr DA, Llado J, Shamblott MJ et al. Human embryonic germ cell
derivatives facilitate motor recovery of rats with diffuse motor neuron
injury. J Neurosci 2003;23:5131–5140.
81 De Felici M., Scaldaferri M. L., Lobascio M et al., Experimental ap-
proaches to the study of primordial germ cell lineage and proliferation.
Hum Reprod Update 2004;10:197–206.
82 Aflatoonian B, Moore H. Human primordial germ cells and embryonic
germ cells, and their use in cell therapy. Curr Opin Biotechnol 2005;16:
530–535.
220 Human Embryonic Germ Cells
 
a
t
 
S
O
U
T
H
A
M
P
T
O
N
 
G
E
N
E
R
A
L
 
H
O
S
P
I
T
A
L
 
o
n
 
N
o
v
e
m
b
e
r
 
3
,
 
2
0
0
8
 
w
w
w
.
S
t
e
m
C
e
l
l
s
.
c
o
m
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 Molecular and Cellular Endocrinology 288 (2008) 111–118
Contents lists available at ScienceDirect
Molecular and Cellular Endocrinology
journal homepage: www.elsevier.com/locate/mce
Origin of pluripotent germ cell tumours: The role of microenvironment
during embryonic development
David Møbjerg Kristensena,∗, Si Brask Sonnea, Anne Marie Ottesena, Rebecca M. Perrettb,
John E. Nielsena, Kristian Almstrupa, Niels E. Skakkebaeka, Henrik Leffersa,
Ewa Rajpert-De Meytsa
a University Department of Growth and Reproduction, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
b Centre for Human Development, Stem Cells & Regeneration/Human Genetics Division, University of Southampton, Southampton SO16 6YD, UK
article info
Article history:
Received 8 November 2007
Received in revised form 7 February 2008
Accepted 25 February 2008
Keywords:
Germ cell differentiation
Pluripotency
Stem cells
Cancer stem cells
Germ cell neoplasm
Carcinoma in situ testis
abstract
Carcinoma in situ (CIS) testis, known also as intratubular germ cell neoplasia, is the cancer stem cell from
which the great majority of testicular germ cell derived tumours (TGCTs) of the testis arise. TGCTs can
proliferate into morphologically homogeneous seminomas or can differentiate into virtually any type of
tissue and form teratomas (non-seminomas). CIS cells display a close phenotypic similarity to fetal germ
cells (primordial germ cells or gonocytes) suggesting an origin due to a developmental delay or arrest of
differentiation of early germ cells. The pluripotency of these neoplasms has recently been explained by a
close resemblance of their expression proﬁle to that of embryonic inner cell mass cells studied in culture
as embryonic stem cells, with high expression of transcription factors associated with pluripotency, such
as NANOG and OCT3/4, as well as proteins found in several tissue speciﬁc stem cells, such as TFAP2C (AP-
2) or KIT. CIS and seminomas highly express a number of pre-meiotic germ cell speciﬁc genes, which
are down-regulated during development to non-seminomas, while the expression of other embryonic
markers, such as SOX2, is up-regulated. The mechanistic pathways and causative factors remain to be
elucidated of both the initial transformation of fetal germ cells into CIS cells and the progression of CIS
cells into an invasive tumour in the young adult. However, evidence supported by epidemiological studies
indicate that disturbances in the hormonal microenvironment of the differentiating gonads may results
in both the neoplasia and a host of other problems later in life, such as genital malformations, decreased
spermatogenesis, and signs of hypogonadism.
© 2008 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
More than 35 years ago the ﬁrst paper describing atypical sper-
matogonia in testicular biopsies from two patients was published
(Skakkebaek, 1972a). Both patients later developed overt testic-
ular tumours indicating that the abnormal cells were precursor
cells of the malignant tumours (Skakkebaek, 1972b). This original
study is to our knowledge one of the ﬁrst descriptions of a true
tumour/cancer stem cell (Nielsen et al., 1974). Today, carcinoma in
situ(CIS)(alsoknownasintratubulargermcellneoplasiaortesticu-
lar intraepithelial neoplasia) is generally accepted as the common
Abbreviations: CIS, carcinoma in situ; TGCT, testicular germ cell tumour; EC,
embryonal carcinoma; PG, primordial germ (cell); TDS, testicular dysgenesis syn-
drome; ES, embryonic stem (cell).
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GR5062, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
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pre-invasive precursor cell that gives rise to testicular germ cell
tumours (TGCTs) of the adolescents and young adults (Ulbright
et al., 1999; Oosterhuis and Looijenga, 2005). There are two other
types of TGCTs, which develop without a CIS stage: spermatocytic
seminoma of elderly men and infantile germ cell tumours. Both
of these tumour types are rare and have remained at a steady low
incidencelevel(Visfeldtetal.,1994).TheoppositeistrueforTGCTs,
originating from the CIS precursor stage, which have increased in
incidenceoverthelastseveraldecadesandnowconstitutethemost
prevalent malignant cancer among young male adults in North-
ern and Western Europe, with a life time frequency in Denmark of
approximately 1% (Richiardi et al., 2004).
The TGCTs originating from CIS are traditionally subdivided into
two histologically distinct groups, seminomas (also called classi-
cal seminoma to distinguish from spermatocytic seminoma) and
non-seminomatous germ cell tumours, each constituting approxi-
mately 50%. Whereas the seminoma is a generally uniform tumour
and resembles early fetal germ cells and CIS cells, the more
malignantnon-seminomasareveryheterogeneousandencompass
0303-7207/$ – see front matter © 2008 Elsevier Ireland Ltd. All rights reserved.
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embryonal carcinoma (EC), choriocarcinoma, teratomas, yolk sac
tumour, and can also contain elements of seminoma (Ulbright et
al., 1999). EC cells of the non-seminomas have the ability to dif-
ferentiate into a wide range of cell types, and show a phenotypic
resemblance to the inner cell mass cells and epiblast from the early
embryo. Hence, EC cells represent a malignant caricature of the
human embryonic stem (ES) cells that are derived in culture from
the inner cell mass (Andrews, 1998; Solter, 2006). However, many
ECcellsshowlimiteddevelopmentalpotency,orevennullipotency,
which might be regarded as the ultimate consequence of adapta-
tion occurring in tumours that have developed over a period of
20 or more years (Baker et al., 2007). Intriguingly, a recent report
suggested that non-seminomas, most likely the yolk sac tumour
component, also may have the potential to differentiate to germ
cells, although this needs independent conﬁrmation (Honecker et
al., 2006). Taken together, the observations from pathology sug-
gest that the common pre-invasive CIS cells have the capability to
develop into many different germinal and somatic tissues and may
be regarded as pluripotent or truly totipotent. In that sense, we
believe that CIS is a cancer stem cell for both TGCT types, semi-
noma and non-seminomatous tumour. However, it is debated that
CIS has to be ﬁrst re-programmed to EC, which then is a stem cell
for somatic components of non-seminomas.
The remarkable potential of CIS cells raises the immediate
question of their origin. A few years after their initial discov-
ery, a morphological similarity to gonocytes was noted and it
was proposed that CIS cells could be remnants of undifferentiated
embryonic/fetal cells (Nielsen et al., 1974; Skakkebaek et al., 1987).
Their fetal origin was supported by immunohistochemical studies
of proteins present in CIS also shown to be present in primordial
germ (PG) cells and gonocytes, and by identifying CIS cells in pre-
pubertal patients, who later developed TGCTs, indicating that the
cells had originated prior to puberty (Muller et al., 1984). Addi-
tional support was provided by epidemiological studies showing
that the increase in TGCTs was related to birth cohort rather than
year of diagnosis (Møller, 1989). Remarkably, further epidemio-
logical studies demonstrated that ﬁrst-generation immigrants to
Sweden had the same risk for developing TGCTs as in their coun-
try of origin, whereas second-generation immigrants had the same
risk as native Swedes (Hemminki et al., 2002; Hemminki and Li,
2002).BesidesstronglyindicatingthefetaloriginofTGCTsinyoung
adults, these epidemiological studies also showed the aetiologi-
cal importance of environmental factors in development of the CIS
cells,althoughsomegeneticpredispositionalsoplaysarole.Hence,
TGCTs in young adults have been proposed to be part of a larger
testicular dysgenesis syndrome (TDS) that includes mild genital
malformations and certain forms of infertility, all thought to be
highly inﬂuenced by environmental exposures (Skakkebaek et al.,
2001). So, 35 years from the initial description of CIS cells, it has
become increasingly clear that the attention of investigators deal-
ing with the TGCTs and their origin has to focus on both the early
in utero gonadal development and the impact of the multitude of
different environmental factors that can negatively affect this pro-
cess, including the so-called endocrine disruptors. In this review,
we will summarise ﬁndings concerning the phenotype and geno-
typic signature of CIS cells and discuss the hypotheses concerning
theiroriginandhowtheseembryoniccellsintheadultdevelopinto
a malignant tumour.
2. Expression of embryonic marker genes in CIS cells and
during invasive progression: the development of a
pluripotent tumour?
CIS cells have many morphological similarities with PG cells
and early gonocytes (Nielsen et al., 1974; Albrechtsen et al., 1982;
Skakkebaek et al., 1987). Relatively early on it was identiﬁed that
the three cell types share the expression of immunohistochemical
markers such as placental-like alkaline phosphatase (PLAP) or the
stem cell factor receptor KIT (Giwercman et al., 1991; Rajpert-
De Meyts and Skakkebaek, 1994; Jorgensen et al., 1995). These
markers are now commonly used in the clinical setting to help
identify CIS in surgical biopsies. More recently, the expression
proﬁles of CIS cells studied by microarrays (Almstrup et al., 2004;
Skotheim et al., 2005) provided a series of candidate marker genes,
such as TFAP2C (AP2)( Hoei-Hansen et al., 2004), which has
shown promising results as a possible marker of CIS cells in semen
samples (Hoei-Hansen et al., 2007).
A landmark in the understanding of CIS and the derived inva-
sive cancers was the identiﬁcation of POU5F1 (OCT3/4) and NANOG
expression, which are known for their association with pluripo-
tency in ES cells (Fig. 1)( Looijenga et al., 2003; Rajpert-De Meyts
et al., 2004; Hoei-Hansen et al., 2005). These two transcription fac-
tors are, together with SOX2, key regulators of the formation and
maintenance of the inner cell mass during pre-implantation devel-
opmentandforsustainingself-renewalinESCs(Scholeretal.,1990;
Nicholsetal.,1998;Niwaetal.,2000;Avilionetal.,2003;Chambers
etal.,2003;Mitsuietal.,2003).Amongothers,knock-outstudiesof
both Pou5f1 and Nanog in mice have implicated these genes in the
ﬁrst and second initial fate decisions in mammalian development,
respectively (Cavaleri and Scholer, 2003; Chambers et al., 2003).
Although very useful, experimental studies in animals have
demonstrated differences in developmental biology between mice
and humans. Stem cells have been isolated from adult mouse
testes that exhibit properties similar to ES cells (Guan et al., 2006;
Seandel et al., 2007), and these studies showed that a subset of
spermatogonial stem cells in mouse testes retain the embryonic
phenotypeofPGcellsandgonocytes.Inhumansadifferentscenario
isseen,whereNANOGandOCT3/4(togetherwithKITandAP2)are
expressedinPGcellsandgonocytes,butaredown-regulatedduring
the second half of pregnancy and until 2–4½ months of post-natal
age (Jorgensen et al., 1995; Rajpert-De Meyts et al., 2004; Hoei-
Hansen et al., 2004, 2005; Honecker et al., 2004). During this early
infantile period, a transient increase in the production of testicular
hormones occurs, known as the ‘mini-puberty’ (Forest et al., 1973),
which coincides with the ﬁnal stage of differentiation of gonocytes
intoinfantilespermatogonia(Hadziselimovicetal.,1986).Although
NANOGandOCT3/4aredown-regulated,downstreamfactorsiden-
tiﬁed in ES cells, UTF1 and REX1 (Niwa, 2001; Kristensen et al.,
2005; Nishimoto et al., 2005), continue to be expressed through-
out the male development in spermatogonia and are still present
in the adult testes (Kristensen et al., 2008). The continued expres-
sion of UTF1 and REX1, apparently uncoupled functionally from
OCT3/4 and NANOG, shows that the partial embryonic phenotype
ofthegermcellsisstillevidentinthematurehumantestes.Thelink
between CIS cells and embryonic cells has been further supported
by a study showing a substantial overlap between human ES cells
and CIS cells’ gene expression proﬁles (Almstrup et al., 2004).
There are, however, marked differences in the expression of
embryonic genes among the histological types of overt tumours
derived from CIS. The phenotype of seminoma is very close to
that of CIS, whereas the phenotype of EC, considered the undif-
ferentiated stem cell compartment of non-seminomas, resembles
much closer that of ES cells, suggesting a re-programming or a de-
differentiation event (Sperger et al., 2003; Almstrup et al., 2005;
Skotheim et al., 2005; Korkola et al., 2006). This is supported by
the high expression of SOX2 in EC, for example, while in seminoma
this marker is virtually negative (Sperger et al., 2003; Santagata
et al., 2007; Perrett et al., in press). A further somatic differentia-
tion of EC is observed in nearly all non-seminomas and this event
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Fig. 1. Expression of pluripotency associated proteins OCT4, NANOG, and AP2 in carcinoma in situ (CIS) cells and testicular germ cell tumours. Images (A), (D), and (G) show
area of normal testis (NT, unstained) adjacent to tubules with CIS cells (stained positively for OCT4, NANOG, and AP2). Images (B), (E), and (H) shows example of classical
seminoma strongly positive for the same transcription factors. Images (C), (F) and (I) show the expression of the three proteins in non-seminomas; note the intensely positive
clusters of embryonal carcinoma (EC), whereas the surrounding teratomatous tissues or atrophic tubules without malignancy (in F) show no staining (scale bar 100m).
pluripotency genes (Figs. 1–3)( Skotheim et al., 2005; Korkola et al.,
2006).
The similarities between the ES cell lines and CIS cells do not
stop at gene expression patterns, there are also remarkably similar
patterns of genomic aberrations in the two cell types. CIS cells are
knowntoundergopolyploidizationandDNAcontentinthetriploid
to hypotetraploid range has been identiﬁed in CIS adjacent to both
seminoma and non-seminoma (Ottesen et al., 2004b). Although
polyploidizationseemstoappearpriortotheestablishmentofextra
12p material (Geurts van Kessel et al., 1989; Oosterhuis et al., 1989;
Ottesen et al., 2004b), the speciﬁc stage at which tumour devel-
opment is initiated and genomic instability introduced remains
unresolved. Due to technical problems only a small number of
cases of CIS have been examined for chromosomal aberrations,
Fig. 2. Schematic ﬁgure showing relative gains in regions of chromosomes (chr) 12, 17, and X detected in three studies analysing CIS adjacent to overt tumours. On the right
side of the chromosomes red, blue, and green bars show the extension of the gains observed in study 1, 2, and 3, respectively. Study 1: Looijenga et al. (2000); study 2: Ottesen
et al. (2003); study 3: Summersgill et al. (2001).114 D.M. Kristensen et al. / Molecular and Cellular Endocrinology 288 (2008) 111–118
Fig. 3. A model of the origin of carcinoma in situ (CIS) of the testis in early development and hypothetical pathways of progression to overt testicular germ cell tumours
(TGCTs). The key events in the origin and progression of TGCT are represented in red: (1) the arrest of differentiating primordial germ cells or gonocytes and (2) the
increased invasiveness with (in embryonal carcinoma, EC) or without (in seminoma) loss of germ cell phenotype. In the case of non-seminomas, EC is the presumed stem
cell compartment that may undergo down-regulation of the pluripotency genes and differentiate to somatic non-seminomatous components such as teratoma (TER), yolk
sac tumour (YSC) or choriocarcinoma (CHC) (modiﬁed from Rajpert-De Meyts, 2006).
however a range of imbalances were detected, including gains of
regions of the chromosomes 7, 8, 12, 14, 15, 17 and X (Looijenga et
al., 2000; Summersgill et al., 2001; Ottesen et al., 2003, 2004a,b)
(Fig. 2). A recurrent gain of 12p material was demonstrated in the
vast majority of overt TGCTs, together with chromosomal aber-
rations established as typical for TGCTs (Atkin and Baker, 1982;
Summersgill et al., 2001; and reviewed in von Eyben, 2004). Fasci-
natingly, the extra 12p material was also observed in several cases
of CIS adjacent to overt tumours but was absent in CIS cells with
no evidence of invasive growth (Looijenga et al., 2000; Ottesen et
al., 2003, 2004a,b; Skotheim et al., 2006). Whereas gains of 17q
were only detected in a few CIS cases (Ottesen et al., 2003, 2004b),
a recurrent gain of 17q has been associated with non-seminomas
in particular, perhaps illustrating the high proliferation potential of
this more aggressive tumour (Kraggerud et al., 2002; Skotheim et
al., 2002).
Gains in largely the same chromosomal regions are seen
in cultured ES cells after prolonged culture indicating that the
microenvironment may play a role in increasing genomic insta-
bility (Draper et al., 2004; Andrews et al., 2005; Baker et al.,
2007). Evidence suggests that the ES cells ‘adapt’ through these
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tain with time in culture. In addition, when cells from such an
‘adapted’ culture were inoculated into a SCID (severe combined
immunodeﬁcient) mouse, a teratocarcinoma containing histologi-
callyrecognisablestemcellswasformed,whichgrewoutwhenthe
tumour was explanted into culture and exhibited properties of the
starting ES cells (Andrews et al., 2005). Therefore, the ‘adapted’ ES
cells resembled the malignant non-seminoma EC cells. As such, ES
cells show adaptive changes during culture which mimic changes
occurring in CIS and later the derived EC cells during tumour
progression. Thus, the non-random genomic aberrations seen in
CIS cells may be caused by selection of cells with a proliferative
advantageduringtumourdevelopmentandprogression(Fig.3),for
example those with an over-expression of the pluripotency-related
genes located on the short arm of chromosome 12 (Clark et al.,
2004;Korkolaetal.,2006).Thesimplistichypothesiswouldbethat
only a few genes are involved, perhaps only one from each region
ampliﬁed. However, the situation may be more complex, which is
supportedbythehistoricaldifﬁcultyinidentifyingsinglegenesthat
underlie common chromosome ampliﬁcations in various cancers,
not only TGCTs (Baker et al., 2007). The fact that the microenviron-
ment plays such a deﬁning role in genomic instability in ES cells
couldindicatethatthesameistrueduringtheformationofCIScells.
It is quite possible that a disturbance or disruption of the original
niche of gonocytes or PG cells may have led to imbalance between
proliferation and differentiation resulting in the genetic instabil-
ity and neoplastic transformation. As time passes, the CIS cells also
develop through selection, eventually resulting in the progression
to a malignant seminoma or non-seminoma.
3. The CIS cancer stem cells
The pathogenesis of TGCTs in young men has not yet been eluci-
dated in detail. However, it is obvious that unravelling the biology
of CIS cells is fundamental for the understanding of the aetiology
of TGCTs. The CIS cell represents an interesting variant of cancer
stem cell since it originates before the tissue that it propagates
in is fully differentiated and functional. The concept that cancers
arise from ‘stem cells’ or ‘germ cells’ was already proposed about
150 years ago and recently, due to advances in stem cell biology,
has been given a revival with the proposal of the ‘cancer stem
cell hypothesis’ (reviewed in Wicha et al., 2006). The two related
concepts of this hypothesis are that (i) tumours originate in either
tissue stem cells or their immediate progeny through malfunctions
in the process of self-renewal. As a result of this (ii) tumours
contain so-called ‘cancer stem cells’ as a cellular subcomponent
that retains key stem cell properties. These properties include
self-renewal, which drives tumourigenesis, and differentiation
that contributes to the cellular heterogeneity seen in most cancers.
However, in contrast to TGCTs, the cellular heterogeneity is limited
to the same tissue type in the vast majority of somatic cancers.
Cancerstemcellsarethoughttofunctioninasimilarwayasnormal
epithelial tissue stem cells that constantly replenish a tissue with
committed differentiated cells not capable of self-renewal. Within
the last couple of years experimental evidence in a variety of
tumours has lent support to the cancer stem cell hypothesis that
represents a paradigm shift in the understanding of carcinogenesis
and tumour cell biology (Wicha et al., 2006).
The initiation of the neoplastic transformation generating CIS
cells, which is discussed in detail below, is most likely triggered
by a disturbance in the embryonic, fetal, or – perhaps in some
cases – also early postnatal microenvironment of differentiating
germ cells. Thus, CIS cells are different from the somatic cancer
stem cells due to their origin in early development long before the
tissue is fully differentiated and also in their ability to give rise
to tumours with pluripotent potential. Regardless of these differ-
ences,CIScellsshouldberegardedasgenuinecancerstemcells.The
cells self-renew and are often found in the periphery of these solid
tumours. The CIS cells are malignant cells that have the ability to
invade all tubules in the testis and form solid seminomas tumours.
In another cases, which tend to be relatively younger men than
those who develop seminomas, CIS cells undergo a further devel-
opment and give rise to non-seminomas, which include a variety of
histologically different invasive tumours. This was already shown
in the ﬁrst description of the cells in 1972, where two patients
with CIS were followed to the point where they developed inva-
sivetumours(Skakkebaek,1972b,1978).Furthermore,laterstudies
showedthatpatientswithCIS,whoseemedcuredafterchemother-
apy, developed cancer after the treatment (von der Maase et al.,
1988; Dieckmann, 1988; Dieckmann and Loy, 1991). This indicates
that the cells have the capacity to repopulate the testis from a sin-
gle or only few cells, which is a classic characteristic of cancer stem
cells. Still, it is unresolved to what degree CIS cells make the transi-
tion to the invasive tumours and whether all CIS cells are destined
to become invasive. It seems likely that only one or a few cells
at a time make the transition to develop into an invasive cancer.
However, testes with both seminoma and non-seminoma tumours
separatedbyanon-malignanttissuearenotuncommon,indicating
a possible polyclonal origin of these tumours from at least two CIS
cells.
Much remains unknown regarding the formation of solid
tumours from CIS cells, especially the development of non-
seminomas. The development of CIS cells to EC is particularly
intriguing since it seems to encompass more than just a classic
differentiation, and resembles a de-differentiation to a more
original embryonic cell, mimicking cells from the inner cell mass
of the early embryo.
4. Does disturbance of the stem cell niche result in
development of CIS cells? The possible role of endocrine
disrupters
Thedifferentiatingcellsinthechildareverysusceptibletoenvi-
ronmental damage, because development is a highly integrated
process in which massive proliferation and extensive differen-
tiation are synchronized with each other and with apoptosis
(Birnbaum and Fenton, 2003). The extensive growth rates allow
for mutagenic and epigenetic alterations. Likewise, differentiation
represents a controlled process in which patterns of gene expres-
sion undergo large changes. Consequently, both cell division and
differentiation offer multiple opportunities for the initiation of
lesions as well as the promotion of the growth of altered cells
initiating the complex process of developing a cancer. Moreover,
physiological barriers protective of external factors such as the
blood–brain barrier and blood–testes barrier are not complete in
utero. Furthermore, the metabolising and elimination capabilities
of the developing organism are not fully developed until after
birth, leaving the fetus and newborn particularly susceptible to
the adverse effects of environmental compounds (Birnbaum and
Fenton, 2003).
Several recent studies have elucidated the mechanism of early
differentiation of sexually bipotential primordial germ cells into
the male cell lineage, however, much deeper insight into the early
humanembryogenesisisneededtounderstandthedevelopmentof
CIS cells. Rare genetic disorders of sex differentiation have yielded
insight into the possible mechanisms of CIS cell formation. For
example, in some individuals with mutations in SRY and 46,XY
gonadal dysgenesis, CIS cells and/or gonadoblastoma may be seen
in the streak or in severely dysgenetic streak gonads (Muller et al.,
1992; Cools et al., 2006). In addition to rare instances of a muta-
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in a subset of cells in the developing testis (a mosaic sex chro-
mosome aneuploidy) would cause a focal lack of masculinisation
and a varying degree of gonadal dysgenesis, often with the occur-
rence of gonadoblastoma or CIS. However, in the vast majority of
cases of sporadic CIS/TGCT in adult men the signs of dysgenesis
are very discreet but nearly always consistent with focal lack of
proper virilization and gonadal maturation, manifested by clusters
ofdistortedtubulesandundifferentiatedSertolicells(Hoei-Hansen
et al., 2003; Nistal et al., 2006). These studies combined with
lessons from disorders of sex differentiation and epidemiologi-
cal observations support the notion that interference with early
male development, either from genetic mutation or environmen-
tal factors, can lead to the development of CIS cells and hence
neoplasia.
Thedifferentiationofhumangonocytesintoinfantilespermato-
goniaspansarelativelylongperiodwithagradualdown-regulation
of the embryonic pluripotency genes and up-regulation of germ
cell-speciﬁc genes with a role in spermatogenesis. Analysis of the
CIS phenotype and the presence of CIS cells in certain conditions
associated with testicular dysgenesis have provided strong evi-
dence that developmental arrest in the differentiation of the early
germ cell lineage is a core pathogenetic event leading to neoplas-
tic transformation into CIS (Fig. 3)( Rajpert-De Meyts et al., 1996,
1998; Rajpert-De Meyts, 2006). Thus, it seems plausible that the
long duration of differentiation leaves a window for disturbances
in the hormonal balance that may topple the delicate balance and
delayorarrestthedifferentiationofPGcellsorgonocytesintoinfan-
tile pre-spermatogonia. Moreover, the differentiation of germ cells
occursinanintimatecontactwithsomaticcellsinthemicrocellular
“niche”, which consists of Sertoli cells, Leydig cells, and peritubu-
lar myoid cells, and it is in these few cell types that hormonal and
paracrinefactorsresponsibleforthedifferentiationprocessarepro-
duced. These cells are therefore the likely targets of environmental
factors such as endocrine disrupters, which is supported by a clear
association of germ cell neoplasia with insufﬁcient function of the
androgen-producing Leydig cells, and with decreased proliferation
of Sertoli cells in association with small testes with reduced sper-
matogenesis (Holm et al., 2003). Problems with poorly developed
or partially hyalinised tubule walls are also a common feature of
CIS tubules. All these features can be reproduced in experimental
animalmodelsbyexposuretoselectedendocrinedisrupters,inpar-
ticular various anti-androgenic compounds, including phthalates
(Mylchreest et al., 1998; Fisher et al., 2003; Sharpe, 2006). There is
stillonlyindirectevidencefromhumanstudies,buttheassociation
of testicular cancer with exposures to some of these compounds
has already been suggested by several studies, indicating that the
development of CIS cells could be directly coupled to endocrine
disruptors disturbing early male development (Hardell et al., 2003;
Swan et al., 2005; Main et al., 2007).
5. Concluding remarks
The study of CIS cells has its focus on two major events: (i) the
initial development in utero of the CIS cell and (ii) the progression
of CIS cells in adulthood to an invasive malignant tumour. There is
growing evidence that disturbances of the cellular microenviron-
ment of developing germ cells, also known as their “niche”, are of a
primary importance in the development of the CIS cells and also in
the origin of other disorders of testicular function, even those man-
ifested in adulthood. As these disorders are becoming increasingly
common, we must consider the negative impact of the modern
lifestyle and strive to ﬁnd the responsible factors together with the
pathways they target, especially during early human embryogene-
sis. Numerous studies have demonstrated that germ cell tumours
derived from CIS cells mimic embryonic development and consti-
tute a model to study pathways of pluripotent cell differentiation.
In this way germ cell tumours and ES cells are highly similar and it
has been shown that during extended culture human ES cells reca-
pitulate features of the malignant transformation seen in germ cell
tumours. Hence, the knowledge obtained from studies of human
ES cells in vitro can help to understand the mechanisms of neo-
plastic transformation of germ cells and invasive progression of
tumours.
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